Dominant	O
negative	O
effect	O
of	O
the	O
APC1309	O
mutation	O
:	O
a	O
possible	O
explanation	O
for	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
familial	B
adenomatous	I
polyposis	I
.	O

Inactivation	O
of	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
product	O
initiates	O
colorectal	O
tumorigenesis	O
.	O

Patients	O
with	O
familial	B
APC	I
(	O
FAP	B
)	O
carry	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
APC	B
gene	O
and	O
develop	O
multiple	O
colorectal	B
adenomas	I
and	O
subsequent	O
carcinomas	B
early	O
in	O
life	O
.	O

The	O
severity	O
of	O
the	O
disease	O
correlates	O
with	O
the	O
position	O
of	O
the	O
inherited	O
APC	B
mutation	O
(	O
genotype	O
-	O
phenotype	O
correlation	O
)	O
.	O

Together	O
with	O
the	O
fact	O
that	O
both	O
germ	O
-	O
line	O
and	O
sporadic	O
APC	B
mutations	O
cluster	O
in	O
the	O
central	O
region	O
of	O
the	O
APC	B
gene	O
,	O
this	O
points	O
to	O
a	O
dominant	O
negative	O
effect	O
of	O
certain	O
APC	B
mutants	O
.	O

Loss	O
of	O
APC	B
function	O
was	O
recently	O
shown	O
to	O
result	O
in	O
enhanced	O
beta	O
-	O
catenin-	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
in	O
colon	O
epithelial	O
cells	O
.	O

Here	O
,	O
we	O
provide	O
experimental	O
evidence	O
for	O
a	O
dominant	O
negative	O
effect	O
of	O
APC	B
gene	O
products	O
associated	O
with	O
severe	O
polyposis	B
.	O

Wild	O
-	O
type	O
APC	B
activity	O
in	O
beta	O
-	O
catenin-	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
was	O
strongly	O
inhibited	O
by	O
a	O
mutant	O
APC	B
that	O
is	O
truncated	O
at	O
codon	O
1309	O
.	O

In	O
contrast	O
,	O
mutant	O
APC	B
gene	O
products	O
that	O
are	O
associated	O
with	O
attenuated	B
polyposis	I
(	O
codon	O
386	O
or	O
1465	O
)	O
interfered	O
only	O
weakly	O
with	O
wild	O
-	O
type	O
APC	B
activity	O
.	O

These	O
results	O
suggest	O
a	O
molecular	O
explanation	O
for	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
FAP	B
patients	O
and	O
support	O
the	O
idea	O
that	O
colorectal	B
tumor	I
growth	O
might	O
be	O
,	O
in	O
part	O
,	O
driven	O
by	O
selection	O
for	O
a	O
mutation	O
in	O
the	O
mutation	O
cluster	O
region	O
..	O

Overgrowth	B
of	I
oral	I
mucosa	I
and	I
facial	I
skin	I
,	O
a	O
novel	O
feature	O
of	O
aspartylglucosaminuria	B
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
lysosomal	B
storage	I
disorder	I
caused	O
by	O
deficiency	B
of	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

The	O
main	O
symptom	O
is	O
progressive	O
mental	B
retardation	I
.	O

A	O
spectrum	O
of	O
different	O
mutations	O
has	O
been	O
reported	O
in	O
this	O
disease	O
,	O
one	O
missense	O
mutation	O
(	O
Cys163Ser	O
)	O
being	O
responsible	O
for	O
the	O
majority	O
of	O
Finnish	O
cases	O
.	O

We	O
were	O
able	O
to	O
examine	O
66	O
Finnish	O
AGU	B
patients	O
for	O
changes	O
in	O
the	O
oral	O
mucosa	O
and	O
44	O
of	O
these	O
for	O
changes	O
in	O
facial	O
skin	O
.	O

Biopsy	O
specimens	O
of	O
16	O
oral	O
lesions	O
,	O
12	O
of	O
them	O
associated	O
with	O
the	O
teeth	O
,	O
plus	O
two	O
facial	B
lesions	I
were	O
studied	O
histologically	O
.	O

Immunohistochemical	O
staining	O
for	O
AGA	O
was	O
performed	O
on	O
15	O
oral	O
specimens	O
.	O

Skin	O
was	O
seborrhoeic	O
in	O
adolescent	O
and	O
adult	O
patients	O
,	O
with	O
erythema	B
of	I
the	I
facial	I
skin	I
already	O
common	O
in	O
childhood	O
.	O

Of	O
44	O
patients	O
,	O
nine	O
(	O
20	O
%	O
)	O
had	O
facial	B
angiofibromas	I
,	O
tumours	B
primarily	O
occurring	O
in	O
association	O
with	O
tuberous	B
sclerosis	I
.	O

Oedemic	B
buccal	I
mucosa	I
(	O
leucoedema	B
)	O
and	O
gingival	B
overgrowths	I
were	O
more	O
frequent	O
in	O
AGU	B
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Of	O
16	O
oral	B
mucosal	I
lesions	I
studied	O
histologically	O
,	O
15	O
represented	O
fibroepithelial	B
or	I
epithelial	I
hyperplasias	I
and	O
were	O
reactive	O
in	O
nature	O
.	O

Cytoplasmic	O
vacuolisation	O
was	O
evident	O
in	O
four	O
.	O

Immunohistochemically	O
,	O
expression	O
of	O
AGA	O
in	O
AGU	B
patients	O
mucosal	B
lesions	I
did	O
not	O
differ	O
from	O
that	O
seen	O
in	O
corresponding	O
lesions	O
of	O
normal	O
subjects	O
.	O

Thus	O
,	O
the	O
high	O
frequency	O
of	O
mucosal	B
overgrowth	I
in	O
AGU	B
patients	O
does	O
not	O
appear	O
to	O
be	O
directly	O
associated	O
with	O
lysosomal	O
storage	O
or	O
with	O
alterations	O
in	O
the	O
level	O
of	O
AGA	O
expression	O
.	O

Sulfate	O
transport	O
is	O
not	O
impaired	O
in	O
pendred	B
syndrome	I
thyrocytes	O
.	O

Pendred	B
syndrome	I
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B
deafness	I
,	O
characterized	O
by	O
dyshormonogenic	B
goiter	I
associated	O
with	O
sensory	B
-	I
neural	I
deafness	I
.	O

The	O
gene	O
responsible	O
for	O
the	O
disease	O
(	O
PDS	B
)	O
has	O
been	O
cloned	O
,	O
but	O
its	O
function	O
is	O
as	O
yet	O
unknown	O
and	O
the	O
connection	O
between	O
thyroid	B
goiter	I
and	O
sensory	B
-	I
neural	I
deafness	I
remains	O
an	O
enigma	O
.	O

PDS	O
codes	O
for	O
a	O
novel	O
protein	O
,	O
pendrin	O
,	O
which	O
is	O
closely	O
related	O
to	O
a	O
number	O
of	O
sufate	O
transporters	O
.	O

Mechanisms	O
by	O
which	O
abnormal	O
sulfate	O
transport	O
could	O
deleteriously	O
affect	O
iodide	O
organification	O
have	O
been	O
proposed	O
.	O

We	O
tested	O
sulfate	O
transport	O
in	O
thyrocytes	O
obtained	O
from	O
Pendred	B
syndrome	I
patients	O
and	O
found	O
that	O
it	O
was	O
not	O
defective	O
.	O

This	O
suggests	O
that	O
pendrin	O
in	O
fact	O
may	O
not	O
be	O
a	O
sulfate	O
transporter	O
,	O
and	O
emphasizes	O
the	O
importance	O
of	O
functional	O
studies	O
on	O
this	O
novel	O
protein	O
..	O

Mutational	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
Finnish	O
alkaptonuria	B
patients	O
.	O

Alkaptonuria	B
(	O
AKU	B
)	O
,	O
the	O
prototypic	O
inborn	B
error	I
of	I
metabolism	I
,	O
has	O
recently	O
been	O
shown	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
homogentisate-1	O
,	O
2-dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O

So	O
far	O
17	O
mutations	O
have	O
been	O
characterised	O
in	O
AKU	B
patients	O
of	O
different	O
ethnic	O
origin	O
.	O

We	O
describe	O
three	O
novel	O
mutations	O
(	O
R58fs	O
,	O
R330S	O
,	O
and	O
H371R	O
)	O
and	O
one	O
common	O
AKU	B
mutation	O
(	O
M368V	O
)	O
,	O
detected	O
by	O
mutational	O
and	O
polymorphism	O
analysis	O
of	O
the	O
HGO	O
gene	O
in	O
five	O
Finnish	O
AKU	B
pedigrees	O
.	O

The	O
three	O
novel	O
AKU	B
mutations	O
are	O
most	O
likely	O
specific	O
for	O
the	O
Finnish	O
population	O
and	O
have	O
originated	O
recently	O
..	O

Genetic	O
analysis	O
,	O
phenotypic	O
diagnosis	O
,	O
and	O
risk	O
of	O
venous	B
thrombosis	I
in	O
families	O
with	O
inherited	O
deficiencies	B
of	I
protein	I
S.	I
Protein	B
S	I
deficiency	I
is	O
a	O
recognized	O
risk	O
factor	O
for	O
venous	B
thrombosis	I
.	O

Of	O
all	O
the	O
inherited	O
thrombophilic	B
conditions	I
,	O
it	O
remains	O
the	O
most	O
difficult	O
to	O
diagnose	O
because	O
of	O
phenotypic	O
variability	O
,	O
which	O
can	O
lead	O
to	O
inconclusive	O
results	O
.	O

We	O
have	O
overcome	O
this	O
problem	O
by	O
studying	O
a	O
cohort	O
of	O
patients	O
from	O
a	O
single	O
center	O
where	O
the	O
diagnosis	O
was	O
confirmed	O
at	O
the	O
genetic	O
level	O
.	O

Twenty	O
-	O
eight	O
index	O
patients	O
with	O
protein	B
S	I
deficiency	I
and	O
a	O
PROS1	B
gene	I
defect	I
were	O
studied	O
,	O
together	O
with	O
109	O
first	O
-	O
degree	O
relatives	O
.	O

To	O
avoid	O
selection	O
bias	O
,	O
we	O
confined	O
analysis	O
of	O
total	O
and	O
free	O
protein	O
S	O
levels	O
and	O
thrombotic	O
risk	O
to	O
the	O
patients	O
relatives	O
.	O

In	O
this	O
group	O
of	O
relatives	O
,	O
a	O
low	O
free	O
protein	O
S	O
level	O
was	O
the	O
most	O
reliable	O
predictor	O
of	O
a	O
PROS1	B
gene	I
defect	I
(	O
sensitivity	O
97	O
.	O
7	O
%	O
,	O
specificity	O
100	O
%	O
)	O
.	O

First	O
-	O
degree	O
relatives	O
with	O
a	O
PROS1	B
gene	I
defect	I
had	O
a	O
5	O
.	O

0-fold	O
higher	O
risk	O
of	O
thrombosis	B
(	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
5	O
-	O
16	O
.	O

8)	O
than	O
those	O
with	O
a	O
normal	O
PROS1	O
gene	O
and	O
no	O
other	O
recognized	O
thrombophilic	B
defect	I
.	O

Although	O
pregnancy	O
/	O
puerperium	O
and	O
immobility	O
/	O
trauma	B
were	O
important	O
precipitating	O
factors	O
for	O
thrombosis	B
,	O
almost	O
half	O
of	O
the	O
events	O
were	O
spontaneous	O
.	O

Relatives	O
with	O
splice	O
-	O
site	O
or	O
major	O
structural	O
defects	B
in	I
the	I
PROS1	I
gene	I
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
thrombotic	O
event	O
and	O
had	O
significantly	O
lower	O
total	O
and	O
free	O
protein	O
S	O
levels	O
than	O
those	O
relatives	O
having	O
missense	O
mutations	O
.	O

We	O
conclude	O
that	O
persons	O
with	O
PROS1	B
gene	I
defects	I
and	O
protein	B
S	I
deficiency	I
are	O
at	O
increased	O
risk	O
of	O
thrombosis	B
and	O
that	O
free	O
protein	O
S	O
estimation	O
offers	O
the	O
most	O
reliable	O
way	O
of	O
diagnosing	O
the	O
deficiency	O
.	O

(	O
Blood	O
.	O

2000	O
;	O
95	O
1935	O
-	O
1941	O
)	O
.	O

Autoinhibition	O
and	O
activation	O
mechanisms	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
.	O

The	O
Rho	O
-	O
family	O
GTPase	O
,	O
Cdc42	O
,	O
can	O
regulate	O
the	O
actin	O
cytoskeleton	O
through	O
activation	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
family	O
members	O
.	O

Activation	O
relieves	O
an	O
autoinhibitory	O
contact	O
between	O
the	O
GTPase	O
-	O
binding	O
domain	O
and	O
the	O
carboxy	O
-	O
terminal	O
region	O
of	O
WASP	O
proteins	O
.	O

Here	O
we	O
report	O
the	O
autoinhibited	O
structure	O
of	O
the	O
GTPase	O
-	O
binding	O
domain	O
of	O
WASP	O
,	O
which	O
can	O
be	O
induced	O
by	O
the	O
C	O
-	O
terminal	O
region	O
or	O
by	O
organic	O
co	O
-	O
solvents	O
.	O

In	O
the	O
autoinhibited	O
complex	O
,	O
intramolecular	O
interactions	O
with	O
the	O
GTPase	O
-	O
binding	O
domain	O
occlude	O
residues	O
of	O
the	O
C	O
terminus	O
that	O
regulate	O
the	O
Arp2	O
/	O
3	O
actin	O
-	O
nucleating	O
complex	O
.	O

Binding	O
of	O
Cdc42	O
to	O
the	O
GTPase	O
-	O
binding	O
domain	O
causes	O
a	O
dramatic	O
conformational	O
change	O
,	O
resulting	O
in	O
disruption	O
of	O
the	O
hydrophobic	O
core	O
and	O
release	O
of	O
the	O
C	O
terminus	O
,	O
enabling	O
its	O
interaction	O
with	O
the	O
actin	O
regulatory	O
machinery	O
.	O

These	O
data	O
show	O
that	O
intrinsically	O
unstructured	O
peptides	O
such	O
as	O
the	O
GTPase	O
-	O
binding	O
domain	O
of	O
WASP	O
can	O
be	O
induced	O
into	O
distinct	O
structural	O
and	O
functional	O
states	O
depending	O
on	O
context	O
..	O

Locus	O
heterogeneity	O
in	O
Friedreich	B
ataxia	I
.	O

Friedreich	B
ataxia	I
(	O
FRDA	B
)	O
is	O
the	O
most	O
common	O
form	O
of	O
autosomal	B
recessive	I
ataxia	I
.	O

The	O
disease	O
locus	O
was	O
assigned	O
to	O
chromosome	O
9	O
and	O
the	O
disease	O
gene	O
,	O
STM7	O
/	O
X25	O
,	O
has	O
been	O
isolated	O
.	O

To	O
date	O
most	O
data	O
suggest	O
locus	O
homogeneity	O
in	O
FRDA	B
.	O

We	O
now	O
provide	O
strong	O
evidence	O
of	O
a	O
second	O
FRDA	B
locus	O
.	O

Studying	O
two	O
siblings	O
with	O
FRDA	B
from	O
two	O
families	O
we	O
did	O
not	O
detect	O
a	O
mutation	O
in	O
STM7	O
/	O
X25	O
.	O

Haplotype	O
analysis	O
of	O
the	O
STM7	O
/	O
X25	O
region	O
of	O
chromosome	O
9	O
demonstrated	O
that	O
the	O
relevant	O
portion	O
of	O
chromosome	O
9	O
differs	O
in	O
the	O
patients	O
.	O

Although	O
the	O
patients	O
studied	O
had	O
typical	O
FRDA	B
,	O
one	O
sibpair	O
had	O
the	O
uncommon	O
symptom	O
of	O
retained	O
tendon	O
reflexes	O
.	O

In	O
order	O
to	O
investigate	O
whether	O
retained	O
tendon	O
reflexes	O
are	O
characteristic	O
of	O
FRDA	B
caused	O
by	O
the	O
second	O
locus	O
,	O
FRDA2	O
,	O
we	O
studied	O
an	O
unrelated	O
FRDA	B
patient	O
with	O
retained	O
tendon	O
reflexes	O
.	O

The	O
observation	O
of	O
typical	O
mutations	O
in	O
STM7	O
/	O
X25	O
(	O
GAA	O
expansions	O
)	O
in	O
this	O
patient	O
demonstrates	O
that	O
the	O
two	O
genetically	O
different	O
forms	O
of	O
FRDA	B
can	O
not	O
be	O
distinguished	O
clinically	O
..	O

Restoration	O
of	O
photoreceptor	O
ultrastructure	O
and	O
function	O
in	O
retinal	B
degeneration	I
slow	O
mice	O
by	O
gene	O
therapy	O
.	O

The	O
gene	O
Prph2	O
encodes	O
a	O
photoreceptor	O
-	O
specific	O
membrane	O
glycoprotein	O
,	O
peripherin-2	O
(	O
also	O
known	O
as	O
peripherin	O
/	O
rds	O
)	O
,	O
which	O
is	O
inserted	O
into	O
the	O
rims	O
of	O
photoreceptor	O
outer	O
segment	O
discs	O
in	O
a	O
complex	O
with	O
rom-1	O
(	O
ref	O
.	O

2	O
)	O
.	O

The	O
complex	O
is	O
necessary	O
for	O
the	O
stabilization	O
of	O
the	O
discs	O
,	O
which	O
are	O
renewed	O
constantly	O
throughout	O
life	O
,	O
and	O
which	O
contain	O
the	O
visual	O
pigments	O
necessary	O
for	O
photon	O
capture	O
.	O

Mutations	O
in	O
Prph2	O
have	O
been	O
shown	O
to	O
result	O
in	O
a	O
variety	O
of	O
photoreceptor	B
dystrophies	I
,	O
including	O
autosomal	B
dominant	I
retinitis	I
pigmentosa	I
and	O
macular	B
dystrophy	I
.	O

A	O
common	O
feature	O
of	O
these	O
diseases	O
is	O
the	O
loss	O
of	O
photoreceptor	O
function	O
,	O
also	O
seen	O
in	O
the	O
retinal	B
degeneration	I
slow	O
(	O
rds	O
or	O
Prph2	O
Rd2	O
/	O
Rd2	O
)	O
mouse	O
,	O
which	O
is	O
homozygous	O
for	O
a	O
null	O
mutation	O
in	O
Prph2	O
.	O

It	O
is	O
characterized	O
by	O
a	O
complete	O
failure	O
to	O
develop	O
photoreceptor	O
discs	O
and	O
outer	O
segments	O
,	O
downregulation	O
of	O
rhodopsin	O
and	O
apoptotic	O
loss	O
of	O
photoreceptor	O
cells	O
.	O

The	O
electroretinograms	O
(	O
ERGs	O
)	O
of	O
Prph2Rd2	O
/	O
Rd2	O
mice	O
have	O
greatly	O
diminished	O
a	O
-	O
wave	O
and	O
b	O
-	O
wave	O
amplitudes	O
,	O
which	O
decline	O
to	O
virtually	O
undetectable	O
concentrations	O
by	O
two	O
months	O
.	O

Subretinal	O
injection	O
of	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
encoding	O
a	O
Prph2	O
transgene	O
results	O
in	O
stable	O
generation	O
of	O
outer	O
segment	O
structures	O
and	O
formation	O
of	O
new	O
stacks	O
of	O
discs	O
containing	O
both	O
perpherin-2	O
and	O
rhodopsin	O
,	O
which	O
in	O
many	O
cases	O
are	O
morphologically	O
similar	O
to	O
normal	O
outer	O
segments	O
.	O

Moreover	O
,	O
the	O
re	O
-	O
establishment	O
of	O
the	O
structural	O
integrity	O
of	O
the	O
photoreceptor	O
layer	O
also	O
results	O
in	O
electrophysiological	O
correction	O
.	O

These	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
complex	O
ultrastructural	O
cell	O
defect	O
can	O
be	O
corrected	O
both	O
morphologically	O
and	O
functionally	O
by	O
in	O
vivo	O
gene	O
transfer	O
..	O

Function	O
of	O
an	O
axonal	O
chemoattractant	O
modulated	O
by	O
metalloprotease	O
activity	O
.	O

The	O
axonal	O
chemoattractant	O
netrin-1	O
guides	O
spinal	O
commissural	O
axons	O
by	O
activating	O
its	O
receptor	O
DCC	O
(	O
Deleted	O
in	O
Colorectal	B
Cancer	I
)	O
.	O

We	O
have	O
found	O
that	O
chemical	O
inhibitors	O
of	O
metalloproteases	O
potentiate	O
netrin	O
-	O
mediated	O
axon	O
outgrowth	O
in	O
vitro	O
.	O

We	O
have	O
also	O
found	O
that	O
DCC	O
is	O
a	O
substrate	O
for	O
metalloprotease	O
-	O
dependent	O
ectodomain	O
shedding	O
,	O
and	O
that	O
the	O
inhibitors	O
block	O
proteolytic	O
processing	O
of	O
DCC	O
and	O
cause	O
an	O
increase	O
in	O
DCC	O
protein	O
levels	O
on	O
axons	O
within	O
spinal	O
cord	O
explants	O
.	O

Thus	O
,	O
potentiation	O
of	O
netrin	O
activity	O
by	O
inhibitors	O
may	O
result	O
from	O
stabilization	O
of	O
DCC	O
on	O
the	O
axons	O
,	O
and	O
proteolytic	O
activity	O
may	O
regulate	O
axon	O
migration	O
by	O
controlling	O
the	O
number	O
of	O
functional	O
extracellular	O
axon	O
guidance	O
receptors	O
..	O

Myotonic	B
dystrophy	I
in	O
transgenic	O
mice	O
expressing	O
an	O
expanded	O
CUG	O
repeat	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
the	O
most	O
common	O
form	O
of	O
muscular	B
dystrophy	I
in	O
adult	O
humans	O
,	O
results	O
from	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
gene	O
.	O

The	O
mutant	O
DMPK	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
contains	O
an	O
expanded	O
CUG	O
repeat	O
and	O
is	O
retained	O
in	O
the	O
nucleus	O
.	O

We	O
have	O
expressed	O
an	O
untranslated	O
CUG	O
repeat	O
in	O
an	O
unrelated	O
mRNA	O
in	O
transgenic	O
mice	O
.	O

Mice	O
that	O
expressed	O
expanded	O
CUG	O
repeats	O
developed	O
myotonia	B
and	O
myopathy	B
,	O
whereas	O
mice	O
expressing	O
a	O
nonexpanded	O
repeat	O
did	O
not	O
.	O

Thus	O
,	O
transcripts	O
with	O
expanded	O
CUG	O
repeats	O
are	O
sufficient	O
to	O
generate	O
a	O
DM	B
phenotype	O
.	O

This	O
result	O
supports	O
a	O
role	O
for	O
RNA	O
gain	O
of	O
function	O
in	O
disease	O
pathogenesis	O
..	O

Malignant	B
neoplasms	I
in	O
the	O
families	O
of	O
patients	O
with	O
ataxia	B
-	I
telangiectasia	I
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
is	O
an	O
autosomal	B
recessive	I
syndrome	I
associated	O
with	O
a	O
greatly	O
increased	O
incidence	O
of	O
malignant	B
neoplasms	I
in	O
homozygous	O
affected	O
individuals	O
.	O

Heterozygotes	O
for	O
the	O
gene	O
for	O
A	B
-	I
T	I
are	O
thought	O
to	O
comprise	O
about	O
1	O
%	O
of	O
the	O
general	O
population	O
and	O
,	O
therefore	O
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
this	O
gene	O
also	O
predisposes	O
the	O
heterozygous	O
carrier	O
to	O
cancers	B
.	O

Heterozygous	O
carriers	O
of	O
this	O
gene	O
are	O
common	O
among	O
the	O
close	O
relatives	O
of	O
patients	O
with	O
A	B
-	I
T	I
,	O
although	O
individual	O
carriers	O
can	O
not	O
be	O
identified	O
by	O
any	O
clinical	O
criterion	O
or	O
laboratory	O
test	O
.	O

For	O
this	O
reason	O
,	O
we	O
compared	O
the	O
incidence	O
of	O
death	O
from	O
malignant	B
neoplasms	I
in	O
2	O
families	O
of	O
patients	O
with	O
A	B
-	I
T	I
to	O
that	O
expected	O
in	O
a	O
random	O
sample	O
of	O
the	O
general	O
population	O
.	O

There	O
were	O
59	O
deaths	O
from	O
malignant	B
neoplasms	I
in	O
relatives	O
dying	O
before	O
age	O
75	O
,	O
compared	O
to	O
42	O
.	O

6	O
expected	O
(	O
p	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

For	O
A	B
-	I
T	I
heterozygotes	O
younger	O
than	O
age	O
45	O
,	O
the	O
risk	O
of	O
dying	O
from	O
a	O
malignant	B
neoplasm	I
was	O
estimated	O
to	O
be	O
greater	O
than	O
5	O
times	O
the	O
risk	O
for	O
the	O
general	O
population	O
.	O

A	B
-	I
T	I
heterozygotes	O
may	O
comprise	O
more	O
than	O
5	O
%	O
of	O
all	O
persons	O
dying	O
from	O
a	O
cancer	B
before	O
age	O
45	O
.	O

The	O
incidence	O
of	O
ovarian	B
,	I
gastric	I
,	I
and	I
biliary	I
system	I
carcinomas	I
and	O
of	O
leukemia	B
and	O
lymphoma	B
was	O
increased	O
in	O
these	O
A	B
-	I
T	I
families	O
.	O

Other	O
neoplasms	B
that	O
may	O
be	O
associated	O
with	O
this	O
gene	O
in	O
heterozygotes	O
include	O
pancreatic	B
,	I
basal	I
cell	I
,	I
colonic	I
,	I
breast	I
,	I
and	I
cervical	I
carcinomas	I
.	O

Analbuminemia	B
in	O
an	O
American	O
Indian	O
girl	O
.	O

Analbuminemia	B
was	O
fortuitously	O
detected	O
in	O
a	O
nonedematous	O
12-year	O
-	O
old	O
American	O
Indian	O
girl	O
with	O
atopic	B
dermatitis	I
,	O
mild	O
bronchial	B
asthma	I
,	O
a	O
mild	O
seizure	B
disorder	I
,	O
and	O
hyperlipoproteinemia	B
with	O
a	O
corneal	B
arcus	I
.	O

Immunologic	O
methods	O
revealed	O
trace	O
amounts	O
(	O
17	O
mg	O
/	O
100	O
ml	O
)	O
of	O
apparently	O
normal	O
serum	O
albumin	O
.	O

The	O
patients	O
parents	O
were	O
remotely	O
related	O
.	O

The	O
pedigree	O
and	O
clinical	O
findings	O
were	O
compatible	O
with	O
autosomal	O
recessive	O
transmission	O
of	O
analbuminemia	B
.	O

Heterozygotes	O
had	O
subnormal	O
levels	O
of	O
serum	O
albumin	O
.	O

The	O
Gc	O
-	O
locus	O
is	O
closely	O
linked	O
to	O
the	O
structural	O
albumin	O
locus	O
.	O

Gc	O
-	O
protein	O
levels	O
were	O
normal	O
in	O
the	O
patient	O
and	O
together	O
with	O
normal	O
chromosomal	O
banding	O
studies	O
make	O
it	O
unlikely	O
that	O
a	O
chromosomal	O
deletion	O
caused	O
analbuminemia	B
.	O

Gc	O
-	O
types	O
in	O
the	O
family	O
were	O
compatible	O
with	O
,	O
but	O
did	O
not	O
prove	O
,	O
linkage	O
of	O
analbuminemia	B
to	O
the	O
Gc	O
-	O
locus	O
.	O

These	O
findings	O
suggest	O
a	O
""""	O
thalassemia	B
""""	O
-like	O
mutation	O
for	O
this	O
disorder	O
..	O

Detection	O
of	O
a	O
nonsense	O
mutation	O
in	O
the	O
dystrophin	O
gene	O
by	O
multiple	O
SSCP	O
.	O

A	O
combination	O
of	O
multiplex	O
PCR	O
with	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
was	O
employed	O
to	O
screen	O
for	O
point	O
mutations	O
in	O
the	O
human	O
dystrophin	O
gene	O
.	O

Co	O
-	O
amplification	O
of	O
11	O
exons	O
from	O
genomic	O
DNA	O
of	O
Duchenne	B
and	I
Becker	I
muscular	I
dystrophy	I
(	O
DMD	B
/	O
BMD	B
)	O
patients	O
with	O
no	O
deletion	O
or	O
duplication	O
was	O
performed	O
and	O
the	O
samples	O
subjected	O
to	O
multiple	O
SSCP	O
analysis	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
nonsense	O
mutation	O
in	O
a	O
Duchenne	B
patient	O
identified	O
by	O
this	O
approach	O
.	O

The	O
mutation	O
introduces	O
a	O
termination	O
codon	O
within	O
exon	O
8	O
of	O
the	O
dystrophin	O
gene	O
.	O

It	O
is	O
predicted	O
to	O
cause	O
a	O
very	O
premature	O
translational	O
termination	O
accounting	O
for	O
the	O
severe	O
phenotype	O
observed	O
.	O

The	O
patient	O
inherited	O
this	O
mutation	O
from	O
his	O
mother	O
.	O

In	O
addition	O
the	O
analysis	O
revealed	O
5	O
polymorphisms	O
useful	O
for	O
internal	O
control	O
..	O

Linkage	O
of	O
gene	O
for	O
C2	B
deficiency	I
and	O
the	O
major	O
histocompatibility	O
complex	O
MHC	O
in	O
man	O
.	O

Family	O
study	O
of	O
a	O
further	O
case	O
.	O

Close	O
linkage	O
between	O
HL	O
-	O
A	O
and	O
C2	B
deficiency	I
was	O
first	O
reported	O
by	O
FU	O
and	O
co	O
-	O
workers	O
in	O
1974	O
.	O

We	O
present	O
here	O
a	O
pedigree	O
of	O
a	O
31-year	O
-	O
old	O
C2-deficient	B
individual	O
with	O
clinical	O
manifestations	O
of	O
Hodgkins	B
disease	I
.	O

The	O
following	O
markers	O
were	O
tested	O
C2	O
levels	O
,	O
factor	O
B	O
polymorphism	O
,	O
blood	O
groups	O
,	O
and	O
enzyme	O
typing	O
.	O

In	O
addition	O
to	O
close	O
linkage	O
between	O
HL	O
-	O
A	O
and	O
C2	B
deficiency	I
,	O
both	O
parents	O
were	O
heterozygous	O
for	O
Bf	O
(	O
HL	O
-	O
A	O
linked	O
,	O
electrophoretic	O
variation	O
of	O
B	O
)	O
.	O

The	O
two	O
HL	O
-	O
A	O
haplotypes	O
closely	O
linked	O
to	O
C2	B
deficiency	I
are	O
different	O
2	O
,	O
W18	O
and	O
W24	O
,	O
W18	O
.	O

They	O
share	O
,	O
however	O
,	O
the	O
SD2	O
antigen	O
W18	O
and	O
the	O
LD	O
type	O
7a	O
..	O

Late	O
-	O
onset	O
metachromatic	B
leukodystrophy	I
:	O
molecular	O
pathology	O
in	O
two	O
siblings	O
.	O

We	O
report	O
on	O
a	O
new	O
allele	O
at	O
the	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
locus	O
causing	O
late	O
-	O
onset	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

In	O
that	O
allele	O
arginine84	O
,	O
a	O
residue	O
that	O
is	O
highly	O
conserved	O
in	O
the	O
arylsulfatase	O
gene	O
family	O
,	O
is	O
replaced	O
by	O
glutamine	O
.	O

In	O
contrast	O
to	O
alleles	O
that	O
cause	O
early	O
-	O
onset	O
MLD	B
,	O
the	O
arginine84	O
to	O
glutamine	O
substitution	O
is	O
associated	O
with	O
some	O
residual	O
ARSA	O
activity	O
.	O

A	O
comparison	O
of	O
genotypes	O
,	O
ARSA	O
activities	O
,	O
and	O
clinical	O
data	O
on	O
4	O
individuals	O
carrying	O
the	O
allele	O
of	O
81	O
patients	O
with	O
MLD	B
examined	O
,	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	O
ARSA	O
activity	O
are	O
the	O
basis	O
of	O
phenotypical	O
variation	O
in	O
MLD	B
..	O

Trisomy	B
15	I
with	O
loss	O
of	O
the	O
paternal	O
15	O
as	O
a	O
cause	O
of	O
Prader	B
-	I
Willi	I
syndrome	I
due	O
to	O
maternal	B
disomy	I
.	O

Uniparental	B
disomy	I
has	O
recently	O
been	O
recognized	O
to	O
cause	O
human	O
disorders	O
,	O
including	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
describe	O
a	O
particularly	O
instructive	O
case	O
which	O
raises	O
important	O
issues	O
concerning	O
the	O
mechanisms	O
producing	O
uniparental	B
disomy	I
and	O
whose	O
evaluation	O
provides	O
evidence	O
that	O
trisomy	O
may	O
precede	O
uniparental	B
disomy	I
in	O
a	O
fetus	O
.	O

Chorionic	O
villus	O
sampling	O
performed	O
for	O
advanced	O
maternal	O
age	O
revealed	O
trisomy	B
15	I
in	O
all	O
direct	O
and	O
cultured	O
cells	O
,	O
though	O
the	O
fetus	O
appeared	O
normal	O
.	O

Chromosome	O
analysis	O
of	O
amniocytes	O
obtained	O
at	O
15	O
wk	O
was	O
normal	O
in	O
over	O
100	O
cells	O
studied	O
.	O

The	O
child	O
was	O
hypotonic	B
at	O
birth	O
,	O
and	O
high	O
-	O
resolution	O
banding	O
failed	O
to	O
reveal	O
the	O
deletion	O
of	O
15q11	O
-	O
13	O
,	O
a	O
deletion	O
which	O
is	O
found	O
in	O
50	O
%	O
-70	O
%	O
of	O
patients	O
with	O
PWS	B
.	O

Over	O
time	O
,	O
typical	O
features	O
of	O
PWS	B
developed	O
.	O

Molecular	O
genetic	O
analysis	O
using	O
probes	O
for	O
chromosome	O
15	O
revealed	O
maternal	O
disomy	O
.	O

Maternal	O
nondisjunction	O
with	O
fertilization	O
of	O
a	O
disomic	O
egg	O
by	O
a	O
normal	O
sperm	O
,	O
followed	O
by	O
loss	O
of	O
the	O
paternal	O
15	O
,	O
is	O
a	O
likely	O
cause	O
of	O
confined	O
placental	O
mosaicism	O
and	O
uniparental	B
disomy	I
in	O
this	O
case	O
of	O
PWS	B
,	O
and	O
advanced	O
maternal	O
age	O
may	O
be	O
a	O
predisposing	O
factor	O
..	O

Genetic	O
heterogeneity	O
in	O
X	B
-	I
linked	I
amelogenesis	I
imperfecta	I
.	O

The	O
AMELX	O
gene	O
located	O
at	O
Xp22	O
.	O

1-p22	O
.	O

3	O
encodes	O
for	O
the	O
enamel	O
protein	O
amelogenin	O
and	O
has	O
been	O
implicated	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
inherited	B
dental	I
abnormality	I
X	B
-	I
linked	I
amelogenesis	I
imperfecta	I
(	O
XAI	B
)	O
.	O

Three	O
families	O
with	O
XAI	B
have	O
been	O
investigated	O
using	O
polymorphic	O
DNA	O
markers	O
flanking	O
the	O
position	O
of	O
AMELX	O
.	O

Using	O
two	O
-	O
point	O
linkage	O
analysis	O
,	O
linkage	O
was	O
established	O
between	O
XAI	B
and	O
several	O
of	O
these	O
markers	O
in	O
two	O
families	O
,	O
with	O
a	O
combined	O
lod	O
score	O
of	O
6	O
.	O

05	O
for	O
DXS16	O
at	O
theta	O
=	O
0	O
.	O
04	O
04	O
.	O

This	O
supports	O
the	O
involvement	O
of	O
AMELX	O
,	O
located	O
close	O
to	O
DXS16	O
,	O
in	O
the	O
XAI	B
disease	I
process	O
(	O
AIH1	O
)	O
in	O
those	O
families	O
.	O

Using	O
multipoint	O
linkage	O
analysis	O
,	O
the	O
combined	O
maximum	O
lod	O
score	O
for	O
these	O
two	O
families	O
was	O
7	O
.	O
30	O
for	O
a	O
location	O
of	O
AIH1	O
at	O
2	O
cM	O
distal	O
to	O
DXS16	O
.	O

The	O
support	O
interval	O
around	O
this	O
location	O
extended	O
about	O
8	O
cM	O
proximal	O
to	O
DXS92	O
,	O
and	O
the	O
AIH1	O
location	O
could	O
not	O
be	O
precisely	O
defined	O
by	O
multipoint	O
mapping	O
.	O

Study	O
of	O
recombination	O
events	O
indicated	O
that	O
AIH1	O
lies	O
in	O
the	O
interval	O
between	O
DXS143	O
and	O
DXS85	O
.	O

There	O
was	O
significant	O
evidence	O
against	O
linkage	O
to	O
this	O
region	O
in	O
the	O
third	O
family	O
,	O
indicating	O
locus	O
heterogeneity	O
in	O
XAI	B
.	O

Further	O
analysis	O
with	O
markers	O
on	O
the	O
long	O
arm	O
of	O
the	O
X	O
chromosome	O
showed	O
evidence	O
of	O
linkage	O
to	O
DXS144E	O
and	O
F9	O
with	O
no	O
recombination	O
with	O
either	O
of	O
these	O
markers	O
.	O

Two	O
-	O
point	O
analysis	O
gave	O
a	O
peak	O
lod	O
score	O
at	O
DXS144E	O
with	O
a	O
maximum	O
lod	O
score	O
of	O
2	O
.	O

83	O
at	O
theta	O
=	O
0	O
,	O
with	O
a	O
peak	O
lod	O
score	O
in	O
multipoint	O
linkage	O
analysis	O
of	O
2	O
.	O
84	O
at	O
theta	O
=	O
0	O
.	O

The	O
support	O
interval	O
extended	O
9	O
cM	O
proximal	O
to	O
DXS144E	O
and	O
14	O
cM	O
distal	O
to	O
F9	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

Typical	O
and	O
partial	O
cat	B
eye	I
syndrome	I
:	O
identification	O
of	O
the	O
marker	O
chromosome	O
by	O
FISH	O
.	O

Three	O
children	O
are	O
reported	O
with	O
typical	O
cat	B
eye	I
syndrome	I
(	O
CES	B
)	O
and	O
three	O
more	O
children	O
with	O
partial	O
CES	B
because	O
of	O
absence	O
of	O
coloboma	O
,	O
in	O
which	O
the	O
supernumerary	O
marker	O
chromosome	O
was	O
studied	O
by	O
FISH	O
.	O

Using	O
a	O
genomic	O
library	O
,	O
and	O
also	O
a	O
centromeric	O
and	O
particularly	O
a	O
cosmid	O
probe	O
of	O
22q11	O
,	O
partial	O
tetrasomy	B
was	O
shown	O
in	O
all	O
cases	O
..	O

Linkage	O
analysis	O
in	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
and	O
application	O
in	O
post-	O
and	O
prenatal	O
diagnosis	O
.	O

We	O
have	O
performed	O
linkage	O
analysis	O
with	O
the	O
DNA	O
markers	O
DXS52	O
and	O
the	O
clotting	O
factor	O
VIII	O
gene	O
(	O
F8C	O
)	O
,	O
in	O
several	O
large	O
families	O
with	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
.	O

The	O
tight	O
linkage	O
to	O
DXS52	O
could	O
be	O
extended	O
giving	O
a	O
maximal	O
LOD	O
score	O
of	O
22	O
.	O

5	O
at	O
1	O
cM.	O
F8C	O
was	O
also	O
tightly	O
linked	O
to	O
ALD	B
with	O
a	O
maximal	O
LOD	O
score	O
of	O
7	O
.	O
8	O
without	O
recombination	O
.	O

Multipoint	O
linkage	O
analysis	O
with	O
the	O
markers	O
DXS304	O
,	O
DXS52	O
,	O
and	O
F8C	O
indicated	O
that	O
both	O
the	O
gene	O
for	O
ALD	B
and	O
for	O
F8C	O
are	O
distal	O
to	O
DXS52	O
.	O

In	O
four	O
patients	O
with	O
ALD	B
,	O
no	O
major	O
structural	O
rearrangement	O
in	O
the	O
Xqter	O
region	O
was	O
observed	O
;	O
in	O
particular	O
,	O
there	O
were	O
no	O
abnormalities	B
in	I
the	I
vision	I
blindness	I
genes	I
.	O

DNA	O
analysis	O
appeared	O
to	O
be	O
of	O
use	O
in	O
determination	O
of	O
the	O
carrier	O
status	O
of	O
females	O
at	O
risk	O
,	O
for	O
the	O
determination	O
of	O
the	O
origin	O
of	O
the	O
mutation	O
in	O
a	O
particular	O
family	O
,	O
and	O
for	O
prenatal	O
diagnosis	O
.	O

Huntington	B
disease	I
and	O
childhood	O
-	O
onset	O
Tourette	B
syndrome	I
.	O

A	O
40-year	O
-	O
old	O
man	O
with	O
childhood	O
-	O
onset	O
Tourette	B
syndrome	I
(	O
TS	B
)	O
developed	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

We	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
childhood	O
-	O
onset	O
TS	B
with	O
adult	O
onset	O
HD	B
.	O

Discovery	O
of	O
other	O
cases	O
with	O
both	O
disorders	O
may	O
provide	O
clues	O
to	O
the	O
pathophysiology	O
of	O
both	O
conditions	O
..	O

Linkage	O
of	O
aspartylglucosaminuria	B
(	O
AGU	B
)	O
to	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
caused	O
by	O
deficient	O
activity	O
of	O
the	O
enzyme	O
aspartylglucosaminidase	O
(	O
AGA	O
)	O
.	O

The	O
structural	O
gene	O
for	O
AGA	O
has	O
been	O
assigned	O
to	O
the	O
region	O
4q21-qter	O
of	O
chromosome	O
4	O
.	O

We	O
have	O
studied	O
the	O
map	O
position	O
of	O
the	O
AGU	O
locus	O
in	O
relation	O
to	O
other	O
marker	O
loci	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
4	O
using	O
linkage	O
analyses	O
.	O

Restriction	O
fragment	O
length	O
polymorphism	O
alleles	O
for	O
the	O
ADH2	O
,	O
ADH3	O
,	O
EGF	O
,	O
FG	O
alpha	O
and	O
FG	O
beta	O
loci	O
and	O
blood	O
group	O
antigens	O
for	O
the	O
MNS	O
locus	O
were	O
determined	O
in	O
a	O
panel	O
of	O
12	O
Finnish	O
AGU	B
families	O
.	O

The	O
heterozygous	O
family	O
members	O
were	O
identified	O
by	O
reduced	O
activity	O
of	O
AGA	O
in	O
lymphocytes	O
.	O

Linkage	O
studies	O
were	O
performed	O
using	O
both	O
pairwise	O
and	O
multipoint	O
analyses	O
.	O

Loose	O
linkage	O
of	O
the	O
AGU	B
locus	O
to	O
the	O
FG	O
and	O
MNS	O
loci	O
was	O
observed	O
(	O
z	O
=	O
1	O
.	O
16	O
,	O
z	O
=	O
1	O
.	O
39	O
,	O
respectively	O
)	O
.	O

Multipoint	O
analysis	O
to	O
the	O
fixed	O
map	O
[	O
ADH-	O
(	O
0	O
.	O
03	O
)	O
-EGF-	O
(	O
0	O
.	O
35	O
)	O
-FG-	O
(	O
0	O
.	O
11	O
)	O
-MNS	O
]	O
suggests	O
that	O
the	O
location	O
of	O
the	O
AGU	O
locus	O
is	O
0	O
.	O
05	O
-	O
0	O
.	O
30	O
recombination	O
units	O
distal	O
to	O
MNS	O
(	O
z	O
=	O
3	O
.	O
03	O
)	O
.	O

The	O
order	O
cen	O
-	O
ADH	O
-	O
EGF	O
-	O
FG	O
-	O
MNS	O
-	O
AGU	O
is	O
35	O
times	O
more	O
likely	O
than	O
the	O
next	O
best	O
order	O
cen	O
-	O
ADH	O
-	O
EGF	O
-	O
AGU	O
-	O
FG	O
-	O
MNS	O
.	O

Detection	O
of	O
98	O
%	O
of	O
DMD	B
/	O
BMD	B
gene	O
deletions	O
by	O
polymerase	O
chain	O
reaction	O
.	O

We	O
describe	O
oligonucleotide	O
primer	O
sequences	O
that	O
can	O
be	O
used	O
to	O
amplify	O
eight	O
exons	O
plus	O
the	O
muscle	O
promoter	O
of	O
the	O
dystrophin	O
gene	O
in	O
a	O
single	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

When	O
used	O
in	O
conjunction	O
with	O
an	O
existing	O
primer	O
set	O
,	O
these	O
two	O
multiplex	O
reactions	O
detect	O
about	O
98	O
%	O
of	O
deletions	O
in	O
patients	O
with	O
Duchenne	B
or	I
Becker	I
muscular	I
dystrophy	I
(	O
DMD	B
,	O
BMD	B
)	O
.	O

Furthermore	O
,	O
these	O
primers	O
amplify	O
most	O
of	O
the	O
exons	O
in	O
the	O
deletion	O
prone	O
""""	O
hot	O
spot	O
""""	O
region	O
around	O
exons	O
44	O
to	O
53	O
,	O
allowing	O
determination	O
of	O
deletion	O
endpoints	O
and	O
prediction	O
of	O
mutational	O
effects	O
on	O
the	O
translational	O
reading	O
frame	O
.	O

Thus	O
,	O
use	O
of	O
these	O
PCR	O
-	O
based	O
assays	O
will	O
allow	O
deletion	O
detection	O
and	O
prenatal	O
diagnosis	O
for	O
most	O
DMD	B
/	O
BMD	B
patients	O
in	O
a	O
fraction	O
of	O
the	O
time	O
required	O
for	O
Southern	O
blot	O
analysis	O
..	O

Statistical	O
analysis	O
of	O
the	O
two	O
stage	O
mutation	O
model	O
in	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
,	O
and	O
in	O
sporadic	B
cerebellar	I
haemangioblastoma	I
and	O
renal	B
cell	I
carcinoma	I
.	O

Analysis	O
of	O
the	O
age	O
incidence	O
curves	O
for	O
unilateral	B
and	I
bilateral	I
retinoblastoma	I
led	O
Knudson	O
to	O
propose	O
that	O
hereditary	B
tumours	I
may	O
arise	O
by	O
a	O
single	O
event	O
and	O
sporadic	B
tumours	I
by	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

It	O
has	O
been	O
suggested	O
recently	O
that	O
sporadic	B
renal	I
cell	I
carcinoma	I
may	O
arise	O
from	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

We	O
analysed	O
the	O
age	O
incidence	O
curves	O
for	O
symptomatic	O
renal	B
cell	I
carcinoma	I
(	O
n	O
=	O
26	O
)	O
and	O
cerebellar	B
haemangioblastoma	I
(	O
n	O
=	O
68	O
)	O
in	O
109	O
patients	O
with	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
,	O
and	O
compared	O
them	O
to	O
104	O
patients	O
with	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
43	O
patients	O
with	O
sporadic	B
cerebellar	I
haemangioblastoma	I
.	O

The	O
age	O
incidence	O
curves	O
for	O
renal	B
cell	I
carcinoma	I
and	O
cerebellar	B
haemangioblastoma	I
in	O
VHL	B
disease	I
were	O
compatible	O
with	O
a	O
single	O
mutation	O
model	O
,	O
whereas	O
the	O
age	O
incidence	O
curves	O
for	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
cerebellar	B
haemangioblastoma	I
suggested	O
a	O
two	O
stage	O
mutation	O
process	O
.	O

These	O
data	O
are	O
compatible	O
with	O
the	O
VHL	B
gene	O
functioning	O
as	O
a	O
recessive	O
tumour	B
suppressor	O
gene	O
.	O

Sporadic	B
cerebellar	I
haemangioblastoma	I
and	O
some	O
renal	B
cell	I
carcinoma	I
may	O
arise	O
from	O
somatic	O
mutations	O
inactivating	O
both	O
alleles	O
at	O
the	O
VHL	B
locus	O
..	O

Molecular	O
and	O
phenotypic	O
analysis	O
of	O
patients	O
with	O
deletions	O
within	O
the	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
.	O

Eighty	O
unrelated	O
individuals	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
or	O
Becker	B
muscular	I
dystrophy	I
(	O
BMD	B
)	O
were	O
found	O
to	O
have	O
deletions	O
in	O
the	O
major	O
deletion	O
-	O
rich	O
region	O
of	O
the	O
DMD	B
locus	O
.	O

This	O
region	O
includes	O
the	O
last	O
five	O
exons	O
detected	O
by	O
cDNA5b-7	O
,	O
all	O
exons	O
detected	O
by	O
cDNA8	O
,	O
and	O
the	O
first	O
two	O
exons	O
detected	O
by	O
cDNA9	O
.	O

These	O
80	O
individuals	O
account	O
for	O
approximately	O
75	O
%	O
of	O
109	O
deletions	O
of	O
the	O
gene	O
,	O
detected	O
among	O
181	O
patients	O
analyzed	O
with	O
the	O
entire	O
dystrophin	O
cDNA	O
.	O

Endpoints	O
for	O
many	O
of	O
these	O
deletions	O
were	O
further	O
characterized	O
using	O
two	O
genomic	O
probes	O
,	O
p20	O
(	O
DXS269	O
;	O
Wapenaar	O
et	O
al.	O
)	O
and	O
GMGX11	O
(	O
DXS239	O
;	O
present	O
paper	O
)	O
.	O

Clinical	O
findings	O
are	O
presented	O
for	O
all	O
80	O
patients	O
allowing	O
a	O
correlation	O
of	O
phenotypic	O
severity	O
with	O
the	O
genotype	O
.	O

Thirty	O
-	O
eight	O
independent	O
patients	O
were	O
old	O
enough	O
to	O
be	O
classified	O
as	O
DMD	B
,	O
BMD	B
,	O
or	O
intermediate	O
phenotype	O
and	O
had	O
deletions	O
of	O
exons	O
with	O
sequenced	O
intron	O
/	O
exon	O
boundaries	O
.	O

Of	O
these	O
,	O
eight	O
BMD	B
patients	O
and	O
one	O
intermediate	O
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
while	O
21	O
DMD	B
patients	O
,	O
7	O
intermediate	O
patients	O
,	O
and	O
1	O
BMD	B
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
disrupt	O
the	O
reading	O
frame	O
.	O

Thus	O
,	O
with	O
two	O
exceptions	O
,	O
frameshift	O
deletions	O
of	O
the	O
gene	O
resulted	O
in	O
more	O
severe	O
phenotype	O
than	O
did	O
in	O
-	O
frame	O
deletions	O
.	O

This	O
is	O
in	O
agreement	O
with	O
recent	O
findings	O
by	O
Baumbach	O
et	O
al.	O
and	O
Koenig	O
et	O
al.	O
but	O
is	O
in	O
contrast	O
to	O
findings	O
,	O
by	O
Malhotra	O
et	O
al.	O
at	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

X	B
-	I
linked	I
glucose-6-phosphate	I
dehydrogenase	I
deficiency	I
in	O
Mus	O
musculus	O
.	O

A	O
mouse	O
with	O
X	B
-	I
linked	I
glucose-6-phosphate	I
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
has	O
been	O
recovered	O
in	O
offspring	O
of	O
1-ethyl-1-nitrosourea	O
-	O
treated	O
male	O
mice	O
.	O

The	O
activity	O
alteration	O
was	O
detected	O
in	O
blood	O
but	O
can	O
also	O
be	O
observed	O
in	O
other	O
tissue	O
extracts	O
.	O

Hemizygous	O
,	O
heterozygous	O
,	O
and	O
homozygous	O
mutants	O
have	O
,	O
respectively	O
,	O
about	O
15	O
,	O
60	O
,	O
and	O
15	O
%	O
G6PD	O
remaining	O
activity	O
in	O
the	O
blood	O
as	O
compared	O
to	O
the	O
wild	O
type	O
.	O

Erythrocyte	O
indices	O
did	O
not	O
show	O
differences	O
between	O
mutants	O
and	O
wild	O
types	O
.	O

The	O
mutation	O
does	O
not	O
affect	O
the	O
electrophoretic	O
migration	O
,	O
the	O
isoelectric	O
point	O
,	O
or	O
the	O
thermal	O
stability	O
.	O

Kinetic	O
properties	O
,	O
such	O
as	O
the	O
Km	O
for	O
glucose-6-phosphate	O
or	O
for	O
NADP	O
and	O
the	O
relative	O
utilization	O
of	O
substrate	O
analogues	O
,	O
showed	O
no	O
differences	O
between	O
wild	O
types	O
and	O
mutants	O
with	O
the	O
exception	O
of	O
the	O
relative	O
utilization	O
of	O
deamino	O
-	O
NADP	O
which	O
was	O
significantly	O
lower	O
in	O
mutants	O
.	O

This	O
is	O
presently	O
the	O
only	O
animal	O
model	O
for	O
X	B
-	I
linked	I
G6PD	I
deficiency	I
in	O
humans	O
..	O

Genetic	O
analysis	O
in	O
families	O
with	O
van	B
der	I
Woude	I
syndrome	I
.	O

We	O
have	O
brought	O
together	O
information	O
on	O
864	O
affected	O
individuals	O
in	O
164	O
families	O
(	O
including	O
three	O
new	O
pedigrees	O
)	O
reported	O
in	O
the	O
137	O
year	O
period	O
since	O
1845	O
when	O
Demarquay	O
first	O
described	O
a	O
family	O
with	O
what	O
was	O
later	O
called	O
van	B
der	I
Woude	I
syndrome	I
(	O
VWS	B
)	O
.	O

Both	O
types	O
of	O
oral	B
cleft	I
,	O
cleft	B
palate	I
(	O
CP	B
)	O
and	O
cleft	B
lip	I
with	O
or	O
without	O
CP	B
(	O
CLP	B
)	O
,	O
segregate	O
in	O
these	O
families	O
together	O
with	O
lower	O
lip	B
pits	I
or	O
fistulae	B
in	O
an	O
autosomal	O
dominant	O
mode	O
with	O
high	O
penetrance	O
estimated	O
to	O
be	O
K	O
=	O
.	O

89	O
and	O
.	O
99	O
by	O
different	O
methods	O
.	O

Cleft	O
types	O
(	O
CLP	B
and	O
CP	B
)	O
occur	O
in	O
VWS	B
in	O
the	O
same	O
proportions	O
as	O
in	O
the	O
general	O
non	O
-	O
VWS	O
population	O
,	O
ie	O
,	O
about	O
twice	O
as	O
many	O
cleft	O
-	O
bearing	O
individuals	O
have	O
CLP	B
as	O
have	O
CP	B
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
do	O
not	O
find	O
the	O
usually	O
observed	O
excess	O
of	O
females	O
with	O
CP	B
and	O
excess	O
of	O
males	O
with	O
CLP	B
;	O
in	O
VWS	B
the	O
sex	O
ratios	O
are	O
more	O
nearly	O
equal	O
.	O

Lip	B
pits	I
also	O
are	O
equally	O
distributed	O
between	O
the	O
sexes	O
.	O

Affected	O
males	O
and	O
females	O
are	O
equally	O
likely	O
to	O
transmit	O
VWS	B
.	O

However	O
,	O
there	O
is	O
an	O
excess	O
of	O
less	O
severely	O
affected	O
individuals	O
among	O
transmitters	O
and	O
a	O
deficiency	O
of	O
more	O
severely	O
affected	O
,	O
brought	O
about	O
by	O
a	O
proband	O
bias	O
and	O
differential	O
fecundity	O
.	O

The	O
expression	O
of	O
VWS	B
is	O
significantly	O
modified	O
by	O
the	O
genetic	O
background	O
More	O
extreme	O
phenotypes	O
in	O
parents	O
tend	O
to	O
produce	O
more	O
extreme	O
expression	O
in	O
their	O
children	O
.	O

For	O
a	O
VWS	B
gene	O
carrier	O
the	O
relative	O
risk	O
of	O
transmitting	O
a	O
cleft	O
is	O
26	O
.	O
45	O
%	O
;	O
that	O
of	O
transmitting	O
lower	O
lip	B
pits	I
is	O
23	O
.	O
55	O
%	O
.	O

Three	O
pedigrees	O
of	O
lip	B
pits	I
in	O
the	O
literature	O
show	O
no	O
clefts	O
among	O
a	O
significant	O
number	O
of	O
affected	O
individuals	O
.	O

Control	O
of	O
gene	O
expression	O
in	O
VWS	B
in	O
the	O
three	O
target	O
tissues	O
appears	O
to	O
be	O
independent	O
and	O
separately	O
designated	O
.	O

Mutation	O
rate	O
of	O
the	O
VWS	B
gene	O
is	O
calculated	O
to	O
be	O
1	O
.	O
8	O
X	O
10	O
(	O
-5	O
)	O

Familial	B
discoid	I
lupus	I
erythematosus	I
associated	O
with	O
heterozygote	O
C2	B
deficiency	I
.	O

Two	O
siblings	O
with	O
chronic	B
discoid	I
lupus	I
erythematosus	I
and	O
several	O
family	O
members	O
were	O
found	O
with	O
heterozygous	O
C2	B
deficiency	I
.	O

An	O
association	O
with	O
histocompatibility	O
markers	O
HLA	O
-	O
B18	O
and	O
HLA	O
-	O
Dw2	O
was	O
demonstrated	O
,	O
and	O
the	O
slow	O
allotype	O
of	O
factor	O
B	O
was	O
present	O
.	O

Linkage	O
studies	O
in	O
this	O
family	O
suggested	O
a	O
close	O
linkage	O
between	O
the	O
C2	B
deficiency	I
gene	O
and	O
genes	O
coding	O
for	O
B18	O
,	O
Dw2	O
,	O
and	O
BfS	O
antigens	O
.	O

One	O
HLA	O
-	O
ACB	O
/	O
DBf	O
recombinant	O
was	O
observed	O
showing	O
closer	O
linkage	O
between	O
HLA	O
-	O
D	O
and	O
Bf	O
than	O
between	O
HLA	O
-	O
B	O
and	O
Bf	O
..	O

New	O
genetic	O
variants	O
of	O
glucose	O
6-phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
in	O
Italy	O
.	O

Six	O
new	O
variants	O
of	O
human	O
erythrocyte	O
G6PD	O
have	O
been	O
characterized	O
.	O

All	O
of	O
them	O
were	O
found	O
in	O
Italian	O
males	O
and	O
all	O
were	O
associated	O
with	O
enzyme	B
deficiency	I
,	O
but	O
only	O
two	O
with	O
signs	O
of	O
haemolysis	B
.	O

These	O
and	O
other	O
variants	O
reported	O
in	O
the	O
literature	O
,	O
which	O
must	O
thus	O
far	O
be	O
regarded	O
as	O
sporadic	O
,	O
are	O
found	O
to	O
map	O
in	O
parts	O
of	O
Italy	O
where	O
common	O
types	O
of	O
G6PD	B
deficiency	I
are	O
also	O
prevalent	O
..	O

Aberrant	O
subcellular	O
localization	O
of	O
BRCA1	O
in	O
breast	B
cancer	I
.	O

The	O
BRCA1	O
gene	O
product	O
was	O
identified	O
as	O
a	O
220-kilodalton	O
nuclear	O
phosphoprotein	O
in	O
normal	O
cells	O
,	O
including	O
breast	O
ductal	O
epithelial	O
cells	O
,	O
and	O
in	O
18	O
of	O
20	O
tumor	B
cell	O
lines	O
derived	O
from	O
tissues	O
other	O
than	O
breast	O
and	O
ovary	O
.	O

In	O
16	O
of	O
17	O
breast	B
and	I
ovarian	I
cancer	I
lines	O
and	O
17	O
of	O
17	O
samples	O
of	O
cells	O
obtained	O
from	O
malignant	O
effusions	O
,	O
however	O
,	O
BRCA1	O
localized	O
mainly	O
in	O
cytoplasm	O
.	O

Absence	O
of	O
BRCA1	O
or	O
aberrant	O
subcellular	O
location	O
was	O
also	O
observed	O
to	O
a	O
variable	O
extent	O
in	O
histological	O
sections	O
of	O
many	O
breast	B
cancer	I
biopsies	O
.	O

These	O
findings	O
suggest	O
that	O
BRCA1	B
abnormalities	I
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
many	O
breast	B
cancers	I
,	O
sporadic	O
as	O
well	O
as	O
familial	O
..	O

The	O
carrier	O
frequency	O
of	O
the	O
BRCA1	O
185delAG	O
mutation	O
is	O
approximately	O
1	O
percent	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
.	O

Since	O
BRCA1	O
,	O
the	O
first	O
major	O
gene	O
responsible	O
for	O
inherited	B
breast	I
cancer	I
,	O
was	O
cloned	O
,	O
more	O
than	O
50	O
unique	O
mutations	O
have	O
been	O
detected	O
in	O
the	O
germline	O
of	O
individuals	O
with	O
breast	B
and	I
ovarian	I
cancer	I
.	O

In	O
high	O
-	O
risk	O
pedigrees	O
,	O
female	O
carriers	O
of	O
BRCA1	O
mutations	O
have	O
an	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
,	O
and	O
a	O
40	O
-	O
50	O
%	O
risk	O
of	O
ovarian	B
cancer	I
.	O

However	O
,	O
the	O
mutation	O
stats	O
of	O
individuals	O
unselected	O
for	O
breast	B
or	I
ovarian	I
cancer	I
has	O
not	O
been	O
determined	O
,	O
and	O
it	O
is	O
not	O
known	O
whether	O
mutations	O
in	O
such	O
individuals	O
confer	O
the	O
same	O
risk	O
of	O
cancer	B
as	O
in	O
individuals	O
from	O
the	O
high	O
-	O
risk	O
families	O
studied	O
so	O
far	O
.	O

Following	O
the	O
finding	O
of	O
a	O
185delAG	O
frameshift	O
mutation	O
in	O
several	O
Ashkenazi	O
Jewish	O
breast	O
/	O
ovarian	O
families	O
,	O
we	O
have	O
determined	O
the	O
frequency	O
of	O
this	O
mutation	O
in	O
858	O
Ashkenazim	O
seeking	O
genetic	O
testing	O
for	O
conditions	O
unrelated	O
to	O
cancer	B
,	O
and	O
in	O
815	O
reference	O
individuals	O
not	O
selected	O
for	O
ethnic	O
origin	O
.	O

We	O
observed	O
the	O
185delAG	O
mutation	O
in	O
0	O
.	O
9	O
%	O
of	O
Ashkenazim	O
(	O
95	O
%	O
confidence	O
limit	O
,	O
0	O
.	O
4	O
-	O
1	O
.	O
8	O
%	O
)	O
and	O
in	O
none	O
of	O
the	O
reference	O
samples	O
.	O

Our	O
results	O
suggest	O
that	O
one	O
in	O
a	O
hundred	O
women	O
of	O
Ashkenazi	O
descent	O
may	O
be	O
at	O
especially	O
high	O
risk	O
of	O
developing	O
breast	B
and/or	I
ovarian	I
cancer	I
.	O

The	O
protein	O
deficient	O
in	O
Lowe	B
syndrome	I
is	O
a	O
phosphatidylinositol-4,5-bisphosphate	O
5-phosphatase	O
.	O

Lowe	B
syndrome	I
,	O
also	O
known	O
as	O
oculocerebrorenal	B
syndrome	I
,	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
X	O
chromosome	O
-	O
encoded	O
OCRL	O
gene	O
.	O

The	O
OCRL	O
protein	O
is	O
51	O
%	O
identical	O
to	O
inositol	O
polyphosphate	O
5-phosphatase	O
II	O
(	O
5-phosphatase	O
II	O
)	O
from	O
human	O
platelets	O
over	O
a	O
span	O
of	O
744	O
aa	O
,	O
suggesting	O
that	O
OCRL	O
may	O
be	O
a	O
similar	O
enzyme	O
.	O

We	O
engineered	O
a	O
construct	O
of	O
the	O
OCRL	O
cDNA	O
that	O
encodes	O
amino	O
acids	O
homologous	O
to	O
the	O
platelet	O
5-phosphatase	O
for	O
expression	O
in	O
baculovirus	O
-	O
infected	O
Sf9	O
insect	O
cells	O
.	O

This	O
cDNA	O
encodes	O
aa	O
264	O
-	O
968	O
of	O
the	O
OCRL	O
protein	O
.	O

The	O
recombinant	O
protein	O
was	O
found	O
to	O
catalyze	O
the	O
reactions	O
also	O
carried	O
out	O
by	O
platelet	O
5-phosphatase	O
II	O
.	O

Thus	O
OCRL	O
converts	O
inositol	O
1	O
,	O
4	O
,	O
5-trisphosphate	O
to	O
inositol	O
1	O
,	O
4-bisphosphate	O
,	O
and	O
it	O
converts	O
inositol	O
1	O
,	O
3	O
,	O
4	O
,	O
5-tetrakisphosphate	O
to	O
inositol	O
1	O
,	O
3	O
,	O
4-trisphosphate	O
.	O

Most	O
important	O
,	O
the	O
enzyme	O
converts	O
phosphatidylinositol	O
4	O
,	O
5-bisphosphate	O
to	O
phosphatidylinositol	O
4-phosphate	O
.	O

The	O
relative	O
ability	O
of	O
OCRL	O
to	O
catalyze	O
the	O
three	O
reactions	O
is	O
different	O
from	O
that	O
of	O
5-phosphatase	O
II	O
and	O
from	O
that	O
of	O
another	O
5-phosphatase	O
isoenzyme	O
from	O
platelets	O
,	O
5-phosphatase	O
I.	O
The	O
recombinant	O
OCRL	O
protein	O
hydrolyzes	O
the	O
phospholipid	O
substrate	O
10-	O
to	O
30-fold	O
better	O
than	O
5-phosphatase	O
II	O
,	O
and	O
5-phosphatase	O
I	O
does	O
not	O
cleave	O
the	O
lipid	O
at	O
all	O
.	O

We	O
also	O
show	O
that	O
OCRL	O
functions	O
as	O
a	O
phosphatidylinositol	O
4	O
,	O
5-bisphosphate	O
5-phosphatase	O
in	O
OCRL	O
-	O
expressing	O
Sf9	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
OCRL	O
is	O
mainly	O
a	O
lipid	O
phosphatase	O
that	O
may	O
control	O
cellular	O
levels	O
of	O
a	O
critical	O
metabolite	O
,	O
phosphatidylinositol	O
4	O
,	O
5-bisphosphate	O
.	O

Deficiency	O
of	O
this	O
enzyme	O
apparently	O
causes	O
the	O
protean	O
manifestations	O
of	O
Lowe	B
syndrome	I
..	O

A	O
single	O
amino	O
acid	O
substitution	O
(	O
G103D	O
)	O
in	O
the	O
type	O
II	O
collagen	O
triple	O
helix	O
produces	O
Kniest	B
dysplasia	I
.	O

Kniest	B
dysplasia	I
is	O
a	O
moderately	O
severe	O
chondrodysplasia	B
phenotype	O
that	O
results	O
from	O
mutations	O
in	O
the	O
gene	O
for	O
type	O
II	O
collagen	O
,	O
COL2A1	O
.	O

Characteristics	O
of	O
the	O
disorder	O
include	O
a	O
short	B
trunk	I
and	I
extremities	I
,	O
mid	B
-	I
face	I
hypoplasia	I
,	O
cleft	B
palate	I
,	O
myopia	B
,	O
retinal	B
detachment	I
,	O
and	O
hearing	B
loss	I
.	O

Recently	O
,	O
deletions	O
of	O
all	O
or	O
part	O
of	O
exon	O
12	O
have	O
been	O
identified	O
in	O
individuals	O
with	O
Kniest	B
dysplasia	I
,	O
suggesting	O
that	O
mutations	O
within	O
this	O
region	O
of	O
the	O
protein	O
may	O
primarily	O
result	O
in	O
the	O
Kniest	B
dysplasia	I
phenotype	O
.	O

We	O
used	O
SSCP	O
to	O
analyze	O
an	O
amplified	O
genomic	O
DNA	O
fragment	O
containing	O
exon	O
12	O
from	O
seven	O
individuals	O
with	O
Kniest	B
dysplasia	I
.	O

An	O
abnormality	O
was	O
identified	O
in	O
one	O
patient	O
.	O

DNA	O
sequence	O
analysis	O
demonstrated	O
that	O
the	O
patient	O
was	O
heterozygous	O
for	O
a	O
G	O
to	O
A	O
transition	O
that	O
implied	O
substitution	O
of	O
glycine103	O
of	O
the	O
triple	O
helical	O
domain	O
by	O
aspartate	O
.	O

The	O
mutation	O
was	O
not	O
observed	O
in	O
DNA	O
from	O
either	O
of	O
the	O
clinically	O
unaffected	O
parents	O
of	O
the	O
proband	O
.	O

Protein	O
microsequencing	O
demonstrated	O
expression	O
of	O
the	O
abnormal	O
allele	O
in	O
cartilage	O
.	O

These	O
data	O
demonstrate	O
that	O
point	O
mutations	O
which	O
result	O
in	O
single	O
amino	O
acid	O
substitutions	O
can	O
produce	O
Kniest	B
dysplasia	I
and	O
further	O
support	O
the	O
hypothesis	O
that	O
alteration	O
of	O
a	O
domain	O
,	O
which	O
includes	O
the	O
region	O
encoded	O
by	O
exon	O
12	O
,	O
in	O
the	O
type	O
II	O
collagen	O
protein	O
leads	O
to	O
this	O
disorder	O
..	O

Mutation	O
spectrum	O
in	O
the	O
CHM	B
gene	O
of	O
Danish	O
and	O
Swedish	O
choroideremia	B
patients	O
.	O

The	O
recent	O
isolation	O
of	O
the	O
complete	O
open	O
reading	O
frame	O
of	O
the	O
choroideremia	B
(	O
CHM	B
)	O
gene	O
and	O
the	O
characterization	O
of	O
the	O
exon	O
-	O
intron	O
boundaries	O
has	O
paved	O
the	O
way	O
to	O
mutation	O
detection	O
in	O
patients	O
with	O
classical	O
choroideremia	B
.	O

We	O
have	O
performed	O
mutation	O
screening	O
in	O
patients	O
from	O
15	O
Danish	O
and	O
Swedish	O
families	O
by	O
using	O
Southern	O
blot	O
hybridization	O
and	O
the	O
polymerase	O
chain	O
reaction	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
technique	O
.	O

Causative	O
mutations	O
in	O
the	O
CHM	B
gene	O
were	O
detected	O
in	O
at	O
least	O
12	O
families	O
,	O
indicating	O
that	O
a	O
substantial	O
part	O
of	O
the	O
mutations	O
can	O
be	O
identified	O
by	O
this	O
approach	O
.	O

In	O
four	O
of	O
these	O
families	O
deletions	O
of	O
different	O
sizes	O
were	O
found	O
.	O

Thus	O
,	O
in	O
one	O
patient	O
,	O
the	O
deletion	O
resulted	O
in	O
the	O
absence	O
of	O
only	O
one	O
exon	O
,	O
while	O
in	O
another	O
the	O
deletion	O
comprised	O
the	O
entire	O
CHM	B
gene	O
.	O

Mapping	O
of	O
the	O
deletion	O
endpoints	O
in	O
these	O
four	O
patients	O
and	O
in	O
another	O
11	O
male	O
patients	O
with	O
sizeable	O
deletions	O
enabled	O
us	O
to	O
construct	O
a	O
very	O
detailed	O
map	O
of	O
intervals	O
2	O
and	O
3	O
of	O
Xq21	O
.	O

In	O
the	O
remaining	O
11	O
Danish	O
and	O
Swedish	O
families	O
at	O
least	O
8	O
causative	O
mutations	O
were	O
found	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Interestingly	O
,	O
all	O
CHM	B
gene	O
mutations	O
detected	O
thus	O
far	O
in	O
choroideremia	B
patients	O
give	O
rise	O
to	O
the	O
introduction	O
of	O
a	O
premature	O
stop	O
codon	O
..	O

X	B
-	I
linked	I
spastic	I
paraplegia	I
and	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
are	O
allelic	B
disorders	I
at	O
the	O
proteolipid	O
protein	O
locus	O
.	O

Three	O
forms	O
of	O
X	B
-	I
linked	I
spastic	I
paraplegia	I
(	O
SPG	B
)	O
have	O
been	O
defined	O
.	O

One	O
locus	O
(	O
SPG	O
1	O
)	O
maps	O
to	O
Xq28	O
while	O
two	O
clinically	O
distinct	O
forms	O
map	O
to	O
Xq22	O
(	O
SPG2	O
)	O
.	O

A	O
rare	O
X	B
-	I
linked	I
dysmyelinating	I
disorder	I
of	O
the	O
central	O
nervous	O
system	O
,	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
,	O
has	O
also	O
been	O
mapped	O
to	O
Xq21-q22	O
,	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
which	O
encodes	O
two	O
myelin	O
proteins	O
,	O
PLP	O
and	O
DM20	O
.	O

While	O
narrowing	O
the	O
genetic	O
interval	O
containing	O
SPG2	O
in	O
a	O
large	O
pedigree	O
,	O
we	O
found	O
that	O
PLP	O
was	O
the	O
closest	O
marker	O
to	O
the	O
disease	O
locus	O
,	O
implicating	O
PLP	O
as	O
a	O
possible	O
candidate	O
gene	O
.	O

We	O
have	O
found	O
that	O
a	O
point	O
mutation	O
(	O
His139Tyr	O
)	O
in	O
exon	O
3B	O
of	O
an	O
affected	O
male	O
produces	O
a	O
mutant	O
PLP	O
but	O
a	O
normal	O
DM20	O
,	O
and	O
segregates	O
with	O
the	O
disease	O
(	O
Zmax	O
=	O
6	O
.	O
63	O
,	O
theta	O
=	O
0	O
.	O
00	O
)	O
.	O

It	O
appears	O
,	O
therefore	O
,	O
that	O
SPG2	O
and	O
PMD	B
are	O
allelic	B
disorders	I

Huntington	B
disease	I
without	O
CAG	O
expansion	O
:	O
phenocopies	O
or	O
errors	O
in	O
assignment	O
?	O

Huntington	B
disease	I
(	O
HD	B
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
an	O
expanded	O
CAG	O
repeat	O
within	O
a	O
novel	O
gene	O
on	O
4p16	O
.	O

3	O
(	O
IT15	O
)	O
.	O

A	O
total	O
of	O
30	O
of	O
1	O
,	O
022	O
affected	O
persons	O
(	O
2	O
.	O
9	O
%	O
of	O
our	O
cohort	O
)	O
did	O
not	O
have	O
an	O
expanded	O
CAG	O
in	O
the	O
disease	O
range	O
.	O

The	O
reasons	O
for	O
not	O
observing	O
expansion	O
in	O
affected	O
individuals	O
are	O
important	O
for	O
determining	O
the	O
sensitivity	O
of	O
using	O
repeat	O
length	O
both	O
for	O
diagnosis	O
of	O
affected	O
patients	O
and	O
for	O
predictive	O
testing	O
programs	O
and	O
may	O
have	O
biological	O
relevance	O
for	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
underlying	O
HD	B
.	O

Here	O
we	O
show	O
that	O
the	O
majority	O
(	O
18	O
)	O
of	O
the	O
individuals	O
with	O
normal	O
sized	O
alleles	O
represent	O
misdiagnosis	O
,	O
sample	O
mix	O
-	O
up	O
,	O
or	O
clerical	O
error	O
.	O

The	O
remaining	O
12	O
patients	O
represent	O
possible	O
phenocopies	O
for	O
HD	B
.	O

In	O
at	O
least	O
four	O
cases	O
,	O
family	O
studies	O
of	O
these	O
phenocopies	O
excluded	O
4p16	O
.	O

3	O
as	O
the	O
region	O
responsible	O
for	O
the	O
phenotype	O
.	O

Mutations	O
in	O
the	O
HD	B
gene	O
that	O
are	O
other	O
than	O
CAG	O
expansion	O
have	O
not	O
been	O
excluded	O
for	O
the	O
remaining	O
eight	O
cases	O
;	O
however	O
,	O
in	O
as	O
many	O
as	O
seven	O
of	O
these	O
persons	O
,	O
retrospective	O
review	O
of	O
these	O
patients	O
clinical	O
features	O
identified	O
characteristics	O
not	O
typical	O
for	O
HD	B
.	O

This	O
study	O
shows	O
that	O
on	O
rare	O
occasions	O
mutations	O
in	O
other	O
,	O
as	O
-	O
yet	O
-	O
undefined	O
genes	O
can	O
present	O
with	O
a	O
clinical	O
phenotype	O
very	O
similar	O
to	O
that	O
of	O
HD	B

Assignment	O
of	O
the	O
human	O
Na+	O
/	O
glucose	O
cotransporter	O
gene	O
SGLT1	O
to	O
chromosome	O
22q13.1	O
.	O

The	O
Na	O
+	O
/glucose	O
cotransporter	O
gene	O
SGLT1	O
encodes	O
the	O
primary	O
carrier	O
protein	O
responsible	O
for	O
the	O
uptake	O
of	O
the	O
dietary	O
sugars	O
glucose	O
and	O
galactose	O
from	O
the	O
intestinal	O
lumen	O
.	O

SGLT1	O
transport	O
activity	O
is	O
currently	O
exploited	O
in	O
oral	O
rehydration	O
therapy	O
.	O

The	O
75-kDa	O
glycoprotein	O
is	O
localized	O
in	O
the	O
brush	O
border	O
of	O
the	O
intestinal	O
epithelium	O
and	O
is	O
predicted	O
to	O
comprise	O
12	O
membrane	O
spans	O
.	O

In	O
two	O
patients	O
with	O
the	O
autosomal	B
recessive	I
disease	I
glucose	I
/	I
galactose	I
malabsorption	I
,	O
the	O
underlying	O
cause	O
was	O
found	O
to	O
be	O
a	O
missense	O
mutation	O
in	O
SGLT1	O
,	O
and	O
the	O
Asp28	O
-	O
-	O
>	O
Asn	O
change	O
was	O
demonstrated	O
in	O
vitro	O
to	O
eliminate	O
SGLT1	O
transport	O
activity	O
.	O

The	O
SGLT1	O
gene	O
was	O
previously	O
shown	O
to	O
reside	O
on	O
the	O
distal	O
q	O
arm	O
of	O
chromosome	O
22	O
(	O
11	O
.	O
2	O
-	O
-	O
>	O
qter	O
)	O
.	O

We	O
have	O
used	O
a	O
cosmid	O
probe	O
for	O
fluorescence	O
in	O
situ	O
hybridization	O
,	O
which	O
refines	O
the	O
localization	O
to	O
22q13	O
.	O

1	O
,	O
and	O
provide	O
an	O
example	O
of	O
the	O
utility	O
of	O
the	O
SGLT1	O
probe	O
as	O
a	O
diagnostic	O
for	O
genetic	B
diseases	I
associated	O
with	O
translocations	O
of	O
chromosome	O
22	O
.	O

Haplotype	O
studies	O
in	O
Wilson	B
disease	I
.	O

In	O
51	O
families	O
with	O
Wilson	B
disease	I
,	O
we	O
have	O
studied	O
DNA	O
haplotypes	O
of	O
dinucleotide	O
repeat	O
polymorphisms	O
(	O
CA	O
repeats	O
)	O
in	O
the	O
13q14	O
.	O

3	O
region	O
,	O
to	O
examine	O
these	O
markers	O
for	O
association	O
with	O
the	O
Wilson	B
disease	I
gene	O
(	O
WND	B
)	O
.	O

In	O
addition	O
to	O
a	O
marker	O
(	O
D13S133	O
)	O
described	O
elsewhere	O
,	O
we	O
have	O
developed	O
three	O
new	O
highly	O
polymorphic	O
markers	O
(	O
D13S314	O
,	O
D13S315	O
,	O
and	O
D13S316	O
)	O
close	O
to	O
the	O
WND	B
locus	O
.	O

We	O
have	O
examined	O
the	O
distribution	O
of	O
marker	O
alleles	O
at	O
the	O
loci	O
studied	O
and	O
have	O
found	O
that	O
D13S314	O
,	O
D13S133	O
,	O
and	O
D13S316	O
each	O
show	O
nonrandom	O
distribution	O
on	O
chromosomes	O
carrying	O
the	O
WND	B
mutation	O
.	O

We	O
have	O
studied	O
haplotypes	O
of	O
these	O
three	O
markers	O
and	O
have	O
found	O
that	O
there	O
are	O
highly	O
significant	O
differences	O
between	O
WND	B
and	O
normal	O
haplotypes	O
in	O
northern	O
European	O
families	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
mutation	O
detection	O
and	O
molecular	O
diagnosis	O
in	O
families	O
with	O
Wilson	B
disease	I
.	O

Brca1	B
deficiency	I
results	O
in	O
early	O
embryonic	B
lethality	I
characterized	O
by	O
neuroepithelial	B
abnormalities	I
.	O

The	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
,	O
BRCA1	O
,	O
has	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
zinc	O
-	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
for	O
at	O
least	O
80	O
%	O
of	O
families	O
with	O
both	O
breast	B
and	I
ovarian	I
cancer	I
,	O
as	O
well	O
as	O
some	O
non	O
-	O
familial	O
sporadic	O
ovarian	B
cancers	I
.	O

The	O
loss	O
of	O
wild	O
-	O
type	O
BRCA1	O
in	O
tumours	B
of	O
individuals	O
carrying	O
one	O
nonfunctional	O
BRCA1	O
allele	O
suggests	O
that	O
BRCA1	O
encodes	O
a	O
tumour	B
suppressor	O
that	O
may	O
inhibit	O
the	O
proliferation	O
of	O
mammary	O
epithelial	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
BRCA1	O
in	O
normal	O
tissue	O
growth	O
and	O
differentiation	O
,	O
and	O
to	O
generate	O
a	O
potential	O
model	O
for	O
the	O
cancer	B
susceptibility	O
associated	O
with	O
loss	O
of	O
BRCA1	O
function	O
,	O
we	O
have	O
created	O
a	O
mouse	O
line	O
carrying	O
a	O
mutation	O
in	O
one	O
Brca1	O
allele	O
.	O

Analysis	O
of	O
mice	O
homozygous	O
for	O
the	O
mutant	O
allele	O
indicate	O
that	O
Brca1	O
is	O
critical	O
for	O
normal	O
development	O
,	O
as	O
these	O
mice	O
died	O
in	O
utero	O
between	O
10	O
and	O
13	O
days	O
of	O
gestation	O
(	O
E10-E13	O
)	O
.	O

Abnormalities	O
in	O
Brca1-deficient	B
embryos	O
were	O
most	O
evident	O
in	O
the	O
neural	O
tube	O
,	O
with	O
40	O
%	O
of	O
the	O
embryos	O
presenting	O
with	O
varying	O
degrees	O
of	O
spina	B
bifida	I
and	O
anencephaly	B
.	O

In	O
addition	O
,	O
the	O
neuroepithelium	O
in	O
Brca1-deficient	B
embryos	O
appeared	O
disorganized	O
,	O
with	O
signs	O
of	O
both	O
rapid	O
proliferation	O
and	O
excessive	O
cell	O
death	O
..	O

BRCA1	O
is	O
secreted	O
and	O
exhibits	O
properties	O
of	O
a	O
granin	O
.	O

Germline	O
mutations	O
in	O
BRCA1	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
inherited	B
breast	I
and	I
ovarian	I
cancer	I
.	O

However	O
,	O
the	O
function	O
of	O
the	O
BRCA1	O
protein	O
has	O
remained	O
elusive	O
.	O

We	O
now	O
show	O
that	O
BRCA1	O
encodes	O
a	O
190-kD	O
protein	O
with	O
sequence	O
homology	O
and	O
biochemical	O
analogy	O
to	O
the	O
granin	O
protein	O
family	O
.	O

Interestingly	O
,	O
BRCA2	O
also	O
includes	O
a	O
motif	O
similar	O
to	O
the	O
granin	O
consensus	O
at	O
the	O
C	O
terminus	O
of	O
the	O
protein	O
.	O

Both	O
BRCA1	O
and	O
the	O
granins	O
localize	O
to	O
secretory	O
vesicles	O
,	O
are	O
secreted	O
by	O
a	O
regulated	O
pathway	O
,	O
are	O
post	O
-	O
translationally	O
glycosylated	O
and	O
are	O
responsive	O
to	O
hormones	O
.	O

As	O
a	O
regulated	O
secretory	O
protein	O
,	O
BRCA1	O
appears	O
to	O
function	O
by	O
a	O
mechanism	O
not	O
previously	O
described	O
for	O
tumour	B
suppressor	O
gene	O
products	O
..	O

Ovarian	B
cancer	I
risk	O
in	O
BRCA1	O
carriers	O
is	O
modified	O
by	O
the	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
)	O
locus	O
.	O

Women	O
who	O
carry	O
a	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
(	O
on	O
chromosome	O
17q21	O
)	O
,	O
have	O
an	O
80	O
%	O
risk	O
of	O
breast	B
cancer	I
and	O
a	O
40	O
%	O
risk	O
of	O
ovarian	B
cancer	I
by	O
the	O
age	O
of	O
70	O
(	O
ref	O
.	O

1	O
)	O
.	O

The	O
variable	O
penetrance	O
of	O
BRCA1	O
suggests	O
that	O
other	O
genetic	O
and	O
non	O
-	O
genetic	O
factors	O
play	O
a	O
role	O
in	O
tumourigenesis	O
in	O
these	O
individuals	O
.	O

The	O
HRAS1	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
VNTR	O
)	O
polymorphism	O
,	O
located	O
1	O
kilobase	O
(	O
kb	O
)	O
downstream	O
of	O
the	O
HRAS1	O
proto	O
-	O
oncogene	O
(	O
chromosome	O
11p15	O
.	O

5	O
)	O
is	O
one	O
possible	O
genetic	O
modifier	O
of	O
cancer	B
penetrance	O
.	O

Individuals	O
who	O
have	O
rare	O
alleles	O
of	O
the	O
VNTR	O
have	O
an	O
increased	O
risk	O
of	O
certain	O
types	O
of	O
cancers	B
,	O
including	O
breast	B
cancer	I
(	O
2	O
-	O
4	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
increases	O
susceptibility	O
to	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
,	O
we	O
have	O
typed	O
a	O
panel	O
of	O
307	O
female	O
BRCA1	O
carriers	O
at	O
this	O
locus	O
using	O
a	O
PCR	O
-	O
based	O
technique	O
.	O

The	O
risk	O
for	O
ovarian	B
cancer	I
was	O
2	O
.	O
11	O
times	O
greater	O
for	O
BRCA1	O
carriers	O
harbouring	O
one	O
or	O
two	O
rare	O
HRAS1	O
alleles	O
,	O
compared	O
to	O
carriers	O
with	O
only	O
common	O
alleles	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
relative	O
risk	O
associated	O
with	O
a	O
rare	O
HRAS1	O
allele	O
was	O
not	O
altered	O
by	O
adjusting	O
for	O
the	O
other	O
known	O
risk	O
factors	O
for	O
hereditary	B
ovarian	I
cancer	I
(	O
5	O
)	O
.	O

Susceptibility	O
to	O
breast	B
cancer	I
did	O
not	O
appear	O
to	O
be	O
affected	O
by	O
the	O
presence	O
of	O
rare	O
HRAS1	O
alleles	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
effect	O
of	O
a	O
modifying	O
gene	O
on	O
the	O
penetrance	O
of	O
an	O
inherited	B
cancer	I
syndrome	I

A	O
novel	O
homeodomain	O
-	O
encoding	O
gene	O
is	O
associated	O
with	O
a	O
large	O
CpG	O
island	O
interrupted	O
by	O
the	O
myotonic	B
dystrophy	I
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
expansion	O
in	O
the	O
3-untranslated	O
region	O
of	O
a	O
protein	O
kinase	O
-	O
encoding	O
gene	O
,	O
DMPK	O
,	O
which	O
maps	O
to	O
chromosome	O
19q13	O
.	O

3	O
.	O
Characterisation	O
of	O
the	O
expression	O
of	O
this	O
gene	O
in	O
patient	O
tissues	O
has	O
thus	O
far	O
generated	O
conflicting	O
data	O
on	O
alterations	O
in	O
the	O
steady	O
state	O
levels	O
of	O
DMPK	O
mRNA	O
,	O
and	O
on	O
the	O
final	O
DMPK	O
protein	O
levels	O
in	O
the	O
presence	O
of	O
the	O
expansion	O
.	O

The	O
DM	B
region	O
of	O
chromosome	O
19	O
is	O
gene	O
rich	O
,	O
and	O
it	O
is	O
possible	O
that	O
the	O
repeat	O
expansion	O
may	O
lead	O
to	O
dysfunction	O
of	O
a	O
number	O
of	O
transcription	O
units	O
in	O
the	O
vicinity	O
,	O
perhaps	O
as	O
a	O
consequence	O
of	O
chromatin	O
disruption	O
.	O

We	O
have	O
searched	O
for	O
genes	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
3	O
end	O
of	O
DMPK	O
.	O

Sequencing	O
of	O
this	O
region	O
shows	O
that	O
the	O
island	O
extends	O
over	O
3	O
.	O
5	O
kb	O
and	O
is	O
interrupted	O
by	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
.	O

Comparison	O
of	O
genomic	O
sequences	O
downstream	O
(	O
centromeric	O
)	O
of	O
the	O
repeat	O
in	O
human	O
and	O
mouse	O
identified	O
regions	O
of	O
significant	O
homology	O
.	O

These	O
correspond	O
to	O
exons	O
of	O
a	O
gene	O
predicted	O
to	O
encode	O
a	O
homeodomain	O
protein	O
.	O

RT	O
-	O
PCR	O
analysis	O
shows	O
that	O
this	O
gene	O
,	O
which	O
we	O
have	O
called	O
DM	B
locus	O
-	O
associated	O
homeodomain	O
protein	O
(	O
DMAHP	O
)	O
,	O
is	O
expressed	O
in	O
a	O
number	O
of	O
human	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
heart	O
and	O
brain	O
.	O

Germline	O
mutations	O
in	O
the	O
RB1	O
gene	O
in	O
patients	O
with	O
hereditary	B
retinoblastoma	I
.	O

We	O
have	O
analyzed	O
the	O
27	O
exons	O
and	O
the	O
promoter	O
region	O
of	O
the	O
RB1	O
gene	O
in	O
familial	B
or	I
sporadic	I
bilateral	I
retinoblastoma	I
by	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O

For	O
improvement	O
over	O
previous	O
studies	O
,	O
a	O
new	O
set	O
of	O
primers	O
has	O
been	O
designed	O
,	O
which	O
allow	O
for	O
amplification	O
of	O
the	O
coding	O
and	O
splicing	O
sequences	O
only	O
.	O

The	O
positioning	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
primers	O
was	O
such	O
that	O
the	O
resulting	O
PCR	O
products	O
were	O
of	O
different	O
sizes	O
,	O
which	O
enabled	O
us	O
to	O
analyze	O
two	O
different	O
exons	O
simultaneously	O
and	O
still	O
distinguish	O
between	O
the	O
banding	O
profiles	O
for	O
both	O
(	O
biplex	O
analysis	O
)	O
.	O

By	O
using	O
this	O
approach	O
,	O
we	O
were	O
able	O
to	O
identify	O
mutation	O
in	O
22	O
new	O
patients	O
,	O
but	O
the	O
overall	O
efficiency	O
of	O
the	O
procedure	O
when	O
we	O
used	O
a	O
single	O
-	O
pass	O
regimen	O
was	O
only	O
48	O
%	O
.	O

The	O
mutations	O
were	O
small	O
insertions	O
and	O
deletions	O
and	O
point	O
mutations	O
in	O
roughly	O
equal	O
proportions	O
..	O

Type	B
II	I
human	I
complement	I
C2	I
deficiency	I
.	O

Allele	O
-	O
specific	O
amino	O
acid	O
substitutions	O
(	O
Ser189	O
--	O
>	O
Phe	O
;	O
Gly444	O
--	O
>	O
Arg	O
)	O
cause	O
impaired	O
C2	O
secretion	O
.	O

Type	B
II	I
complement	I
protein	I
C2	I
deficiency	I
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
.	O

The	O
Type	O
II	O
C2	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
linked	O
to	O
two	O
major	O
histocompatibility	O
haplotypes	O
(	O
MHC	O
)	O
that	O
differ	O
from	O
the	O
MHC	O
of	O
the	O
more	O
common	O
Type	B
I	I
C2	I
deficiency	I
.	O

To	O
determine	O
the	O
molecular	O
basis	O
of	O
Type	B
II	I
deficiency	I
the	O
two	O
Type	O
II	O
C2Q0	O
genes	O
were	O
isolated	O
and	O
transfected	O
separately	O
into	O
L	O
-	O
cells	O
.	O

Subsequent	O
molecular	O
biology	O
,	O
biosynthetic	O
,	O
and	O
immunofluorescence	O
studies	O
demonstrated	O
that	O
C2	O
secretion	O
is	O
impaired	O
in	O
Type	B
II	I
C2	I
deficiency	I
because	O
of	O
different	O
missense	O
mutations	O
at	O
highly	O
conserved	O
residues	O
in	O
each	O
of	O
the	O
C2Q0	O
alleles	O
.	O

One	O
is	O
in	O
exon	O
5	O
(	O
nucleotide	O
C566	O
--	O
>	O
T	O
;	O
Ser189	O
--	O
>	O
Phe	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A11	O
,	O
B35	O
,	O
DRw1	O
,	O
BFS	O
,	O
C4A0B1	O
.	O

The	O
other	O
is	O
in	O
exon	O
11	O
(	O
G1930	O
--	O
>	O
A	O
;	O
Gly444	O
--	O
>	O
Arg	O
)	O
of	O
the	O
C2Q0	O
gene	O
linked	O
to	O
the	O
MHC	O
haplotype	O
A2	O
,	O
B5	O
,	O
DRw4	O
,	O
BFS	O
,	O
C4A3B1	O
.	O

Each	O
mutant	O
C2	O
gene	O
product	O
is	O
retained	O
early	O
in	O
the	O
secretory	O
pathway	O
.	O

These	O
mutants	O
provide	O
models	O
for	O
elucidating	O
the	O
C2	O
secretory	O
pathway	O
..	O

Defective	O
dimerization	O
of	O
von	B
Willebrand	I
factor	O
subunits	O
due	O
to	O
a	O
Cys-	O
>	O
Arg	O
mutation	O
in	O
type	B
IID	I
von	I
Willebrand	I
disease	I
.	O

The	O
same	O
heterozygous	O
T	O
-	O
>	O
C	O
transition	O
at	O
nt	O
8567	O
of	O
the	O
von	B
Willebrand	I
factor	O
(	O
vWF	O
)	O
transcript	O
was	O
found	O
in	O
two	O
unrelated	O
patients	O
with	O
type	B
IID	I
von	I
Willebrand	I
disease	I
,	O
with	O
no	O
other	O
apparent	O
abnormality	O
.	O

In	O
one	O
family	O
,	O
both	O
alleles	O
were	O
normal	O
in	O
the	O
parents	O
and	O
one	O
sister	O
;	O
thus	O
,	O
the	O
mutation	O
originated	O
de	O
novo	O
in	O
the	O
proposita	O
.	O

The	O
second	O
patient	O
also	O
had	O
asymptomatic	O
parents	O
who	O
,	O
however	O
,	O
were	O
not	O
available	O
for	O
study	O
.	O

The	O
structural	O
consequences	O
of	O
the	O
identified	O
mutation	O
,	O
resulting	O
in	O
the	O
CyS2010	O
-	O
>	O
Arg	O
substitution	O
,	O
were	O
evaluated	O
by	O
expression	O
of	O
the	O
vWF	O
carboxyl	O
-	O
terminal	O
domain	O
containing	O
residues	O
1366	O
-	O
2050	O
.	O

Insect	O
cells	O
infected	O
with	O
recombinant	O
baculovirus	O
expressing	O
normal	O
vWF	O
sequence	O
secreted	O
a	O
disulfide	O
linked	O
dimeric	O
molecule	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
150	O
kDa	O
before	O
reduction	O
,	O
yielding	O
a	O
single	O
band	O
of	O
80	O
kDa	O
after	O
disulfide	O
bond	O
reduction	O
.	O

In	O
contrast	O
,	O
cells	O
expressing	O
the	O
mutant	O
fragment	O
secreted	O
a	O
monomeric	O
molecule	O
of	O
apparent	O
molecular	O
mass	O
of	O
80	O
kDa	O
,	O
which	O
remained	O
unchanged	O
after	O
reduction	O
.	O

We	O
conclude	O
that	O
CyS2010	O
is	O
essential	O
for	O
normal	O
dimerization	O
of	O
vWF	O
subunits	O
through	O
disulfide	O
bonding	O
of	O
carboxyl	O
-	O
terminal	O
domains	O
and	O
that	O
a	O
heterozygous	O
mutation	O
in	O
the	O
corresponding	O
codon	O
is	O
responsible	O
for	O
defective	O
multimer	O
formation	O
in	O
type	B
IID	I
von	I
Willebrand	I
disease	I
..	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
,	O
a	O
novel	O
effector	O
for	O
the	O
GTPase	O
CDC42Hs	O
,	O
is	O
implicated	O
in	O
actin	O
polymerization	O
.	O

The	O
Rho	O
family	O
of	O
GTPases	O
control	O
diverse	O
biological	O
processes	O
,	O
including	O
cell	O
morphology	O
and	O
mitogenesis	O
.	O

We	O
have	O
identified	O
WASP	O
,	O
the	O
protein	O
that	O
is	O
defective	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
as	O
a	O
novel	O
effector	O
for	O
CDC42Hs	O
,	O
but	O
not	O
for	O
the	O
other	O
Rho	O
family	O
members	O
,	O
Rac	O
and	O
Rho	O
.	O

This	O
interaction	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
G	O
protein	O
-	O
binding	O
domain	O
.	O

Cellular	O
expression	O
of	O
epitope	O
-	O
tagged	O
WASP	O
produces	O
clusters	O
of	O
WASP	O
that	O
are	O
highly	O
enriched	O
in	O
polymerized	O
actin	O
.	O

This	O
clustering	O
is	O
not	O
observed	O
with	O
a	O
C	O
-	O
terminally	O
deleted	O
WASP	O
and	O
is	O
inhibited	O
by	O
coexpression	O
with	O
dominant	O
negative	O
CDC42Hs	O
-	O
N17	O
,	O
but	O
not	O
with	O
dominant	O
negative	O
forms	O
of	O
Rac	O
or	O
Rho	O
.	O

Thus	O
,	O
WASP	O
provides	O
a	O
novel	O
link	O
between	O
CDC42Hs	O
and	O
the	O
actin	O
cytoskeleton	O
,	O
which	O
suggests	O
a	O
molecular	O
mechanism	O
for	O
many	O
of	O
the	O
cellular	O
abnormalities	O
in	O
WAS	B
.	O

The	O
WASP	O
sequence	O
contains	O
two	O
novel	O
domains	O
that	O
are	O
homologous	O
to	O
other	O
proteins	O
involved	O
in	O
action	O
organization	O
..	O

X	B
-	I
linked	I
adrenoleukodystrophy	I
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addison	B
's	I
disease	I
in	O
young	O
adult	O
male	O
patients	O
.	O

X	B
-	I
Linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
is	O
a	O
genetic	B
disease	I
associated	O
with	O
demyelination	B
of	I
the	I
central	I
nervous	I
system	I
,	O
adrenal	B
insufficiency	I
,	O
and	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
tissue	O
and	O
body	O
fluids	O
.	O

ALD	B
is	O
due	O
to	O
mutation	O
of	O
a	O
gene	O
located	O
in	O
Xq28	O
that	O
encodes	O
a	O
peroxisomal	O
transporter	O
protein	O
of	O
unknown	O
function	O
.	O

The	O
most	O
common	O
phenotype	O
of	O
ALD	B
is	O
the	O
cerebral	O
form	O
(	O
45	O
%	O
)	O
that	O
develops	O
in	O
boys	O
between	O
5	O
-	O
12	O
yr	O
.	O

Adrenomyeloneuropathy	B
(	O
AMN	B
)	O
involves	O
the	O
spinal	O
cord	O
and	O
peripheral	O
nerves	O
in	O
young	O
adults	O
(	O
35	O
%	O
)	O
.	O

Adrenal	B
insufficiency	I
(	O
Addisons	B
disease	I
)	O
is	O
frequently	O
associated	O
with	O
AMN	B
or	O
cerebral	B
ALD	I
and	O
may	O
remain	O
the	O
only	O
clinical	O
expression	O
of	O
ALD	B
(	O
8	O
%	O
of	O
cases	O
)	O
.	O

The	O
prevalence	O
of	O
ALD	B
among	O
adults	O
with	O
Addisons	B
disease	I
remains	O
unknown	O
.	O

To	O
evaluate	O
this	O
prevalence	O
,	O
we	O
performed	O
biochemical	O
analysis	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
14	O
male	O
patients	O
(	O
age	O
ranging	O
from	O
12	O
-	O
45	O
yr	O
at	O
diagnosis	O
)	O
previously	O
diagnosed	O
as	O
having	O
primary	O
idiopathic	O
adrenocortical	B
insufficiency	I
.	O

In	O
5	O
of	O
14	O
patients	O
(	O
35	O
%	O
)	O
,	O
elevated	O
plasma	O
concentrations	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
were	O
detected	O
.	O

None	O
of	O
these	O
patients	O
had	O
adrenocortical	O
antibodies	O
.	O

By	O
electrophysiological	O
tests	O
and	O
magnetic	O
resonance	O
imaging	O
it	O
was	O
determined	O
that	O
two	O
patients	O
had	O
cerebral	B
ALD	I
,	O
one	O
had	O
adrenomyeloneuropathy	B
with	O
cerebral	O
involvement	O
,	O
and	O
two	O
had	O
preclinical	O
AMN	B
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
ALD	B
is	O
a	O
frequent	O
cause	O
of	O
idiopathic	O
Addisons	B
disease	I
in	O
children	O
and	O
adults	O
..	O

Tumor	B
suppression	O
and	O
apoptosis	O
of	O
human	O
prostate	B
carcinoma	I
mediated	O
by	O
a	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
.	O

Prostate	B
cancer	I
is	O
the	O
second	O
leading	O
cause	O
of	O
male	O
cancer	B
deaths	O
in	O
the	O
United	O
States	O
.	O

Yet	O
,	O
despite	O
a	O
large	O
international	O
effort	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
this	O
devastating	O
disease	O
.	O

Prostate	O
secretory	O
epithelial	O
cells	O
and	O
androgen	O
-	O
dependent	O
prostate	B
carcinomas	I
undergo	O
apoptosis	O
in	O
response	O
to	O
androgen	O
deprivation	O
and	O
,	O
furthermore	O
,	O
most	O
prostate	B
carcinomas	I
become	O
androgen	O
independent	O
and	O
refractory	O
to	O
further	O
therapeutic	O
manipulations	O
during	O
disease	O
progression	O
.	O

Definition	O
of	O
the	O
genetic	O
events	O
that	O
trigger	O
apoptosis	O
in	O
the	O
prostate	O
could	O
provide	O
important	O
insights	O
into	O
critical	O
pathways	O
in	O
normal	O
development	O
as	O
well	O
as	O
elucidate	O
the	O
perturbations	O
of	O
those	O
key	O
pathways	O
in	O
neoplastic	O
transformation	O
.	O

We	O
report	O
the	O
functional	O
definition	O
of	O
a	O
novel	O
genetic	O
locus	O
within	O
human	O
chromosome	O
10pter	O
-	O
q11	O
that	O
mediates	O
both	O
in	O
vivo	O
tumor	O
suppression	O
and	O
in	O
vitro	O
apoptosis	O
of	O
prostatic	B
adenocarcinoma	I
cells	O
.	O

A	O
defined	O
fragment	O
of	O
human	O
chromosome	O
10	O
was	O
transferred	O
via	O
microcell	O
fusion	O
into	O
a	O
prostate	B
adenocarcinoma	I
cell	O
line	O
.	O

Microcell	O
hybrids	O
containing	O
only	O
the	O
region	O
10pter	O
-	O
q11	O
were	O
suppressed	O
for	O
tumorigenicity	O
following	O
injection	O
of	O
microcell	O
hybrids	O
into	O
nude	O
mice	O
.	O

Furthermore	O
,	O
the	O
complemented	O
hybrids	O
undergo	O
programmed	O
cell	O
death	O
in	O
vitro	O
via	O
a	O
mechanism	O
that	O
does	O
not	O
require	O
nuclear	O
localization	O
of	O
p53	O
.	O

These	O
data	O
functionally	O
define	O
a	O
novel	O
genetic	O
locus	O
,	O
designated	O
PAC1	O
,	O
for	O
prostate	O
adenocarcinoma	O
1	O
,	O
involved	O
in	O
tumor	O
suppression	O
of	O
human	O
prostate	B
carcinoma	I
and	O
furthermore	O
strongly	O
suggest	O
that	O
the	O
cell	O
death	O
pathway	O
can	O
be	O
functionally	O
restored	O
in	O
prostatic	B
adenocarcinoma	I
..	O

Low	O
incidence	O
of	O
BRCA2	O
mutations	O
in	O
breast	B
carcinoma	I
and	O
other	O
cancers	B
.	O

Inherited	O
mutant	O
alleles	O
of	O
familial	O
tumour	B
suppressor	O
genes	O
predispose	O
individuals	O
to	O
particular	O
types	O
of	O
cancer	B
.	O

In	O
addition	O
to	O
an	O
involvement	O
in	O
inherited	O
susceptibility	O
to	O
cancer	B
,	O
these	O
tumour	B
suppressor	O
genes	O
are	O
targets	O
for	O
somatic	O
mutations	O
in	O
sporadic	B
cancers	I
of	O
the	O
same	O
type	O
found	O
in	O
the	O
familial	O
forms	O
.	O

An	O
exception	O
is	O
BRCA1	O
,	O
which	O
contributes	O
to	O
a	O
significant	O
fraction	O
of	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
,	O
but	O
undergoes	O
mutation	O
at	O
very	O
low	O
rates	O
in	O
sporadic	B
breast	I
and	I
ovarian	I
cancers	I
.	O

This	O
finding	O
suggests	O
that	O
other	O
genes	O
may	O
be	O
the	O
principal	O
targets	O
for	O
somatic	O
mutation	O
in	O
breast	B
carcinoma	I
.	O

A	O
second	O
,	O
recently	O
identified	O
familial	B
breast	I
cancer	I
gene	O
,	O
BRCA2	O
(	O
refs	O
5	O
-	O
8	O
)	O
,	O
accounts	O
for	O
a	O
proportion	O
of	O
breast	B
cancer	I
roughly	O
equal	O
to	O
BRCA1	O
.	O

Like	O
BRCA1	O
,	O
BRCA2	O
behaves	O
as	O
a	O
dominantly	O
inherited	O
tumour	B
suppressor	O
gene	O
.	O

Individuals	O
who	O
inherit	O
one	O
mutant	O
allele	O
are	O
at	O
increased	O
risk	O
for	O
breast	B
cancer	I
,	O
and	O
the	O
tumours	B
they	O
develop	O
lose	O
the	O
wild	O
-	O
type	O
allele	O
by	O
heterozygous	O
deletion	O
.	O

The	O
BRCA2	O
coding	O
sequence	O
is	O
huge	O
,	O
composed	O
of	O
26	O
exons	O
that	O
span	O
10	O
,	O
443	O
bp	O
.	O

Here	O
we	O
investigate	O
the	O
rate	O
of	O
BRCA2	O
mutation	O
in	O
sporadic	B
breast	I
cancers	I
and	O
in	O
a	O
set	O
of	O
cell	O
lines	O
that	O
represent	O
twelve	O
other	O
tumour	B
types	O
.	O

Surprisingly	O
,	O
mutations	O
in	O
BRCA2	O
are	O
infrequent	O
in	O
cancers	B
including	O
breast	B
carcinoma	I
.	O

However	O
,	O
a	O
probable	O
germline	O
mutation	O
in	O
a	O
pancreatic	B
tumour	I
cell	O
line	O
suggests	O
a	O
role	O
for	O
BRCA2	O
in	O
susceptibility	O
to	O
pancreatic	B
cancer	I
..	O

Founding	O
BRCA1	O
mutations	O
in	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
in	O
southern	O
Sweden	O
.	O

Nine	O
different	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
were	O
identified	O
in	O
15	O
of	O
47	O
kindreds	O
from	O
southern	O
Sweden	O
,	O
by	O
use	O
of	O
SSCP	O
and	O
heteroduplex	O
analysis	O
of	O
all	O
exons	O
and	O
flanking	O
intron	O
region	O
and	O
by	O
a	O
protein	O
-	O
truncation	O
test	O
for	O
exon	O
11	O
,	O
followed	O
by	O
direct	O
sequencing	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	O
are	O
predicted	O
to	O
give	O
rise	O
to	O
premature	O
translation	O
termination	O
and	O
include	O
seven	O
frameshift	O
insertions	O
or	O
deletions	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
splice	O
acceptor	O
site	O
mutation	O
.	O

The	O
remaining	O
mutation	O
is	O
a	O
missense	O
mutation	O
(	O
Cys61Gly	O
)	O
in	O
the	O
zinc	O
-	O
binding	O
motif	O
.	O

Four	O
novel	O
Swedish	O
founding	O
mutations	O
were	O
identified	O
the	O
nucleotide	O
2595	O
deletion	O
A	O
was	O
found	O
in	O
five	O
families	O
,	O
the	O
C	O
1806	O
T	O
nonsense	O
mutation	O
in	O
three	O
families	O
,	O
the	O
3166	O
insertion	O
TGAGA	O
in	O
three	O
families	O
,	O
and	O
the	O
nucleotide	O
1201	O
deletion	O
11	O
in	O
two	O
families	O
.	O

Analysis	O
of	O
the	O
intragenic	O
polymorphism	O
D17S855	O
supports	O
common	O
origins	O
of	O
the	O
mutations	O
.	O

Eleven	O
of	O
the	O
15	O
kindreds	O
manifesting	O
BRCA1	O
mutations	O
were	O
breast	B
-	I
ovarian	I
cancer	I
families	O
,	O
several	O
of	O
them	O
with	O
a	O
predominant	O
ovarian	B
cancer	I
phenotype	O
.	O

The	O
set	O
of	O
32	O
families	O
in	O
which	O
no	O
BRCA1	O
alterations	O
were	O
detected	O
included	O
1	O
breast	B
-	I
ovarian	I
cancer	I
kindred	O
manifesting	O
clear	O
linkage	O
to	O
the	O
BRCA1	O
region	O
and	O
loss	O
of	O
the	O
wild	O
-	O
type	O
chromosome	O
in	O
associated	O
tumors	B
.	O

Other	O
tumor	B
types	O
found	O
in	O
BRCA1	O
mutation	O
/	O
haplotype	O
carriers	O
included	O
prostatic	B
,	I
pancreas	I
,	I
skin	I
,	I
and	I
lung	I
cancer	I
,	O
a	O
malignant	B
melanoma	I
,	O
an	O
oligodendroglioma	B
,	O
and	O
a	O
carcinosarcoma	B
.	O

In	O
all	O
,	O
12	O
of	O
16	O
kindreds	O
manifesting	O
BRCA1	O
mutation	O
or	O
linkage	O
contained	O
ovarian	B
cancer	I
,	O
as	O
compared	O
with	O
only	O
6	O
of	O
the	O
remaining	O
31	O
families	O
(	O
P	O
<	O
.	O

001	O
)	O
.	O

The	O
present	O
study	O
confirms	O
the	O
involvement	O
of	O
BRCA1	O
in	O
disease	O
predisposition	O
for	O
a	O
subset	O
of	O
hereditary	B
breast	I
cancer	I
families	O
often	O
characterized	O
by	O
ovarian	B
cancers	I
.	O

Rapid	O
detection	O
of	O
regionally	O
clustered	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
by	O
multiplex	O
heteroduplex	O
analysis	O
.	O

UKCCCR	O
Familial	O
Ovarian	B
Cancer	I
Study	O
Group	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
are	O
responsible	O
for	O
a	O
substantial	O
proportion	O
of	O
families	O
with	O
multiple	O
cases	O
of	O
early	O
-	O
onset	O
breast	B
and/or	I
ovarian	I
cancer	I
.	O

Since	O
the	O
isolation	O
of	O
BRCA1	O
last	O
year	O
,	O
>	O
65	O
distinct	O
mutations	O
scattered	O
throughout	O
the	O
coding	O
region	O
have	O
been	O
detected	O
,	O
making	O
analysis	O
of	O
the	O
gene	O
time	O
consuming	O
and	O
technically	O
challenging	O
.	O

We	O
have	O
developed	O
a	O
multiplex	O
heteroduplex	O
analysis	O
that	O
is	O
designed	O
to	O
analyze	O
one	O
-	O
quarter	O
of	O
the	O
coding	O
sequence	O
in	O
a	O
single	O
-	O
step	O
screening	O
procedure	O
and	O
that	O
will	O
detect	O
approximately	O
50	O
%	O
of	O
all	O
BRCA1	O
mutations	O
so	O
far	O
reported	O
in	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

We	O
have	O
used	O
this	O
technique	O
to	O
analyze	O
BRCA1	O
in	O
162	O
families	O
with	O
a	O
history	O
of	O
breast	B
and/or	I
ovarian	I
cancer	I
and	O
identified	O
12	O
distinct	O
mutations	O
in	O
35	O
families	O
..	O

A	O
previously	O
undescribed	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
of	O
TP53	O
in	O
a	O
family	O
with	O
Li	B
-	I
Fraumeni	I
syndrome	I
.	O

We	O
report	O
details	O
of	O
a	O
family	O
with	O
classic	O
Li	B
-	I
Fraumeni	I
syndrome	I
in	O
which	O
there	O
is	O
a	O
mutation	O
in	O
codon	O
344	O
of	O
the	O
tumour	B
suppressor	O
gene	O
TP53	O
.	O

Codon	O
344	O
is	O
a	O
key	O
residue	O
within	O
the	O
tetramerisation	O
domain	O
,	O
and	O
the	O
amino	O
acid	O
substitution	O
of	O
a	O
proline	O
for	O
a	O
leucine	O
is	O
predicted	O
to	O
have	O
profound	O
implications	O
for	O
tetramerisation	O
and	O
potentially	O
DNA	O
binding	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
mutation	O
at	O
this	O
residue	O
in	O
either	O
sporadic	B
tumours	I
or	O
in	O
the	O
germline	O
and	O
the	O
first	O
report	O
of	O
a	O
germline	O
mutation	O
within	O
the	O
tetramerisation	O
domain	O
.	O

The	O
family	O
does	O
not	O
appear	O
to	O
be	O
remarkable	O
in	O
the	O
spectrum	O
of	O
tumours	B
,	O
and	O
there	O
is	O
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
a	O
leiomyosarcoma	B
from	O
the	O
proband	O
.	O

A	O
cell	O
line	O
has	O
been	O
established	O
from	O
the	O
tumour	B
of	O
the	O
proband	O
and	O
cytogenetic	O
and	O
molecular	O
studies	O
carried	O
out	O
,	O
providing	O
an	O
extensive	O
analysis	O
in	O
this	O
family	O
..	O

The	O
spectrum	O
of	O
RB1	O
germ	O
-	O
line	O
mutations	O
in	O
hereditary	B
retinoblastoma	I
.	O

We	O
have	O
searched	O
for	O
germ	O
-	O
line	O
RB1	O
mutations	O
in	O
119	O
patients	O
with	O
hereditary	B
retinoblastoma	I
.	O

Previous	O
investigations	O
by	O
Southern	O
blot	O
hybridization	O
and	O
PCR	O
fragment	O
-	O
length	O
analysis	O
had	O
revealed	O
mutations	O
in	O
48	O
patients	O
.	O

Here	O
we	O
report	O
on	O
the	O
analysis	O
of	O
the	O
remaining	O
71	O
patients	O
.	O

By	O
applying	O
heteroduplex	O
analysis	O
,	O
nonisotopic	O
SSCP	O
,	O
and	O
direct	O
sequencing	O
,	O
we	O
detected	O
germ	O
-	O
line	O
mutations	O
resulting	O
in	O
premature	O
termination	O
codons	O
or	O
disruption	O
of	O
splice	O
signals	O
in	O
51	O
(	O
72	O
%	O
)	O
of	O
the	O
71	O
patients	O
.	O

Four	O
patients	O
also	O
showed	O
rare	O
sequence	O
variants	O
.	O

No	O
region	O
of	O
the	O
RB1	O
gene	O
was	O
preferentially	O
involved	O
in	O
single	O
base	O
substitutions	O
.	O

Recurrent	O
transitions	O
were	O
observed	O
at	O
most	O
of	O
the	O
14	O
codons	O
within	O
the	O
RB1	O
.	O

No	O
mutation	O
was	O
observed	O
in	O
exons	O
25	O
-	O
27	O
,	O
although	O
this	O
region	O
contains	O
two	O
CGA	O
codons	O
.	O

This	O
suggests	O
that	O
mutations	O
within	O
the	O
3-terminal	O
region	O
of	O
the	O
RB1	O
gene	O
may	O
not	O
be	O
oncogenic	O
.	O

When	O
these	O
data	O
were	O
combined	O
with	O
the	O
results	O
of	O
our	O
previous	O
investigations	O
,	O
mutations	O
were	O
identified	O
in	O
a	O
total	O
of	O
99	O
(	O
83	O
%	O
)	O
of	O
119	O
patients	O
.	O

The	O
spectrum	O
comprises	O
15	O
%	O
large	O
deletions	O
,	O
26	O
%	O
small	O
length	O
alterations	O
,	O
and	O
42	O
%	O
base	O
substitutions	O
.	O

No	O
correlation	O
between	O
the	O
location	O
of	O
frameshift	O
or	O
nonsense	O
mutations	O
and	O
phenotypic	O
features	O
,	O
including	O
age	O
at	O
diagnosis	O
,	O
the	O
number	O
of	O
tumor	B
foci	O
,	O
and	O
manifestation	O
of	O
nonocular	B
tumors	I
was	O
observed	O
..	O

Phenotypic	O
characterization	O
of	O
individuals	O
with	O
30	O
-	O
40	O
CAG	O
repeats	O
in	O
the	O
Huntington	B
disease	I
(	O
HD	B
)	O
gene	O
reveals	O
HD	B
cases	O
with	O
36	O
repeats	O
and	O
apparently	O
normal	O
elderly	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
.	O

Abnormal	O
CAG	O
expansions	O
in	O
the	O
IT-15	O
gene	O
are	O
associated	O
with	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

In	O
the	O
diagnostic	O
setting	O
it	O
is	O
necessary	O
to	O
define	O
the	O
limits	O
of	O
the	O
CAG	O
size	O
ranges	O
on	O
normal	O
and	O
HD	B
-	O
associated	O
chromosomes	O
.	O

Most	O
large	O
analyses	O
that	O
defined	O
the	O
limits	O
of	O
the	O
normal	O
and	O
pathological	O
size	O
ranges	O
employed	O
PCR	O
assays	O
,	O
which	O
included	O
the	O
CAG	O
repeats	O
and	O
a	O
CCG	O
repeat	O
tract	O
that	O
was	O
thought	O
to	O
be	O
invariant	O
.	O

Many	O
of	O
these	O
experiments	O
found	O
an	O
overlap	O
between	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
.	O

Subsequent	O
findings	O
that	O
the	O
CCG	O
repeats	O
vary	O
by	O
8	O
trinucleotide	O
lengths	O
suggested	O
that	O
the	O
limits	O
of	O
the	O
normal	O
and	O
disease	O
size	O
ranges	O
should	O
be	O
reevaluated	O
with	O
assays	O
that	O
exclude	O
the	O
CCG	O
polymorphism	O
.	O

Since	O
patients	O
with	O
between	O
30	O
and	O
40	O
repeats	O
are	O
rare	O
,	O
a	O
consortium	O
was	O
assembled	O
to	O
collect	O
such	O
individuals	O
.	O

All	O
178	O
samples	O
were	O
reanalyzed	O
in	O
Cambridge	O
by	O
using	O
assays	O
specific	O
for	O
the	O
CAG	O
repeats	O
.	O

We	O
have	O
optimized	O
methods	O
for	O
reliable	O
sizing	O
of	O
CAG	O
repeats	O
and	O
show	O
cases	O
that	O
demonstrate	O
the	O
dangers	O
of	O
using	O
PCR	O
assays	O
that	O
include	O
both	O
the	O
CAG	O
and	O
CCG	O
polymorphisms	O
.	O

Seven	O
HD	B
patients	O
had	O
36	O
repeats	O
,	O
which	O
confirms	O
that	O
this	O
allele	O
is	O
associated	O
with	O
disease	O
.	O

Individuals	O
without	O
apparent	O
symptoms	O
or	O
signs	O
of	O
HD	B
were	O
found	O
at	O
36	O
repeats	O
(	O
aged	O
74	O
,	O
78	O
,	O
79	O
,	O
and	O
87	O
years	O
)	O
,	O
37	O
repeats	O
(	O
aged	O
69	O
years	O
)	O
,	O
38	O
repeats	O
(	O
aged	O
69	O
and	O
90	O
years	O
)	O
,	O
and	O
39	O
repeats	O
(	O
aged	O
67	O
,	O
90	O
,	O
and	O
95	O
years	O
)	O
.	O

The	O
detailed	O
case	O
histories	O
of	O
an	O
exceptional	O
case	O
from	O
this	O
series	O
will	O
be	O
presented	O
a	O
95-year	O
-	O
old	O
man	O
with	O
39	O
repeats	O
who	O
did	O
not	O
have	O
classical	O
features	O
of	O
HD	B
.	O

The	O
apparently	O
healthy	O
survival	O
into	O
old	O
age	O
of	O
some	O
individuals	O
with	O
36	O
-	O
39	O
repeats	O
suggests	O
that	O
the	O
HD	B
mutation	O
may	O
not	O
always	O
be	O
fully	O
penetrant	O
..	O

Identification	O
and	O
expression	O
of	O
eight	O
novel	O
mutations	O
among	O
non	O
-	O
Jewish	O
patients	O
with	O
Canavan	B
disease	I
.	O

Canavan	B
disease	I
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
caused	O
by	O
the	O
deficiency	B
of	I
aspartoacylase	I
(	O
ASPA	O
)	O
.	O

The	O
majority	O
of	O
patients	O
with	O
Canavan	B
disease	I
are	O
from	O
an	O
Ashkenazi	O
Jewish	O
background	O
.	O

Mutations	O
in	O
ASPA	O
that	O
lead	O
to	O
loss	O
of	O
enzymatic	O
activity	O
have	O
been	O
identified	O
,	O
and	O
E285A	O
and	O
Y231X	O
are	O
the	O
two	O
predominant	O
mutations	O
that	O
account	O
for	O
97	O
%	O
of	O
the	O
mutant	O
chromosomes	O
in	O
Ashkenazi	O
Jewish	O
patients	O
.	O

The	O
current	O
study	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
basis	O
of	O
Canavan	B
disease	I
in	O
25	O
independent	O
patients	O
of	O
non	O
-	O
Jewish	O
background	O
.	O

Eight	O
novel	O
and	O
three	O
previously	O
characterized	O
mutations	O
accounted	O
for	O
80	O
%	O
(	O
40	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
.	O

The	O
A305E	O
missense	O
mutation	O
accounted	O
for	O
48	O
%	O
(	O
24	O
/	O
50	O
)	O
of	O
mutant	O
chromosomes	O
in	O
patients	O
of	O
western	O
European	O
descent	O
,	O
while	O
the	O
two	O
predominant	O
Jewish	O
mutations	O
each	O
accounted	O
for	O
a	O
single	O
mutant	O
chromosome	O
.	O

The	O
eight	O
novel	O
mutations	O
identified	O
included	O
1-	O
and	O
4-bp	O
deletions	O
(	O
32	O
deltaT	O
and	O
876	O
deltaAGAA	O
,	O
respectively	O
)	O
and	O
I16	O
T	O
,	O
G27R	O
,	O
D114E	O
,	O
G123E	O
,	O
C152Y	O
,	O
and	O
R168C	O
missense	O
mutations	O
.	O

The	O
homozygous	O
32	O
deltaT	O
deletion	O
was	O
identified	O
in	O
the	O
only	O
known	O
patient	O
of	O
African	O
-	O
American	O
origin	O
with	O
Canavan	B
disease	I
.	O

The	O
heterozygosity	O
for	O
876	O
deltaAGAA	O
mutation	O
was	O
identified	O
in	O
three	O
independent	O
patients	O
from	O
England	O
.	O

Six	O
single	O
-	O
base	O
changes	O
leading	O
to	O
missense	O
mutations	O
were	O
identified	O
in	O
patients	O
from	O
Turkey	O
(	O
D114E	O
,	O
R168C	O
)	O
,	O
The	O
Netherlands	O
(	O
I16	O
T	O
)	O
,	O
Germany	O
(	O
G27R	O
)	O
,	O
Ireland	O
(	O
C152Y	O
)	O
,	O
and	O
Canada	O
(	O
G123E	O
)	O
.	O

A	O
PCR	O
-	O
based	O
protocol	O
is	O
described	O
that	O
was	O
used	O
to	O
introduce	O
mutations	O
in	O
wild	O
-	O
type	O
cDNA	O
.	O

In	O
vitro	O
expression	O
of	O
mutant	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
mutations	O
led	O
to	O
a	O
deficiency	B
of	I
ASPA	I
and	O
should	O
therefore	O
result	O
in	O
Canavan	B
disease	I
..	O

Identification	O
and	O
chromosomal	O
localization	O
of	O
Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
.	O

Atm	O
,	O
the	O
mouse	O
homolog	O
of	O
the	O
human	O
ATM	O
gene	O
defective	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
has	O
been	O
identified	O
.	O

The	O
entire	O
coding	O
sequence	O
of	O
the	O
Atm	O
transcript	O
was	O
cloned	O
and	O
found	O
to	O
contain	O
an	O
open	O
reading	O
frame	O
encoding	O
a	O
protein	O
of	O
3066	O
amino	O
acids	O
with	O
84	O
%	O
overall	O
identity	O
and	O
91	O
%	O
similarity	O
to	O
the	O
human	O
ATM	O
protein	O
.	O

Variable	O
levels	O
of	O
expression	O
of	O
Atm	O
were	O
observed	O
in	O
different	O
tissues	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
and	O
linkage	O
analysis	O
located	O
the	O
Atm	O
gene	O
on	O
mouse	O
chromosome	O
9	O
,	O
band	O
9C	O
,	O
in	O
a	O
region	O
homologous	O
to	O
the	O
ATM	O
region	O
on	O
human	O
chromosome	O
11q22-q23	O
..	O

The	O
mouse	O
homolog	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
gene	O
is	O
highly	O
conserved	O
and	O
maps	O
near	O
the	O
scurfy	O
(	O
sf	O
)	O
mutation	O
on	O
the	O
X	O
chromosome	O
.	O

The	O
mouse	O
WASP	O
gene	O
,	O
the	O
homolog	O
of	O
the	O
gene	O
mutated	O
in	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
,	O
has	O
been	O
isolated	O
and	O
sequenced	O
.	O

the	O
predicted	O
amino	O
acid	O
sequence	O
is	O
86	O
%	O
identical	O
to	O
the	O
human	O
WASP	O
sequence	O
.	O

A	O
distinct	O
feature	O
of	O
the	O
mouse	O
gene	O
is	O
an	O
expanded	O
polymorphic	O
GGA	O
trinucleotide	O
repeat	O
that	O
codes	O
for	O
polyglycine	O
and	O
varies	O
from	O
15	O
to	O
17	O
triplets	O
in	O
different	O
Mus	O
musculus	O
strains	O
.	O

The	O
genomic	O
structure	O
of	O
the	O
mouse	O
WASP	O
gene	O
is	O
expressed	O
as	O
an	O
approximately	O
2	O
.	O

4-kb	O
mRNA	O
in	O
thymus	O
and	O
spleen	O
.	O

Chromosomal	O
mapping	O
in	O
an	O
interspecific	O
M.	O
Musculus	O
/	O
M.	O
spretus	O
backcross	O
placed	O
the	O
Wasp	O
locus	O
near	O
the	O
centromere	O
of	O
the	O
mouse	O
X	O
chromosome	O
,	O
inseparable	O
from	O
Gata1	O
,	O
Tcfe3	O
,	O
and	O
scurfy	O
(	O
sf	O
)	O
.	O

This	O
localization	O
makes	O
Wasp	O
a	O
candidate	O
for	O
involvement	O
in	O
scurfy	O
,	O
a	O
T	O
cell	O
-	O
mediated	O
fatal	B
lymphoreticular	I
disease	I
of	O
mice	O
that	O
has	O
previously	O
been	O
proposed	O
as	O
a	O
mouse	O
homolog	O
of	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

Northern	O
analysis	O
of	O
sf	O
tissue	O
samples	O
indicated	O
the	O
presence	O
of	O
WASP	O
mRNA	O
in	O
liver	O
and	O
skin	O
,	O
presumably	O
as	O
a	O
consequence	O
of	O
lymphocytic	O
infiltration	O
,	O
but	O
non	O
abnormalities	O
in	O
the	O
amount	O
or	O
size	O
of	O
mRNA	O
present	O
.	O

Colchicine	O
in	O
breast	O
milk	O
of	O
patients	O
with	O
familial	B
Mediterranean	I
fever	I
.	O

OBJECTIVE	O
.	O

To	O
clarify	O
whether	O
colchicine	O
is	O
excreted	O
in	O
breast	O
milk	O
,	O
and	O
to	O
compare	O
its	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
lactating	O
women	O
who	O
have	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
.	O

METHODS	O
.	O

Using	O
a	O
specific	O
radioimmunoassay	O
,	O
we	O
determined	O
colchicine	O
concentrations	O
in	O
the	O
serum	O
and	O
breast	O
milk	O
of	O
4	O
patients	O
at	O
various	O
time	O
points	O
,	O
following	O
oral	O
administration	O
of	O
the	O
drug	O
.	O

The	O
study	O
evaluated	O
4	O
patients	O
with	O
FMF	B
who	O
had	O
been	O
taking	O
colchicine	O
on	O
a	O
long	O
-	O
term	O
basis	O
.	O

RESULTS	O
.	O

Colchicine	O
was	O
found	O
to	O
be	O
excreted	O
in	O
breast	O
milk	O
.	O

Its	O
levels	O
ranged	O
between	O
1	O
.	O
9	O
and	O
8	O
.	O
6	O
ng	O
/	O
ml	O
,	O
which	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
serum	O
(	O
parallel	O
concentration	O
time	O
curves	O
)	O
.	O

However	O
,	O
there	O
appeared	O
to	O
be	O
a	O
considerable	O
variation	O
in	O
colchicine	O
milk	O
concentration	O
among	O
the	O
different	O
patients	O
,	O
which	O
might	O
be	O
related	O
to	O
individual	O
breast	O
milk	O
composition	O
and	O
,	O
possibly	O
,	O
to	O
other	O
nutritional	O
or	O
metabolic	O
factors	O
.	O

CONCLUSION	O
.	O

The	O
extensive	O
peripheral	O
tissue	O
binding	O
and	O
relatively	O
low	O
concentration	O
of	O
colchicine	O
in	O
breast	O
milk	O
suggests	O
that	O
the	O
amount	O
ingested	O
by	O
the	O
infant	O
is	O
small	O
.	O

Furthermore	O
,	O
based	O
on	O
our	O
clinical	O
experience	O
,	O
nursing	O
appears	O
to	O
be	O
safe	O
for	O
lactating	O
women	O
with	O
FMF	B
who	O
continue	O
to	O
take	O
colchicine	O
.	O

Abnormal	O
myotonic	B
dystrophy	I
protein	O
kinase	O
levels	O
produce	O
only	O
mild	O
myopathy	B
in	O
mice	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
commonly	O
associated	O
with	O
CTG	O
repeat	O
expansions	O
within	O
the	O
gene	O
for	O
DM	O
-	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

The	O
effect	O
of	O
altered	O
expression	O
levels	O
of	O
DMPK	O
,	O
which	O
is	O
ubiquitously	O
expressed	O
in	O
all	O
muscle	O
cell	O
lineages	O
during	O
development	O
,	O
was	O
examined	O
by	O
disrupting	O
the	O
endogenous	O
Dmpk	O
gene	O
and	O
overexpressing	O
a	O
normal	O
human	O
DMPK	O
transgene	O
in	O
mice	O
.	O

Nullizygous	O
(	O
-	O
/	O
-	O
)	O
mice	O
showed	O
only	O
inconsistent	O
and	O
minor	O
size	O
changes	O
in	O
head	O
and	O
neck	O
muscle	O
fibres	O
at	O
older	O
age	O
,	O
animals	O
with	O
the	O
highest	O
DMPK	O
transgene	O
expression	O
showed	O
hypertrophic	B
cardiomyopathy	I
and	O
enhanced	O
neonatal	O
mortality	O
.	O

However	O
,	O
both	O
models	O
lack	O
other	O
frequent	O
DM	B
symptoms	O
including	O
the	O
fibre	O
-	O
type	O
dependent	O
atrophy	B
,	O
myotonia	B
,	O
cataract	B
and	O
male	B
-	I
infertility	I
.	O

These	O
results	O
strengthen	O
the	O
contention	O
that	O
simple	O
loss-	O
or	O
gain	O
-	O
of	O
-	O
expression	O
of	O
DMPK	O
is	O
not	O
the	O
only	O
crucial	O
requirement	O
for	O
development	O
of	O
the	O
disease	O
..	O

Mice	O
lacking	O
the	O
myotonic	B
dystrophy	I
protein	O
kinase	O
develop	O
a	O
late	O
onset	O
progressive	O
myopathy	B
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disorder	I
resulting	O
from	O
the	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
putative	O
protein	O
kinase	O
(	O
DMPK	O
)	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
DMPK	O
in	O
DM	B
pathogenesis	O
we	O
have	O
developed	O
Dmpk	B
deficient	I
(	O
Dmpk-	O
/	O
-	O
)	O
mice	O
.	O

Dmpk-	O
/	O
-mice	O
develop	O
a	O
late	O
-	O
onset	O
,	O
progressive	B
skeletal	I
myopathy	I
that	O
shares	O
some	O
pathological	O
features	O
with	O
DM	B
.	O

Muscles	O
from	O
mature	O
mice	O
show	O
variation	O
in	O
fibre	O
size	O
,	O
increased	O
fibre	B
degeneration	I
and	O
fibrosis	B
.	O

Adult	O
Dmpk-	O
/	O
-mice	O
show	O
ultrastructural	O
changes	O
in	O
muscle	O
and	O
a	O
50	O
%	O
decrease	O
in	O
force	O
generation	O
compared	O
to	O
young	O
mice	O
.	O

Our	O
results	O
indicate	O
that	O
DMPK	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
skeletal	O
muscle	O
structure	O
and	O
function	O
and	O
suggest	O
that	O
a	O
decrease	O
in	O
DMPK	O
levels	O
may	O
contribute	O
to	O
DM	B
pathology	O
..	O

The	O
tumor	B
suppressor	O
gene	O
Brca1	O
is	O
required	O
for	O
embryonic	O
cellular	O
proliferation	O
in	O
the	O
mouse	O
.	O

Mutations	O
of	O
the	O
BRCA1	O
gone	O
in	O
humans	O
are	O
associated	O
with	O
predisposition	O
to	O
breast	B
and	I
ovarian	I
cancers	I
.	O

We	O
show	O
here	O
that	O
Brca1	O
+	O
/-	O

mice	O
are	O
normal	O
and	O
fertile	O
and	O
lack	O
tumors	B
by	O
age	O
eleven	O
months	O
.	O

Homozygous	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O

5	O
of	O
embryogenesis	O
.	O

Mutant	O
embryos	O
are	O
poorly	O
developed	O
,	O
with	O
no	O
evidence	O
of	O
mesoderm	O
formation	O
.	O

The	O
extraembryonic	O
region	O
is	O
abnormal	O
,	O
but	O
aggregation	O
with	O
wild	O
-	O
type	O
tetraploid	O
embryos	O
does	O
not	O
rescue	O
the	O
lethality	O
.	O

In	O
vivo	O
,	O
mutant	O
embryos	O
do	O
not	O
exhibit	O
increased	O
apoptosis	O
but	O
show	O
reduced	O
cell	O
proliferation	O
accompanied	O
by	O
decreased	O
expression	O
of	O
cyclin	O
E	O
and	O
mdm-2	O
,	O
a	O
regulator	O
of	O
p53	O
activity	O
.	O

The	O
expression	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21	O
is	O
dramatically	O
increased	O
in	O
the	O
mutant	O
embryos	O
.	O

Buttressing	O
these	O
in	O
vivo	O
observations	O
is	O
the	O
fact	O
that	O
mutant	O
blastocyst	O
growth	O
is	O
grossly	O
impaired	O
in	O
vitro	O
.	O

Thus	O
,	O
the	O
death	O
of	O
Brca1	O
(	O
5	O
-	O
6	O
)	O
mutant	O
embryos	O
prior	O
to	O
gastrulation	O
may	O
be	O
due	O
to	O
a	O
failure	O
of	O
the	O
proliferative	O
burst	O
required	O
for	O
the	O
development	O
of	O
the	O
different	O
germ	O
layers	O
.	O

Increased	O
coronary	B
heart	I
disease	I
in	O
Japanese	O
-	O
American	O
men	O
with	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
despite	O
increased	O
HDL	O
levels	O
.	O

Plasma	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
levels	O
are	O
strongly	O
genetically	O
determined	O
and	O
show	O
a	O
general	O
inverse	O
relationship	O
with	O
coronary	B
heart	I
disease	I
(	O
CHD	B
)	O
.	O

The	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
mediates	O
the	O
transfer	O
of	O
cholesteryl	O
esters	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
and	O
is	O
a	O
key	O
participant	O
in	O
the	O
reverse	O
transport	O
of	O
cholesterol	O
from	O
the	O
periphery	O
to	O
the	O
liver	O
.	O

A	O
high	O
prevalence	O
of	O
two	O
different	O
CETP	O
gene	O
mutations	O
(	O
D442	O
G	O
,	O
5	O
.	O
1	O
%	O
;	O
intron	O
14	O
G	O
A	O
,	O
0	O
.	O
5	O
%	O
)	O
,	O
was	O
found	O
in	O
3	O
,	O
469	O
men	O
of	O
Japanese	O
ancestry	O
in	O
the	O
Honolulu	O
Heart	O
Program	O
and	O
mutations	O
were	O
associated	O
with	O
decreased	O
CETP	O
(	O
-35	O
%	O
)	O
and	O
increased	O
HDL	O
chol	O
levels	O
(	O
+	O
10	O
%	O
for	O
D442	O
G	O
)	O
.	O

However	O
,	O
the	O
overall	O
prevalence	O
of	O
definite	O
CHD	B
was	O
21	O
%	O
in	O
men	O
with	O
mutations	O
and	O
16	O
%	O
in	O
men	O
without	O
mutations	O
.	O

The	O
relative	O
risk	O
(	O
RR	O
)	O
of	O
CHD	B
was	O
1	O
.	O
43	O
in	O
men	O
with	O
mutations	O
(	O
P	O
<	O
.	O
05	O
)	O
;	O
after	O
adjustment	O
for	O
CHD	B
risk	O
factors	O
,	O
the	O
RR	O
was	O
1	O
.	O
55	O
(	O
P	O
=	O
.	O
02	O
)	O
;	O
after	O
additional	O
adjustment	O
for	O
HDL	O
levels	O
,	O
the	O
RR	O
was	O
1	O
.	O
68	O
(	O
P	O
=	O
.	O
008	O
)	O
.	O

Similar	O
RR	O
values	O
were	O
obtained	O
for	O
the	O
D442	O
G	O
mutation	O
alone	O
.	O

Increased	O
CHD	B
in	O
men	O
with	O
mutations	O
was	O
primarily	O
observed	O
for	O
HDL	O
chol	O
41	O
-	O
60	O
mg	O
/	O
dl	O
;	O
for	O
HDL	O
chol	O
>	O
60	O
mg	O
/	O
dl	O
men	O
with	O
and	O
without	O
mutations	O
had	O
low	O
CHD	B
prevalence	O
.	O

Thus	O
,	O
genetic	O
CETP	B
deficiency	I
appears	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
CHD	B
,	O
primarily	O
due	O
to	O
increased	O
CHD	B
prevalence	O
in	O
men	O
with	O
the	O
D442	O
G	O
mutation	O
and	O
HDL	O
cholesterol	O
between	O
41	O
and	O
60	O
mg	O
/	O
dl	O
.	O

The	O
findings	O
suggest	O
that	O
both	O
HDL	O
concentration	O
and	O
the	O
dynamics	O
of	O
cholesterol	O
transport	O
through	O
HDL	O
(	O
i.	O
e.	O
,	O
reverse	O
cholesterol	O
transport	O
)	O
determine	O
the	O
anti	O
-	O
atherogenicity	O
of	O
the	O
HDL	O
fraction	O
.	O

Mapping	O
the	O
homolog	O
of	O
the	O
human	O
Rb1	O
gene	O
to	O
chromosome	O
14	O
of	O
higher	O
primates	O
.	O

The	O
Rb1	O
gene	O
has	O
been	O
implicated	O
with	O
retinoblastoma	B
and	O
is	O
located	O
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
13q14	O
.	O

2	O
2	O
.	O

A	O
unique	O
sequence	O
human	O
Rb1	O
cosmid	O
DNA	O
probe	O
has	O
been	O
used	O
to	O
localize	O
this	O
region	O
on	O
apes	O
Chr	O
14	O
by	O
the	O
FISH	O
technique	O
.	O

The	O
conservation	O
of	O
the	O
Rb1	O
gene	O
in	O
higher	O
primates	O
at	O
the	O
corresponding	O
equivalent	O
chromosome	O
locus	O
(	O
14q14	O
)	O
of	O
the	O
human	O
may	O
serve	O
as	O
a	O
phylogenetic	O
marker	O
to	O
further	O
trace	O
the	O
evolutionary	O
pathway	O
of	O
human	O
descent	O
.	O

Wiskott	B
-	I
Aldrich	I
syndrome	I
:	O
no	O
strict	O
genotype	O
-	O
phenotype	O
correlations	O
but	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
amino	O
-	O
terminal	O
part	O
of	O
the	O
WASP	O
gene	O
product	O
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
protein	O
(	O
WASP	O
)	O
gene	O
was	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
presenting	O
with	O
WAS	B
and	O
in	O
patients	O
showing	O
X	B
-	I
linked	I
thrombocytopenia	I
.	O

Mutation	O
analysis	O
in	O
19	O
families	O
of	O
German	O
,	O
Swiss	O
and	O
Turkish	O
descent	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
sequencing	O
resulted	O
in	O
the	O
detection	O
of	O
seven	O
novel	O
and	O
10	O
known	O
mutations	O
.	O

A	O
striking	O
clustering	O
of	O
missense	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
contrasted	O
with	O
a	O
random	O
distribution	O
of	O
nonsense	O
mutations	O
.	O

More	O
than	O
85	O
%	O
of	O
all	O
known	O
missense	O
mutations	O
were	O
localized	O
in	O
the	O
amino	O
-	O
terminal	O
stretch	O
of	O
the	O
WASP	O
gene	O
product	O
;	O
this	O
region	O
contained	O
a	O
mutational	O
hot	O
spot	O
at	O
codon	O
86	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
emerged	O
after	O
a	O
comparison	O
of	O
the	O
identified	O
mutations	O
with	O
the	O
resulting	O
clinical	O
picture	O
for	O
a	O
classical	O
WAS	B
phenotype	O
.	O

A	O
substitution	O
at	O
codon	O
86	O
resulted	O
in	O
an	O
extremely	O
variable	O
expression	O
of	O
the	O
disease	O
in	O
a	O
large	O
Swiss	O
family	O
.	O

An	O
extended	O
homology	O
search	O
revealed	O
a	O
distant	O
relationship	O
of	O
this	O
stretch	O
to	O
the	O
vasodilator	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
maintenance	O
of	O
cyto	O
-	O
architecture	O
by	O
interacting	O
with	O
actin	O
-	O
like	O
filaments	O
..	O

Influence	O
of	O
PAX6	O
gene	O
dosage	O
on	O
development	O
:	O
overexpression	O
causes	O
severe	O
eye	B
abnormalities	I
.	O

Aniridia	B
in	O
man	O
and	O
Small	O
eye	O
in	O
mice	O
are	O
semidominant	B
developmental	I
disorders	I
caused	O
by	O
mutations	O
within	O
the	O
paired	O
box	O
gene	O
PAX6	O
.	O

Whereas	O
heterozygotes	O
suffer	O
from	O
iris	B
hypoplasia	I
,	O
homozygous	O
mice	O
lack	O
eyes	O
and	O
nasal	O
cavities	O
and	O
exhibit	O
brain	B
abnormalities	I
.	O

To	O
investigate	O
the	O
role	O
of	O
gene	O
dosage	O
in	O
more	O
detail	O
,	O
we	O
have	O
generated	O
yeast	O
artificial	O
chromosome	O
transgenic	O
mice	O
carrying	O
the	O
human	O
PAX6	O
locus	O
.	O

When	O
crossed	O
onto	O
the	O
Small	O
eye	O
background	O
,	O
the	O
transgene	O
rescues	O
the	O
mutant	O
phenotype	O
.	O

Strikingly	O
,	O
mice	O
carrying	O
multiple	O
copies	O
on	O
a	O
wild	O
-	O
type	O
background	O
show	O
specific	O
developmental	B
abnormalities	I
of	I
the	I
eye	I
,	O
but	O
not	O
of	O
other	O
tissues	O
expressing	O
the	O
gene	O
.	O

Thus	O
,	O
at	O
least	O
five	O
different	O
eye	O
phenotypes	O
are	O
associated	O
with	O
changes	O
in	O
PAX6	O
expression	O
.	O

We	O
provide	O
evidence	O
that	O
not	O
only	O
reduced	O
,	O
but	O
also	O
increased	O
levels	O
of	O
transcriptional	O
regulators	O
can	O
cause	O
developmental	B
defects	I
..	O

Heterodimer	O
formation	O
and	O
activity	O
in	O
the	O
human	O
enzyme	O
galactose-1-phosphate	O
uridylyltransferase	O
.	O

One	O
of	O
the	O
fundamental	O
questions	O
concerning	O
expression	O
and	O
function	O
of	O
dimeric	O
enzymes	O
involves	O
the	O
impact	O
of	O
naturally	O
occurring	O
mutations	O
on	O
subunit	O
assembly	O
and	O
heterodimer	O
activity	O
.	O

This	O
question	O
is	O
of	O
particular	O
interest	O
for	O
the	O
human	O
enzyme	O
galactose	O
-	O
l	O
-	O
phosphate	O
uridylyl	O
-	O
transferase	O
(	O
GALT	O
)	O
,	O
impairment	O
of	O
which	O
results	O
in	O
the	O
inherited	B
metabolic	I
disorder	I
galactosemia	B
,	O
because	O
many	O
if	O
not	O
most	O
patients	O
studied	O
to	O
date	O
are	O
compound	O
heterozygotes	O
rather	O
than	O
true	O
molecular	O
homozygotes	O
.	O

Furthermore	O
,	O
the	O
broad	O
range	O
of	O
phenotypic	O
severity	O
observed	O
in	O
these	O
patients	O
raises	O
the	O
possibility	O
that	O
allelic	O
combination	O
,	O
not	O
just	O
allelic	O
constitution	O
,	O
may	O
play	O
some	O
role	O
in	O
determining	O
outcome	O
.	O

In	O
the	O
work	O
described	O
herein	O
,	O
we	O
have	O
selected	O
two	O
distinct	O
naturally	O
occurring	O
null	O
mutations	O
of	O
GALT	O
,	O
Q188R	O
and	O
R333W	O
,	O
and	O
asked	O
the	O
questions	O
(	O
i	O
)	O
what	O
are	O
the	O
impacts	O
of	O
these	O
mutations	O
on	O
subunit	O
assembly	O
,	O
and	O
(	O
ii	O
)	O
if	O
heterodimers	O
do	O
form	O
,	O
are	O
they	O
active	O
?	O

To	O
answer	O
these	O
questions	O
,	O
we	O
have	O
established	O
a	O
yeast	O
system	O
for	O
the	O
coexpression	O
of	O
epitope	O
-	O
tagged	O
alleles	O
of	O
human	O
GALT	O
and	O
investigated	O
both	O
the	O
extent	O
of	O
specific	O
GALT	O
subunit	O
interactions	O
and	O
the	O
activity	O
of	O
defined	O
heterodimer	O
pools	O
.	O

We	O
have	O
found	O
that	O
both	O
homodimers	O
and	O
heterodimers	O
do	O
form	O
involving	O
each	O
of	O
the	O
mutant	O
subunits	O
tested	O
and	O
that	O
both	O
heterodimer	O
pools	O
retain	O
substantial	O
enzymatic	O
activity	O
.	O

These	O
results	O
are	O
significant	O
not	O
only	O
in	O
terms	O
of	O
their	O
implications	O
for	O
furthering	O
our	O
understanding	O
of	O
galactosemia	B
and	O
GALT	O
holoenzyme	O
structure	O
-	O
function	O
relationships	O
but	O
also	O
because	O
the	O
system	O
described	O
may	O
serve	O
as	O
a	O
model	O
for	O
similar	O
studies	O
of	O
other	O
complexes	O
composed	O
of	O
multiple	O
subunits	O
..	O

Cleavage	O
of	O
huntingtin	O
by	O
apopain	O
,	O
a	O
proapoptotic	O
cysteine	O
protease	O
,	O
is	O
modulated	O
by	O
the	O
polyglutamine	O
tract	O
.	O

Apoptosis	O
has	O
recently	O
been	O
recognized	O
as	O
a	O
mode	O
of	O
cell	O
death	O
in	O
Huntington	B
disease	I
(	O
HD	B
)	O
.	O

Apopain	O
,	O
a	O
human	O
counterpart	O
of	O
the	O
nematode	O
cysteine	O
protease	O
death	O
-	O
gene	O
product	O
,	O
CED-3	O
,	O
has	O
a	O
key	O
role	O
in	O
proteolytic	O
events	O
leading	O
to	O
apoptosis	O
.	O

Here	O
we	O
show	O
that	O
apoptotic	O
extracts	O
and	O
apopain	O
itself	O
specifically	O
cleave	O
the	O
HD	B
gene	O
product	O
,	O
huntingtin	O
.	O

The	O
rate	O
of	O
cleavage	O
increases	O
with	O
the	O
length	O
of	O
the	O
huntingtin	O
polyglutamine	O
tract	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
associated	O
with	O
CAG	O
expansion	O
.	O

Our	O
results	O
show	O
that	O
huntingtin	O
is	O
cleaved	O
by	O
cysteine	O
proteases	O
and	O
suggest	O
that	O
HD	B
might	O
be	O
a	O
disorder	B
of	I
inappropriate	I
apoptosis	I
..	O

The	O
5	O
'	O
end	O
of	O
the	O
BRCA1	O
gene	O
lies	O
within	O
a	O
duplicated	O
region	O
of	O
human	O
chromosome	O
17q21	O
.	O

To	O
begin	O
to	O
address	O
the	O
hypothesis	O
that	O
abnormal	O
regulation	O
of	O
the	O
breast	B
/	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
is	O
a	O
critical	O
step	O
in	O
sporadic	O
breast	O
/	O
ovarian	O
tumorigenesis	O
,	O
we	O
have	O
determined	O
the	O
detailed	O
structure	O
of	O
the	O
BRCA1	O
genomic	O
region	O
.	O

We	O
show	O
that	O
this	O
region	O
of	O
the	O
genome	O
contains	O
a	O
tandem	O
duplication	O
of	O
approximately	O
30	O
kilobases	O
,	O
which	O
results	O
in	O
two	O
copies	O
of	O
BRCA1	O
exons	O
1	O
and	O
2	O
,	O
of	O
exons	O
1	O
and	O
3	O
of	O
the	O
adjacent	O
1A1	O
-	O
3B	O
gene	O
and	O
of	O
the	O
previously	O
reported	O
295	O
base	O
pair	O
intergenic	O
region	O
.	O

Sequence	O
analysis	O
of	O
the	O
duplicated	O
exons	O
of	O
BRCA1	O
and	O
1A1	O
-	O
3B	O
and	O
flanking	O
genomic	O
DNA	O
reveals	O
maintenance	O
of	O
the	O
intron	O
-	O
exon	O
structure	O
and	O
a	O
high	O
degree	O
of	O
nucleotide	O
sequence	O
identity	O
,	O
suggesting	O
that	O
these	O
are	O
non	O
-	O
processed	O
pseudogenes	O
and	O
that	O
the	O
duplication	O
is	O
a	O
recent	O
event	O
in	O
evolutionary	O
terms	O
.	O

We	O
also	O
show	O
that	O
a	O
processed	O
pseudogene	O
of	O
the	O
acidic	O
ribosomal	O
phosphoprotein	O
P1	O
(	O
ARPP1	O
)	O
is	O
inserted	O
directly	O
upstream	O
of	O
pseudo	O
-	O
BRCA1	O
exon	O
1A	O
.	O

We	O
believe	O
that	O
these	O
findings	O
could	O
not	O
only	O
confound	O
BRCA1	O
mutation	O
analysis	O
,	O
but	O
could	O
have	O
implications	O
for	O
the	O
normal	O
and	O
abnormal	O
regulation	O
of	O
BRCA1	O
transcription	O
,	O
translation	O
and	O
function	O
..	O

Deletion	O
of	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
:	O
two	O
sibs	O
with	O
the	O
typical	O
phenotype	O
without	O
a	O
cytogenetic	O
deletion	O
in	O
chromosome	O
15q	O
.	O

The	O
small	O
nuclear	O
ribonucleoprotein	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
is	O
regarded	O
as	O
one	O
of	O
the	O
candidates	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
describe	O
two	O
sibs	O
with	O
typical	O
PWS	B
presenting	O
deletion	O
of	O
SNRPN	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Neither	O
a	O
cytogenetically	O
detectable	O
15q12	O
deletion	O
nor	O
a	O
deletion	O
for	O
the	O
D15S11	O
,	O
D15S10	O
,	O
and	O
GABRB3	O
cosmid	O
probes	O
were	O
found	O
in	O
either	O
patient	O
.	O

This	O
implies	O
a	O
smaller	O
deletion	O
limited	O
to	O
the	O
PWS	B
critical	O
region	O
.	O

FISH	O
with	O
a	O
SNRPN	O
probe	O
will	O
permit	O
analysis	O
of	O
PWS	B
patients	O
with	O
limited	O
deletions	O
not	O
detectable	O
with	O
other	O
probes	O
..	O

Expression	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
tumour	I
suppressor	O
gene	O
during	O
human	O
embryogenesis	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
disease	I
product	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
transcription	O
by	O
antagonizing	O
elongin	O
-	O
enhanced	O
transcriptional	O
elongation	O
.	O

Germline	O
VHL	B
gene	O
mutations	O
predispose	O
to	O
the	O
development	O
of	O
retinal	B
,	I
cerebellar	I
and	I
spinal	I
haemangioblastomas	I
,	O
renal	B
cell	I
carcinoma	I
and	O
phaeochromocytoma	B
.	O

In	O
addition	O
,	O
somatic	O
Inactivation	O
of	O
the	O
VHL	B
gene	O
is	O
frequent	O
in	O
sporadic	B
renal	I
cell	I
carcinoma	I
and	O
haemangioblastoma	B
.	O

Regulation	O
of	O
transcript	O
elongation	O
is	O
an	O
important	O
control	O
mechanism	O
for	O
gene	O
expression	O
and	O
the	O
VHL	B
gene	O
might	O
modify	O
the	O
expression	O
of	O
proto	O
-	O
oncogenes	O
and	O
growth	O
suppressor	O
genes	O
during	O
embryogenesis	O
.	O

We	O
therefore	O
investigated	O
the	O
expression	O
of	O
VHL	B
mRNA	O
during	O
human	O
embryogenesis	O
by	O
in	O
situ	O
hybridization	O
studies	O
at	O
4	O
,	O
6	O
and	O
10	O
weeks	O
post	O
conception	O
.	O

Although	O
VHL	B
mRNA	O
was	O
expressed	O
in	O
all	O
three	O
germ	O
layers	O
,	O
strong	O
expression	O
was	O
noted	O
in	O
the	O
central	O
nervous	O
system	O
,	O
kidneys	O
,	O
testis	O
and	O
lung	O
.	O

Within	O
the	O
kidney	O
,	O
VHL	B
mRNA	O
was	O
differentially	O
expressed	O
within	O
renal	O
tubules	O
suggesting	O
that	O
the	O
VHL	B
gene	O
product	O
may	O
have	O
a	O
specific	O
role	O
in	O
kidney	O
development	O
.	O

Two	O
alternatively	O
spliced	O
VHL	B
mRNAs	O
characterized	O
by	O
inclusion	O
(	O
isoform	O
I	O
)	O
or	O
exclusion	O
(	O
isoform	O
II	O
)	O
of	O
exon	O
2	O
are	O
transcribed	O
in	O
adult	O
tissues	O
.	O

To	O
investigate	O
if	O
the	O
two	O
isoforms	O
are	O
differentially	O
expressed	O
during	O
embryogenesis	O
,	O
VHL	B
mRNA	O
was	O
reverse	O
transcribed	O
from	O
13	O
fetal	O
tissues	O
(	O
8	O
-	O
10	O
weeks	O
gestation	O
)	O
.	O

The	O
quantitative	O
distribution	O
of	O
VHL	B
mRNA	O
within	O
fetal	O
tissues	O
reflected	O
that	O
seen	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
ratio	O
of	O
the	O
two	O
VHL	B
isoforms	O
was	O
similar	O
between	O
tissues	O
.	O

Although	O
the	O
genes	O
regulated	O
by	O
the	O
VHL	B
gene	O
product	O
have	O
not	O
yet	O
been	O
identified	O
,	O
our	O
findings	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
VHL	B
-	O
mediated	O
control	O
of	O
transcriptional	O
elongation	O
may	O
have	O
a	O
role	O
in	O
normal	O
human	O
development	O
..	O

Genetic	O
heterogeneity	O
in	O
hereditary	B
breast	I
cancer	I
:	O
role	O
of	O
BRCA1	O
and	O
BRCA2	O
.	O

The	O
common	O
hereditary	O
forms	O
of	O
breast	B
cancer	I
have	O
been	O
largely	O
attributed	O
to	O
the	O
inheritance	O
of	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
genes	O
.	O

However	O
,	O
it	O
is	O
not	O
yet	O
clear	O
what	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
is	O
explained	O
by	O
BRCA1	O
and	O
BRCA2	O
or	O
by	O
some	O
other	O
unidentified	O
susceptibility	O
gene	O
(	O
s	O
)	O
.	O

We	O
describe	O
the	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
explained	O
by	O
BRCA1	O
or	O
BRCA2	O
in	O
a	O
sample	O
of	O
North	O
American	O
hereditary	B
breast	I
cancers	I
and	O
assess	O
the	O
evidence	O
for	O
additional	O
susceptibility	O
genes	O
that	O
may	O
confer	O
hereditary	B
breast	I
or	I
ovarian	I
cancer	I
risk	O
.	O

Twenty	O
-	O
three	O
families	O
were	O
identified	O
through	O
two	O
high	O
-	O
risk	O
breast	B
cancer	I
research	O
programs	O
.	O

Genetic	O
analysis	O
was	O
undertaken	O
to	O
establish	O
linkage	O
between	O
the	O
breast	B
or	I
ovarian	I
cancer	I
cases	O
and	O
markers	O
on	O
chromosomes	O
17q	O
(	O
BRCA1	O
)	O
and	O
13q	O
(	O
BRCA2	O
)	O
.	O

Mutation	O
analysis	O
in	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
was	O
also	O
undertaken	O
in	O
all	O
families	O
.	O

The	O
pattern	O
of	O
hereditary	B
cancer	I
in	O
14	O
(	O
61	O
%	O
)	O
of	O
the	O
23	O
families	O
studied	O
was	O
attributed	O
to	O
BRCA1	O
by	O
a	O
combination	O
of	O
linkage	O
and	O
mutation	O
analyses	O
.	O

No	O
families	O
were	O
attributed	O
to	O
BRCA2	O
.	O

Five	O
families	O
(	O
22	O
%	O
)	O
provided	O
evidence	O
against	O
linkage	O
to	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

No	O
BRCA1	O
or	O
BRCA2	O
mutations	O
were	O
detected	O
in	O
these	O
five	O
families	O
.	O

The	O
BRCA1	O
or	O
BRCA2	O
status	O
of	O
four	O
families	O
(	O
17	O
%	O
)	O
could	O
not	O
be	O
determined	O
.	O

BRCA1	O
and	O
BRCA2	O
probably	O
explain	O
the	O
majority	O
of	O
hereditary	B
breast	I
cancer	I
that	O
exists	O
in	O
the	O
North	O
American	O
population	O
.	O

However	O
,	O
one	O
or	O
more	O
additional	O
genes	O
may	O
yet	O
be	O
found	O
that	O
explain	O
some	O
proportion	O
of	O
hereditary	B
breast	I
cancer	I
..	O

An	O
intronic	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
sequence	O
is	O
a	O
direct	O
cause	O
of	O
an	O
inherited	B
human	I
disorder	I
(	O
fish	B
-	I
eye	I
disease	I
)	O
.	O

The	O
first	O
step	O
in	O
the	O
splicing	O
of	O
an	O
intron	O
from	O
nuclear	O
precursors	O
of	O
mRNA	O
results	O
in	O
the	O
formation	O
of	O
a	O
lariat	O
structure	O
.	O

A	O
distinct	O
intronic	O
nucleotide	O
sequence	O
,	O
known	O
as	O
the	O
branchpoint	O
region	O
,	O
plays	O
a	O
central	O
role	O
in	O
this	O
process	O
.	O

We	O
here	O
describe	O
a	O
point	O
mutation	O
in	O
such	O
a	O
sequence	O
.	O

Three	O
sisters	O
were	O
shown	O
to	O
suffer	O
from	O
fish	B
-	I
eye	I
disease	I
(	O
FED	B
)	O
,	O
a	O
disorder	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
coding	O
for	O
lecithin	O
cholesterol	O
acyltransferase	O
(	O
LCAT	O
)	O
.	O

Sequencing	O
of	O
the	O
LCAT	O
gene	O
of	O
all	O
three	O
probands	O
revealed	O
compound	O
heterozygosity	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
4	O
which	O
is	O
reported	O
to	O
underlie	O
the	O
FED	B
phenotype	O
,	O
and	O
a	O
point	O
mutation	O
located	O
in	O
intron	O
4	O
(	O
IVS4	O
T-22C	O
)	O
.	O

By	O
performing	O
in	O
vitro	O
expression	O
of	O
LCAT	O
minigenes	O
and	O
reverse	O
transcriptase	O
PCR	O
on	O
mRNA	O
isolated	O
from	O
leukocytes	O
of	O
the	O
patient	O
,	O
this	O
gene	O
defect	O
was	O
shown	O
to	O
cause	O
a	O
null	O
allele	O
as	O
the	O
result	O
of	O
complete	O
intron	O
retention	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrated	O
that	O
a	O
point	O
mutation	O
in	O
a	O
lariat	O
branchpoint	O
consensus	O
sequence	O
causes	O
a	O
null	O
allele	O
in	O
a	O
patient	O
with	O
FED	B
.	O

In	O
addition	O
,	O
our	O
finding	O
illustrates	O
the	O
importance	O
of	O
this	O
sequence	O
for	O
normal	O
human	O
mRNA	O
processing	O
.	O

Finally	O
,	O
this	O
report	O
provides	O
a	O
widely	O
applicable	O
strategy	O
which	O
ensures	O
fast	O
and	O
effective	O
screening	O
for	O
intronic	O
defects	O
that	O
underlie	O
differential	O
gene	O
expression	O
..	O

Mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B
-	I
telangiectasia	I
.	O

We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	O
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-15	O
%	O
of	O
A	B
-	I
T	I
families	O
identified	O
in	O
the	O
United	O
Kingdom	O
)	O
.	O

In	O
10	O
of	O
these	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137-bp	O
insertion	O
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
.	O

The	O
second	O
A	B
-	I
T	I
allele	O
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	O
.	O

We	O
show	O
that	O
the	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	O
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
.	O

The	O
level	O
of	O
the	O
137-bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	O
who	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	B
ataxia	I
.	O

A	O
further	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
insertion	O
have	O
been	O
identified	O
.	O

Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
A	B
-	I
T	I
patients	O
.	O

The	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	B
-	I
T	I
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	O
mutations	O
are	O
more	O
common	O
than	O
we	O
realize	O
..	O

Mutation	O
of	O
the	O
VHL	O
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
.	O

To	O
define	O
the	O
possible	O
role	O
of	O
the	O
VHL	B
gene	O
in	O
the	O
development	O
of	O
sporadic	B
renal	I
cell	I
carcinomas	I
,	O
91	O
different	O
parenchymal	B
tumours	I
of	I
the	I
kidney	I
have	O
been	O
investigated	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
and/or	O
heteroduplex	O
(	O
HD	O
)	O
techniques	O
.	O

Chromosome	O
3p	O
deletion	O
was	O
detected	O
in	O
98	O
per	O
cent	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
and	O
in	O
25	O
per	O
cent	O
of	O
chromophobe	O
renal	B
cell	I
carcinomas	I
.	O

In	O
22	O
of	O
the	O
43	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinomas	I
,	O
abnormally	O
migrating	O
DNA	O
bands	O
were	O
detected	O
by	O
SSCP	O
and/or	O
HD	O
analysis	O
.	O

No	O
mobility	O
shift	O
was	O
seen	O
in	O
any	O
of	O
the	O
23	O
chromophobe	O
renal	B
cell	I
carcinomas	I
.	O

In	O
addition	O
,	O
15	O
papillary	B
renal	I
cell	I
tumours	I
and	O
ten	O
renal	B
oncocytomas	I
,	O
which	O
are	O
characterized	O
by	O
genetic	O
changes	O
other	O
than	O
loss	O
of	O
chromosome	O
3p	O
sequences	O
,	O
were	O
analysed	O
for	O
mutation	O
of	O
the	O
VHL	B
gene	O
.	O

None	O
of	O
these	O
tumours	B
showed	O
abnormal	O
migration	O
patterns	O
.	O

The	O
results	O
indicate	O
that	O
mutation	O
of	O
the	O
VHL	B
gene	O
is	O
associated	O
exclusively	O
with	O
the	O
development	O
of	O
non	B
-	I
papillary	I
renal	I
cell	I
carcinoma	I
..	O

The	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
protein	O
,	O
emerin	O
,	O
is	O
a	O
nuclear	O
membrane	O
protein	O
.	O

A	O
large	O
fragment	O
of	O
emerin	O
cDNA	O
was	O
prepared	O
by	O
PCR	O
and	O
expressed	O
as	O
a	O
recombinant	O
protein	O
in	O
Escherichia	O
coli	O
.	O

Using	O
this	O
as	O
immunogen	O
,	O
we	O
prepared	O
a	O
panel	O
of	O
12	O
monoclonal	O
antibodies	O
which	O
recognise	O
at	O
least	O
four	O
different	O
epitopes	O
on	O
emerin	O
in	O
order	O
to	O
ensure	O
that	O
emerin	O
can	O
be	O
distinguished	O
from	O
non	O
-	O
specific	O
cross	O
-	O
reacting	O
proteins	O
.	O

All	O
the	O
mAbs	O
recognised	O
a	O
34	O
kDa	O
protein	O
in	O
all	O
tissues	O
tested	O
,	O
though	O
minor	O
emerin	O
-	O
related	O
bands	O
were	O
also	O
detected	O
in	O
some	O
tissues	O
.	O

Immunofluorescence	O
microscopy	O
showed	O
that	O
emerin	O
is	O
located	O
at	O
the	O
nuclear	O
rim	O
in	O
all	O
tissues	O
examined	O
.	O

A	O
muscle	O
biopsy	O
from	O
an	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EMDM	B
)	O
patient	O
showed	O
complete	O
absence	O
of	O
emerin	O
by	O
both	O
Western	O
blotting	O
and	O
immunohistochemistry	O
,	O
suggesting	O
a	O
simple	O
diagnostic	O
antibody	O
test	O
for	O
EDMD	B
families	O
.	O

Biochemical	O
fractionation	O
of	O
brain	O
and	O
liver	O
tissues	O
showed	O
that	O
emerin	O
was	O
present	O
in	O
nuclei	O
purified	O
by	O
centrifugation	O
through	O
65	O
%	O
sucrose	O
and	O
was	O
absent	O
from	O
soluble	O
fractions	O
(	O
post-100	O
,	O
000	O
g	O
)	O
.	O

From	O
these	O
results	O
,	O
together	O
with	O
sequence	O
and	O
structural	O
homologies	O
between	O
emerin	O
,	O
thymopoietins	O
and	O
the	O
nuclear	O
lamina	O
-	O
associated	O
protein	O
,	O
LAP2	O
,	O
we	O
suggest	O
that	O
emerin	O
will	O
prove	O
to	O
be	O
one	O
member	O
of	O
a	O
family	O
of	O
inner	O
nuclear	O
membrane	O
proteins	O
..	O

Mutation	O
of	O
MSH3	O
in	O
endometrial	B
cancer	I
and	O
evidence	O
for	O
its	O
functional	O
role	O
in	O
heteroduplex	O
repair	O
.	O

Many	O
human	O
tumours	B
have	O
length	O
alterations	O
in	O
repetitive	O
sequence	O
elements	O
.	O

Although	O
this	O
microsatellite	B
instability	I
has	O
been	O
attributed	O
to	O
mutations	O
in	O
four	O
DNA	O
mismatch	O
repair	O
genes	O
in	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindreds	O
,	O
many	O
sporadic	B
tumours	I
exhibit	O
instability	O
but	O
no	O
detectable	O
mutations	O
in	O
these	O
genes	O
.	O

It	O
is	O
therefore	O
of	O
interest	O
to	O
identify	O
other	O
genes	O
that	O
contribute	O
to	O
this	O
instability	O
.	O

In	O
yeast	O
,	O
mutations	O
in	O
several	O
genes	O
,	O
including	O
RTH	O
and	O
MSH3	O
,	O
cause	O
microsatellite	O
instability	O
.	O

Thus	O
,	O
we	O
screened	O
16	O
endometrial	B
carcinomas	I
with	O
microsatellite	O
instability	O
for	O
alterations	O
in	O
FEN1	O
(	O
the	O
human	O
homolog	O
of	O
RTH	O
)	O
and	O
in	O
MSH3	O
(	O
refs	O
12	O
-	O
14	O
)	O
.	O

Although	O
we	O
found	O
no	O
FEN1	O
mutations	O
,	O
a	O
frameshift	O
mutation	O
in	O
MSH3	O
was	O
observed	O
in	O
an	O
endometrial	B
carcinoma	I
and	O
in	O
an	O
endometrial	B
carcinoma	I
cell	O
line	O
.	O

Extracts	O
of	O
the	O
cell	O
line	O
were	O
deficient	O
in	O
repair	O
of	O
DNA	O
substrates	O
containing	O
mismatches	O
or	O
extra	O
nucleotides	O
.	O

Introducing	O
chromosome	O
5	O
,	O
encoding	O
the	O
MSH3	O
gene	O
,	O
into	O
the	O
mutant	O
cell	O
line	O
increased	O
the	O
stability	O
of	O
some	O
but	O
not	O
all	O
microsatellites	O
.	O

Extracts	O
of	O
these	O
cells	O
repaired	O
certain	O
substrates	O
containing	O
extra	O
nucleotides	O
,	O
but	O
were	O
deficient	O
in	O
repair	O
of	O
those	O
containing	O
mismatches	O
or	O
other	O
extra	O
nucleotides	O
.	O

A	O
subsequent	O
search	O
revealed	O
a	O
second	O
gene	O
mutation	O
in	O
HHUA	O
cells	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
MSH6	O
gene	O
.	O

Together	O
the	O
data	O
suggest	O
that	O
the	O
MSH3	O
gene	O
encodes	O
a	O
product	O
that	O
functions	O
in	O
repair	O
of	O
some	O
but	O
not	O
all	O
pre	O
-	O
mutational	O
intermediates	O
,	O
its	O
mutation	O
in	O
tumours	B
can	O
result	O
in	O
genomic	O
instability	O
and	O
,	O
as	O
in	O
yeast	O
,	O
MSH3	O
and	O
MSH6	O
are	O
partially	O
redundant	O
for	O
mismatch	O
repair	O
..	O

Comparative	O
genome	O
mapping	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
region	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
.	O

Chromosomal	O
locations	O
of	O
the	O
Atm	O
(	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
-mutated	O
)	O
and	O
Acat1	O
(	O
mitochondrial	O
acetoacetyl	O
-	O
CoA	O
thiolase	O
)	O
genes	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
were	O
determined	O
by	O
direct	O
R	O
-	O
banding	O
FISH	O
.	O

Both	O
genes	O
were	O
colocalized	O
to	O
the	O
C	O
-	O
D	O
band	O
of	O
mouse	O
chromosome	O
9	O
,	O
the	O
proximal	O
end	O
of	O
q24	O
.	O

1	O
of	O
rat	O
chromosome	O
8	O
,	O
and	O
qa4-qa5	O
of	O
Syrian	O
hamster	O
chromosome	O
12	O
.	O

The	O
regions	O
in	O
the	O
mouse	O
and	O
rat	O
were	O
homologous	O
to	O
human	O
chromosome	O
11q	O
.	O

Fine	O
genetic	O
linkage	O
mapping	O
of	O
the	O
mouse	O
AT	B
region	O
was	O
performed	O
using	O
the	O
interspecific	O
backcross	O
mice	O
.	O

Atm	O
,	O
Acat1	O
,	O
and	O
Npat	O
,	O
which	O
is	O
a	O
new	O
gene	O
isolated	O
from	O
the	O
AT	O
region	O
,	O
and	O
12	O
flanking	O
microsatellite	O
DNA	O
markers	O
were	O
examined	O
.	O

No	O
recombinations	O
were	O
found	O
among	O
the	O
Atm	O
,	O
Npat	O
,	O
Acat1	O
,	O
and	O
D9Mit6	O
loci	O
,	O
and	O
these	O
loci	O
were	O
mapped	O
2	O
.	O

0	O
cM	O
distal	O
to	O
D9Mit99	O
and	O
1	O
.	O
3	O
cM	O
proximal	O
to	O
D9Mit102	O
.	O

Comparison	O
of	O
the	O
linkage	O
map	O
of	O
mouse	O
chromosome	O
9	O
(	O
MMU9	O
)	O
and	O
that	O
of	O
human	O
chromosome	O
11	O
(	O
HSA11	O
)	O
indicates	O
that	O
there	O
is	O
a	O
chromosomal	O
rearrangement	O
due	O
to	O
an	O
inversion	O
between	O
Ets1	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
and	O
that	O
the	O
inversion	O
of	O
MMU9	O
originated	O
from	O
the	O
chromosomal	O
breakage	O
at	O
the	O
boundary	O
between	O
Gria4	O
and	O
Atm	O
-	O
Npat	O
-	O
Acat1	O
on	O
HSA11	O
.	O

This	O
type	O
of	O
inversion	O
appeared	O
to	O
be	O
conserved	O
in	O
the	O
three	O
rodent	O
species	O
,	O
mouse	O
,	O
rat	O
,	O
and	O
Syrian	O
hamster	O
,	O
using	O
additional	O
comparative	O
mapping	O
data	O
with	O
the	O
Rck	O
gene	O

An	O
animal	O
model	O
for	O
Norrie	B
disease	I
(	O
ND	B
)	O
:	O
gene	O
targeting	O
of	O
the	O
mouse	O
ND	B
gene	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
cellular	O
and	O
molecular	O
processes	O
which	O
are	O
involved	O
in	O
Norrie	B
disease	I
(	O
ND	B
)	O
,	O
we	O
have	O
used	O
gene	O
targeting	O
technology	O
to	O
generate	O
ND	B
mutant	O
mice	O
.	O

The	O
murine	O
homologue	O
of	O
the	O
ND	B
gene	O
was	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
polypeptide	O
that	O
shares	O
94	O
%	O
of	O
the	O
amino	O
acid	O
sequence	O
with	O
its	O
human	O
counterpart	O
.	O

RNA	O
in	O
situ	O
hybridization	O
revealed	O
expression	O
in	O
retina	O
,	O
brain	O
and	O
the	O
olfactory	O
bulb	O
and	O
epithelium	O
of	O
2	O
week	O
old	O
mice	O
.	O

Hemizygous	O
mice	O
carrying	O
a	O
replacement	O
mutation	O
in	O
exon	O
2	O
of	O
the	O
ND	B
gene	O
developed	O
retrolental	O
structures	O
in	O
the	O
vitreous	O
body	O
and	O
showed	O
an	O
overall	O
disorganization	O
of	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
.	O

The	O
outer	O
plexiform	O
layer	O
disappears	O
occasionally	O
,	O
resulting	O
in	O
a	O
juxtaposed	O
inner	O
and	O
outer	O
nuclear	O
layer	O
.	O

At	O
the	O
same	O
regions	O
,	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptor	O
cell	O
layer	O
are	O
no	O
longer	O
present	O
.	O

These	O
ocular	O
findings	O
are	O
consistent	O
with	O
observations	O
in	O
ND	B
patients	O
and	O
the	O
generated	O
mouse	O
line	O
provides	O
a	O
faithful	O
model	O
for	O
study	O
of	O
early	O
pathogenic	O
events	O
in	O
this	O
severe	O
X	B
-	I
linked	I
recessive	I
neurological	I
disorder	I
..	O

The	O
hybrid	O
PAX3-FKHR	O
fusion	O
protein	O
of	O
alveolar	B
rhabdomyosarcoma	I
transforms	O
fibroblasts	O
in	O
culture	O
.	O

Pediatric	B
alveolar	I
rhabdomyosarcoma	I
is	O
characterized	O
by	O
a	O
chromosomal	O
translocation	O
that	O
fuses	O
parts	O
of	O
the	O
PAX3	O
and	O
FKHR	O
genes	O
.	O

PAX3	O
codes	O
for	O
a	O
transcriptional	O
regulator	O
that	O
controls	O
developmental	O
programs	O
,	O
and	O
FKHR	O
codes	O
for	O
a	O
forkhead	O
-	O
winged	O
helix	O
protein	O
,	O
also	O
a	O
likely	O
transcription	O
factor	O
.	O

The	O
PAX3-FKHR	O
fusion	O
product	O
retains	O
the	O
DNA	O
binding	O
domains	O
of	O
the	O
PAX3	O
protein	O
and	O
the	O
putative	O
activator	O
domain	O
of	O
the	O
FKHR	O
protein	O
.	O

The	O
PAX3-FKHR	O
protein	O
has	O
been	O
shown	O
to	O
function	O
as	O
a	O
transcriptional	O
activator	O
.	O

Using	O
the	O
RCAS	O
retroviral	O
vector	O
,	O
we	O
have	O
introduced	O
the	O
PAX3-FKHR	O
gene	O
into	O
chicken	O
embryo	O
fibroblasts	O
.	O

Expression	O
of	O
the	O
PAX3-FKHR	O
protein	O
in	O
these	O
cells	O
leads	O
to	O
transformation	O
the	O
cells	O
become	O
enlarged	O
,	O
grow	O
tightly	O
packed	O
and	O
in	O
multiple	O
layers	O
,	O
and	O
acquire	O
the	O
ability	O
for	O
anchorage	O
-	O
independent	O
growth	O
.	O

This	O
cellular	O
transformation	O
in	O
vitro	O
will	O
facilitate	O
studies	O
on	O
the	O
mechanism	O
of	O
PAX3-FKHR	O
-	O
induced	O
oncogenesis	O
..	O

Somatic	O
-	O
cell	O
selection	O
is	O
a	O
major	O
determinant	O
of	O
the	O
blood	O
-	O
cell	O
phenotype	O
in	O
heterozygotes	O
for	O
glucose-6-phosphate	O
dehydrogenase	O
mutations	O
causing	O
severe	O
enzyme	B
deficiency	I
.	O

X	O
-	O
chromosome	O
inactivation	O
in	O
mammals	O
is	O
regarded	O
as	O
an	O
essentially	O
random	O
process	O
,	O
but	O
the	O
resulting	O
somatic	O
-	O
cell	O
mosaicism	O
creates	O
the	O
opportunity	O
for	O
cell	O
selection	O
.	O

In	O
most	O
people	O
with	O
red	O
-	O
blood	O
-	O
cell	O
glucose-6-phosphate	B
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
,	O
the	O
enzyme	O
-	O
deficient	O
phenotype	O
is	O
only	O
moderately	O
expressed	O
in	O
nucleated	O
cells	O
.	O

However	O
,	O
in	O
a	O
small	O
subset	O
of	O
hemizygous	O
males	O
who	O
suffer	O
from	O
chronic	B
nonspherocytic	I
hemolytic	I
anemia	I
,	O
the	O
underlying	O
mutations	O
(	O
designated	O
class	O
I	O
)	O
cause	O
more	O
-	O
severe	O
G6PD	B
deficiency	I
,	O
and	O
this	O
might	O
provide	O
an	O
opportunity	O
for	O
selection	O
in	O
heterozygous	O
females	O
during	O
development	O
.	O

In	O
order	O
to	O
test	O
this	O
possibility	O
we	O
have	O
analyzed	O
four	O
heterozygotes	O
for	O
class	O
I	O
G6PD	O
mutations	O
two	O
with	O
G6PD	O
Portici	O
(	O
1178G--	O
>	O
A	O
)	O
and	O
two	O
with	O
G6PD	O
Bari	O
(	O
1187C--	O
>	O
T	O
)	O
.	O

We	O
found	O
that	O
in	O
fractionated	O
blood	O
cell	O
types	O
(	O
including	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
cell	O
lineages	O
)	O
there	O
was	O
a	O
significant	O
excess	O
of	O
G6PD	O
-	O
normal	O
cells	O
.	O

The	O
significant	O
concordance	O
that	O
we	O
have	O
observed	O
in	O
the	O
degree	O
of	O
imbalance	O
in	O
the	O
different	O
blood	O
-	O
cell	O
lineages	O
indicates	O
that	O
a	O
selective	O
mechanism	O
is	O
likely	O
to	O
operate	O
at	O
the	O
level	O
of	O
pluripotent	O
blood	O
stem	O
cells	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
severe	O
G6PD	B
deficiency	I
affects	O
adversely	O
the	O
proliferation	O
or	O
the	O
survival	O
of	O
nucleated	O
blood	O
cells	O
and	O
that	O
this	O
phenotypic	O
characteristic	O
is	O
critical	O
during	O
hematopoiesis	O
..	O

Analysis	O
of	O
meiotic	O
segregation	O
,	O
using	O
single	O
-	O
sperm	O
typing	O
:	O
meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
.	O

Meiotic	O
drive	O
at	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
locus	O
has	O
recently	O
been	O
suggested	O
as	O
being	O
responsible	O
for	O
maintaining	O
the	O
frequency	O
,	O
in	O
the	O
human	O
population	O
,	O
of	O
DM	B
chromosomes	O
capable	O
of	O
expansion	O
to	O
the	O
disease	O
state	O
.	O

In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
studied	O
samples	O
of	O
single	O
sperm	O
from	O
three	O
individuals	O
heterozygous	O
at	O
the	O
DM	B
locus	O
,	O
each	O
with	O
one	O
allele	O
larger	O
and	O
one	O
allele	O
smaller	O
than	O
19	O
CTG	O
repeats	O
.	O

To	O
guard	O
against	O
the	O
possible	O
problem	O
of	O
differential	O
PCR	O
amplification	O
rates	O
based	O
on	O
the	O
lengths	O
of	O
the	O
alleles	O
,	O
the	O
sperm	O
were	O
also	O
typed	O
at	O
another	O
closely	O
linked	O
marker	O
whose	O
allele	O
size	O
was	O
unrelated	O
to	O
the	O
allele	O
size	O
at	O
the	O
DM	B
locus	O
.	O

Using	O
statistical	O
models	O
specifically	O
designed	O
to	O
study	O
single	O
-	O
sperm	O
segregation	O
data	O
,	O
we	O
find	O
no	O
evidence	O
of	O
meiotic	O
segregation	O
distortion	O
.	O

The	O
upper	O
limit	O
of	O
the	O
two	O
-	O
sided	O
95	O
%	O
confidence	O
interval	O
for	O
the	O
estimate	O
of	O
the	O
common	O
segregation	O
probability	O
for	O
the	O
three	O
donors	O
is	O
at	O
or	O
below	O
.	O

515	O
for	O
all	O
models	O
considered	O
,	O
and	O
no	O
statistically	O
significant	O
difference	O
from	O
.	O

5	O
is	O
detected	O
in	O
any	O
of	O
the	O
models	O
.	O

This	O
suggests	O
that	O
any	O
greater	O
amount	O
of	O
segregation	O
distortion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
must	O
result	O
from	O
events	O
following	O
sperm	O
ejaculation	O
.	O

LPP	O
,	O
the	O
preferred	O
fusion	O
partner	O
gene	O
of	O
HMGIC	O
in	O
lipomas	B
,	O
is	O
a	O
novel	O
member	O
of	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

A	O
major	O
cytogenetic	O
subgroup	O
of	O
lipomas	B
is	O
characterized	O
by	O
recurrent	O
chromosome	O
aberrations	O
,	O
mainly	O
translocations	O
,	O
that	O
involve	O
chromosome	O
segment	O
12q13-q15	O
.	O

Multiple	O
chromosomes	O
have	O
been	O
found	O
as	O
the	O
translocation	O
partners	O
of	O
chromosome	O
12	O
but	O
3q27-q28	O
is	O
preferentially	O
involved	O
.	O

In	O
previous	O
studies	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
protein	O
gene	O
HMGIC	O
at	O
12q15	O
is	O
consistently	O
rearranged	O
as	O
a	O
consequence	O
of	O
these	O
translocations	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
chromosome	O
3-derived	O
translocation	O
partner	O
gene	O
,	O
which	O
we	O
have	O
designated	O
LPP	O
(	O
lipoma	B
preferred	O
partner	O
gene	O
)	O
.	O

Using	O
3-RACE	O
analysis	O
of	O
HMGIC	O
fusion	O
transcripts	O
in	O
lipoma	B
cell	O
line	O
Li-501	O
/	O
SV40	O
,	O
ectopic	O
genetic	O
sequences	O
were	O
obtained	O
,	O
which	O
by	O
CASH	O
(	O
chromosome	O
assignment	O
using	O
somatic	O
cell	O
hybrids	O
)	O
and	O
FISH	O
(	O
fluorescence	O
in	O
situ	O
hybridization	O
)	O
analysis	O
were	O
found	O
to	O
originate	O
from	O
chromosome	O
segment	O
3q27-q28	O
.	O

In	O
Northern	O
blot	O
analysis	O
,	O
an	O
mRNA	O
of	O
over	O
10	O
kb	O
was	O
detected	O
by	O
these	O
ectopic	O
sequences	O
in	O
a	O
variety	O
of	O
human	O
tissues	O
but	O
not	O
in	O
brain	O
and	O
peripheral	O
blood	O
leukocytes	O
.	O

Upon	O
partial	O
cDNA	O
cloning	O
,	O
features	O
of	O
the	O
genetic	O
organization	O
of	O
LPP	O
were	O
established	O
.	O

The	O
gene	O
was	O
found	O
to	O
span	O
a	O
genomic	O
region	O
of	O
over	O
400	O
kb	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
a	O
composite	O
cDNA	O
of	O
LPP	O
revealed	O
an	O
open	O
reading	O
frame	O
of	O
1836	O
nucleotides	O
encoding	O
a	O
proline	O
-	O
rich	O
protein	O
containing	O
a	O
leucine	O
-	O
zipper	O
motif	O
in	O
its	O
amino	O
-	O
terminal	O
region	O
and	O
three	O
LIM	O
domains	O
in	O
its	O
carboxy	O
-	O
terminal	O
region	O
.	O

The	O
LPP	O
-	O
encoded	O
protein	O
should	O
be	O
classified	O
as	O
a	O
novel	O
member	O
of	O
the	O
group	O
3	O
proteins	O
of	O
the	O
LIM	O
protein	O
gene	O
family	O
.	O

Using	O
reverse	O
transcriptase	O
combined	O
with	O
polymerase	O
chain	O
reactions	O
in	O
the	O
analysis	O
of	O
a	O
number	O
of	O
lipoma	B
cell	O
lines	O
and	O
primary	B
lipomas	I
,	O
it	O
appeared	O
that	O
LPP	O
is	O
frequently	O
rearranged	O
also	O
in	O
cases	O
without	O
a	O
cytogenetically	O
detectable	O
involvement	O
of	O
3q27-q28	O
.	O

Two	O
alternative	O
HMGIC	O
/	O
LPP	O
hybrid	O
transcripts	O
have	O
been	O
detected	O
;	O
the	O
difference	O
between	O
them	O
is	O
mainly	O
the	O
presence	O
of	O
either	O
two	O
or	O
three	O
LIM	O
domains	O
in	O
the	O
predicted	O
HMGI	O
-	O
C	O
/	O
LPP	O
fusion	O
proteins	O
..	O

Absence	O
of	O
disease	O
phenotype	O
and	O
intergenerational	O
stability	O
of	O
the	O
CAG	O
repeat	O
in	O
transgenic	O
mice	O
expressing	O
the	O
human	O
Huntington	B
disease	I
transcript	O
.	O

The	O
mutation	O
underlying	O
Huntington	B
disease	I
(	O
HD	B
)	O
is	O
CAG	O
expansion	O
in	O
the	O
first	O
exon	O
of	O
the	O
HD	B
gene	O
.	O

In	O
order	O
to	O
investigate	O
the	O
role	O
of	O
CAG	O
expansion	O
in	O
the	O
pathogenesis	O
of	O
HD	B
,	O
we	O
have	O
produced	O
transgenic	O
mice	O
containing	O
the	O
full	O
length	O
human	O
HD	B
cDNA	O
with	O
44	O
CAG	O
repeats	O
.	O

By	O
1	O
year	O
,	O
these	O
mice	O
have	O
no	O
behavioral	B
abnormalities	I
and	O
morphometric	O
analysis	O
at	O
6	O
(	O
one	O
animal	O
)	O
and	O
9	O
(	O
two	O
animals	O
)	O
months	O
age	O
revealed	O
no	O
changes	O
.	O

Despite	O
high	O
levels	O
of	O
mRNA	O
expression	O
,	O
there	O
was	O
no	O
evidence	O
of	O
the	O
HD	B
gene	O
product	O
in	O
any	O
of	O
these	O
transgenic	O
mice	O
.	O

In	O
vitro	O
transfection	O
studies	O
indicated	O
that	O
the	O
inclusion	O
of	O
120	O
bp	O
of	O
the	O
5	O
UTR	O
in	O
the	O
cDNA	O
construct	O
and	O
the	O
presence	O
of	O
a	O
frameshift	O
mutation	O
at	O
nucleotide	O
2349	O
prevented	O
expression	O
of	O
the	O
HD	B
cDNA	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
pathogenesis	O
of	O
HD	B
is	O
not	O
mediated	O
through	O
DNA	O
-	O
protein	O
interaction	O
and	O
that	O
presence	O
of	O
the	O
RNA	O
transcript	O
with	O
an	O
expanded	O
CAG	O
repeat	O
is	O
insufficient	O
to	O
cause	O
the	O
disease	O
.	O

Rather	O
,	O
translation	O
of	O
the	O
CAG	O
is	O
crucial	O
for	O
the	O
pathogenesis	O
of	O
HD	B
.	O

In	O
contrast	O
to	O
that	O
seen	O
in	O
humans	O
,	O
the	O
CAG	O
repeat	O
in	O
these	O
mice	O
was	O
remarkably	O
stable	O
in	O
97	O
meioses	O
.	O

This	O
suggests	O
that	O
genomic	O
sequences	O
may	O
play	O
a	O
critical	O
role	O
in	O
influencing	O
repeat	O
instability	O
..	O

FISH	O
studies	O
in	O
a	O
patient	O
with	O
sporadic	B
aniridia	I
and	O
t	O
(	O
7;11	O
)	O
(	O
q31.2;p13	O
)	O
.	O

A	O
2	O
year	O
old	O
female	O
presenting	O
with	O
bilateral	B
sporadic	I
aniridia	I
was	O
found	O
to	O
have	O
an	O
apparently	O
balanced	O
reciprocal	O
translocation	O
with	O
a	O
chromosome	O
11	O
breakpoint	O
within	O
band	O
p13	O
.	O

Fluorescence	O
in	O
situ	O
hybridisation	O
(	O
FISH	O
)	O
studies	O
with	O
distal	O
11p13	O
specific	O
cosmids	O
showed	O
that	O
the	O
chromosome	O
11	O
breakpoint	O
lay	O
between	O
the	O
aniridia	B
(	O
PAX6	O
)	O
locus	O
and	O
a	O
region	O
approximately	O
100	O
kb	O
distal	O
to	O
PAX6	O
defined	O
by	O
the	O
cosmid	O
FO2121	O
.	O

Although	O
this	O
patient	O
did	O
not	O
have	O
a	O
detectable	O
deletion	O
within	O
PAX6	O
,	O
her	O
aniridia	B
may	O
have	O
resulted	O
from	O
a	O
disruption	O
of	O
the	O
distal	O
chromatin	O
domain	O
containing	O
either	O
enhancers	O
or	O
regulators	O
for	O
PAX6	O
.	O

This	O
case	O
may	O
therefore	O
be	O
another	O
example	O
of	O
aniridia	B
caused	O
by	O
a	O
position	O
effect	O
as	O
recently	O
described	O
in	O
two	O
familial	B
aniridia	I
patients	O
in	O
which	O
the	O
phenotype	O
cosegregated	O
with	O
chromosome	B
abnormalities	I
with	O
11p13	O
breakpoints	O
..	O

Muscle	O
expression	O
of	O
glucose-6-phosphate	B
dehydrogenase	I
deficiency	I
in	O
different	O
variants	O
.	O

Muscle	O
expression	O
of	O
G6PD	B
deficiency	I
has	O
been	O
investigated	O
in	O
Mediterranean	O
,	O
Seattle	O
-	O
like	O
and	O
A	O
-	O
variants	O
.	O

G6PD	O
activity	O
was	O
detected	O
in	O
samples	O
obtained	O
from	O
biopsies	O
on	O
the	O
quadriceps	O
muscle	O
of	O
seven	O
males	O
and	O
one	O
female	O
.	O

The	O
type	O
of	O
genetic	O
variant	O
was	O
determined	O
by	O
molecular	O
analysis	O
of	O
DNA	O
,	O
extracted	O
from	O
blood	O
samples	O
.	O

All	O
variants	O
showed	O
the	O
enzyme	O
defect	O
in	O
muscle	O
.	O

A	O
statistically	O
significant	O
relationship	O
was	O
found	O
in	O
the	O
activity	O
of	O
G6PD	O
between	O
erythrocytes	O
and	O
muscle	O
of	O
the	O
male	O
subjects	O
(	O
r	O
=	O
0	O
.	O
968	O
;	O
p	O
=	O
0	O
.	O
00008	O
)	O
.	O

The	O
equation	O
for	O
the	O
best	O
fit	O
line	O
was	O
Y	O
=	O
0	O
.	O

390X	O
+	O
0	O
.	O
198	O
198	O
.	O

The	O
results	O
suggest	O
that	O
,	O
for	O
a	O
given	O
variant	O
,	O
the	O
extent	O
of	O
the	O
enzyme	O
defect	O
in	O
muscle	O
may	O
be	O
determined	O
,	O
using	O
this	O
equation	O
,	O
from	O
the	O
G6PD	O
activity	O
of	O
erythrocytes	O

Gene	O
therapy	O
for	O
phenylketonuria	B
.	O

Classical	O
phenylketonuria	B
(	O
PKU	B
)	O
is	O
an	O
autosomal	B
recessive	I
disorder	I
caused	O
by	O
a	O
deficiency	B
of	I
hepatic	I
phenylalanine	I
hydroxylase	I
(	O
PAH	O
)	O
.	O

Limitations	O
of	O
the	O
current	O
dietary	O
treatment	O
for	O
PKU	B
have	O
led	O
to	O
the	O
development	O
of	O
potential	O
treatments	O
based	O
on	O
somatic	O
gene	O
transfer	O
.	O

Three	O
different	O
vector	O
systems	O
have	O
been	O
examined	O
.	O

Vectors	O
derived	O
from	O
a	O
recombinant	O
retrovirus	O
or	O
a	O
DNA	O
/	O
protein	O
complex	O
can	O
efficiently	O
transduce	O
the	O
PAH	O
cDNA	O
into	O
PAH	B
-	I
deficient	I
hepatocytes	O
in	O
vitro	O
,	O
but	O
the	O
application	O
of	O
these	O
vector	O
systems	O
is	O
presently	O
limited	O
by	O
their	O
low	O
transduction	O
efficiency	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
a	O
vector	O
derived	O
from	O
a	O
recombinant	O
adenovirus	O
can	O
restore	O
10	O
%	O
-80	O
%	O
of	O
normal	O
hepatic	O
PAH	O
activity	O
into	O
PAH	B
-	I
deficient	I
mice	O
,	O
which	O
completely	O
normalizes	O
serum	O
phenylalanine	O
levels	O
.	O

This	O
treatment	O
is	O
transient	O
and	O
can	O
not	O
be	O
effectively	O
re	O
-	O
administered	O
due	O
to	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
directed	O
against	O
the	O
recombinant	O
adenoviral	O
vector	O
.	O

However	O
,	O
these	O
findings	O
suggest	O
that	O
PKU	B
can	O
be	O
completely	O
corrected	O
by	O
somatic	O
gene	O
therapy	O
,	O
and	O
provide	O
some	O
direction	O
for	O
the	O
future	O
development	O
of	O
adenoviral	O
vectors	O
..	O

Exon	O
-	O
intron	O
structure	O
of	O
the	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
(	O
CHRNA4	O
)	O
.	O

The	O
human	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha	O
4	O
subunit	O
gene	O
(	O
CHRNA4	O
)	O
is	O
located	O
in	O
the	O
candidate	O
region	O
for	O
three	O
different	O
phenotypes	O
benign	B
familial	I
neonatal	I
convulsions	I
,	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
,	O
and	O
low	O
-	O
voltage	O
EEG	O
.	O

Recently	O
,	O
a	O
missense	O
mutation	O
in	O
transmembrane	O
domain	O
2	O
of	O
CHRNA4	O
was	O
found	O
to	O
be	O
associated	O
with	O
autosomal	B
dominant	I
nocturnal	I
frontal	I
lobe	I
epilepsy	I
in	O
one	O
extended	O
pedigree	O
.	O

We	O
have	O
determined	O
the	O
genomic	O
organization	O
of	O
CHRNA4	O
,	O
which	O
consists	O
of	O
six	O
exons	O
distributed	O
over	O
approximately	O
17	O
kb	O
of	O
genomic	O
DNA	O
.	O

The	O
nucleotide	O
sequence	O
obtained	O
from	O
the	O
genomic	O
regions	O
adjacent	O
to	O
the	O
exon	O
boundaries	O
enabled	O
us	O
to	O
develop	O
a	O
set	O
of	O
primer	O
pairs	O
for	O
PCR	O
amplification	O
of	O
the	O
complete	O
coding	O
region	O
.	O

The	O
sequence	O
analysis	O
provides	O
the	O
basis	O
for	O
a	O
comprehensive	O
mutation	O
screening	O
of	O
CHRNA4	O
in	O
the	O
above	O
-	O
mentioned	O
phenotypes	O
and	O
possibly	O
in	O
other	O
types	O
of	O
idiopathic	B
epilepsies	I
..	O

Ashkenazi	O
Jewish	O
population	O
frequencies	O
for	O
common	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
.	O

BRCA1	O
and	O
BRCA2	O
are	O
the	O
two	O
major	O
identified	O
causes	O
of	O
inherited	B
breast	I
cancer	I
,	O
with	O
mutations	O
in	O
either	O
gene	O
conferring	O
up	O
to	O
80	O
-	O
90	O
%	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
in	O
carrier	O
females	O
.	O

Mutations	O
in	O
BRCA1	O
account	O
for	O
approximately	O
45	O
%	O
of	O
familial	B
breast	I
cancer	I
and	O
90	O
%	O
of	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
,	O
whereas	O
mutations	O
in	O
BRCA2	O
account	O
for	O
a	O
comparable	O
percentage	O
of	O
inherited	B
breast	I
cancer	I
cases	O
.	O

Over	O
85	O
distinct	O
BRCA1	O
mutations	O
and	O
a	O
growing	O
list	O
of	O
BRCA2	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
the	O
majority	O
resulting	O
in	O
protein	O
truncation	O
.	O

A	O
specific	O
BRCA1	O
mutation	O
,	O
185delAG	O
,	O
has	O
a	O
reported	O
increased	O
carrier	O
frequency	O
of	O
approximately	O
0	O
.	O
9	O
%	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
is	O
also	O
found	O
in	O
rare	O
non	O
-	O
Jewish	O
patients	O
with	O
a	O
different	O
haplotype	O
.	O

The	O
6174delT	O
mutation	O
in	O
BRCA2	O
was	O
recently	O
identified	O
as	O
a	O
frequent	O
mutation	O
in	O
8	O
out	O
of	O
107	O
Ashkenazi	O
Jewish	O
women	O
diagnosed	O
with	O
breast	B
cancer	I
by	O
age	O
50	O
(	O
ref	O
.	O

8)	O
,	O
as	O
well	O
as	O
in	O
three	O
Ashkenazi	O
male	B
breast	I
cancer	I
patients	O
.	O

We	O
have	O
conducted	O
a	O
large	O
-	O
scale	O
population	O
study	O
to	O
investigate	O
the	O
prevalence	O
of	O
specific	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
Ashkenazi	O
Jewish	O
individuals	O
who	O
were	O
unselected	O
for	O
breast	B
cancer	I
.	O

BRCA1	O
mutation	O
screening	O
on	O
approximately	O
3	O
,	O
000	O
Ashkenazi	O
Jewish	O
samples	O
determined	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O
09	O
%	O
for	O
the	O
185delAG	O
mutation	O
and	O
0	O
.	O
13	O
%	O
for	O
the	O
5382insC	O
mutation	O
.	O

BRCA2	O
analysis	O
on	O
3	O
,	O
085	O
individuals	O
from	O
the	O
same	O
population	O
showed	O
a	O
carrier	O
frequency	O
of	O
1	O
.	O
52	O
%	O
for	O
the	O
6174delT	O
mutation	O
.	O

This	O
expanded	O
population	O
-	O
based	O
study	O
confirms	O
that	O
the	O
BRCA1	O
185delAG	O
mutation	O
and	O
the	O
BRCA2	O
6174delT	O
mutation	O
constitute	O
the	O
two	O
most	O
frequent	O
mutation	O
alleles	O
predisposing	O
to	O
hereditary	B
breast	I
cancer	I
among	O
the	O
Ashkenazim	O
,	O
and	O
suggests	O
a	O
relatively	O
lower	O
penetrance	O
for	O
the	O
6174delT	O
mutation	O
in	O
BRCA2	O

Dual	O
roles	O
of	O
ATM	O
in	O
the	O
cellular	O
response	O
to	O
radiation	O
and	O
in	O
cell	O
growth	O
control	O
.	O

The	O
gene	O
mutated	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
AT	B
)	O
patients	O
,	O
denoted	O
ATM	O
,	O
encodes	O
a	O
putative	O
protein	O
or	O
lipid	O
kinase	O
.	O

To	O
elucidate	O
the	O
functions	O
of	O
ATM	O
,	O
we	O
disrupted	O
the	O
mouse	O
ATM	O
gene	O
through	O
homologous	O
recombination	O
in	O
mice	O
.	O

Consistent	O
with	O
cellular	O
defects	O
of	O
AT	B
patients	O
,	O
the	O
ATM-	O
/	O
-	O
cells	O
are	O
hypersensitive	O
to	O
gamma	O
-	O
irradiation	O
and	O
defective	O
in	O
cell	O
-	O
cycle	O
arrest	O
following	O
radiation	O
,	O
correlating	O
with	O
a	O
defective	O
up	O
-	O
regulation	O
of	O
p53	O
.	O

In	O
addition	O
,	O
ATM-	O
/	O
-	O
mouse	O
thymocytes	O
are	O
more	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
gamma	O
-	O
irradiation	O
than	O
normal	O
thymocytes	O
.	O

ATM-	O
/	O
-	O
fibroblasts	O
are	O
inefficient	O
in	O
G1	O
to	O
S	O
-	O
phase	O
progression	O
following	O
serum	O
stimulation	O
and	O
senesce	O
after	O
only	O
a	O
few	O
passages	O
in	O
culture	O
.	O

They	O
have	O
an	O
increased	O
constitutive	O
level	O
of	O
p21CP1	O
/	O
WAF1	O
.	O

The	O
ATM	O
protein	O
is	O
therefore	O
critical	O
both	O
for	O
cellular	O
responses	O
to	O
ionizing	O
radiation	O
and	O
for	O
normal	O
cell	O
-	O
cycle	O
progression	O
.	O

ATM	O
+	O
/-	O
fibroblasts	O
and	O
thymocytes	O
showed	O
intermediately	O
defective	O
responses	O
to	O
irradiation	O
but	O
no	O
growth	O
defect	O
,	O
suggesting	O
that	O
the	O
increased	O
cancer	B
risk	O
of	O
AT	B
heterozygotes	O
could	O
be	O
attributable	O
to	O
poor	O
checkpoint	O
function	O
..	O

Targeted	O
disruption	O
of	O
ATM	O
leads	O
to	O
growth	B
retardation	I
,	O
chromosomal	B
fragmentation	I
during	I
meiosis	I
,	O
immune	B
defects	I
,	O
and	O
thymic	B
lymphoma	I
.	O

ATM	O
,	O
the	O
gene	O
mutated	O
in	O
the	O
inherited	B
human	I
disease	I
ataxia	B
-	I
telangiectasia	I
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
involved	O
in	O
DNA	O
metabolism	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
control	O
.	O

To	O
help	O
clarify	O
the	O
physiological	O
roles	O
of	O
the	O
ATM	O
protein	O
,	O
we	O
disrupted	O
the	O
ATM	O
gene	O
in	O
mice	O
through	O
homologous	O
recombination	O
.	O

Initial	O
evaluation	O
of	O
the	O
ATM	O
knockout	O
animals	O
indicates	O
that	O
inactivation	O
of	O
the	O
mouse	O
ATM	O
gene	O
recreates	O
much	O
of	O
the	O
phenotype	O
of	O
ataxia	B
-	I
telangiectasia	I
.	O

The	O
homozygous	O
mutant	O
(	O
ATM-	O
/	O
-	O
)	O
mice	O
are	O
viable	O
,	O
growth	O
-	O
retarded	O
,	O
and	O
infertile	O
.	O

The	O
infertility	B
of	O
ATM-	O
/	O
-	O
mice	O
results	O
from	O
meiotic	O
failure	O
.	O

Meiosis	O
is	O
arrested	O
at	O
the	O
zygotene	O
/	O
pachytene	O
stage	O
of	O
prophase	O
I	O
as	O
a	O
result	O
of	O
abnormal	O
chromosomal	O
synapsis	O
and	O
subsequent	O
chromosome	O
fragmentation	O
.	O

Immune	B
defects	I
also	O
are	O
evident	O
in	O
ATM-	O
/	O
-	O
mice	O
,	O
including	O
reduced	O
numbers	O
of	O
B220	O
+	O
CD43-	O
pre	O
-	O
B	O
cells	O
,	O
thymocytes	O
,	O
and	O
peripheral	O
T	O
cells	O
,	O
as	O
well	O
as	O
functional	O
impairment	O
of	O
T	O
-	O
cell	O
-	O
dependent	O
immune	O
responses	O
.	O

The	O
cerebella	O
of	O
ATM-	O
/	O
-	O
mice	O
appear	O
normal	O
by	O
histologic	O
examination	O
at	O
3	O
to	O
4	O
months	O
and	O
the	O
mice	O
have	O
no	O
gross	O
behavioral	B
abnormalities	I
.	O

The	O
majority	O
of	O
mutant	O
mice	O
rapidly	O
develop	O
thymic	B
lymphomas	I
and	O
die	O
before	O
4	O
months	O
of	O
age	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
ATM	O
gene	O
product	O
plays	O
an	O
essential	O
role	O
in	O
a	O
diverse	O
group	O
of	O
cellular	O
processes	O
,	O
including	O
meiosis	O
,	O
the	O
normal	O
growth	O
of	O
somatic	O
tissues	O
,	O
immune	O
development	O
,	O
and	O
tumor	B
suppression	O
..	O

Cloning	O
and	O
characterization	O
of	O
human	O
very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
cDNA	O
,	O
chromosomal	O
assignment	O
of	O
the	O
gene	O
and	O
identification	O
in	O
four	O
patients	O
of	O
nine	O
different	O
mutations	O
within	O
the	O
VLCAD	O
gene	O
.	O

Very	O
-	O
long	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
VLCAD	O
)	O
is	O
one	O
of	O
four	O
straight	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
ACD	O
)	O
enzymes	O
,	O
which	O
are	O
all	O
nuclear	O
encoded	O
mitochondrial	O
flavoproteins	O
catalyzing	O
the	O
initial	O
step	O
in	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
.	O

We	O
have	O
used	O
the	O
very	O
fast	O
,	O
Rapid	O
Amplification	O
of	O
cDNA	O
Ends	O
(	O
RACE	O
)	O
based	O
strategy	O
to	O
obtain	O
the	O
sequence	O
of	O
cDNAs	O
encoding	O
human	O
VLCAD	O
from	O
placenta	O
and	O
fibroblasts	O
.	O

Alignment	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
of	O
human	O
VLCAD	O
with	O
those	O
of	O
the	O
other	O
human	O
ACD	O
enzymes	O
revealed	O
extensive	O
sequence	O
homology	O
.	O

Moreover	O
,	O
human	O
VLCAD	O
and	O
human	O
acyl	O
-	O
CoA	O
oxidase	O
showed	O
extensive	O
sequence	O
homology	O
corroborating	O
the	O
notion	O
that	O
these	O
genes	O
are	O
evolutionarily	O
related	O
.	O

Southern	O
blot	O
analysis	O
of	O
genomic	O
DNA	O
from	O
hybrid	O
cell	O
lines	O
was	O
used	O
to	O
localize	O
the	O
VLCAD	O
gene	O
to	O
human	O
chromosome	O
17p11	O
.	O

2-p11	O
.	O

13105	O
.	O

Using	O
Northern	O
and	O
Western	O
blot	O
analysis	O
to	O
investigate	O
the	O
tissue	O
specific	O
distribution	O
of	O
VLCAD	O
mRNA	O
and	O
protein	O
in	O
several	O
human	O
tissues	O
we	O
showed	O
that	O
VLCAD	O
is	O
most	O
abundant	O
in	O
heart	O
and	O
skeletal	O
muscle	O
.	O

This	O
agrees	O
well	O
with	O
the	O
fact	O
that	O
cardiac	O
and	O
muscle	O
symptoms	O
are	O
characteristic	O
for	O
patients	O
with	O
VLCAD	B
deficiency	I
.	O

Northern	O
blot	O
analysis	O
and	O
sequencing	O
of	O
cloned	O
PCR	O
amplified	O
VLCAD	O
cDNA	O
from	O
four	O
unrelated	O
patients	O
with	O
VLCAD	B
deficiency	I
showed	O
that	O
VLCAD	O
mRNA	O
was	O
undetectable	O
in	O
one	O
patient	O
and	O
that	O
the	O
other	O
three	O
have	O
mutations	O
in	O
both	O
VLCAD	O
alleles	O
.	O

Western	O
blot	O
analysis	O
of	O
patient	O
fibroblasts	O
showed	O
that	O
the	O
identified	O
mutations	O
result	O
in	O
severely	O
reduced	O
amounts	O
of	O
VLCAD	O
protein	O
.	O

Molecular	O
bases	O
of	O
combined	B
subtotal	I
deficiencies	I
of	I
C6	I
and	I
C7	I
:	O
their	O
effects	O
in	O
combination	O
with	O
other	O
C6	B
and	I
C7	I
deficiencies	I
.	O

Combined	B
subtotal	I
deficiency	I
of	I
C6	I
and	I
C7	I
,	O
in	O
which	O
both	O
proteins	O
are	O
expressed	O
at	O
very	O
low	O
levels	O
,	O
has	O
been	O
observed	O
in	O
homozygous	O
form	O
in	O
two	O
families	O
.	O

A	O
defect	O
at	O
the	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15	O
of	O
the	O
C6	O
gene	O
explains	O
the	O
low	O
molecular	O
weight	O
of	O
the	O
C6	O
protein	O
and	O
is	O
probably	O
responsible	O
for	O
its	O
low	O
expressed	O
concentration	O
.	O

The	O
C7	O
defect	O
is	O
more	O
enigmatic	O
the	O
protein	O
is	O
of	O
normal	O
molecular	O
weight	O
,	O
low	O
circulating	O
concentration	O
,	O
and	O
altered	O
isoelectric	O
point	O
.	O

An	O
Arg	O
>	O
Ser	O
codon	O
substitution	O
in	O
exon	O
11	O
is	O
the	O
only	O
molecular	O
alteration	O
within	O
the	O
mature	O
C7	O
protein	O
.	O

These	O
defects	O
are	O
associated	O
with	O
a	O
characteristic	O
set	O
of	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
C6	O
/	O
C7	O
region	O
,	O
forming	O
a	O
distinct	O
haplotype	O
.	O

The	O
haplotype	O
has	O
been	O
found	O
in	O
combination	O
with	O
a	O
number	O
of	O
other	O
haplotypes	O
containing	O
defective	O
genes	O
that	O
lead	O
either	O
to	O
C6	B
or	I
C7	I
deficiency	I
,	O
but	O
with	O
different	O
consequences	O
.	O

Where	O
it	O
is	O
combined	O
with	O
a	O
C6-deficient	B
gene	O
,	O
the	O
serum	O
C7	O
levels	O
can	O
be	O
surprisingly	O
high	O
,	O
possibly	O
because	O
there	O
is	O
no	O
C6	O
generating	O
C56	O
to	O
consume	O
the	O
C7	O
.	O

In	O
contrast	O
,	O
where	O
the	O
C7	O
genes	O
are	O
both	O
defective	O
(	O
but	O
still	O
partially	O
functional	O
)	O
,	O
there	O
may	O
be	O
a	O
profound	O
deficit	O
of	O
circulating	O
C7	O
because	O
there	O
is	O
ample	O
C6	O
to	O
produce	O
C56	O
and	O
consume	O
the	O
already	O
small	O
amount	O
of	O
C7	O
.	O

Each	O
molecular	O
defect	O
has	O
also	O
been	O
found	O
in	O
isolation	O
and	O
has	O
the	O
expected	O
effect	O
..	O

Genetic	O
bases	O
of	O
human	O
complement	B
C7	I
deficiency	I
.	O

Complement	B
C7	I
deficiency	I
(	O
C7D	B
)	O
is	O
associated	O
frequently	O
with	O
recurrent	O
bacterial	B
infections	I
,	O
especially	O
meningitis	B
caused	O
by	O
Neisseria	B
meningitidis	I
.	O

We	O
report	O
in	O
this	O
work	O
the	O
molecular	O
bases	O
of	O
C7D	B
in	O
two	O
unrelated	O
Japanese	O
males	O
.	O

We	O
used	O
exon	O
-	O
specific	O
PCR	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
as	O
a	O
screening	O
step	O
for	O
mutations	O
.	O

Subsequent	O
direct	O
sequencing	O
of	O
the	O
target	O
exons	O
identified	O
homozygous	O
mutations	O
in	O
exon	O
16	O
of	O
case	O
1	O
and	O
in	O
exon	O
15	O
of	O
case	O
2	O
.	O

The	O
mutation	O
of	O
case	O
1	O
was	O
a	O
homozygous	O
T	O
to	O
A	O
transversion	O
at	O
nucleotide	O
2250	O
,	O
the	O
third	O
nucleotide	O
of	O
the	O
codon	O
TGT	O
for	O
Cys728	O
,	O
leading	O
to	O
a	O
stop	O
codon	O
TGA	O
(	O
C728X	O
)	O
.	O

In	O
case	O
2	O
,	O
a	O
homozygous	O
2-bp	O
deletion	O
(	O
2137delTG	O
/	O
2138delGT	O
/	O
2139delTG	O
)	O
caused	O
a	O
frameshift	O
,	O
generating	O
a	O
premature	O
termination	O
codon	O
4	O
to	O
6	O
nucleotides	O
downstream	O
.	O

Family	O
study	O
in	O
case	O
1	O
confirmed	O
the	O
genetic	O
nature	O
of	O
the	O
defect	O
.	O

Moreover	O
,	O
we	O
detected	O
a	O
novel	O
polymorphism	O
in	O
intron	O
11	O
that	O
presumably	O
is	O
linked	O
to	O
the	O
mutation	O
responsible	O
for	O
C7D	B
in	O
case	O
1	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
pathogenesis	O
of	O
C7D	B
is	O
heterogeneous	O
like	O
most	O
of	O
the	O
other	O
deficiencies	B
of	I
complement	I
components	I
..	O

HPRT	B
-	I
APRT	I
-	I
deficient	I
mice	O
are	O
not	O
a	O
model	O
for	O
lesch	B
-	I
nyhan	I
syndrome	I
.	O

Complete	B
hypoxanthine	I
-	I
guanine	I
phosphoribosyl	I
-	I
transferase	I
(	I
HPRT	I
)	I
deficiency	I
in	O
humans	O
results	O
in	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
which	O
is	O
characterized	O
,	O
among	O
other	O
features	O
,	O
by	O
compulsive	O
self	O
-	O
injurious	O
behavior	O
.	O

HPRT	B
-	I
deficient	I
mice	O
generated	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
exhibit	O
none	O
of	O
the	O
behavioral	O
symptoms	O
associated	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

Administration	O
of	O
drugs	O
that	O
inhibit	O
adenine	O
phosphoribosyltransferase	O
(	O
APRT	O
)	O
in	O
HPRT	B
-	I
deficient	I
mice	O
has	O
produced	O
the	O
suggestion	O
that	O
deficiency	B
of	I
APRT	I
in	O
combination	O
with	O
HPRT	B
-	I
deficiency	I
in	O
mice	O
may	O
lead	O
to	O
self	O
-	O
mutilation	O
behavior	O
[	O
C.	O
L.	O
Wu	O
and	O
D.	O
W.	O
Melton	O
(	O
1993	O
)	O
Nature	O
Genet	O
.	O

3	O
,	O
235	O
-	O
240	O
]	O
.	O

To	O
test	O
this	O
proposition	O
,	O
we	O
bred	O
HPRT	B
-	I
APRT	I
-	I
deficient	I
mice	O
.	O

Although	O
the	O
doubly	O
-	O
deficient	O
mice	O
excrete	O
adenine	O
and	O
its	O
highly	O
insoluble	O
derivative	O
,	O
2	O
,	O
8-dihydroxyadenine	O
,	O
which	O
are	O
also	O
associated	O
with	O
human	O
APRT	B
deficiency	I
,	O
additional	O
abnormalities	O
or	O
any	O
self	O
-	O
injurious	O
behavior	O
were	O
not	O
detected	O
.	O

Thus	O
,	O
APRT	B
-	I
HPRT	I
-	I
deficient	I
mice	O
,	O
which	O
are	O
devoid	O
of	O
any	O
purine	O
salvage	O
pathways	O
,	O
show	O
no	O
novel	O
phenotype	O
and	O
are	O
not	O
a	O
model	O
for	O
the	O
behavioral	B
abnormalities	I
associated	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
as	O
previously	O
suggested	O

Somatic	O
alterations	O
of	O
the	O
DPC4	O
gene	O
in	O
human	O
colorectal	B
cancers	I
in	O
vivo	O
.	O

BACKGROUND	O
&	O
AIMS	O
The	O
chromosome	O
region	O
18q21	O
has	O
been	O
shown	O
to	O
be	O
frequently	O
deleted	O
in	O
colorectal	B
cancers	I
,	O
and	O
such	O
frequent	O
allelic	O
loss	O
is	O
a	O
hallmark	O
of	O
the	O
presence	O
of	O
a	O
tumor	O
-	O
suppressor	O
gene	O
.	O

The	O
DPC4	O
gene	O
,	O
which	O
is	O
located	O
at	O
18q21	O
,	O
has	O
been	O
identified	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
from	O
examination	O
of	O
pancreatic	B
cancers	I
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
it	O
might	O
also	O
be	O
altered	O
in	O
colorectal	B
cancers	I
.	O

METHODS	O
Mutation	O
analyses	O
of	O
the	O
DPC4	O
gene	O
were	O
performed	O
on	O
complementary	O
DNA	O
samples	O
from	O
31	O
primary	O
colorectal	B
cancer	I
specimens	O
using	O
a	O
combination	O
of	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
Four	O
missense	O
mutations	O
producing	O
amino	O
acid	O
substitutions	O
and	O
a	O
somatic	O
12-base	O
pair	O
deletion	O
in	O
the	O
coding	O
region	O
of	O
the	O
DPC4	O
gene	O
were	O
detected	O
in	O
the	O
31	O
cancers	B
(	O
16	O
%	O
;	O
5	O
of	O
31	O
)	O
.	O

CONCLUSIONS	O
The	O
DPC4	O
gene	O
may	O
play	O
a	O
role	O
as	O
a	O
tumor	O
-	O
suppressor	O
gene	O
in	O
a	O
fraction	O
of	O
colorectal	B
cancers	I
;	O
however	O
,	O
while	O
allelic	O
loss	O
at	O
18q21	O
is	O
very	O
often	O
seen	O
in	O
colorectal	B
cancers	I
,	O
only	O
a	O
minority	O
show	O
DPC4	O
mutations	O
,	O
suggesting	O
that	O
there	O
might	O
be	O
another	O
tumor	O
-	O
suppressor	O
gene	O
in	O
this	O
chromosome	O
region	O
..	O

Pleiotropic	O
defects	O
in	O
ataxia	B
-	I
telangiectasia	I
protein	O
-	O
deficient	O
mice	O
.	O

We	O
have	O
generated	O
a	O
mouse	O
model	O
for	O
ataxia	B
-	I
telangiectasia	I
by	O
using	O
gene	O
targeting	O
to	O
generate	O
mice	O
that	O
do	O
not	O
express	O
the	O
Atm	O
protein	O
.	O

Atm	O
-	O
deficient	O
mice	O
are	O
retarded	O
in	O
growth	O
,	O
do	O
not	O
produce	O
mature	O
sperm	O
,	O
and	O
exhibit	O
severe	O
defects	O
in	O
T	O
cell	O
maturation	O
while	O
going	O
on	O
to	O
develop	O
thymomas	B
.	O

Atm	O
-	O
deficient	O
fibroblasts	O
grow	O
poorly	O
in	O
culture	O
and	O
display	O
a	O
high	O
level	O
of	O
double	O
-	O
stranded	O
chromosome	O
breaks	O
.	O

Atm	O
-	O
deficient	O
thymocytes	O
undergo	O
spontaneous	O
apoptosis	O
in	O
vitro	O
significantly	O
more	O
than	O
controls	O
.	O

Atm	O
-	O
deficient	O
mice	O
then	O
exhibit	O
many	O
of	O
the	O
same	O
symptoms	O
found	O
in	O
ataxia	B
-	I
telangiectasia	I
patients	O
and	O
in	O
cells	O
derived	O
from	O
them	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
Atm	O
protein	O
exists	O
as	O
two	O
discrete	O
molecular	O
species	O
,	O
and	O
that	O
loss	O
of	O
one	O
or	O
of	O
both	O
of	O
these	O
can	O
lead	O
to	O
the	O
development	O
of	O
the	O
disease	O
..	O

The	O
DCC	O
protein	O
and	O
prognosis	O
in	O
colorectal	B
cancer	I
.	O

BACKGROUND	O
Allelic	O
loss	O
of	O
chromosome	O
18q	O
predicts	O
a	O
poor	O
outcome	O
in	O
patients	O
with	O
stage	B
II	I
colorectal	I
cancer	I
.	O

Although	O
the	O
specific	O
gene	O
inactivated	O
by	O
this	O
allelic	O
loss	O
has	O
not	O
been	O
elucidated	O
,	O
the	O
DCC	O
(	O
deleted	O
in	O
colorectal	B
cancer	I
)	O
gene	O
is	O
a	O
candidate	O
.	O

We	O
investigated	O
whether	O
the	O
expression	O
of	O
the	O
DCC	O
protein	O
in	O
tumor	B
cells	O
is	O
a	O
prognostic	O
marker	O
in	O
colorectal	B
carcinoma	I
.	O

METHODS	O
The	O
expression	O
of	O
DCC	O
was	O
evaluated	O
immunohistochemically	O
in	O
132	O
paraffin	O
-	O
embedded	O
samples	O
from	O
patients	O
with	O
curatively	O
resected	O
stage	B
II	I
and	I
III	I
colorectal	I
carcinomas	I
.	O

The	O
Cox	O
proportional	O
-	O
hazards	O
model	O
was	O
used	O
to	O
adjust	O
for	O
covariates	O
including	O
age	O
,	O
sex	O
,	O
tumor	B
site	O
,	O
degree	O
of	O
tumor	B
differentiation	O
,	O
and	O
use	O
of	O
adjuvant	O
therapy	O
.	O

RESULTS	O
The	O
expression	O
of	O
DCC	O
was	O
a	O
strong	O
positive	O
predictive	O
factor	O
for	O
survival	O
in	O
both	O
stage	B
II	I
and	I
stage	I
III	I
colorectal	I
carcinomas	I
.	O

In	O
patients	O
with	O
stage	O
II	O
disease	O
whose	O
tumors	B
expressed	O
DCC	O
,	O
the	O
five	O
-	O
year	O
survival	O
rate	O
was	O
94	O
.	O
3	O
percent	O
,	O
whereas	O
in	O
patients	O
with	O
DCC	B
-	I
negative	I
tumors	I
,	O
the	O
survival	O
rate	O
was	O
61	O
.	O
6	O
percent	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
patients	O
with	O
stage	B
III	I
disease	I
,	O
the	O
respective	O
survival	O
rates	O
were	O
59	O
.	O

3	O
percent	O
and	O
33	O
.	O

2	O
percent	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

CONCLUSIONS	O
DCC	O
is	O
a	O
prognostic	O
marker	O
in	O
patients	O
with	O
stage	B
II	I
or	I
stage	I
III	I
colorectal	I
cancer	I
.	O

In	O
stage	B
II	I
colorectal	I
carcinomas	I
,	O
the	O
absence	O
of	O
DCC	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
lesions	O
that	O
behave	O
like	O
stage	B
III	I
cancers	I
.	O

These	O
findings	O
may	O
thus	O
have	O
therapeutic	O
implications	O
in	O
this	O
group	O
of	O
patients	O

Association	O
of	O
anxiety	B
-	I
related	I
traits	I
with	O
a	O
polymorphism	O
in	O
the	O
serotonin	O
transporter	O
gene	O
regulatory	O
region	O
.	O

Transporter	O
-	O
facilitated	O
uptake	O
of	O
serotonin	O
(	O
5-hydroxytryptamine	O
or	O
5-HT	O
)	O
has	O
been	O
implicated	O
in	O
anxiety	B
in	O
humans	O
and	O
animal	O
models	O
and	O
is	O
the	O
site	O
of	O
action	O
of	O
widely	O
used	O
uptake	O
-	O
inhibiting	O
antidepressant	O
and	O
antianxiety	O
drugs	O
.	O

Human	O
5-HT	O
transporter	O
(	O
5-HTT	O
)	O
gene	O
transcription	O
is	O
modulated	O
by	O
a	O
common	O
polymorphism	O
in	O
its	O
upstream	O
regulatory	O
region	O
.	O

The	O
short	O
variant	O
of	O
the	O
polymorphism	O
reduces	O
the	O
transcriptional	O
efficiency	O
of	O
the	O
5-HTT	O
gene	O
promoter	O
,	O
resulting	O
in	O
decreased	O
5-HTT	O
expression	O
and	O
5-HT	O
uptake	O
in	O
lymphoblasts	O
.	O

Association	O
studies	O
in	O
two	O
independent	O
samples	O
totaling	O
505	O
individuals	O
revealed	O
that	O
the	O
5-HTT	O
polymorphism	O
accounts	O
for	O
3	O
to	O
4	O
percent	O
of	O
total	O
variation	O
and	O
7	O
to	O
9	O
percent	O
of	O
inherited	O
variance	O
in	O
anxiety	B
-	I
related	I
personality	I
traits	I
in	O
individuals	O
as	O
well	O
as	O
sibships	O
..	O

Phenotypic	O
and	O
genotypic	O
overlap	O
between	O
atelosteogenesis	B
type	I
2	I
and	O
diastrophic	B
dysplasia	I
.	O

Mutations	O
in	O
the	O
diastrophic	B
dysplasia	I
sulfate	O
transporter	O
gene	O
DTDST	O
have	O
been	O
associated	O
with	O
a	O
family	O
of	O
chondrodysplasias	B
that	O
comprises	O
,	O
in	O
order	O
of	O
increasing	O
severity	O
,	O
diastrophic	B
dysplasia	I
(	O
DTD	B
)	O
,	O
atelosteogenesis	B
type	I
2	I
(	O
AO2	B
)	O
,	O
and	O
achondrogenesis	B
type	I
1B	I
(	O
ACG1B	B
)	O
.	O

To	O
learn	O
more	O
about	O
the	O
molecular	O
basis	O
of	O
DTDST	B
chondrodysplasias	I
and	O
about	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
we	O
studied	O
fibroblast	O
cultures	O
of	O
three	O
new	O
patients	O
one	O
with	O
AO-2	B
,	O
one	O
with	O
DTD	B
,	O
and	O
one	O
with	O
an	O
intermediate	O
phenotype	O
(	O
AO2	B
/	O
DTD	B
)	O
.	O

Reduced	O
incorporation	O
of	O
inorganic	O
sulfate	O
into	O
macromolecules	O
was	O
found	O
in	O
all	O
three	O
.	O

Each	O
of	O
the	O
three	O
patients	O
was	O
found	O
to	O
be	O
heterozygous	O
for	O
a	O
c862	O
t	O
transition	O
predicting	O
a	O
R279W	O
substitution	O
in	O
the	O
third	O
extracellular	O
loop	O
of	O
DTDST	O
.	O

In	O
two	O
patients	O
(	O
DTD	B
and	O
AO2	B
/	O
DTD	B
)	O
,	O
no	O
other	O
structural	O
mutation	O
was	O
found	O
,	O
but	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
fibroblast	O
cDNA	O
showed	O
reduced	O
mRNA	O
levels	O
of	O
the	O
wild	O
-	O
type	O
DTDST	O
allele	O
these	O
two	O
patients	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
""""	O
Finnish	O
""""	O
mutation	O
(	O
as	O
yet	O
uncharacterized	O
at	O
the	O
DNA	O
level	O
)	O
,	O
which	O
causes	O
reduced	O
expression	O
of	O
DTDST	O
.	O

The	O
third	O
patient	O
(	O
with	O
AO2	B
)	O
had	O
the	O
R279W	O
mutation	O
compounded	O
with	O
a	O
novel	O
mutation	O
,	O
the	O
deletion	O
of	O
cytosine	O
418	O
(	O
delta	O
c418	O
)	O
,	O
predicting	O
a	O
frameshift	O
with	O
premature	O
termination	O
.	O

Also	O
the	O
delta	O
c418	O
allele	O
was	O
underrepresented	O
in	O
the	O
cDNA	O
,	O
in	O
accordance	O
with	O
previous	O
observations	O
that	O
premature	O
stop	O
codons	O
reduce	O
mRNA	O
levels	O
.	O

The	O
presence	O
of	O
the	O
DTDST	O
R279W	O
mutation	O
in	O
a	O
total	O
of	O
11	O
patients	O
with	O
AO2	B
or	O
DTD	B
emphasizes	O
the	O
overlap	O
between	O
these	O
conditions	O
.	O

This	O
mutation	O
has	O
not	O
been	O
found	O
so	O
far	O
in	O
8	O
analyzed	O
ACG1B	B
patients	O
,	O
suggesting	O
that	O
it	O
allows	O
some	O
residual	O
activity	O
of	O
the	O
sulfate	O
transporter	O
..	O

Identification	O
of	O
WASP	O
mutations	O
,	O
mutation	O
hotspots	O
and	O
genotype	O
-	O
phenotype	O
disparities	O
in	O
24	O
patients	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

The	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
,	O
an	O
X	B
-	I
linked	I
immunodeficiency	I
disease	I
caused	O
by	O
mutation	O
in	O
the	O
recently	O
isolated	O
gene	O
encoding	O
WAS	B
protein	O
(	O
WASP	O
)	O
,	O
is	O
known	O
to	O
be	O
associated	O
with	O
extensive	O
clinical	O
heterogeneity	O
.	O

Cumulative	O
mutation	O
data	O
have	O
revealed	O
that	O
WASP	O
genotypes	O
are	O
also	O
highly	O
variable	O
among	O
WAS	B
patients	O
,	O
but	O
the	O
relationship	O
of	O
phenotype	O
with	O
genotype	O
in	O
this	O
disease	O
remains	O
unclear	O
.	O

To	O
address	O
this	O
issue	O
we	O
characterized	O
WASP	O
mutations	O
in	O
24	O
unrelated	O
WAS	B
patients	O
,	O
including	O
18	O
boys	O
with	O
severe	O
classical	O
WAS	B
and	O
6	O
boys	O
expressing	O
mild	O
forms	O
of	O
the	O
disease	O
,	O
and	O
then	O
examined	O
the	O
degree	O
of	O
correlation	O
of	O
these	O
as	O
well	O
as	O
all	O
previously	O
published	O
WASP	O
mutations	O
with	O
disease	O
severity	O
.	O

By	O
analysis	O
of	O
these	O
compiled	O
mutation	O
data	O
,	O
we	O
demonstrated	O
clustering	O
of	O
WASP	O
mutations	O
within	O
the	O
four	O
most	O
N	O
-	O
terminal	O
exons	O
of	O
the	O
gene	O
and	O
also	O
identified	O
several	O
sites	O
within	O
this	O
region	O
as	O
hotspots	O
for	O
WASP	O
mutation	O
.	O

These	O
characteristics	O
were	O
observed	O
,	O
however	O
,	O
in	O
both	O
severe	O
and	O
mild	O
cases	O
of	O
the	O
disease	O
.	O

Similarly	O
,	O
while	O
the	O
cumulative	O
data	O
revealed	O
a	O
predominance	O
of	O
missense	O
mutations	O
among	O
the	O
WASP	O
gene	O
lesions	O
observed	O
in	O
boys	O
with	O
isolated	B
thrombocytopenia	I
,	O
missense	O
mutations	O
were	O
not	O
exclusively	O
associated	O
with	O
milder	O
WAS	B
phenotypes	O
,	O
but	O
also	O
comprised	O
a	O
substantial	O
portion	O
(	O
38	O
%	O
)	O
of	O
the	O
WASP	O
gene	O
defects	O
found	O
in	O
patients	O
with	O
severe	O
disease	O
.	O

These	O
findings	O
,	O
as	O
well	O
as	O
the	O
detection	O
of	O
identical	O
WASP	O
mutations	O
in	O
patients	O
with	O
disparate	O
phenotypes	O
,	O
reveal	O
a	O
lack	O
of	O
phenotype	O
concordance	O
with	O
genotype	O
in	O
WAS	B
and	O
thus	O
imply	O
that	O
phenotypic	O
outcome	O
in	O
this	O
disease	O
can	O
not	O
be	O
reliably	O
predicted	O
solely	O
on	O
the	O
basis	O
of	O
WASP	O
genotypes	O
..	O

Germline	O
mutations	O
in	O
the	O
3	O
'	O
part	O
of	O
APC	B
exon	O
15	O
do	O
not	O
result	O
in	O
truncated	O
proteins	O
and	O
are	O
associated	O
with	O
attenuated	O
adenomatous	B
polyposis	I
coli	I
.	O

Familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
an	O
inherited	O
predisposition	O
to	O
colorectal	B
cancer	I
characterized	O
by	O
the	O
development	O
of	O
numerous	O
adenomatous	B
polyps	I
predominantly	O
in	O
the	O
colorectal	O
region	O
.	O

Germline	O
mutations	O
in	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
are	O
responsible	O
for	O
most	O
cases	O
of	O
FAP	B
.	O

Mutations	O
at	O
the	O
5	O
end	O
of	O
APC	B
are	O
known	O
to	O
be	O
associated	O
with	O
a	O
relatively	O
mild	O
form	O
of	O
the	O
disease	O
,	O
called	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
.	O

We	O
identified	O
a	O
frameshift	O
mutation	O
in	O
the	O
3	O
part	O
of	O
exon	O
15	O
,	O
resulting	O
in	O
a	O
stop	O
codon	O
at	O
1862	O
,	O
in	O
a	O
large	O
Dutch	O
kindred	O
with	O
AAPC	B
.	O

Western	O
blot	O
analysis	O
of	O
lymphoblastoid	O
cell	O
lines	O
derived	O
from	O
affected	O
family	O
members	O
from	O
this	O
kindred	O
,	O
as	O
well	O
as	O
from	O
a	O
previously	O
reported	O
Swiss	O
family	O
carrying	O
a	O
frameshift	O
mutation	O
at	O
codon	O
1987	O
and	O
displaying	O
a	O
similar	O
attenuated	O
phenotype	O
,	O
showed	O
only	O
the	O
wild	O
-	O
type	O
APC	B
protein	O
.	O

Our	O
study	O
indicates	O
that	O
chain	O
-	O
terminating	O
mutations	O
located	O
in	O
the	O
3	O
part	O
of	O
APC	B
do	O
not	O
result	O
in	O
detectable	O
truncated	O
polypeptides	O
and	O
we	O
hypothesize	O
that	O
this	O
is	O
likely	O
to	O
be	O
the	O
basis	O
for	O
the	O
observed	O
AAPC	B
phenotype	O
..	O

Complete	O
genomic	O
sequence	O
and	O
analysis	O
of	O
117	O
kb	O
of	O
human	O
DNA	O
containing	O
the	O
gene	O
BRCA1	O
.	O

Over	O
100	O
distinct	O
disease	O
-	O
associated	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
breast	B
-	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
.	O

Loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
>	O
90	O
%	O
of	O
tumors	B
from	O
patients	O
with	O
inherited	O
BRCA1	O
mutations	O
indicates	O
tumor	B
suppressive	O
function	O
.	O

The	O
low	O
incidence	O
of	O
somatic	O
mutations	O
suggests	O
that	O
BRCA1	O
inactivation	O
in	O
sporadic	O
tumors	B
occurs	O
by	O
alternative	O
mechanisms	O
,	O
such	O
as	O
interstitial	O
chromosomal	O
deletion	O
or	O
reduced	O
transcription	O
.	O

To	O
identify	O
possible	O
features	O
of	O
the	O
BRCA1	O
genomic	O
region	O
that	O
may	O
contribute	O
to	O
chromosomal	O
instability	O
as	O
well	O
as	O
potential	O
transcriptional	O
regulatory	O
elements	O
,	O
a	O
117	O
,	O
143-bp	O
DNA	O
sequence	O
encompassing	O
BRCA1	O
was	O
obtained	O
by	O
random	O
sequencing	O
of	O
four	O
cosmids	O
identified	O
from	O
a	O
human	O
chromosome	O
17	O
specific	O
library	O
.	O

The	O
24	O
exons	O
of	O
BRCA1	O
span	O
an	O
81-kb	O
region	O
that	O
has	O
an	O
unusually	O
high	O
density	O
of	O
Alu	O
repetitive	O
DNA	O
(	O
41	O
.	O
5	O
%	O
)	O
,	O
but	O
relatively	O
low	O
density	O
(	O
4	O
.	O
8	O
%	O
)	O
of	O
other	O
repetitive	O
sequences	O
.	O

BRCA1	O
intron	O
lengths	O
range	O
in	O
size	O
from	O
403	O
bp	O
to	O
9	O
.	O
2	O
kb	O
and	O
contain	O
the	O
intragenic	O
microsatellite	O
markers	O
D17S1323	O
,	O
D17S1322	O
,	O
and	O
D17S855	O
,	O
which	O
localize	O
to	O
introns	O
12	O
,	O
19	O
,	O
and	O
20	O
,	O
respectively	O
.	O

In	O
addition	O
to	O
BRCA1	O
,	O
the	O
contig	O
contains	O
two	O
complete	O
genes	O
Rho7	O
,	O
a	O
member	O
of	O
the	O
rho	O
family	O
of	O
GTP	O
binding	O
proteins	O
,	O
and	O
VAT1	O
,	O
an	O
abundant	O
membrane	O
protein	O
of	O
cholinergic	O
synaptic	O
vesicles	O
.	O

Partial	O
sequences	O
of	O
the	O
1A1	O
-	O
3B	O
B	O
-	O
box	O
protein	O
pseudogene	O
and	O
IFP	O
35	O
,	O
an	O
interferon	O
induced	O
leucine	O
zipper	O
protein	O
,	O
reside	O
within	O
the	O
contig	O
.	O

An	O
L21	O
ribosomal	O
protein	O
pseudogene	O
is	O
embedded	O
in	O
BRCA1	O
intron	O
13	O
.	O

The	O
order	O
of	O
genes	O
on	O
the	O
chromosome	O
is	O
centromere-1FP	O
35-VAT1-Rho7-BRCA1	O
-	O
1A1	O
-	O
3B	O
-	O
telomere	O

Identification	O
of	O
a	O
RING	O
protein	O
that	O
can	O
interact	O
in	O
vivo	O
with	O
the	O
BRCA1	O
gene	O
product	O
.	O

The	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
encodes	O
a	O
large	O
polypeptide	O
that	O
contains	O
the	O
cysteine	O
-	O
rich	O
RING	O
motif	O
,	O
a	O
zinc	O
-	O
binding	O
domain	O
found	O
in	O
a	O
variety	O
of	O
regulatory	O
proteins	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
protein	O
that	O
interacts	O
in	O
vivo	O
with	O
the	O
N	O
-	O
terminal	O
region	O
of	O
BRCA1	O
.	O

This	O
BRCA1-associated	O
RING	O
domain	O
(	O
BARD1	O
)	O
protein	O
contains	O
an	O
N	O
-	O
terminal	O
RING	O
motif	O
,	O
three	O
tandem	O
ankyrin	O
repeats	O
,	O
and	O
a	O
C	O
-	O
terminal	O
sequence	O
with	O
significant	O
homology	O
to	O
the	O
phylogenetically	O
conserved	O
BRCT	O
domains	O
that	O
lie	O
near	O
the	O
C	O
terminus	O
of	O
BRCA1	O
.	O

The	O
BARD1	O
/	O
BRCA1	O
interaction	O
is	O
disrupted	O
by	O
BRCA1	O
missense	O
mutations	O
that	O
segregate	O
with	O
breast	B
cancer	I
susceptibility	O
,	O
indicating	O
that	O
BARD1	O
may	O
be	O
involved	O
in	O
mediating	O
tumour	B
suppression	O
by	O
BRCA1	O
..	O

Detection	O
of	O
heterozygous	O
mutations	O
in	O
BRCA1	O
using	O
high	O
density	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
colour	O
fluorescence	O
analysis	O
.	O

The	O
ability	O
to	O
scan	O
a	O
large	O
gene	O
rapidly	O
and	O
accurately	O
for	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
large	O
numbers	O
of	O
patient	O
samples	O
will	O
be	O
critical	O
for	O
the	O
future	O
of	O
medicine	O
.	O

We	O
have	O
designed	O
high	O
-	O
density	O
arrays	O
consisting	O
of	O
over	O
96	O
,	O
600	O
oligonucleotides	O
20-nucleotides	O
(	O
nt	O
)	O
in	O
length	O
to	O
screen	O
for	O
a	O
wide	O
range	O
of	O
heterozygous	O
mutations	O
in	O
the	O
3	O
.	O

45-kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
BRCA1	O
.	O

Reference	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
arrays	O
and	O
differences	O
in	O
hybridization	O
patterns	O
quantitated	O
by	O
two	O
-	O
colour	O
analysis	O
.	O

Fourteen	O
of	O
fifteen	O
patient	O
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
false	O
positive	O
mutations	O
were	O
identified	O
in	O
20	O
control	O
samples	O
.	O

Eight	O
single	O
nucleotide	O
polymorphisms	O
were	O
also	O
readily	O
detected	O
.	O

DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
valuable	O
new	O
technology	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
efficient	O
detection	O
of	O
genetic	O
alterations	O
.	O

Autosomal	O
dominant	O
primary	O
hyperparathyroidism	B
and	I
jaw	I
tumor	I
syndrome	I
associated	O
with	O
renal	B
hamartomas	I
and	O
cystic	B
kidney	I
disease	I
:	O
linkage	O
to	O
1q21-q32	O
and	O
loss	O
of	O
the	O
wild	O
type	O
allele	O
in	O
renal	B
hamartomas	I
.	O

Hereditary	B
hyperparathyroidism	I
-	I
jaw	I
tumor	I
syndrome	I
(	O
HPT	B
-	I
JT	I
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
(	O
OMIM	O
145001	O
)	O
that	O
has	O
recently	O
been	O
mapped	O
to	O
chromosomal	O
region	O
1q21-q32	O
(	O
HRPT2	O
)	O
.	O

Here	O
we	O
report	O
two	O
families	O
with	O
HPT	B
-	I
JT	I
syndrome	I
in	O
which	O
adult	B
renal	I
hamartomas	I
or	O
cystic	B
kidney	I
disease	I
were	O
prominent	O
associated	O
features	O
,	O
possibly	O
representing	O
a	O
new	O
phenotypic	O
variant	O
of	O
the	O
HPT	B
-	I
JT	I
syndrome	I
.	O

In	O
the	O
first	O
family	O
,	O
renal	B
lesions	I
were	O
present	O
in	O
five	O
out	O
of	O
six	O
affected	O
individuals	O
,	O
whereas	O
HPT	B
and	O
JT	B
were	O
seen	O
in	O
four	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

In	O
the	O
second	O
family	O
,	O
JT	B
was	O
found	O
in	O
three	O
of	O
the	O
five	O
affected	O
individuals	O
and	O
two	O
affected	O
members	O
also	O
exhibited	O
polycystic	B
kidney	I
disease	I
.	O

The	O
possibility	O
of	O
the	O
latter	O
cosegregating	O
as	O
a	O
separate	O
autosomal	O
dominant	O
gene	O
can	O
not	O
be	O
ruled	O
out	O
.	O

A	O
sex	O
-	O
dependent	O
penetrance	O
of	O
primary	B
HPT	I
,	O
resulting	O
in	O
predominantly	O
male	O
-	O
affected	O
cases	O
was	O
evident	O
in	O
the	O
two	O
families	O
.	O

Twenty	O
microsatellite	O
markers	O
in	O
the	O
HRPT2	O
region	O
were	O
typed	O
,	O
in	O
addition	O
to	O
markers	O
in	O
the	O
multiple	B
endocrine	I
neoplasia	I
(	I
MEN	I
)	I
types	I
1	I
and	I
2	I
regions	O
at	O
11q13	O
and	O
10q11	O
.	O

The	O
disease	O
in	O
these	O
two	O
kindreds	O
was	O
linked	O
to	O
five	O
markers	O
in	O
the	O
1q21-q32	O
region	O
(	O
logarithm	O
-	O
of	O
-	O
odds	O
scores	O
3	O
.	O
2	O
-	O
4	O
2	O
-	O
4	O
.	O
2	O
)	O
,	O
whereas	O
linkage	O
to	O
the	O
MEN1	B
and	O
MEN2	B
regions	O
was	O
excluded	O
.	O

Meiotic	O
recombinations	O
detected	O
in	O
affected	O
individuals	O
placed	O
the	O
locus	O
telomeric	O
of	O
D1S215	O
,	O
thus	O
narrowing	O
the	O
HRPT2	O
region	O
from	O
>	O
60	O
to	O
approximately	O
34	O
centimorgans	O
.	O

Loss	O
of	O
heterozygosity	O
was	O
studied	O
in	O
seven	O
renal	B
hamartomas	I
from	O
two	O
affected	O
individuals	O
in	O
the	O
first	O
family	O
,	O
as	O
well	O
as	O
in	O
a	O
jaw	B
tumor	I
and	O
a	O
parathyroid	B
tumor	I
from	O
the	O
second	O
family	O
.	O

All	O
renal	B
hamartomas	I
showed	O
loss	O
of	O
heterozygosity	O
at	O
the	O
1q21-q32	O
region	O
.	O

The	O
losses	O
invariably	O
involved	O
the	O
wild	O
type	O
allele	O
derived	O
from	O
the	O
unaffected	O
parent	O
,	O
suggesting	O
the	O
inactivation	O
of	O
a	O
tumor	B
suppressor	O
gene	O
in	O
this	O
region	O

Independent	O
origin	O
of	O
single	O
and	O
double	O
mutations	O
in	O
the	O
human	O
glucose	O
6-phosphate	O
dehydrogenase	O
gene	O
.	O

The	O
vast	O
majority	O
of	O
both	O
polymorphic	O
and	O
sporadic	O
G6PD	O
variants	O
are	O
due	O
to	O
single	O
missense	O
mutations	O
.	O

In	O
the	O
four	O
polymorphic	O
variants	O
that	O
have	O
two	O
point	O
mutations	O
,	O
one	O
of	O
the	O
mutations	O
is	O
always	O
376	O
A--	O
>	O
G	O
(	O
126	O
Asn--	O
>	O
Asp	O
)	O
,	O
which	O
on	O
its	O
own	O
gives	O
rise	O
to	O
the	O
nondeficient	O
polymorphic	O
variant	O
,	O
G6PD	O
A.	O
In	O
a	O
study	O
of	O
G6PD	B
deficient	I
patients	O
who	O
presented	O
with	O
clinical	O
favism	B
in	O
Spain	O
,	O
we	O
have	O
found	O
a	O
new	O
polymorphic	O
variant	O
that	O
we	O
have	O
called	O
G6PD	O
Malaga	O
,	O
whose	O
only	O
abnormality	O
is	O
a	O
542	O
A--	O
>	O
T	O
(	O
181	O
Asp--	O
>	O
Val	O
)	O
mutation	O
.	O

This	O
is	O
the	O
same	O
mutation	O
as	O
previously	O
found	O
in	O
association	O
with	O
the	O
mutation	O
of	O
G6PD	O
A	O
in	O
the	O
double	O
mutant	O
,	O
G6PD	O
Santamaria	O
.	O

G6PD	O
Malaga	O
is	O
associated	O
with	O
enzyme	B
deficiency	I
(	O
class	O
III	O
)	O
,	O
and	O
the	O
enzymic	O
properties	O
of	O
G6PD	O
Malaga	O
and	O
G6PD	O
Santamaria	O
are	O
quite	O
similar	O
,	O
indicating	O
that	O
in	O
this	O
case	O
the	O
effects	O
of	O
the	O
two	O
mutations	O
are	O
additive	O
rather	O
than	O
synergistic	O
.	O

G6PD	O
Santamaria	O
might	O
have	O
been	O
produced	O
by	O
recombination	O
between	O
G6PD	O
A	O
and	O
G6PD	O
Malaga	O
;	O
however	O
haplotype	O
analysis	O
,	O
including	O
the	O
use	O
of	O
a	O
new	O
silent	O
polymorphism	O
,	O
suggests	O
that	O
the	O
same	O
542	O
A--	O
>	O
T	O
mutation	O
has	O
taken	O
place	O
independently	O
in	O
a	O
G6PD	O
B	O
gene	O
to	O
give	O
G6PD	O
Malaga	O
and	O
in	O
a	O
G6PD	O
A	O
gene	O
to	O
give	O
G6PD	O
Santamaria	O
.	O

These	O
findings	O
help	O
to	O
outline	O
the	O
relationship	O
and	O
evolution	O
of	O
mutations	O
in	O
the	O
human	O
G6PD	O
locus	O
..	O

BRCA1	O
R841W	O
:	O
a	O
strong	O
candidate	O
for	O
a	O
common	O
mutation	O
with	O
moderate	O
phenotype	O
.	O

BRCA1	O
mutations	O
cause	O
increased	O
risk	O
for	O
breast	B
and	I
ovarian	I
cancer	I
,	O
frequently	O
of	O
early	O
onset	O
.	O

Many	O
different	O
mutations	O
occur	O
in	O
BRCA1	O
,	O
including	O
several	O
examples	O
of	O
recurrent	O
mutations	O
,	O
each	O
of	O
which	O
accounts	O
for	O
a	O
significant	O
number	O
of	O
families	O
with	O
heritable	O
cancer	B
predisposition	O
.	O

These	O
common	O
mutations	O
have	O
an	O
etiological	O
role	O
in	O
many	O
breast	B
and	I
ovarian	I
cancer	I
cases	O
and	O
provide	O
the	O
opportunity	O
to	O
examine	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
genotype	O
-	O
environment	O
interactions	O
in	O
individuals	O
with	O
the	O
identical	O
BRCA1	O
lesion	O
.	O

We	O
report	O
a	O
novel	O
missense	O
change	O
in	O
BRCA1	O
,	O
2640	O
C--	O
>	O
T	O
(	O
R841W	O
)	O
,	O
found	O
in	O
3	O
cases	O
from	O
a	O
subject	O
group	O
of	O
305	O
breast	B
and	I
79	I
ovarian	I
cancer	I
cases	O
from	O
Orange	O
County	O
,	O
CA	O
.	O

These	O
are	O
consecutive	O
,	O
population	O
-	O
based	O
cases	O
not	O
selected	O
for	O
age	O
or	O
family	O
history	O
.	O

In	O
all	O
three	O
cases	O
,	O
there	O
is	O
a	O
strong	O
family	O
history	O
of	O
breast	B
,	I
ovarian	I
,	I
or	I
other	I
cancers	I
possibly	O
related	O
to	O
a	O
BRCA1	O
defect	O
and	O
family	O
members	O
showed	O
a	O
high	O
concordance	O
of	O
cancer	B
incidence	O
with	O
the	O
presence	O
of	O
R841W	O
.	O

The	O
age	O
of	O
cancer	B
onset	O
was	O
not	O
always	O
distinct	O
from	O
typical	O
sporadic	O
cases	O
.	O

Testing	O
of	O
a	O
sample	O
of	O
413	O
unrelated	O
individuals	O
to	O
examine	O
the	O
hypothesis	O
that	O
R841W	O
might	O
be	O
a	O
rare	O
polymorphism	O
detected	O
one	O
additional	O
instance	O
in	O
a	O
woman	O
with	O
breast	B
cancer	I
diagnosed	O
at	O
age	O
77	O
years	O
,	O
and	O
cancer	B
in	O
one	O
parent	O
.	O

R841W	O
is	O
likely	O
to	O
be	O
an	O
etiologically	O
significant	O
lesion	O
with	O
involvement	O
in	O
close	O
to	O
1	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
of	O
0	O
-	O
1	O
.	O
7	O
%	O
)	O
of	O
all	O
breast	B
and	I
ovarian	I
cancers	I
in	O
this	O
population	O
.	O

Ataxia	B
-	I
telangiectasia	I
:	O
founder	O
effect	O
among	O
north	O
African	O
Jews	O
.	O

The	O
ATM	O
gene	O
is	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
characterized	O
by	O
cerebellar	B
degeneration	I
,	O
immunodeficiency	B
and	O
cancer	B
predisposition	I
.	O

A	B
-	I
T	I
carriers	O
were	O
reported	O
to	O
be	O
moderately	O
cancer	B
-	I
prone	I
.	O

A	O
wide	O
variety	O
of	O
A	B
-	I
T	I
mutations	O
,	O
most	O
of	O
which	O
are	O
unique	O
to	O
single	O
families	O
,	O
were	O
identified	O
in	O
various	O
ethnic	O
groups	O
,	O
precluding	O
carrier	O
screening	O
with	O
mutation	O
-	O
specific	O
assays	O
.	O

However	O
,	O
a	O
single	O
mutation	O
was	O
observed	O
in	O
32	O
/	O
33	O
defective	O
ATM	O
alleles	O
in	O
Jewish	O
A	B
-	I
T	I
families	O
of	O
North	O
African	O
origin	O
,	O
coming	O
from	O
various	O
regions	O
of	O
Morocco	O
and	O
Tunisia	O
.	O

This	O
mutation	O
,	O
103C--	O
>	O
T	O
,	O
results	O
in	O
a	O
stop	O
codon	O
at	O
position	O
35	O
of	O
the	O
ATM	O
protein	O
.	O

In	O
keeping	O
with	O
the	O
nature	O
of	O
this	O
mutation	O
,	O
various	O
antibodies	O
directed	O
against	O
the	O
ATM	O
protein	O
failed	O
to	O
defect	O
this	O
protein	O
in	O
patient	O
cells	O
.	O

A	O
rapid	O
carrier	O
detection	O
assay	O
detected	O
this	O
mutation	O
in	O
three	O
out	O
of	O
488	O
ATM	O
alleles	O
of	O
Jewish	O
Moroccan	O
or	O
Tunisian	O
origin	O
.	O

This	O
founder	O
effect	O
provides	O
a	O
unique	O
opportunity	O
for	O
population	O
-	O
based	O
screening	O
for	O
A	B
-	I
T	I
carriers	O
in	O
a	O
large	O
Jewish	O
community	O
..	O

Mutation	O
analysis	O
of	O
BRCA1	O
and	O
BRCA2	O
in	O
a	O
male	B
breast	I
cancer	I
population	O
.	O

A	O
population	O
-	O
based	O
series	O
of	O
54	O
male	B
breast	I
cancer	I
cases	O
from	O
Southern	O
California	O
were	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
inherited	B
breast	I
/	I
ovarian	I
cancer	I
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
.	O

Nine	O
(	O
17	O
%	O
)	O
of	O
the	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B
and/or	I
ovarian	I
cancer	I
in	O
at	O
least	O
one	O
first	O
-	O
degree	O
relative	O
.	O

A	O
further	O
seven	O
(	O
13	O
%	O
)	O
of	O
the	O
patients	O
reported	O
breast	B
/	I
ovarian	I
cancer	I
in	O
at	O
least	O
one	O
second	O
-	O
degree	O
relative	O
and	O
in	O
no	O
first	O
-	O
degree	O
relatives	O
.	O

No	O
germ	O
-	O
line	O
BRCA1	O
mutations	O
were	O
found	O
.	O

Two	O
male	B
breast	I
cancer	I
patients	O
(	O
4	O
%	O
of	O
the	O
total	O
)	O
were	O
found	O
to	O
carry	O
novel	O
truncating	O
mutations	O
in	O
the	O
BRCA2	O
gene	O
.	O

Only	O
one	O
of	O
the	O
two	O
male	B
breast	I
cancer	I
patients	O
carrying	O
a	O
BRCA2	O
mutation	O
had	O
a	O
family	O
history	O
of	O
cancer	B
,	O
with	O
one	O
case	O
of	O
ovarian	B
cancer	I
in	O
a	O
first	O
-	O
degree	O
relative	O
.	O

The	O
remaining	O
eight	O
cases	O
(	O
89	O
%	O
)	O
of	O
male	B
breast	I
cancer	I
with	O
a	O
family	O
history	O
of	O
breast	B
/	I
ovarian	I
cancer	I
in	O
first	O
-	O
degree	O
relatives	O
remain	O
unaccounted	O
for	O
by	O
mutations	O
in	O
either	O
the	O
BRCA1	O
gene	O
or	O
the	O
BRCA2	O
gene	O
..	O

Molecular	O
basis	O
for	O
Duarte	B
and	I
Los	I
Angeles	I
variant	I
galactosemia	I
.	O

Human	O
orythrocytes	O
that	O
are	O
homozygous	O
for	O
the	O
Duarte	B
enzyme	I
variant	I
of	I
galactosemia	I
(	O
D	O
/	O
D	O
)	O
have	O
a	O
characteristic	O
isoform	O
on	O
isoelectric	O
focusing	O
and	O
50	O
%	O
reduction	O
in	O
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
enzyme	O
activity	O
.	O

The	O
Duarte	O
biochemical	O
phenotype	O
has	O
a	O
molecular	O
genotype	O
of	O
N314D	O
/	O
N314D	O
.	O

The	O
characteristic	O
Duarte	O
isoform	O
is	O
also	O
associated	O
with	O
a	O
variant	O
called	O
the	O
""""	O
Los	O
Angeles	O
(	O
LA	O
)	O
phenotype	O
,	O
""""	O
which	O
has	O
increased	O
GALT	O
enzyme	O
activity	O
.	O

We	O
evaluated	O
GALT	O
enzyme	O
activity	O
and	O
screened	O
the	O
GALT	O
genes	O
of	O
145	O
patients	O
with	O
one	O
or	O
more	O
N314D	O
-	O
containing	O
alleles	O
.	O

We	O
found	O
seven	O
with	O
the	O
LA	O
biochemical	O
phenotype	O
,	O
and	O
all	O
had	O
a	O
1721C--	O
>	O
T	O
transition	O
in	O
exon	O
7	O
in	O
cis	O
with	O
the	O
N314D	O
missense	O
mutation	O
.	O

The	O
1721C--	O
>	O
T	O
transition	O
is	O
a	O
neutral	O
polymorphism	O
for	O
leucine	O
at	O
amino	O
acid	O
218	O
(	O
L218L	O
)	O
.	O

In	O
pedigree	O
analyses	O
,	O
this	O
1721C--	O
>	O
T	O
transition	O
segregated	O
with	O
the	O
LA	O
phenotype	O
of	O
increased	O
GALT	O
activity	O
in	O
three	O
different	O
biochemical	O
phenotypes	O
(	O
LA	O
/	O
N	O
,	O
LA	O
/	O
G	O
,	O
and	O
LA	O
/	O
D	O
)	O
.	O

To	O
determine	O
the	O
mechanism	O
for	O
increased	O
activity	O
of	O
the	O
LA	O
variant	O
,	O
we	O
compared	O
GALT	O
mRNA	O
,	O
protein	O
abundance	O
,	O
and	O
enzyme	O
thermal	O
stability	O
in	O
lymphoblast	O
cell	O
lines	O
of	O
D	O
and	O
LA	O
phenotypes	O
with	O
comparable	O
genotypes	O
.	O

GALT	O
protein	O
abundance	O
was	O
increased	O
in	O
LA	O
compared	O
to	O
D	O
alleles	O
,	O
but	O
mRNA	O
was	O
similar	O
among	O
all	O
genotypes	O
.	O

When	O
LA	O
/	O
D	O
and	O
D	O
/	O
D	O
GALT	O
biochemical	O
phenotypes	O
were	O
compared	O
to	O
N	O
/	O
N	O
GALT	O
phenotypes	O
,	O
both	O
had	O
50	O
%	O
,	O
as	O
compared	O
to	O
21	O
%	O
,	O
reduction	O
in	O
GALT	O
activity	O
in	O
the	O
wild	O
type	O
(	O
N	O
/	O
N	O
)	O
after	O
exposure	O
at	O
identical	O
initial	O
enzyme	O
activity	O
to	O
50	O
degrees	O
C	O
for	O
15	O
min	O
.	O

We	O
conclude	O
that	O
the	O
codon	O
change	O
N314D	O
in	O
cis	O
with	O
the	O
base	O
-	O
pair	O
transition	O
1721C--	O
>	O
T	O
produces	O
the	O
LA	B
variant	I
of	I
galactosemia	I
and	O
that	O
this	O
nucleotide	O
change	O
increases	O
GALT	O
activity	O
by	O
increasing	O
GALT	O
protein	O
abundance	O
without	O
increasing	O
transcription	O
or	O
decreasing	O
thermal	O
lability	O
.	O

A	O
favorable	O
codon	O
bias	O
for	O
the	O
mutated	O
codon	O
with	O
consequently	O
increased	O
translation	O
rates	O
is	O
postulated	O
as	O
the	O
mechanism	O
..	O

The	O
TSG101	O
tumor	B
susceptibility	O
gene	O
is	O
located	O
in	O
chromosome	O
11	O
band	O
p15	O
and	O
is	O
mutated	O
in	O
human	O
breast	B
cancer	I
.	O

Recent	O
work	O
has	O
identified	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
whose	O
inactivation	O
in	O
fibroblasts	O
results	O
in	O
cellular	O
transformation	O
and	O
the	O
ability	O
to	O
produce	O
metastatic	B
tumors	I
in	O
nude	O
mice	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
human	O
homolog	O
,	O
TSG101	O
,	O
which	O
we	O
isolated	O
and	O
mapped	O
to	O
chromosome	O
11	O
,	O
bands	O
15	O
.	O
1	O
-	O
15	O
1	O
-	O
15	O
.	O
2	O
,	O
a	O
region	O
proposed	O
to	O
contain	O
tumor	B
suppressor	O
gene	O
(	O
s	O
)	O
,	O
is	O
mutated	O
at	O
high	O
frequency	O
in	O
human	O
breast	B
cancer	I
.	O

In	O
7	O
of	O
15	O
uncultured	O
primary	O
human	O
breast	B
carcinomas	I
,	O
intragenic	O
deletions	O
were	O
shown	O
in	O
TSG101	O
genomic	O
DNA	O
and	O
transcripts	O
by	O
gel	O
and	O
sequence	O
analysis	O
,	O
and	O
mutations	O
affecting	O
two	O
TSG101	O
alleles	O
were	O
identified	O
in	O
four	O
of	O
these	O
cancers	B
.	O

No	O
TSG101	O
defects	O
were	O
found	O
in	O
matched	O
normal	O
breast	O
tissue	O
from	O
the	O
breast	B
cancer	I
patients	O
.	O

These	O
findings	O
strongly	O
implicate	O
TSG101	O
mutations	O
in	O
human	O
breast	B
cancer	I

Moderate	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
a	O
55-CTG	O
repeat	O
in	O
transgenic	O
mice	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
associated	O
with	O
the	O
expansion	O
of	O
a	O
(	O
CTG	O
)	O
n	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
.	O

The	O
(	O
CTG	O
)	O
n	O
repeat	O
is	O
polymorphic	O
and	O
varies	O
in	O
size	O
between	O
5	O
and	O
37	O
repeats	O
in	O
unaffected	O
individuals	O
whereas	O
in	O
affected	O
patients	O
there	O
are	O
between	O
50	O
and	O
4	O
,	O
000	O
CTGs	O
.	O

The	O
size	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
which	O
increases	O
through	O
generations	O
,	O
generally	O
correlates	O
with	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

The	O
instability	O
of	O
the	O
CTG	O
repeat	O
appears	O
to	O
depend	O
on	O
its	O
size	O
as	O
well	O
as	O
on	O
the	O
sex	O
of	O
the	O
transmitting	O
parent	O
.	O

Moreover	O
,	O
mitotic	O
instability	O
analysis	O
of	O
different	O
human	O
DM	B
tissues	O
shows	O
length	O
mosaicism	O
between	O
different	O
cell	O
lineages	O
.	O

The	O
molecular	O
mechanisms	O
of	O
triplet	O
instability	O
remain	O
elusive	O
.	O

To	O
investigate	O
the	O
role	O
of	O
genomic	O
sequences	O
in	O
instability	O
,	O
we	O
produced	O
transgenic	O
mice	O
containing	O
a	O
45-kb	O
genomic	O
segment	O
with	O
a	O
55-CTG	O
repeat	O
cloned	O
from	O
a	O
mildly	O
affected	O
patient	O
.	O

In	O
contrast	O
to	O
other	O
mouse	O
models	O
containing	O
CAG	O
repeats	O
within	O
cDNAs	O
,	O
these	O
mice	O
showed	O
both	O
intergenerational	O
and	O
somatic	O
repeat	O
instability	O
..	O

Missense	O
mutations	O
in	O
the	O
Fas	O
gene	O
resulting	O
in	O
autoimmune	B
lymphoproliferative	I
syndrome	I
:	O
a	O
molecular	O
and	O
immunological	O
analysis	O
.	O

Programmed	O
cell	O
death	O
(	O
or	O
apoptosis	O
)	O
is	O
a	O
physiological	O
process	O
essential	O
to	O
the	O
normal	O
development	O
and	O
homeostatic	O
maintenance	O
of	O
the	O
immune	O
system	O
.	O

The	O
Fas	O
/	O
Apo-1	O
receptor	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
apoptosis	O
,	O
as	O
demonstrated	O
by	O
lymphoproliferation	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
mice	O
and	O
by	O
the	O
recently	O
described	O
autoimmune	B
lymphoproliferative	I
syndrome	I
(	O
ALPS	B
)	O
in	O
humans	O
,	O
both	O
of	O
which	O
are	O
due	O
to	O
mutations	O
in	O
the	O
Fas	O
gene	O
.	O

We	O
describe	O
a	O
novel	O
family	O
with	O
ALPS	B
in	O
which	O
three	O
affected	O
siblings	O
carry	O
two	O
distinct	O
missense	O
mutations	O
on	O
both	O
the	O
Fas	O
gene	O
alleles	O
and	O
show	O
lack	O
of	O
Fas	O
-	O
induced	O
apoptosis	O
.	O

The	O
children	O
share	O
common	O
clinical	O
features	O
including	O
splenomegaly	B
and	O
lymphadenopathy	B
,	O
but	O
only	O
one	O
developed	O
severe	O
autoimmune	B
manifestations	I
.	O

In	O
all	O
three	O
siblings	O
,	O
we	O
demonstrated	O
the	O
presence	O
of	O
anergic	O
CD3	O
+	O
CD4-CD8-	O
(	O
double	O
negative	O
,	O
[	O
DN	O
]	O
)	O
T	O
cells	O
;	O
moreover	O
,	O
a	O
chronic	O
lymphocyte	O
activation	O
was	O
found	O
,	O
as	O
demonstrated	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
HLA	O
-	O
DR	O
expression	O
on	O
peripheral	O
CD3	O
+	O
cells	O
and	O
by	O
the	O
presence	O
of	O
high	O
levels	O
of	O
serum	O
activation	O
markers	O
such	O
as	O
soluble	O
interleukin-2	O
receptor	O
(	O
slL-2R	O
)	O
and	O
soluble	O
CD30	O
(	O
sCD30	O
)	O
..	O

The	O
ataxia	B
-	I
telangiectasia	I
gene	O
product	O
,	O
a	O
constitutively	O
expressed	O
nuclear	O
protein	O
that	O
is	O
not	O
up	O
-	O
regulated	O
following	O
genome	O
damage	O
.	O

The	O
product	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
(	O
ATM	O
)	O
was	O
identified	O
by	O
using	O
an	O
antiserum	O
developed	O
to	O
a	O
peptide	O
corresponding	O
to	O
the	O
deduced	O
amino	O
acid	O
sequence	O
.	O

The	O
ATM	O
protein	O
is	O
a	O
single	O
,	O
high	O
-	O
molecular	O
weight	O
protein	O
predominantly	O
confined	O
to	O
the	O
nucleus	O
of	O
human	O
fibroblasts	O
,	O
but	O
is	O
present	O
in	O
both	O
nuclear	O
and	O
microsomal	O
fractions	O
from	O
human	O
lymphoblast	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
.	O

ATM	O
protein	O
levels	O
and	O
localization	O
remain	O
constant	O
throughout	O
all	O
stages	O
of	O
the	O
cell	O
cycle	O
.	O

Truncated	O
ATM	O
protein	O
was	O
not	O
detected	O
in	O
lymphoblasts	O
from	O
ataxia	B
-	I
telangiectasia	I
patients	O
homozygous	O
for	O
mutations	O
leading	O
to	O
premature	O
protein	O
termination	O
.	O

Exposure	O
of	O
normal	O
human	O
cells	O
to	O
gamma	O
-	O
irradiation	O
and	O
the	O
radiomimetic	O
drug	O
neocarzinostatin	O
had	O
no	O
effect	O
on	O
ATM	O
protein	O
levels	O
,	O
in	O
contrast	O
to	O
a	O
noted	O
rise	O
in	O
p53	O
levels	O
over	O
the	O
same	O
time	O
interval	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
role	O
for	O
the	O
ATM	O
protein	O
in	O
ensuring	O
the	O
fidelity	O
of	O
DNA	O
repair	O
and	O
cell	O
cycle	O
regulation	O
following	O
genome	O
damage	O
..	O

Type	O
III	O
collagen	O
is	O
crucial	O
for	O
collagen	O
I	O
fibrillogenesis	O
and	O
for	O
normal	O
cardiovascular	O
development	O
.	O

Type	O
III	O
collagen	O
is	O
a	O
fibrillar	O
forming	O
collagen	O
comprising	O
three	O
alpha1	O
(	O
III	O
)	O
chains	O
and	O
is	O
expressed	O
in	O
early	O
embryos	O
and	O
throughout	O
embryogenesis	O
.	O

In	O
the	O
adult	O
,	O
type	O
III	O
collagen	O
is	O
a	O
major	O
component	O
of	O
the	O
extracellular	O
matrix	O
in	O
a	O
variety	O
of	O
internal	O
organs	O
and	O
skin	O
.	O

Mutations	O
in	O
the	O
COL3A1	O
gene	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
,	O
a	O
disease	O
leading	O
to	O
aortic	B
rupture	I
in	O
early	O
adult	O
life	O
.	O

To	O
directly	O
study	O
the	O
role	O
of	O
Col3a1	O
in	O
development	O
and	O
disease	O
,	O
we	O
have	O
inactivated	O
the	O
Col3a1	O
gene	O
in	O
embryonic	O
stem	O
cells	O
by	O
homologous	O
recombination	O
.	O

The	O
mutated	O
allele	O
was	O
transmitted	O
through	O
the	O
mouse	O
germ	O
line	O
and	O
homozygous	O
mutant	O
animals	O
were	O
derived	O
from	O
heterozygous	O
intercrosses	O
.	O

About	O
10	O
%	O
of	O
the	O
homozygous	O
mutant	O
animals	O
survived	O
to	O
adulthood	O
but	O
have	O
a	O
much	O
shorter	O
life	O
span	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

The	O
major	O
cause	O
of	O
death	O
of	O
mutant	O
mice	O
was	O
rupture	O
of	O
the	O
major	O
blood	O
vessels	O
,	O
similar	O
to	O
patients	O
with	O
type	B
IV	I
Ehlers	I
-	I
Danlos	I
syndrome	I
.	O

Ultrastructural	O
analysis	O
of	O
tissues	O
from	O
mutant	O
mice	O
revealed	O
that	O
type	O
III	O
collagen	O
is	O
essential	O
for	O
normal	O
collagen	O
I	O
fibrillogenesis	O
in	O
the	O
cardiovascular	O
system	O
and	O
other	O
organs	O
..	O

Nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

We	O
report	O
a	O
G--	O
>	O
A	O
transition	O
at	O
nucleotide	O
431	O
of	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
results	O
in	O
a	O
nonsense	O
codon	O
in	O
a	O
family	O
with	O
an	O
unusual	O
form	O
of	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
(	O
PMD	B
)	O
.	O

The	O
mutation	O
,	O
which	O
creates	O
a	O
second	O
AluI	O
restriction	O
site	O
,	O
results	O
in	O
a	O
nonsense	O
mutation	O
in	O
PLP	O
.	O

The	O
clinical	O
picture	O
resembles	O
somewhat	O
that	O
of	O
X	B
-	I
linked	I
spastic	I
paraplegia	I
(	O
SPG	B
)	O
.	O

It	O
differs	O
from	O
this	O
and	O
both	O
the	O
classical	O
and	O
connatal	O
forms	O
of	O
PMD	B
in	O
that	O
it	O
is	O
relatively	O
mild	O
in	O
form	O
,	O
onset	O
is	O
delayed	O
beyond	O
age	O
2	O
years	O
,	O
nystagmus	B
is	O
absent	O
,	O
tremors	B
are	O
prominent	O
,	O
mental	B
retardation	I
is	O
not	O
severe	O
,	O
some	O
patients	O
show	O
dementia	B
or	O
personality	B
disorders	I
,	O
the	O
disease	O
is	O
progressive	O
rather	O
than	O
static	O
in	O
some	O
,	O
and	O
several	O
females	O
show	O
signs	O
of	O
disease	O
.	O

The	O
nonsense	O
mutation	O
,	O
which	O
is	O
in	O
exon	O
3B	O
,	O
should	O
block	O
the	O
synthesis	O
of	O
normal	O
PLP	O
but	O
spare	O
DM20	O
,	O
the	O
isoform	O
whose	O
persistence	O
has	O
been	O
associated	O
with	O
mild	O
forms	O
of	O
PLP	B
-	I
associated	I
disease	I
in	O
both	O
humans	O
and	O
mice	O
..	O

Common	O
BRCA1	O
variants	O
and	O
susceptibility	O
to	O
breast	B
and	I
ovarian	I
cancer	I
in	O
the	O
general	O
population	O
.	O

Most	O
multiple	O
case	O
families	O
of	O
young	O
onset	O
breast	B
cancer	I
and	O
ovarian	B
cancer	I
are	O
thought	O
to	O
be	O
due	O
to	O
highly	O
penetrant	O
mutations	O
in	O
the	O
predisposing	O
genes	O
BRCA1	O
and	O
BRCA2	O
.	O

However	O
,	O
these	O
mutations	O
are	O
uncommon	O
in	O
the	O
population	O
and	O
they	O
probably	O
account	O
for	O
only	O
a	O
few	O
percent	O
of	O
all	O
breast	B
cancer	I
incidence	O
.	O

A	O
much	O
larger	O
fraction	O
of	O
breast	B
cancer	I
might	O
,	O
in	O
principle	O
,	O
be	O
due	O
to	O
common	O
variants	O
which	O
confer	O
more	O
modest	O
individual	O
risks	O
.	O

There	O
are	O
several	O
common	O
polymorphisms	O
in	O
the	O
BRCA1	O
gene	O
which	O
generate	O
amino	O
acid	O
substitutions	O
.	O

We	O
have	O
examined	O
the	O
frequency	O
of	O
four	O
of	O
these	O
polymorphisms	O
Gln356Arg	O
,	O
Pro871Leu	O
,	O
Glu1038Gly	O
and	O
Ser1613Gly	O
in	O
large	O
series	O
of	O
breast	B
and	I
ovarian	I
cancer	I
cases	O
and	O
matched	O
controls	O
.	O

Due	O
to	O
strong	O
linkage	O
disequilibrium	O
,	O
these	O
four	O
sites	O
generate	O
only	O
three	O
haplotypes	O
with	O
a	O
frequency	O
>	O
1	O
.	O
3	O
%	O
.	O

The	O
most	O
common	O
haplotypes	O
,	O
defined	O
by	O
the	O
alleles	O
Gln356Pro871Glu1038Ser1613	O
and	O
Gln356Leu871Gly1038Gly1613	O
,	O
have	O
frequencies	O
of	O
0	O
.	O
57	O
and	O
0	O
.	O
32	O
respectively	O
,	O
and	O
these	O
frequencies	O
do	O
not	O
differ	O
significantly	O
between	O
patient	O
and	O
control	O
groups	O
.	O

Thus	O
the	O
most	O
common	O
polymorphisms	O
of	O
the	O
BRCA1	O
gene	O
do	O
not	O
make	O
a	O
significant	O
contribution	O
to	O
breast	B
or	I
ovarian	I
cancer	I
risk	O
.	O

However	O
,	O
our	O
data	O
suggest	O
that	O
the	O
Arg356	O
allele	O
may	O
have	O
a	O
different	O
genotype	O
distribution	O
in	O
breast	B
cancer	I
patients	O
from	O
that	O
in	O
controls	O
(	O
Arg356	O
homozygotes	O
are	O
more	O
frequent	O
in	O
the	O
control	O
groups	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
indicating	O
that	O
it	O
may	O
be	O
protective	O
against	O
breast	B
cancer	I
.	O

If	O
this	O
finding	O
can	O
be	O
confirmed	O
,	O
it	O
may	O
provide	O
an	O
insight	O
into	O
the	O
structural	O
features	O
of	O
the	O
BRCA1	O
protein	O
that	O
are	O
important	O
for	O
its	O
function	O
.	O

Kniest	B
dysplasia	I
:	O
Dr.	O
W.	O
Kniest	O
,	O
his	O
patient	O
,	O
the	O
molecular	O
defect	O
.	O

Kniest	B
dysplasia	I
is	O
a	O
severe	O
chondrodysplasia	B
caused	O
by	O
the	O
defective	B
formation	I
of	I
type	I
II	I
collagen	I
.	O

We	O
report	O
about	O
Dr.	O
Kniest	O
,	O
who	O
first	O
described	O
the	O
condition	O
in	O
1952	O
,	O
and	O
his	O
patient	O
,	O
who	O
,	O
at	O
the	O
age	O
of	O
50	O
years	O
is	O
severely	B
handicapped	I
with	O
short	B
stature	I
,	O
restricted	B
joint	I
mobility	I
,	O
and	O
blindness	B
but	O
is	O
mentally	O
alert	O
and	O
leads	O
an	O
active	O
life	O
.	O

Molecular	O
analysis	O
of	O
the	O
patients	O
DNA	O
showed	O
a	O
single	O
base	O
(	O
G	O
)	O
deletion	O
involving	O
the	O
GT	O
dinucleotide	O
at	O
the	O
start	O
of	O
intron	O
18	O
destroying	O
a	O
splice	O
site	O
of	O
the	O
COL2A1	O
gene	O
.	O

This	O
is	O
in	O
accordance	O
with	O
molecular	O
findings	O
in	O
other	O
patients	O
with	O
Kniest	B
dysplasia	I
and	O
confirms	O
,	O
in	O
the	O
original	O
patient	O
,	O
that	O
the	O
disorder	O
is	O
caused	O
by	O
small	O
inframe	O
deletions	O
often	O
due	O
to	O
exon	O
skipping	O
as	O
a	O
result	O
of	O
COL2A1	O
splice	O
site	O
mutations	O
..	O

Cloning	O
of	O
the	O
homogentisate	O
1,2-dioxygenase	O
gene	O
,	O
the	O
key	O
enzyme	O
of	O
alkaptonuria	B
in	O
mouse	O
.	O

We	O
determined	O
48	O
amino	O
acid	O
residues	O
from	O
five	O
peptides	O
from	O
the	O
homogeneous	O
monomer	O
of	O
homogentisate	O
1	O
,	O
2-dioxygenase	O
(	O
HGO	O
;	O
E.	O
C.	O
1	O
.	O
13	O
.	O
11	O
.	O
15	O
)	O
of	O
mouse	O
liver	O
.	O

After	O
digestion	O
with	O
trypsin	O
,	O
peptides	O
were	O
separated	O
by	O
reversed	O
phase	O
chromatography	O
and	O
amino	O
acid	O
sequenced	O
.	O

The	O
deduced	O
codon	O
sequence	O
of	O
three	O
peptides	O
was	O
used	O
to	O
derive	O
degenerated	O
oligomeres	O
.	O

By	O
combining	O
these	O
oligos	O
,	O
we	O
were	O
able	O
to	O
amplify	O
fragments	O
from	O
100	O
to	O
300	O
bases	O
(	O
b	O
)	O
from	O
mouse	O
liver	O
cDNA	O
by	O
polymerase	O
chain	O
reaction	O
after	O
reverse	O
transcription	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

A	O
fragment	O
of	O
200	O
b	O
was	O
cloned	O
and	O
used	O
as	O
a	O
probe	O
to	O
screen	O
a	O
mouse	O
liver	O
cDNA	O
library	O
.	O

One	O
clone	O
from	O
this	O
library	O
contained	O
the	O
complete	O
cDNA	O
-	O
insert	O
for	O
HGO	O
as	O
determined	O
by	O
sequencing	O
.	O

The	O
cDNA	O
encodes	O
for	O
a	O
protein	O
of	O
50	O
kDa	O
,	O
as	O
predicted	O
.	O

The	O
cDNA	O
of	O
mouse	O
HGO	O
has	O
an	O
overall	O
identity	O
of	O
41	O
%	O
to	O
the	O
corresponding	O
gene	O
hmgA	O
from	O
Aspergillus	O
.	O

Sequence	O
similarities	O
to	O
human	O
expressed	O
sequence	O
tags	O
(	O
EST	O
)	O
clones	O
ranged	O
from	O
70	O
%	O
to	O
20	O
%	O
.	O

The	O
positions	O
of	O
122	O
conserved	O
amino	O
acids	O
could	O
be	O
determined	O
by	O
multiple	O
sequence	O
alignment	O
.	O

We	O
identified	O
one	O
first	O
intron	O
of	O
928	O
b	O
in	O
the	O
mouse	O
gene	O
.	O

The	O
gene	O
for	O
HGO	O
seems	O
to	O
be	O
expressed	O
in	O
various	O
tissues	O
,	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
on	O
different	O
cDNAs	O
.	O

FISH	O
experiments	O
with	O
the	O
whole	O
murine	O
cDNA	O
as	O
probe	O
clearly	O
revealed	O
signals	O
at	O
the	O
human	O
chromosomal	O
band	O
3q13	O
.	O

3-q21	O
.	O

This	O
corresponds	O
well	O
to	O
the	O
previous	O
assignment	O
of	O
the	O
locus	O
for	O
the	O
human	O
alkaptonuria	B
gene	O
(	O
AKU	O
)	O
to	O
the	O
same	O
chromosomal	O
region	O
by	O
multipoint	O
linkage	O
analysis	O
.	O

We	O
therefore	O
conclude	O
that	O
the	O
HGO	O
cDNA	O
encodes	O
the	O
gene	O
responsible	O
for	O
alkaptonuria	B
.	O

PTEN	O
,	O
a	O
putative	O
protein	O
tyrosine	O
phosphatase	O
gene	O
mutated	O
in	O
human	O
brain	B
,	I
breast	I
,	I
and	I
prostate	I
cancer	I
.	O

Mapping	O
of	O
homozygous	O
deletions	O
on	O
human	O
chromosome	O
10q23	O
has	O
led	O
to	O
the	O
isolation	O
of	O
a	O
candidate	O
tumor	B
suppressor	O
gene	O
,	O
PTEN	O
,	O
that	O
appears	O
to	O
be	O
mutated	O
at	O
considerable	O
frequency	O
in	O
human	O
cancers	B
.	O

In	O
preliminary	O
screens	O
,	O
mutations	O
of	O
PTEN	O
were	O
detected	O
in	O
31	O
%	O
(	O
13	O
/	O
42	O
)	O
of	O
glioblastoma	B
cell	O
lines	O
and	O
xenografts	O
,	O
100	O
%	O
(	O
4	O
/	O
4	O
)	O
of	O
prostate	B
cancer	I
cell	O
lines	O
,	O
6	O
%	O
(	O
4	O
/	O
65	O
)	O
of	O
breast	B
cancer	I
cell	O
lines	O
and	O
xenografts	O
,	O
and	O
17	O
%	O
(	O
3	O
/	O
18	O
)	O
of	O
primary	B
glioblastomas	I
.	O

The	O
predicted	O
PTEN	O
product	O
has	O
a	O
protein	O
tyrosine	O
phosphatase	O
domain	O
and	O
extensive	O
homology	O
to	O
tensin	O
,	O
a	O
protein	O
that	O
interacts	O
with	O
actin	O
filaments	O
at	O
focal	O
adhesions	O
.	O

These	O
homologies	O
suggest	O
that	O
PTEN	O
may	O
suppress	O
tumor	B
cell	O
growth	O
by	O
antagonizing	O
protein	O
tyrosine	O
kinases	O
and	O
may	O
regulate	O
tumor	B
cell	O
invasion	O
and	O
metastasis	B
through	O
interactions	O
at	O
focal	O
adhesions	O
..	O

Heterogeneity	O
in	O
Schwartz	B
-	I
Jampel	I
chondrodystrophic	I
myotonia	I
.	O

The	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
;	O
chondrodystrophic	B
myotonia	I
;	O
McK	O
255	O
,	O
800	O
)	O
is	O
a	O
recessively	B
inherited	I
condition	I
defined	O
by	O
myotonia	B
,	O
short	B
stature	I
,	O
and	O
bone	B
dysplasia	I
.	O

Genetic	O
linkage	O
between	O
SJS	B
and	O
chromosomal	O
region	O
1q36	O
-	O
34	O
has	O
been	O
observed	O
in	O
several	O
families	O
,	O
but	O
the	O
gene	O
has	O
not	O
yet	O
been	O
identified	O
.	O

We	O
studied	O
the	O
clinical	O
and	O
radiological	O
features	O
in	O
81	O
patients	O
from	O
the	O
literature	O
and	O
5	O
own	O
patients	O
trying	O
to	O
identify	O
distinct	O
subgroups	O
.	O

In	O
addition	O
,	O
we	O
tested	O
genetic	O
linkage	O
to	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
in	O
one	O
family	O
with	O
two	O
affected	O
sibs	O
.	O

We	O
found	O
that	O
a	O
group	O
of	O
patients	O
have	O
mild	O
skeletal	O
changes	O
which	O
may	O
be	O
secondary	O
consequences	O
of	O
myotonia	B
,	O
while	O
another	O
group	O
of	O
patients	O
appear	O
to	O
have	O
primary	O
bone	B
dysplasia	I
with	O
myotonia	B
.	O

Within	O
this	O
latter	O
group	O
,	O
there	O
are	O
differences	O
in	O
age	O
of	O
manifestation	O
,	O
clinical	O
course	O
and	O
pattern	O
of	O
bone	O
changes	O
.	O

We	O
tentatively	O
isolate	O
three	O
different	O
types	O
of	O
SJS	B
type	I
1A	I
,	O
usually	O
recognized	O
in	O
childhood	O
,	O
with	O
moderate	O
bone	B
dysplasia	I
,	O
corresponding	O
to	O
the	O
original	O
descriptions	O
of	O
Schwartz	O
,	O
Jampel	O
and	O
Aberfeld	O
;	O
type	O
1B	O
,	O
similar	O
to	O
type	O
1A	O
but	O
recognizable	O
at	O
birth	O
,	O
with	O
more	O
pronounced	O
bone	B
dysplasia	I
resembling	O
Kniest	B
dysplasia	I
;	O
and	O
type	O
2	O
,	O
manifest	O
at	O
birth	O
,	O
with	O
increased	O
mortality	O
and	O
bone	B
dysplasia	I
resembling	O
Pyle	B
disease	I
.	O

Genetic	O
analysis	O
of	O
the	O
family	O
with	O
two	O
sibs	O
affected	O
by	O
SJS	B
type	I
2	I
showed	O
evidence	O
against	O
linkage	O
to	O
chromosome	O
1p36	O
-	O
34	O
.	O

CONCLUSIONS	O
SJS	B
is	O
clinically	O
and	O
radiologically	O
heterogeneous	O
.	O

The	O
causes	O
of	O
heterogeneity	O
are	O
not	O
known	O
yet	O
but	O
are	O
likely	O
to	O
include	O
both	O
different	O
mutations	O
at	O
the	O
SJS	B
locus	O
on	O
chromosome	O
1	O
and	O
the	O
presence	O
of	O
a	O
second	O
SJS	B
locus	O
.	O

A	O
tentative	O
clinico	O
-	O
radiological	O
classification	O
can	O
be	O
useful	O
for	O
the	O
characterization	O
of	O
patients	O
and	O
the	O
development	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
..	O

A	O
clinical	O
overview	O
of	O
WT1	O
gene	O
mutations	O
.	O

Mutations	O
in	O
the	O
WT1	O
gene	O
were	O
anticipated	O
to	O
explain	O
the	O
genetic	O
basis	O
of	O
the	O
childhood	O
kidney	B
cancer	I
,	O
Wilms	B
tumour	I
(	O
WT	B
)	O
.	O

Six	O
years	O
on	O
,	O
we	O
review	O
100	O
reports	O
of	O
intragenic	O
WT1	O
mutations	O
and	O
examine	O
the	O
accompanying	O
clinical	O
phenotypes	O
.	O

While	O
only	O
5	O
%	O
of	O
sporadic	B
Wilms	I
tumours	I
have	O
intragenic	O
WT1	O
mutations	O
,	O
>	O
90	O
%	O
of	O
patients	O
with	O
the	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
renal	B
nephropathy	I
,	O
gonadal	B
anomaly	I
,	O
predisposition	B
to	I
WT	I
)	O
carry	O
constitutional	O
intragenic	O
WT1	O
mutations	O
.	O

WT1	O
mutations	O
have	O
also	O
been	O
reported	O
in	O
juvenile	B
granulosa	I
cell	I
tumour	I
,	O
non	B
-	I
asbestos	I
related	I
mesothelioma	I
,	O
desmoplastic	B
small	I
round	I
cell	I
tumour	I
and	O
,	O
most	O
recently	O
,	O
acute	B
myeloid	I
leukemia	I
..	O

A	O
mutation	O
in	O
autosomal	B
dominant	I
myotonia	I
congenita	I
affects	O
pore	O
properties	O
of	O
the	O
muscle	O
chloride	O
channel	O
.	O

Autosomal	B
dominant	I
myotonia	I
congenita	I
is	O
an	O
inherited	B
disorder	I
of	I
skeletal	I
muscle	I
caused	O
by	O
mutations	O
in	O
a	O
voltage	O
-	O
gated	O
Cl-	O
channel	O
gene	O
(	O
CLCN1	O
,	O
7q35	O
)	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
mutation	O
predicting	O
the	O
substitution	O
of	O
Gly	O
230	O
by	O
glutamic	O
acid	O
(	O
G230E	O
)	O
between	O
segments	O
D3	O
and	O
D4	O
dramatically	O
alters	O
the	O
pore	O
properties	O
of	O
a	O
recombinant	O
human	O
muscle	O
Cl-	O
channel	O
(	O
hCIC-1	O
)	O
expressed	O
in	O
a	O
mammalian	O
cell	O
line	O
(	O
tsA201	O
)	O
.	O

The	O
G230E	O
mutation	O
causes	O
substantial	O
changes	O
in	O
anion	O
and	O
cation	O
selectivity	O
as	O
well	O
as	O
a	O
fundamental	O
change	O
in	O
rectification	O
of	O
the	O
current	O
-	O
voltage	O
relationship	O
.	O

Whereas	O
wild	O
-	O
type	O
channels	O
are	O
characterized	O
by	O
pronounced	O
inward	O
rectification	O
and	O
a	O
Cl	O
>	O
thiocyanate	O
>	O
Br	O
>	O
NO	O
(	O
3	O
)	O
>	O
I	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
,	O
G230E	O
exhibits	O
outward	O
rectification	O
at	O
positive	O
potentials	O
and	O
a	O
thiocyanate	O
>	O
NO	O
(	O
3	O
)	O
>	O

I	O
>	O
Br	O
>	O
Cl	O
>	O
CH	O
(	O
3	O
)	O
SO	O
(	O
3	O
)	O
selectivity	O
.	O

Furthermore	O
,	O
the	O
cation	O
-	O
to	O
-	O
anion	O
permeability	O
ratio	O
of	O
the	O
mutant	O
is	O
much	O
greater	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
channel	O
.	O

Voltage	O
-	O
dependent	O
blocks	O
by	O
intracellular	O
and	O
extracellular	O
iodide	O
help	O
to	O
distinguish	O
two	O
distinct	O
ion	O
binding	O
sites	O
within	O
the	O
hClC-1	O
conduction	O
pathway	O
.	O

Both	O
binding	O
sites	O
are	O
preserved	O
in	O
the	O
mutant	O
but	O
have	O
decreased	O
affinities	O
for	O
iodide	O
.	O

These	O
findings	O
suggest	O
that	O
Gly	O
230	O
is	O
critical	O
for	O
normal	O
ion	O
conductance	O
in	O
hClC-1	O
and	O
that	O
this	O
residue	O
resides	O
within	O
the	O
channel	O
pore	O
..	O

The	O
incidence	O
of	O
PAX6	O
mutation	O
in	O
patients	O
with	O
simple	O
aniridia	B
:	O
an	O
evaluation	O
of	O
mutation	O
detection	O
in	O
12	O
cases	O
.	O

Twelve	O
aniridia	B
patients	O
,	O
five	O
with	O
a	O
family	O
history	O
and	O
seven	O
presumed	O
to	O
be	O
sporadic	O
,	O
were	O
exhaustively	O
screened	O
in	O
order	O
to	O
test	O
what	O
proportion	O
of	O
people	O
with	O
aniridia	B
,	O
uncomplicated	O
by	O
associated	O
anomalies	O
,	O
carry	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
.	O

Mutations	O
were	O
detected	O
in	O
90	O
%	O
of	O
the	O
cases	O
.	O

Three	O
mutation	O
detection	O
techniques	O
were	O
used	O
to	O
determine	O
if	O
one	O
method	O
was	O
superior	O
for	O
this	O
gene	O
.	O

The	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
was	O
used	O
on	O
RT	O
-	O
PCR	O
products	O
,	O
SSCP	O
on	O
genomic	O
PCR	O
amplifications	O
,	O
and	O
chemical	O
cleavage	O
of	O
mismatch	O
on	O
both	O
RT	O
-	O
PCR	O
and	O
genomic	O
amplifications	O
.	O

For	O
RT	O
-	O
PCR	O
products	O
,	O
only	O
the	O
translated	O
portion	O
of	O
the	O
gene	O
was	O
screened	O
.	O

On	O
genomic	O
products	O
exons	O
1	O
to	O
13	O
(	O
including	O
740	O
bp	O
of	O
the	O
3	O
untranslated	O
sequence	O
and	O
all	O
intron	O
/	O
exon	O
boundaries	O
)	O
were	O
screened	O
,	O
as	O
was	O
a	O
neuroretina	O
specific	O
enhancer	O
in	O
intron	O
4	O
.	O

Ten	O
of	O
the	O
possible	O
12	O
mutations	O
in	O
the	O
five	O
familial	O
cases	O
and	O
five	O
of	O
the	O
sporadic	O
patients	O
were	O
found	O
,	O
all	O
of	O
which	O
conformed	O
to	O
a	O
functional	O
outcome	O
of	O
haploinsufficiency	O
.	O

Five	O
were	O
splice	O
site	O
mutations	O
(	O
one	O
in	O
the	O
donor	O
site	O
of	O
intron	O
4	O
,	O
two	O
in	O
the	O
donor	O
site	O
of	O
intron	O
6	O
,	O
one	O
in	O
each	O
of	O
the	O
acceptor	O
sites	O
of	O
introns	O
8	O
and	O
9	O
)	O
and	O
five	O
were	O
nonsense	O
mutations	O
in	O
exons	O
8	O
,	O
9	O
,	O
10	O
,	O
11	O
,	O
and	O
12	O
.	O

SSCP	O
analysis	O
of	O
individually	O
amplified	O
exons	O
,	O
with	O
which	O
nine	O
of	O
the	O
10	O
mutations	O
were	O
seen	O
,	O
was	O
the	O
most	O
useful	O
detection	O
method	O
for	O
PAX6	O
..	O

Insulin	O
gene	O
region	O
contributes	O
to	O
genetic	O
susceptibility	O
to	O
,	O
but	O
may	O
not	O
to	O
low	O
incidence	O
of	O
,	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
in	O
Japanese	O
.	O

In	O
the	O
Caucasian	O
population	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
the	O
insulin	O
gene	O
(	O
INS	O
)	O
region	O
contains	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
locus	O
(	O
IDDM2	O
)	O
.	O

In	O
the	O
Japanese	O
population	O
,	O
however	O
,	O
there	O
has	O
been	O
no	O
report	O
demonstrating	O
the	O
contribution	O
of	O
IDDM2	O
to	O
the	O
pathogenesis	O
of	O
IDDM	B
.	O

We	O
conducted	O
an	O
association	O
study	O
of	O
IDDM	B
in	O
a	O
large	O
number	O
of	O
Japanese	O
subjects	O
with	O
multiple	O
polymorphisms	O
in	O
INS	O
region	O
.	O

We	O
found	O
a	O
significant	O
association	O
of	O
the	O
INS	O
region	O
with	O
IDDM	B
.	O

Alleles	O
positively	O
associated	O
with	O
IDDM	B
in	O
INS	O
region	O
were	O
the	O
same	O
as	O
those	O
positively	O
-	O
associated	O
with	O
IDDM	B
in	O
Caucasian	O
population	O
,	O
although	O
positively	O
-	O
associated	O
alleles	O
are	O
very	O
common	O
(	O
allele	O
frequencies	O
>	O
0	O
.	O
9	O
)	O
in	O
the	O
Japanese	O
general	O
population	O
.	O

These	O
data	O
suggest	O
that	O
IDDM2	O
is	O
involved	O
in	O
the	O
genetic	O
susceptibility	O
to	O
IDDM	B
in	O
Japanese	O
.	O

The	O
high	O
frequencies	O
of	O
disease	O
-	O
associated	O
alleles	O
in	O
the	O
general	O
population	O
suggest	O
that	O
IDDM2	O
locus	O
is	O
not	O
responsible	O
for	O
the	O
low	O
incidence	O
of	O
IDDM	B
in	O
Japanese	O
.	O

The	O
human	O
complement	O
C9	O
gene	O
:	O
identification	O
of	O
two	O
mutations	O
causing	O
deficiency	O
and	O
revision	O
of	O
the	O
gene	O
structure	O
.	O

The	O
ninth	O
component	O
of	O
human	O
complement	O
(	O
C9	O
)	O
is	O
the	O
last	O
of	O
the	O
terminal	O
complement	O
components	O
creating	O
the	O
membrane	O
attack	O
complex	O
.	O

C9	O
is	O
a	O
single	O
-	O
chain	O
serum	O
protein	O
that	O
is	O
encoded	O
by	O
a	O
gene	O
located	O
on	O
chromosome	O
5p	O
.	O

Deficiency	B
of	I
terminal	I
complement	I
components	I
is	O
generally	O
associated	O
with	O
recurrent	O
neisseria	B
infections	I
.	O

We	O
studied	O
a	O
previously	O
described	O
Swiss	O
family	O
with	O
inherited	B
C9	I
deficiency	I
.	O

To	O
identify	O
the	O
genetic	O
basis	O
of	O
C9	B
deficiency	I
,	O
we	O
developed	O
an	O
approach	O
using	O
exon	O
-	O
specific	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O
.	O

As	O
a	O
cause	O
of	O
C9	B
deficiency	I
,	O
we	O
found	O
two	O
different	O
point	O
mutations	O
,	O
both	O
generating	O
TGA	O
stop	O
codons	O
in	O
the	O
coding	O
sequence	O
.	O

One	O
mutation	O
,	O
a	O
C	O
to	O
A	O
exchange	O
,	O
was	O
detected	O
in	O
exon	O
2	O
at	O
cDNA	O
position	O
166	O
,	O
the	O
other	O
,	O
a	O
C	O
to	O
T	O
exchange	O
,	O
was	O
located	O
in	O
exon	O
4	O
(	O
cDNA	O
position	O
464	O
)	O
.	O

In	O
family	O
studies	O
of	O
three	O
first	O
-	O
degree	O
relatives	O
with	O
heterozygous	O
C9	B
deficiency	I
,	O
we	O
demonstrated	O
that	O
the	O
two	O
mutations	O
are	O
segregating	O
independently	O
.	O

Therefore	O
,	O
these	O
mutations	O
are	O
sufficient	O
to	O
explain	O
the	O
complete	O
deficiency	O
of	O
both	O
the	O
probands	O
studied	O
.	O

DNA	O
sequencing	O
of	O
the	O
exon	O
-	O
intron	O
junctions	O
revealed	O
a	O
number	O
of	O
revisions	O
regarding	O
the	O
boundaries	O
between	O
exons	O
4	O
,	O
5	O
,	O
and	O
6	O
as	O
well	O
as	O
between	O
exons	O
10	O
and	O
11	O
.	O

No	O
additional	O
introns	O
were	O
detected	O
in	O
exons	O
6	O
and	O
10	O
.	O

Furthermore	O
,	O
DNA	O
marker	O
studies	O
were	O
conducted	O
using	O
known	O
polymorphisms	O
of	O
the	O
C6	O
,	O
C7	O
,	O
and	O
C9	O
genes	O
,	O
confirming	O
the	O
linkage	O
of	O
the	O
observed	O
C9	O
mutations	O
with	O
defined	O
haplotypes	O
..	O

BRCA1	O
mutations	O
in	O
women	O
attending	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B
cancer	I
.	O

BACKGROUND	O
To	O
define	O
the	O
incidence	O
of	O
BRCA1	O
mutations	O
among	O
patients	O
seen	O
in	O
clinics	O
that	O
evaluate	O
the	O
risk	O
of	O
breast	B
cancer	I
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
women	O
seen	O
in	O
this	O
setting	O
and	O
constructed	O
probability	O
tables	O
to	O
provide	O
estimates	O
of	O
the	O
likelihood	O
of	O
finding	O
a	O
BRCA1	O
mutation	O
in	O
individual	O
families	O
.	O

METHODS	O
Clinical	O
information	O
,	O
family	O
histories	O
,	O
and	O
blood	O
for	O
DNA	O
analysis	O
were	O
obtained	O
from	O
263	O
women	O
with	O
breast	B
cancer	I
.	O

Conformation	O
-	O
sensitive	O
gel	O
electrophoresis	O
and	O
DNA	O
sequencing	O
were	O
used	O
to	O
identify	O
BRCA1	O
mutations	O
.	O

RESULTS	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
16	O
percent	O
of	O
women	O
with	O
a	O
family	O
history	O
of	O
breast	B
cancer	I
.	O

Only	O
7	O
percent	O
of	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
breast	B
cancer	I
but	O
not	O
ovarian	B
cancer	I
had	O
BRCA1	O
mutations	O
.	O

The	O
rates	O
were	O
higher	O
among	O
women	O
from	O
families	O
with	O
a	O
history	O
of	O
both	O
breast	B
and	I
ovarian	I
cancer	I
.	O

Among	O
family	O
members	O
,	O
an	O
average	O
age	O
of	O
less	O
than	O
55	O
years	O
at	O
the	O
diagnosis	O
of	O
breast	B
cancer	I
,	O
the	O
presence	O
of	O
ovarian	B
cancer	I
,	O
the	O
presence	O
of	O
breast	B
and	I
ovarian	I
cancer	I
in	O
the	O
same	O
woman	O
,	O
and	O
Ashkenazi	O
Jewish	O
ancestry	O
were	O
all	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
detecting	O
a	O
BRCA1	O
mutation	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
presence	O
of	O
bilateral	O
breast	B
cancer	I
or	O
the	O
number	O
of	O
breast	B
cancers	I
in	O
a	O
family	O
and	O
the	O
detection	O
of	O
a	O
BRCA1	O
mutation	O
,	O
or	O
between	O
the	O
position	O
of	O
the	O
mutation	O
in	O
the	O
BRCA1	O
gene	O
and	O
the	O
presence	O
of	O
ovarian	B
cancer	I
in	O
a	O
family	O
.	O

CONCLUSIONS	O
Among	O
women	O
with	O
breast	B
cancer	I
and	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
the	O
percentage	O
with	O
BRCA1	O
coding	O
-	O
region	O
mutations	O
is	O
less	O
than	O
the	O
45	O
percent	O
predicted	O
by	O
genetic	O
-	O
linkage	O
analysis	O
.	O

These	O
results	O
suggest	O
that	O
even	O
in	O
a	O
referral	O
clinic	O
specializing	O
in	O
screening	O
women	O
from	O
high	O
-	O
risk	O
families	O
,	O
the	O
majority	O
of	O
tests	O
for	O
BRCA1	O
mutations	O
will	O
be	O
negative	O
and	O
therefore	O
uninformative	O
..	O

Mutations	O
in	O
the	O
arginine	O
-	O
rich	O
protein	O
gene	O
(	O
ARP	O
)	O
in	O
pancreatic	B
cancer	I
.	O

The	O
ARP	O
gene	O
encodes	O
a	O
highly	O
conserved	O
arginine	O
-	O
rich	O
protein	O
from	O
chromosomal	O
band	O
3p21	O
.	O

1	O
1	O
.	O

At	O
the	O
cytogenetic	O
level	O
this	O
region	O
is	O
frequently	O
deleted	O
in	O
a	O
variety	O
of	O
different	O
solid	B
tumors	I
,	O
although	O
not	O
in	O
pancreatic	B
cancer	I
.	O

We	O
have	O
reported	O
the	O
presence	O
of	O
a	O
specific	O
mutation	O
(	O
ATG50	O
-	O
-	O
>	O
AGG	O
)	O
or	O
deletion	O
of	O
codon	O
50	O
of	O
the	O
ARP	O
gene	O
in	O
different	O
tumor	B
types	I
(	O
Shridhar	O
et	O
al.	O
,	O
1996	O
,	O
1996a	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
observed	O
mutations	O
involving	O
codon	O
50	O
in	O
11	O
of	O
37	O
pancreatic	B
tumors	I
.	O

The	O
frequency	O
of	O
codon	O
50	O
mutation	O
is	O
roughly	O
the	O
same	O
in	O
pancreatic	B
tumors	I
as	O
in	O
the	O
other	O
types	O
of	O
tumors	B
previously	O
examined	O
.	O

In	O
addition	O
,	O
we	O
have	O
detected	O
mutations	O
at	O
codon	O
51	O
in	O
multiple	O
PCR	O
subclones	O
in	O
two	O
other	O
pancreatic	B
tumors	I
.	O

Mutations	O
in	O
the	O
ARP	O
gene	O
are	O
thus	O
commonly	O
observed	O
in	O
pancreatic	B
cancer	I
,	O
as	O
well	O
as	O
many	O
other	O
cancers	B
.	O

Difficulties	O
in	O
the	O
ascertainment	O
of	O
C9	B
deficiency	I
:	O
lessons	O
to	O
be	O
drawn	O
from	O
a	O
compound	O
heterozygote	O
C9-deficient	B
subject	O
.	O

A	O
group	O
of	O
patients	O
with	O
long	O
-	O
surviving	O
mismatched	O
kidney	O
allografts	O
were	O
investigated	O
for	O
complement	O
function	O
using	O
haemolytic	O
assays	O
in	O
agarose	O
gels	O
.	O

One	O
patient	O
was	O
found	O
to	O
have	O
no	O
alternative	O
pathway	O
activity	O
but	O
a	O
low	O
normal	O
classical	O
pathway	O
.	O

Surprisingly	O
,	O
investigation	O
revealed	O
that	O
the	O
patients	O
complement	O
was	O
normal	O
for	O
all	O
components	O
except	O
C9	O
,	O
which	O
was	O
functionally	O
absent	O
.	O

The	O
patient	O
was	O
shown	O
to	O
be	O
heterozygous	O
for	O
DNA	O
markers	O
in	O
the	O
C6	O
,	O
C7	O
and	O
C9	O
region	O
of	O
chromosome	O
5	O
and	O
therefore	O
appears	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
uncharacterized	O
C9	B
deficiency	I
genes	O
.	O

Serological	O
analysis	O
by	O
ELISA	O
revealed	O
that	O
he	O
has	O
trace	O
concentrations	O
of	O
a	O
non	O
-	O
functional	O
C9	O
molecule	O
.	O

Western	O
blot	O
analysis	O
was	O
not	O
sufficiently	O
sensitive	O
to	O
permit	O
detection	O
of	O
this	O
molecule	O
.	O

We	O
hypothesize	O
that	O
the	O
patient	O
is	O
heterozygous	O
for	O
a	O
complete	B
deficiency	I
of	I
C9	I
and	O
for	O
a	O
gene	O
directing	O
hyposynthesis	O
of	O
a	O
defective	O
C9	O
.	O

We	O
also	O
suggest	O
that	O
C9	B
deficiency	I
may	O
be	O
more	O
common	O
among	O
Caucasians	O
than	O
has	O
been	O
reported	O
..	O

Screening	O
for	O
ESR	O
mutations	O
in	O
breast	B
and	I
ovarian	I
cancer	I
patients	O
.	O

In	O
the	O
present	O
study	O
,	O
leukocyte	O
DNA	O
from	O
143	O
patients	O
with	O
familial	O
clustering	O
of	O
breast	B
and/or	I
ovarian	I
cancer	I
and	O
tumour	B
DNA	O
from	O
96	O
breast	B
carcinomas	I
were	O
screened	O
for	O
base	O
mutations	O
in	O
the	O
estrogen	O
receptor	O
gene	O
(	O
ESR	O
)	O
.	O

Three	O
patients	O
with	O
a	O
family	O
history	O
of	O
cancer	B
were	O
carrying	O
a	O
Gly160Cys	O
germline	O
substitution	O
.	O

This	O
alteration	O
was	O
also	O
detected	O
in	O
eight	O
(	O
four	O
females	O
and	O
four	O
males	O
)	O
of	O
729	O
controls	O
(	O
366	O
female	O
,	O
363	O
males	O
)	O
,	O
indicating	O
that	O
the	O
substitution	O
probably	O
represents	O
a	O
polymorphism	O
.	O

However	O
,	O
in	O
the	O
229	O
female	O
controls	O
in	O
whom	O
family	O
history	O
of	O
cancer	B
was	O
known	O
,	O
one	O
of	O
two	O
who	O
had	O
a	O
sister	O
with	O
breast	B
cancer	I
was	O
carrying	O
the	O
variant	O
allele	O
.	O

Hence	O
,	O
a	O
possible	O
clinical	O
significance	O
of	O
the	O
glycine	O
into	O
cysteine	O
can	O
not	O
be	O
completely	O
ruled	O
out	O
and	O
should	O
be	O
further	O
investigated	O
.	O

Somatic	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
tumours	B
studied	O
,	O
and	O
the	O
present	O
data	O
do	O
not	O
provide	O
support	O
for	O
somatic	O
ESR	O
base	O
mutations	O
as	O
an	O
important	O
mechanism	O
for	O
hormonal	O
therapy	O
resistance	O
in	O
estrogen	B
receptor	I
-	I
positive	I
breast	I
carcinomas	I
..	O

Molecular	O
bases	O
of	O
C7	B
deficiency	I
:	O
three	O
different	O
defects	O
.	O

The	O
molecular	O
basis	O
of	O
C7	B
deficiency	I
has	O
been	O
investigated	O
in	O
two	O
Irish	O
families	O
and	O
a	O
number	O
of	O
Israeli	O
families	O
of	O
Moroccan	O
Sephardic	O
Jewish	O
origin	O
.	O

Exon	O
PCR	O
and	O
sequencing	O
revealed	O
a	O
heterozygous	O
point	O
mutation	O
at	O
the	O
3	O
splice	O
acceptor	O
site	O
of	O
intron	O
1	O
in	O
one	O
Irish	O
family	O
.	O

In	O
the	O
other	O
Irish	O
family	O
,	O
exons	O
7	O
and	O
8	O
failed	O
to	O
amplify	O
and	O
they	O
were	O
shown	O
to	O
be	O
deleted	O
.	O

Marker	O
haplotype	O
studies	O
of	O
the	O
C6	O
and	O
C7	O
gene	O
region	O
and	O
Southern	O
blots	O
show	O
that	O
the	O
Irish	O
family	O
with	O
the	O
splice	O
defect	O
also	O
segregate	O
for	O
the	O
deletion	O
,	O
which	O
is	O
not	O
easily	O
detected	O
in	O
heterozygotes	O
.	O

The	O
Israeli	O
C7-deficient	B
cases	O
all	O
share	O
a	O
C7	O
haplotype	O
and	O
are	O
homozygous	O
for	O
a	O
mis	O
-	O
sense	O
mutation	O
in	O
exon	O
9	O
.	O

However	O
,	O
one	O
individual	O
is	O
heterozygous	O
for	O
markers	O
at	O
adjacent	O
C6	O
loci	O
,	O
showing	O
that	O
there	O
has	O
been	O
an	O
intergenic	O
recombination	O
and	O
suggesting	O
that	O
the	O
deficiency	O
mutation	O
is	O
of	O
appreciable	O
antiquity	O
..	O

Molecular	O
heterogeneity	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
:	O
mutation	O
analysis	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O

Classical	B
galactosemia	I
is	O
caused	O
by	O
one	O
common	O
missense	O
mutation	O
(	O
Q188R	O
)	O
and	O
by	O
several	O
rare	O
mutations	O
in	O
the	O
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
.	O

The	O
most	O
common	O
variant	O
of	O
GALT	O
,	O
the	O
Duarte	O
variant	O
,	O
occurs	O
as	O
two	O
types	O
,	O
Duarte-1	O
(	O
D-1	O
)	O
and	O
Duarte-2	O
(	O
D-2	O
)	O
,	O
both	O
of	O
which	O
carry	O
the	O
sequence	O
change	O
N314D	O
.	O

D-1	O
increases	O
,	O
whereas	O
D-2	O
decreases	O
GALT	O
activity	O
.	O

To	O
study	O
the	O
molecular	O
genetics	O
of	O
classical	B
and	I
Duarte	I
galactosemia	I
,	O
we	O
analyzed	O
the	O
GALT	O
mutations	O
in	O
30	O
families	O
with	O
classical	B
galactosemia	I
,	O
in	O
10	O
families	O
with	O
the	O
D-2	O
variant	O
and	O
in	O
3	O
individuals	O
carrying	O
the	O
D-1	O
allele	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O

DGGE	O
detected	O
59	O
of	O
the	O
60	O
classical	O
galactosemia	B
alleles	O
.	O

Q188R	O
accounted	O
for	O
60	O
%	O
,	O
K285N	O
accounted	O
for	O
28	O
%	O
of	O
these	O
alleles	O
.	O

Eight	O
novel	O
candidate	O
galactosemia	B
mutations	O
were	O
found	O
.	O

On	O
all	O
D-2	O
alleles	O
N314D	O
occurred	O
in	O
cis	O
with	O
two	O
intronic	O
sequence	O
changes	O
,	O
on	O
the	O
D-1	O
alleles	O
in	O
cis	O
with	O
a	O
neutral	O
mutation	O
in	O
exon	O
7	O
.	O

We	O
conclude	O
that	O
the	O
mutations	O
causing	O
galactosemia	B
are	O
highly	O
heterogeneous	O
and	O
that	O
K285N	O
is	O
a	O
second	O
common	O
galactosemia	B
mutation	O
in	O
our	O
population	O
..	O

Isolation	O
of	O
full	O
-	O
length	O
ATM	O
cDNA	O
and	O
correction	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
cellular	O
phenotype	O
.	O

A	O
gene	O
mutated	O
in	O
the	O
human	O
genetic	B
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
,	O
ATM	O
,	O
was	O
recently	O
identified	O
by	O
positional	O
cloning	O
.	O

ATM	O
is	O
a	O
member	O
of	O
the	O
phosphatidylinositol-3-kinase	O
superfamily	O
,	O
some	O
of	O
which	O
are	O
protein	O
kinases	O
and	O
appear	O
to	O
have	O
important	O
roles	O
in	O
cell	O
cycle	O
control	O
and	O
radiation	O
signal	O
transduction	O
.	O

We	O
describe	O
herein	O
,	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
cloning	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
for	O
ATM	O
and	O
correction	O
of	O
multiple	O
aspects	O
of	O
the	O
radio	O
-	O
sensitive	O
phenotype	O
of	O
A	B
-	I
T	I
cells	O
by	O
transfection	O
with	O
this	O
cDNA	O
.	O

Overexpression	O
of	O
ATM	O
cDNA	O
in	O
A	B
-	I
T	I
cells	O
enhanced	O
the	O
survival	O
of	O
these	O
cells	O
in	O
response	O
to	O
radiation	O
exposure	O
,	O
decreased	O
radiation	O
-	O
induced	O
chromosome	O
aberrations	O
,	O
reduced	O
radio	O
-	O
resistant	O
DNA	O
synthesis	O
,	O
and	O
partially	O
corrected	O
defective	O
cell	O
cycle	O
checkpoints	O
and	O
induction	O
of	O
stress	O
-	O
activated	O
protein	O
kinase	O
.	O

This	O
correction	O
of	O
the	O
defects	O
in	O
A	B
-	I
T	I
cells	O
provides	O
further	O
evidence	O
of	O
the	O
multiplicity	O
of	O
effector	O
functions	O
of	O
the	O
ATM	O
protein	O
and	O
suggests	O
possible	O
approaches	O
to	O
gene	O
therapy	O
..	O

Fusion	O
genes	O
resulting	O
from	O
alternative	O
chromosomal	O
translocations	O
are	O
overexpressed	O
by	O
gene	O
-	O
specific	O
mechanisms	O
in	O
alveolar	B
rhabdomyosarcoma	I
.	O

Chromosomal	O
translocations	O
identified	O
in	O
hematopoietic	B
and	I
solid	I
tumors	I
result	O
in	O
deregulated	O
expression	O
of	O
protooncogenes	O
or	O
creation	O
of	O
chimeric	O
proteins	O
with	O
tumorigenic	O
potential	O
.	O

In	O
the	O
pediatric	O
solid	B
tumor	I
alveolar	B
rhabdomyosarcoma	I
,	O
a	O
consistent	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
or	O
variant	O
t	O
(	O
1	O
;	O
13	O
)	O
(	O
p36	O
;	O
q14	O
)	O
translocation	O
generates	O
PAX3-FKHR	O
or	O
PAX7-FKHR	O
fusion	O
proteins	O
,	O
respectively	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
in	O
addition	O
to	O
functional	O
alterations	O
these	O
translocations	O
are	O
associated	O
with	O
fusion	O
product	O
overexpression	O
.	O

Furthermore	O
,	O
PAX3-FKHR	O
and	O
PAX7-FKHR	O
overexpression	O
occurs	O
by	O
distinct	O
mechanisms	O
.	O

Transcription	O
of	O
PAX3-FKHR	O
is	O
increased	O
relative	O
to	O
wild	O
-	O
type	O
PAX3	O
by	O
a	O
copy	O
number	O
-	O
independent	O
process	O
.	O

In	O
contrast	O
,	O
PAX7-FKHR	O
overexpression	O
results	O
from	O
fusion	O
gene	O
amplification	O
.	O

Thus	O
,	O
gene	O
-	O
specific	O
mechanisms	O
were	O
selected	O
to	O
overexpress	O
PAX3-FKHR	O
and	O
PAX7-FKHR	O
in	O
alveolar	B
rhabdomyosarcoma	I
,	O
presumably	O
due	O
to	O
differences	O
in	O
regulation	O
between	O
the	O
wild	O
-	O
type	O
loci	O
.	O

We	O
postulate	O
that	O
these	O
overexpression	O
mechanisms	O
ensure	O
a	O
critical	O
level	O
of	O
gene	O
product	O
for	O
the	O
oncogenic	O
effects	O
of	O
these	O
fusions	O
..	O

atm	O
and	O
p53	O
cooperate	O
in	O
apoptosis	O
and	O
suppression	O
of	O
tumorigenesis	O
,	O
but	O
not	O
in	O
resistance	O
to	O
acute	B
radiation	I
toxicity	I
.	O

Mutations	O
in	O
atm	O
and	O
p53	O
cause	O
the	O
human	O
cancer	B
-	I
associated	I
diseases	I
ataxia	B
-	I
telangiectasia	I
and	O
Li	B
-	I
Fraumeni	I
syndrome	I
,	O
respectively	O
.	O

The	O
two	O
genes	O
are	O
believed	O
to	O
interact	O
in	O
a	O
number	O
of	O
pathways	O
,	O
including	O
regulation	O
of	O
DNA	O
damage	O
-	O
induced	O
cell	O
-	O
cycle	O
checkpoints	O
,	O
apoptosis	O
and	O
radiation	O
sensitivity	O
,	O
and	O
cellular	O
proliferation	O
.	O

Atm	O
-	O
null	O
mice	O
,	O
as	O
well	O
as	O
those	O
null	O
for	O
p53	O
,	O
develop	O
mainly	O
T	B
-	I
cell	I
lymphomas	I
,	O
supporting	O
the	O
view	O
that	O
these	O
genes	O
have	O
similar	O
roles	O
in	O
thymocyte	O
development	O
.	O

To	O
study	O
the	O
interactions	O
of	O
these	O
two	O
genes	O
on	O
an	O
organismal	O
level	O
,	O
we	O
bred	O
mice	O
heterozygous	O
for	O
null	O
alleles	O
of	O
both	O
atm	O
and	O
p53	O
to	O
produce	O
all	O
genotypic	O
combinations	O
.	O

Mice	O
doubly	O
null	O
for	O
atm	O
and	O
p53	O
exhibited	O
a	O
dramatic	O
acceleration	O
of	O
tumour	B
formation	O
relative	O
to	O
singly	O
null	O
mice	O
,	O
indicating	O
that	O
both	O
genes	O
collaborate	O
in	O
a	O
significant	O
manner	O
to	O
prevent	O
tumorigenesis	O
.	O

With	O
respect	O
to	O
their	O
roles	O
in	O
apoptosis	O
,	O
loss	O
of	O
atm	O
rendered	O
thymocytes	O
only	O
partly	O
resistant	O
to	O
irradiation	O
-	O
induced	O
apoptosis	O
,	O
whereas	O
additional	O
loss	O
of	O
p53	O
engendered	O
complete	O
resistance	O
.	O

This	O
implies	O
that	O
the	O
irradiation	O
-	O
induced	O
atm	O
and	O
p53	O
apoptotic	O
pathways	O
are	O
not	O
completely	O
congruent	O
.	O

Finally	O
-	O
and	O
in	O
contrast	O
to	O
prior	O
predictions	O
-	O
atm	O
and	O
p53	O
do	O
not	O
appear	O
to	O
interact	O
in	O
acute	B
radiation	I
toxicity	I
,	O
suggesting	O
a	O
separate	O
atm	O
effector	O
pathway	O
for	O
this	O
DNA	O
damage	O
response	O
and	O
having	O
implications	O
for	O
the	O
prognosis	O
and	O
treatment	O
of	O
human	O
tumours	B
..	O

Trinucleotide	O
repeat	O
expansion	O
at	O
the	O
myotonic	B
dystrophy	I
locus	O
reduces	O
expression	O
of	O
DMAHP	O
.	O

Myotonic	B
dystrophy	I
,	O
or	O
dystrophia	B
myotonica	I
(	O
DM	B
)	O
,	O
is	O
an	O
autosomal	B
dominant	I
multisystem	I
disorder	I
caused	O
by	O
the	O
expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
protein	O
kinase	O
gene	O
on	O
chromosome	O
19q13	O
.	O

3	O
(	O
refs	O
1	O
-	O
3	O
)	O
.	O

Although	O
the	O
DM	B
mutation	O
was	O
identified	O
more	O
than	O
five	O
years	O
ago	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
this	O
most	O
prevalent	O
form	O
of	O
hereditary	O
adult	O
neuromuscular	B
disease	I
remain	O
elusive	O
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
demonstrated	O
that	O
a	O
DNase	O
l	O
-	O
hypersensitive	O
site	O
located	O
adjacent	O
to	O
the	O
repeats	O
on	O
the	O
wild	O
-	O
type	O
allele	O
is	O
eliminated	O
by	O
repeat	O
expansion	O
,	O
indicating	O
that	O
large	O
CTG	O
-	O
repeat	O
arrays	O
may	O
be	O
associated	O
with	O
a	O
local	O
chromatin	O
environment	O
that	O
represses	O
gene	O
expression	O
.	O

Here	O
we	O
report	O
that	O
the	O
hypersensitive	O
site	O
contains	O
an	O
enhancer	O
element	O
that	O
regulates	O
transcription	O
of	O
the	O
adjacent	O
DMAHP	O
homeobox	O
gene	O
.	O

Analysis	O
of	O
DMAHP	O
expression	O
in	O
the	O
cells	O
of	O
DM	B
patients	O
with	O
loss	O
of	O
the	O
hypersensitive	O
site	O
revealed	O
a	O
two-	O
to	O
fourfold	O
reduction	O
in	O
steady	O
-	O
state	O
DMAHP	O
transcript	O
levels	O
relative	O
to	O
wild	O
-	O
type	O
controls	O
.	O

Allele	O
-	O
specific	O
analysis	O
of	O
DMAHP	O
expression	O
showed	O
that	O
steady	O
-	O
state	O
transcript	O
levels	O
from	O
the	O
expanded	O
allele	O
were	O
greatly	O
reduced	O
in	O
comparison	O
to	O
those	O
from	O
the	O
wild	O
-	O
type	O
allele	O
.	O

Together	O
,	O
these	O
results	O
demonstrate	O
that	O
CTG	O
-	O
repeat	O
expansions	O
can	O
suppress	O
local	O
gene	O
expression	O
and	O
implicate	O
DMAHP	O
in	O
DM	B
pathogenesis	O
.	O

Constitutively	O
methylated	O
CpG	O
dinucleotides	O
as	O
mutation	O
hot	O
spots	O
in	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

A	O
wide	O
spectrum	O
of	O
mutations	O
,	O
ranging	O
from	O
point	O
mutations	O
to	O
large	O
deletions	O
,	O
have	O
been	O
described	O
in	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

Mutations	O
have	O
been	O
found	O
throughout	O
the	O
gene	O
;	O
however	O
,	O
these	O
genetic	O
alterations	O
do	O
not	O
appear	O
to	O
be	O
homogeneously	O
distributed	O
.	O

In	O
particular	O
,	O
a	O
significant	O
proportion	O
of	O
disease	O
-	O
causing	O
mutations	O
results	O
in	O
the	O
premature	O
termination	O
of	O
protein	O
synthesis	O
,	O
and	O
the	O
majority	O
of	O
these	O
mutations	O
occur	O
as	O
C--	O
>	O
T	O
transitions	O
at	O
CpG	O
dinucleotides	O
(	O
CpGs	O
)	O
.	O

Such	O
recurrent	O
CpG	O
mutations	O
,	O
including	O
those	O
found	O
in	O
RB1	O
,	O
are	O
likely	O
the	O
result	O
of	O
the	O
deamination	O
of	O
5-methylcytosine	O
within	O
these	O
CpGs	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
the	O
sodiumbisulfite	O
conversion	O
method	O
to	O
detect	O
cytosine	O
methylation	O
in	O
representative	O
exons	O
of	O
RB1	O
.	O

We	O
analyzed	O
DNA	O
from	O
a	O
variety	O
of	O
tissues	O
and	O
specifically	O
targeted	O
CGA	O
codons	O
in	O
RB1	O
,	O
where	O
recurrent	O
premature	O
termination	O
mutations	O
have	O
been	O
reported	O
.	O

We	O
found	O
that	O
DNA	O
methylation	O
within	O
RB1	O
exons	O
8	O
,	O
14	O
,	O
25	O
,	O
and	O
27	O
appeared	O
to	O
be	O
restricted	O
to	O
CpGs	O
,	O
including	O
six	O
CGA	O
codons	O
.	O

Other	O
codons	O
containing	O
methylated	O
cytosines	O
have	O
not	O
been	O
reported	O
to	O
be	O
mutated	O
.	O

Therefore	O
,	O
disease	O
-	O
causing	O
mutations	O
at	O
CpGs	O
in	O
RB1	O
appear	O
to	O
be	O
determined	O
by	O
several	O
factors	O
,	O
including	O
the	O
constitutive	O
presence	O
of	O
DNA	O
methylation	O
at	O
cytosines	O
within	O
CpGs	O
,	O
the	O
specific	O
codon	O
within	O
which	O
the	O
methylated	O
cytosine	O
is	O
located	O
,	O
and	O
the	O
particular	O
region	O
of	O
the	O
gene	O
within	O
which	O
that	O
codon	O
resides	O
..	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
product	O
interacts	O
with	O
Sp1	O
to	O
repress	O
vascular	O
endothelial	O
growth	O
factor	O
promoter	O
activity	O
.	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
(	O
VHL	O
)	O
has	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
clear	B
-	I
cell	I
renal	I
cell	I
carcinoma	I
(	O
RCC	B
)	O
,	O
as	O
VHL	O
mutations	O
have	O
been	O
found	O
in	O
both	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
and	I
sporadic	I
RCCs	I
.	O

Recent	O
studies	O
suggest	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
mRNA	O
is	O
upregulated	O
in	O
RCC-	B
and	I
von	I
Hippel	I
-	I
Lindau	I
disease	I
-	I
associated	I
tumors	I
.	O

We	O
have	O
therefore	O
assessed	O
the	O
effect	O
of	O
the	O
VHL	O
gene	O
product	O
on	O
VEGF	O
expression	O
.	O

VEGF	O
promoter	O
-	O
luciferase	O
constructs	O
were	O
transiently	O
cotransfected	O
with	O
a	O
wild	O
-	O
type	O
VHL	O
(	O
wt	O
-	O
VHL	O
)	O
vector	O
in	O
several	O
cell	O
lines	O
,	O
including	O
293	O
embryonic	O
kidney	O
and	O
RCC	B
cell	O
lines	O
.	O

wt	O
-	O
VHL	O
protein	O
inhibited	O
VEGF	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
up	O
to	O
5-	O
to	O
10-fold	O
.	O

Deletion	O
analysis	O
defined	O
a	O
144-bp	O
region	O
of	O
the	O
VEGF	O
promoter	O
necessary	O
for	O
VHL	O
repression	O
.	O

This	O
VHL	O
-	O
responsive	O
element	O
is	O
GC	O
rich	O
and	O
specifically	O
binds	O
the	O
transcription	O
factor	O
Sp1	O
in	O
crude	O
nuclear	O
extracts	O
.	O

In	O
Drosophila	O
cells	O
,	O
cotransfected	O
VHL	O
represses	O
Sp1-mediated	O
activation	O
but	O
not	O
basal	O
activity	O
of	O
the	O
VEGF	O
promoter	O
.	O

We	O
next	O
demonstrated	O
in	O
coimmunoprecipitates	O
that	O
VHL	O
and	O
Sp1	O
were	O
part	O
of	O
the	O
same	O
complex	O
and	O
,	O
by	O
using	O
a	O
glutathione	O
-	O
S	O
-	O
transferase	O
-	O
VHL	O
fusion	O
protein	O
and	O
purified	O
Sp1	O
,	O
that	O
VHL	O
and	O
Sp1	O
directly	O
interact	O
.	O

Furthermore	O
,	O
endogenous	O
VEGF	O
mRNA	O
levels	O
were	O
suppressed	O
in	O
permanent	O
RCC	B
cell	O
lines	O
expressing	O
wt	O
-	O
VHL	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
studies	O
indicated	O
that	O
VHL	O
regulation	O
of	O
VEGF	O
occurs	O
at	O
least	O
partly	O
at	O
the	O
transcriptional	O
level	O
.	O

These	O
observations	O
support	O
a	O
new	O
mechanism	O
for	O
VHL	O
-	O
mediated	O
transcriptional	O
repression	O
via	O
a	O
direct	O
inhibitory	O
action	O
on	O
Sp1	O
and	O
suggest	O
that	O
loss	O
of	O
Sp1	O
inhibition	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
von	B
Hippel	I
-	I
Lindau	I
disease	I
and	O
RCC	B
..	O

Adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
)	O
:	O
analysis	O
of	O
galactosylceramidase	O
cDNA	O
from	O
four	O
Japanese	O
patients	O
.	O

We	O
examined	O
galactosylceramidase	O
(	O
GALC	O
)	O
cDNA	O
in	O
four	O
Japanese	O
patients	O
with	O
adult	B
onset	I
globoid	I
cell	I
leukodystrophy	I
(	O
Krabbe	B
disease	I
;	O
AO	B
-	I
GLD	I
)	O
by	O
polymerase	O
chain	O
reaction	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
,	O
subsequent	O
sequence	O
determination	O
,	O
and	O
restriction	O
enzyme	O
digestion	O
of	O
PCR	O
products	O
,	O
initial	O
symptoms	O
were	O
the	O
onset	O
of	O
slowly	O
progressive	O
spastic	B
paraplegia	I
from	O
the	O
middle	O
of	O
the	O
second	O
decade	O
,	O
and	O
all	O
patients	O
had	O
diminished	B
GALC	I
activity	I
in	O
their	O
leukocytes	O
.	O

We	O
identified	O
three	O
missense	O
mutations	O
(	O
I66	O
M	O
,	O
G270D	O
,	O
L618S	O
)	O
and	O
one	O
exon-6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
.	O

Two	O
of	O
the	O
patients	O
had	O
only	O
the	O
I66	O
M	O
mutant	O
mRNA	O
,	O
and	O
one	O
only	O
the	O
G27OD	O
mutant	O
mRNA	O
.	O

The	O
fourth	O
patient	O
carried	O
a	O
compound	O
heterozygous	O
mutation	O
of	O
535	O
-	O
573del	O
and	O
L618S	O
.	O

To	O
determine	O
the	O
enzymatic	O
activities	O
produced	O
by	O
these	O
mutations	O
,	O
we	O
constructed	O
mutated	O
GALC	O
cDNAs	O
and	O
expressed	O
them	O
in	O
COS-1	O
cells	O
.	O

Three	O
mutations	O
,	O
viz	O
.	O
,	O
G270D	O
,	O
L618S	O
,	O
and	O
exon-6	O
skipping	O
(	O
535	O
-	O
573del	O
)	O
,	O
produced	O
diminished	B
GALC	I
activity	I
as	O
expected	O
.	O

The	O
I66	O
M	O
mutation	O
in	O
the	O
wild	O
-	O
type	O
GALC	O
cDNA	O
(	O
I289	O
)	O
had	O
normal	O
activity	O
,	O
but	O
when	O
this	O
mutation	O
and	O
the	O
V289	O
polymorphism	O
were	O
introduced	O
into	O
the	O
same	O
allele	O
,	O
it	O
had	O
decreased	O
activity	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
a	O
unique	O
mutation	O
and	O
polymorphism	O
causes	O
conformational	O
change	O
in	O
the	O
GALC	O
enzyme	O
,	O
resulting	O
in	O
low	O
enzymatic	O
activity	O
.	O

AO	B
-	I
GLD	I
mutations	O
,	O
including	O
those	O
found	O
here	O
,	O
are	O
located	O
in	O
the	O
N	O
-	O
terminus	O
(	O
I66	O
M	O
,	O
G270D	O
,	O
535	O
-	O
573del	O
)	O
or	O
C	O
-	O
terminus	O
(	O
L618S	O
)	O
of	O
the	O
GALC	O
enzyme	O
,	O
whereas	O
the	O
reported	O
mutations	O
in	O
the	O
infantile	O
form	O
(	O
IF	B
-	I
GLD	I
)	O
are	O
in	O
the	O
central	O
domain	O
.	O

This	O
difference	O
in	O
mutation	O
sites	O
may	O
affect	O
the	O
clinical	O
features	O
of	O
GLD	B
.	O

Clustering	O
of	O
missense	O
mutations	O
in	O
the	O
ataxia	B
-	I
telangiectasia	I
gene	O
in	O
a	O
sporadic	B
T	I
-	I
cell	I
leukaemia	I
.	O

Ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
is	O
a	O
recessive	B
multi	I
-	I
system	I
disorder	I
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
at	O
11q22-q23	O
(	O
ref	O
.	O

3	O
)	O
.	O

The	O
risk	O
of	O
cancer	B
,	O
especially	O
lymphoid	B
neoplasias	I
,	O
is	O
substantially	O
elevated	O
in	O
A	B
-	I
T	I
patients	O
and	O
has	O
long	O
been	O
associated	O
with	O
chromosomal	O
instability	O
.	O

By	O
analysing	O
tumour	B
DNA	O
from	O
patients	O
with	O
sporadic	B
T	I
-	I
cell	I
prolymphocytic	I
leukaemia	I
(	O
T	B
-	I
PLL	I
)	O
,	O
a	O
rare	O
clonal	B
malignancy	I
with	O
similarities	O
to	O
a	O
mature	B
T	I
-	I
cell	I
leukaemia	I
seen	O
in	O
A	B
-	I
T	I
,	O
we	O
demonstrate	O
a	O
high	O
frequency	O
of	O
ATM	O
mutations	O
in	O
T	B
-	I
PLL	I
.	O

In	O
marked	O
contrast	O
to	O
the	O
ATM	O
mutation	O
pattern	O
in	O
A	B
-	I
T	I
,	O
the	O
most	O
frequent	O
nucleotide	O
changes	O
in	O
this	O
leukaemia	B
were	O
missense	O
mutations	O
.	O

These	O
clustered	O
in	O
the	O
region	O
corresponding	O
to	O
the	O
kinase	O
domain	O
,	O
which	O
is	O
highly	O
conserved	O
in	O
ATM	O
-	O
related	O
proteins	O
in	O
mouse	O
,	O
yeast	O
and	O
Drosophila	O
.	O

The	O
resulting	O
amino	O
-	O
acid	O
substitutions	O
are	O
predicted	O
to	O
interfere	O
with	O
ATP	O
binding	O
or	O
substrate	O
recognition	O
.	O

Two	O
of	O
seventeen	O
mutated	O
T	B
-	I
PLL	I
samples	O
had	O
a	O
previously	O
reported	O
A	B
-	I
T	I
allele	O
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
p53	O
gene	O
,	O
suggesting	O
that	O
this	O
tumour	B
suppressor	O
is	O
not	O
frequently	O
altered	O
in	O
this	O
leukaemia	B
.	O

Occasional	O
missense	O
mutations	O
in	O
ATM	O
were	O
also	O
found	O
in	O
tumour	B
DNA	O
from	O
patients	O
with	O
B	B
-	I
cell	I
non	I
-	I
Hodgkins	I
lymphomas	I
(	O
B	B
-	I
NHL	I
)	O
and	O
a	O
B	B
-	I
NHL	I
cell	O
line	O
.	O

The	O
evidence	O
of	O
a	O
significant	O
proportion	O
of	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
and	O
a	O
complete	O
absence	O
of	O
the	O
normal	O
copy	O
of	O
ATM	O
in	O
the	O
majority	O
of	O
mutated	O
tumours	B
establishes	O
somatic	O
inactivation	O
of	O
this	O
gene	O
in	O
the	O
pathogenesis	O
of	O
sporadic	B
T	I
-	I
PLL	I
and	O
suggests	O
that	O
ATM	O
acts	O
as	O
a	O
tumour	B
suppressor	O
.	O

As	O
constitutional	O
DNA	O
was	O
not	O
available	O
,	O
a	O
putative	O
hereditary	O
predisposition	O
to	O
T	B
-	I
PLL	I
will	O
require	O
further	O
investigation	O
..	O

Myotonic	B
dystrophy	I
protein	O
kinase	O
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	O
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
,	O
the	O
most	O
prevalent	O
muscular	B
disorder	I
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B
protein	O
kinase	O
;	O
DMPK	O
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	O
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	O
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
ATP	O
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	O
.	O

In	O
vitro	O
-	O
differentiated	O
DMPK	O
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	O
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
type	O
Ca2	O
+	O
and	O
Na	O
+	O
channels	O
.	O

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	O
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	O
or	O
high	O
external	O
K	O
+	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
these	O
Ca2	O
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	O
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	O
+	O
channel	O
.	O

Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	O
+	O
/K	O
+	O
ATPase	O
and	O
sarcoplasmic	O
reticulum	O
Ca2	O
+	O
-ATPase	O
are	O
affected	O
by	O
DMPK	O
absence	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	O
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
..	O

Constitutional	O
RB1-gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
.	O

In	O
most	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
tumor	B
development	O
is	O
initiated	O
by	O
somatic	O
inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O
.	O

However	O
,	O
some	O
of	O
these	O
patients	O
can	O
transmit	O
retinoblastoma	B
predisposition	O
to	O
their	O
offspring	O
.	O

To	O
determine	O
the	O
frequency	O
and	O
nature	O
of	O
constitutional	O
RB1-gene	O
mutations	O
in	O
patients	O
with	O
isolated	O
unilateral	B
retinoblastoma	I
,	O
we	O
analyzed	O
DNA	O
from	O
peripheral	O
blood	O
and	O
from	O
tumor	B
tissue	O
.	O

The	O
analysis	O
of	O
tumors	B
from	O
54	O
(	O
71	O
%	O
)	O
of	O
76	O
informative	O
patients	O
showed	O
loss	O
of	O
constitutional	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
intragenic	O
loci	O
.	O

Three	O
of	O
13	O
uninformative	O
patients	O
had	O
constitutional	O
deletions	O
.	O

For	O
39	O
randomly	O
selected	O
tumors	B
,	O
SSCP	O
,	O
hetero	O
-	O
duplex	O
analysis	O
,	O
sequencing	O
,	O
and	O
Southern	O
blot	O
analysis	O
were	O
used	O
to	O
identify	O
mutations	O
.	O

Mutations	O
were	O
detected	O
in	O
21	O
(	O
91	O
%	O
)	O
of	O
23	O
tumors	B
with	O
LOH	O
.	O

In	O
6	O
(	O
38	O
%	O
)	O
of	O
16	O
tumors	B
without	O
LOH	O
,	O
one	O
mutation	O
was	O
detected	O
,	O
and	O
in	O
9	O
(	O
56	O
%	O
)	O
of	O
the	O
tumors	B
without	O
LOH	O
,	O
both	O
mutations	O
were	O
found	O
.	O

Thus	O
,	O
a	O
total	O
of	O
45	O
mutations	O
were	O
identified	O
in	O
tumors	B
of	O
36	O
patients	O
.	O

Thirty	O
-	O
nine	O
of	O
the	O
mutations	O
-	O
including	O
34	O
small	O
mutations	O
,	O
2	O
large	O
structural	O
alterations	O
,	O
and	O
hypermethylation	O
in	O
3	O
tumors	O
-	O
were	O
not	O
detected	O
in	O
the	O
corresponding	O
peripheral	O
blood	O
DNA	O
.	O

In	O
6	O
(	O
17	O
%	O
)	O
of	O
the	O
36	O
patients	O
,	O
a	O
mutation	O
was	O
detected	O
in	O
constitutional	O
DNA	O
,	O
and	O
1	O
of	O
these	O
mutations	O
is	O
known	O
to	O
be	O
associated	O
with	O
reduced	O
expressivity	O
.	O

The	O
presence	O
of	O
a	O
constitutional	O
mutation	O
was	O
not	O
associated	O
with	O
an	O
early	O
age	O
at	O
treatment	O
.	O

In	O
1	O
patient	O
,	O
somatic	O
mosaicism	O
was	O
demonstrated	O
by	O
molecular	O
analysis	O
of	O
DNA	O
and	O
RNA	O
from	O
peripheral	O
blood	O
.	O

In	O
2	O
patients	O
without	O
a	O
detectable	O
mutation	O
in	O
peripheral	O
blood	O
,	O
mosaicism	O
was	O
suggested	O
because	O
1	O
of	O
the	O
patients	O
showed	O
multifocal	O
tumors	B
and	O
the	O
other	O
later	O
developed	O
bilateral	B
retinoblastoma	I
.	O

In	O
conclusion	O
,	O
our	O
results	O
emphasize	O
that	O
the	O
manifestation	O
and	O
transmissibility	O
of	O
retinoblastoma	B
depend	O
on	O
the	O
nature	O
of	O
the	O
first	O
mutation	O
,	O
its	O
time	O
in	O
development	O
,	O
and	O
the	O
number	O
and	O
types	O
of	O
cells	O
that	O
are	O
affected	O
..	O

Hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
in	O
man	O
.	O

I.	O
Clinical	O
,	O
immunochemical	O
,	O
and	O
family	O
studies	O
.	O

The	O
first	O
recognized	O
human	O
kindred	O
with	O
hereditary	B
deficiency	I
of	I
the	I
fifth	I
component	I
of	I
complement	I
(	O
C5	O
)	O
is	O
described	O
.	O

The	O
proband	O
,	O
a	O
20-year	O
-	O
old	O
black	O
female	O
with	O
systemic	B
lupus	I
erythematosus	I
since	O
age	O
11	O
,	O
lacked	O
serum	O
hemolytic	O
complement	O
activity	O
,	O
even	O
during	O
remission	O
.	O

C5	O
was	O
undetectable	O
in	O
her	O
serum	O
by	O
both	O
immunodiffusion	O
and	O
hemolytic	O
assays	O
.	O

Other	O
complement	O
components	O
were	O
normal	O
during	O
remission	O
of	O
lupus	O
,	O
but	O
C1	O
,	O
C4	O
,	O
C2	O
,	O
and	O
C3	O
levels	O
fell	O
during	O
exacerbations	O
.	O

A	O
younger	O
half	O
-	O
sister	O
,	O
who	O
had	O
no	O
underlying	O
disease	O
,	O
was	O
also	O
found	O
to	O
lack	O
immunochemically	O
detectable	O
C5	O
.	O

By	O
hemolytic	O
assay	O
,	O
she	O
exhibited	O
1	O
-	O
2	O
%	O
of	O
the	O
normal	O
serum	O
C5	O
level	O
and	O
normal	O
concentrations	O
of	O
other	O
complement	O
components	O
.	O

C5	O
levels	O
of	O
other	O
family	O
members	O
were	O
either	O
normal	O
or	O
approximately	O
half	O
-	O
normal	O
,	O
consistent	O
with	O
autosomal	O
codominant	O
inheritance	O
of	O
the	O
gene	O
determining	O
C5	B
deficiency	I
.	O

Normal	O
hemolytic	O
titers	O
were	O
restored	O
to	O
both	O
homozygous	O
C5-deficient	B
(	O
C5D	B
)	O
sera	O
by	O
addition	O
of	O
highly	O
purified	O
human	O
C5	O
.	O

In	O
specific	O
C5	O
titrations	O
,	O
however	O
,	O
it	O
was	O
noted	O
that	O
when	O
limited	O
amounts	O
of	O
C5	O
were	O
assayed	O
in	O
the	O
presence	O
of	O
low	O
dilutions	O
of	O
either	O
C5D	B
serum	O
,	O
curving	O
rather	O
than	O
linear	O
dose	O
-	O
response	O
plots	O
were	O
consistently	O
obtained	O
,	O
suggesting	O
some	O
inhibitory	O
effect	O
.	O

Further	O
studies	O
suggested	O
that	O
low	O
dilutions	O
of	O
C5D	B
serum	O
contain	O
a	O
factor	O
(	O
or	O
factors	O
)	O
interfering	O
at	O
some	O
step	O
in	O
the	O
hemolytic	O
assay	O
of	O
C5	O
,	O
rather	O
than	O
a	O
true	O
C5	O
inhibitor	O
or	O
inactivator	O
.	O

Of	O
clinical	O
interest	O
are	O
(	O
a	O
)	O
the	O
documentation	O
of	O
membranous	O
glomerulonephritis	B
,	O
vasculitis	B
,	O
and	O
arthritis	B
in	O
an	O
individual	O
lacking	O
C5	O
(	O
and	O
its	O
biologic	O
functions	O
)	O
,	O
and	O
(	O
b	O
)	O
a	O
remarkable	O
propensity	O
to	O
bacterial	B
infections	I
in	O
the	O
proband	O
,	O
even	O
during	O
periods	O
of	O
low	O
-	O
dose	O
or	O
alternate	O
-	O
day	O
corticosteroid	O
therapy	O
.	O

Other	O
observations	O
indicate	O
that	O
the	O
C5D	B
state	O
is	O
compatible	O
with	O
normal	O
coagulation	O
function	O
and	O
the	O
capacity	O
to	O
mount	O
a	O
neutrophilic	O
leukocytosis	O
during	O
pyogenic	B
infection	I
..	O

Susceptibility	O
to	O
ankylosing	B
spondylitis	I
in	O
twins	O
:	O
the	O
role	O
of	O
genes	O
,	O
HLA	O
,	O
and	O
the	O
environment	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
relative	O
effects	O
of	O
genetic	O
and	O
environmental	O
factors	O
in	O
susceptibility	O
to	O
ankylosing	B
spondylitis	I
(	O
AS	B
)	O
.	O

METHODS	O
Twins	O
with	O
AS	B
were	O
identified	O
from	O
the	O
Royal	O
National	O
Hospital	O
for	O
Rheumatic	B
Diseases	I
database	O
.	O

Clinical	O
and	O
radiographic	O
examinations	O
were	O
performed	O
to	O
establish	O
diagnoses	O
,	O
and	O
disease	O
severity	O
was	O
assessed	O
using	O
a	O
combination	O
of	O
validated	O
scoring	O
systems	O
.	O

HLA	O
typing	O
for	O
HLA	O
-	O
B27	O
,	O
HLA	O
-	O
B60	O
,	O
and	O
HLA	O
-	O
DR1	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
sequence	O
-	O
specific	O
primers	O
,	O
and	O
zygosity	O
was	O
assessed	O
using	O
microsatellite	O
markers	O
.	O

Genetic	O
and	O
environmental	O
variance	O
components	O
were	O
assessed	O
with	O
the	O
program	O
Mx	O
,	O
using	O
data	O
from	O
this	O
and	O
previous	O
studies	O
of	O
twins	O
with	O
AS	B
.	O

RESULTS	O
Six	O
of	O
8	O
monozygotic	O
(	O
MZ	O
)	O
twin	O
pairs	O
were	O
disease	O
concordant	O
,	O
compared	O
with	O
4	O
of	O
15	O
B27-positive	O
dizygotic	O
(	O
DZ	O
)	O
twin	O
pairs	O
(	O
27	O
%	O
)	O
and	O
4	O
of	O
32	O
DZ	O
twin	O
pairs	O
overall	O
(	O
12	O
.	O
5	O
%	O
)	O
.	O

Nonsignificant	O
increases	O
in	O
similarity	O
with	O
regard	O
to	O
age	O
at	O
disease	O
onset	O
and	O
all	O
of	O
the	O
disease	O
severity	O
scores	O
assessed	O
were	O
noted	O
in	O
disease	O
-	O
concordant	O
MZ	O
twins	O
compared	O
with	O
concordant	O
DZ	O
twins	O
.	O

HLA	O
-	O
B27	O
and	O
B60	O
were	O
associated	O
with	O
the	O
disease	O
in	O
probands	O
,	O
and	O
the	O
rate	O
of	O
disease	O
concordance	O
was	O
significantly	O
increased	O
among	O
DZ	O
twin	O
pairs	O
in	O
which	O
the	O
co	O
-	O
twin	O
was	O
positive	O
for	O
both	O
B27	O
and	O
DR1	O
.	O

Additive	O
genetic	O
effects	O
were	O
estimated	O
to	O
contribute	O
97	O
%	O
of	O
the	O
population	O
variance	O
.	O

CONCLUSION	O
Susceptibility	O
to	O
AS	B
is	O
largely	O
genetically	O
determined	O
,	O
and	O
the	O
environmental	O
trigger	O
for	O
the	O
disease	O
is	O
probably	O
ubiquitous	O
.	O

HLA	O
-	O
B27	O
accounts	O
for	O
a	O
minority	O
of	O
the	O
overall	O
genetic	O
susceptibility	O
to	O
AS	B
.	O

Cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
proteins	O
in	O
discrete	O
nuclear	O
domains	O
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
BRCA1	O
gene	O
predispose	O
women	O
to	O
early	O
-	O
onset	O
breast	B
and	I
ovarian	I
cancer	I
by	O
compromising	O
the	O
genes	O
presumptive	O
function	O
as	O
a	O
tumor	B
suppressor	O
.	O

Although	O
the	O
biochemical	O
properties	O
of	O
BRCA1	O
polypeptides	O
are	O
not	O
understood	O
,	O
their	O
expression	O
pattern	O
and	O
subcellular	O
localization	O
suggest	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
regulation	O
.	O

When	O
resting	O
cells	O
are	O
induced	O
to	O
proliferate	O
,	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BRCA1	O
increase	O
in	O
late	O
G1	O
and	O
reach	O
a	O
maximum	O
during	O
S	O
phase	O
.	O

Moreover	O
,	O
in	O
S	O
phase	O
cells	O
,	O
BRCA1	O
polypeptides	O
are	O
hyperphosphorylated	O
and	O
accumulate	O
into	O
discrete	O
subnuclear	O
foci	O
termed	O
""""	O
BRCA1	O
nuclear	O
dots	O
.	O
""""	O
BRCA1	O
associates	O
in	O
vivo	O
with	O
a	O
structurally	O
related	O
protein	O
termed	O
BARD1	O
.	O

Here	O
we	O
show	O
that	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BARD1	O
,	O
unlike	O
those	O
of	O
BRCA1	O
,	O
remain	O
relatively	O
constant	O
during	O
cell	O
cycle	O
progression	O
.	O

However	O
,	O
immunostaining	O
revealed	O
that	O
BARD1	O
resides	O
within	O
BRCA1	O
nuclear	O
dots	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
but	O
not	O
during	O
the	O
G1	O
phase	O
.	O

Nevertheless	O
,	O
BARD1	O
polypeptides	O
are	O
found	O
exclusively	O
in	O
the	O
nuclear	O
fractions	O
of	O
both	O
G1-	O
and	O
S	O
-	O
phase	O
cells	O
.	O

Therefore	O
,	O
progression	O
to	O
S	O
phase	O
is	O
accompanied	O
by	O
the	O
aggregation	O
of	O
nuclear	O
BARD1	O
polypeptides	O
into	O
BRCA1	O
nuclear	O
dots	O
.	O

This	O
cell	O
cycle	O
-	O
dependent	O
colocalization	O
of	O
BARD1	O
and	O
BRCA1	O
indicates	O
a	O
role	O
for	O
BARD1	O
in	O
BRCA1-mediated	O
tumor	B
suppression	O
.	O

Ethnic	O
differences	O
in	O
the	O
HFE	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
hereditary	B
hemochromatosis	I
(	O
HH	B
)	O
is	O
likely	O
to	O
be	O
caused	O
by	O
homozygosity	O
for	O
a	O
Cys282Tyr	O
mutation	O
in	O
the	O
HFE	O
gene	O
located	O
4	O
.	O

5	O
Mb	O
telomeric	O
to	O
HLA	O
-	O
A.	O
Population	O
studies	O
of	O
this	O
polymorphism	O
are	O
facilitated	O
by	O
the	O
fact	O
that	O
the	O
Cys282Tyr	O
mutation	O
creates	O
a	O
Rsal	O
restriction	O
site	O
.	O

We	O
have	O
studied	O
the	O
codon	O
282	O
(	O
Cys	O
/	O
Tyr	O
)	O
polymorphism	O
in	O
different	O
ethnic	O
groups	O
.	O

In	O
agreement	O
with	O
previous	O
observations	O
the	O
Tyr	O
allele	O
appeared	O
to	O
be	O
rare	O
or	O
absent	O
in	O
Asiatic	O
(	O
Indian	O
,	O
Chinese	O
)	O
populations	O
.	O

The	O
highest	O
allele	O
frequency	O
(	O
7	O
.	O
5	O
%	O
)	O
was	O
found	O
in	O
Swedes	O
.	O

Saamis	O
(	O
2	O
%	O
)	O
and	O
Mordvinians	O
(	O
1	O
.	O
8	O
%	O
)	O
had	O
significantly	O
lower	O
frequencies	O
of	O
the	O
Tyr	O
allele	O
.	O

Comparisons	O
with	O
allele	O
frequencies	O
based	O
on	O
prevalence	O
estimates	O
of	O
HH	B
showed	O
some	O
disagreements	O
with	O
the	O
RFLP	O
data	O
,	O
particularly	O
in	O
Finns	O
.	O

The	O
newly	O
described	O
HFE	O
marker	O
provides	O
a	O
new	O
approach	O
to	O
the	O
screening	O
of	O
HH	B
as	O
well	O
as	O
studies	O
of	O
the	O
relationship	O
between	O
the	O
HFE	O
Tyr	O
allele	O
and	O
different	O
disorders	O
including	O
cancer	B

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
associated	O
with	O
a	O
missense	O
mutation	O
encoding	O
Gly23	O
-	O
->Val	O
in	O
neurophysin	O
II	O
.	O

Autosomal	B
dominant	I
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
ADNDI	B
)	O
is	O
an	O
inherited	B
disease	I
caused	O
by	O
progressive	O
degeneration	O
of	O
the	O
magnocellular	O
neurons	O
of	O
the	O
hypothalamus	O
leading	O
to	O
decreased	O
ability	O
to	O
produce	O
the	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
.	O

Affected	O
individuals	O
are	O
not	O
symptomatic	O
at	O
birth	O
,	O
but	O
usually	O
develop	O
diabetes	B
insipidus	I
at	O
1	O
-	O
6	O
yr	O
of	O
age	O
.	O

The	O
genetic	O
locus	O
of	O
the	O
disease	O
is	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
NPII	O
)	O
gene	O
,	O
and	O
mutations	O
that	O
cause	O
ADNDI	B
have	O
been	O
found	O
in	O
both	O
the	O
signal	O
peptide	O
of	O
the	O
prepro	O
-	O
AVP	O
-	O
NPII	O
precursor	O
and	O
within	O
NPII	O
itself	O
.	O

An	O
affected	O
girl	O
who	O
presented	O
at	O
9	O
months	O
of	O
age	O
and	O
her	O
similarly	O
affected	O
younger	O
brother	O
and	O
father	O
were	O
all	O
found	O
to	O
have	O
a	O
novel	O
missense	O
mutation	O
(	O
G1758	O
-	O
-	O
>	O
T	O
)	O
encoding	O
the	O
amino	O
acid	O
substitution	O
Gly23	O
-	O
-	O
>	O
Val	O
within	O
NPII	O
.	O

The	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
.	O

A	O
T1-weighted	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
fathers	O
pituitary	O
gland	O
demonstrates	O
an	O
attenuated	O
posterior	O
pituitary	O
bright	O
spot	O
.	O

This	O
mutation	O
may	O
be	O
valuable	O
for	O
developing	O
models	O
of	O
dominantly	B
inherited	I
neurodegeneration	I
,	O
as	O
the	O
early	O
age	O
of	O
onset	O
of	O
symptoms	O
suggests	O
that	O
this	O
mutation	O
may	O
be	O
particularly	O
deleterious	O
to	O
the	O
magnocellular	O
neuron	O
..	O

Frequent	O
inactivation	O
of	O
PTEN	O
/	O
MMAC1	O
in	O
primary	O
prostate	B
cancer	I
.	O

Sporadic	B
prostate	I
carcinoma	I
is	O
the	O
most	O
common	O
male	B
cancer	I
in	O
the	O
Western	O
world	O
,	O
yet	O
many	O
of	O
the	O
major	O
genetic	O
events	O
involved	O
in	O
the	O
progression	O
of	O
this	O
often	O
fatal	O
cancer	B
remain	O
to	O
be	O
elucidated	O
.	O

Numerous	O
cytogenetic	O
and	O
allelotype	O
studies	O
have	O
reported	O
frequent	O
loss	O
of	O
heterozygosity	O
on	O
chromosomal	O
arm	O
10q	O
in	O
sporadic	B
prostate	I
cancer	I
.	O

Deletion	O
mapping	O
studies	O
have	O
unambiguously	O
identified	O
a	O
region	O
of	O
chromosome	O
10q23	O
to	O
be	O
the	O
minimal	O
area	O
of	O
loss	O
.	O

A	O
new	O
tumor	B
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
was	O
isolated	O
recently	O
at	O
this	O
region	O
of	O
chromosome	O
10q23	O
and	O
found	O
to	O
be	O
inactivated	O
by	O
mutation	O
in	O
three	O
prostate	B
cancer	I
cell	O
lines	O
.	O

We	O
screened	O
80	O
prostate	B
tumors	I
by	O
microsatellite	O
analysis	O
and	O
found	O
chromosome	O
10q23	O
to	O
be	O
deleted	O
in	O
23	O
cases	O
.	O

We	O
then	O
proceeded	O
with	O
sequence	O
analysis	O
of	O
the	O
entire	O
PTEN	O
/	O
MMAC1	O
coding	O
region	O
and	O
tested	O
for	O
homozygous	O
deletion	O
with	O
new	O
intragenic	O
markers	O
in	O
these	O
23	O
cases	O
with	O
10q23	O
loss	O
of	O
heterozygosity	O
.	O

The	O
identification	O
of	O
the	O
second	O
mutational	O
event	O
in	O
10	O
(	O
43	O
%	O
)	O
tumors	B
establishes	O
PTEN	O
/	O
MMAC1	O
as	O
a	O
main	O
inactivation	O
target	O
of	O
10q	O
loss	O
in	O
sporadic	B
prostate	I
cancer	I
..	O

Risk	O
reversals	O
in	O
predictive	O
testing	O
for	O
Huntington	B
disease	I
.	O

The	O
first	O
predictive	O
testing	O
for	O
Huntington	B
disease	I
(	O
HD	B
)	O
was	O
based	O
on	O
analysis	O
of	O
linked	O
polymorphic	O
DNA	O
markers	O
to	O
estimate	O
the	O
likelihood	O
of	O
inheriting	O
the	O
mutation	O
for	O
HD	B
.	O

Limits	O
to	O
accuracy	O
included	O
recombination	O
between	O
the	O
DNA	O
markers	O
and	O
the	O
mutation	O
,	O
pedigree	O
structure	O
,	O
and	O
whether	O
DNA	O
samples	O
were	O
available	O
from	O
family	O
members	O
.	O

With	O
direct	O
tests	O
for	O
the	O
HD	B
mutation	O
,	O
we	O
have	O
assessed	O
the	O
accuracy	O
of	O
results	O
obtained	O
by	O
linkage	O
approaches	O
when	O
requested	O
to	O
do	O
so	O
by	O
the	O
test	O
individuals	O
.	O

For	O
six	O
such	O
individuals	O
,	O
there	O
was	O
significant	O
disparity	O
between	O
the	O
tests	O
.	O

Three	O
went	O
from	O
a	O
decreased	O
risk	O
to	O
an	O
increased	O
risk	O
,	O
while	O
in	O
another	O
three	O
the	O
risk	O
was	O
decreased	O
.	O

Knowledge	O
of	O
the	O
potential	O
reasons	O
for	O
these	O
changes	O
in	O
results	O
and	O
impact	O
of	O
these	O
risk	O
reversals	O
on	O
both	O
patients	O
and	O
the	O
counseling	O
team	O
can	O
assist	O
in	O
the	O
development	O
of	O
strategies	O
for	O
the	O
prevention	O
and	O
,	O
where	O
necessary	O
,	O
management	O
of	O
a	O
risk	O
reversal	O
in	O
any	O
predictive	O
testing	O
program	O
..	O

A	O
novel	O
common	O
missense	O
mutation	O
G301C	O
in	O
the	O
N	O
-	O
acetylgalactosamine-6-sulfate	O
sulfatase	O
gene	O
in	O
mucopolysaccharidosis	B
IVA	I
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
recessive	I
lysosomal	I
storage	I
disorder	I
caused	O
by	O
a	O
genetic	B
defect	I
in	O
N	O
-	O
acetylgalactosamine-6-sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

In	O
previous	O
studies	O
,	O
we	O
have	O
found	O
two	O
common	O
mutations	O
in	O
Caucasians	O
and	O
Japanese	O
,	O
respectively	O
.	O

To	O
characterize	O
the	O
mutational	O
spectrum	O
in	O
various	O
ethnic	O
groups	O
,	O
mutations	O
in	O
the	O
GALNS	O
gene	O
in	O
Colombian	O
MPS	B
IVA	I
patients	O
were	O
investigated	O
,	O
and	O
genetic	O
backgrounds	O
were	O
extensively	O
analyzed	O
to	O
identify	O
racial	O
origin	O
,	O
based	O
on	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
lineages	O
.	O

Three	O
novel	O
missense	O
mutations	O
never	O
identified	O
previously	O
in	O
other	O
populations	O
and	O
found	O
in	O
16	O
out	O
of	O
19	O
Colombian	O
MPS	B
IVA	I
unrelated	O
alleles	O
account	O
for	O
84	O
.	O

2	O
%	O
of	O
the	O
alleles	O
in	O
this	O
study	O
.	O

The	O
G301C	O
and	O
S162F	O
mutations	O
account	O
for	O
68	O
.	O
4	O
%	O
and	O
10	O
.	O
5	O
%	O
of	O
mutations	O
,	O
respectively	O
,	O
whereas	O
the	O
remaining	O
F69V	O
is	O
limited	O
to	O
a	O
single	O
allele	O
.	O

The	O
skewed	O
prevalence	O
of	O
G301C	O
in	O
only	O
Colombian	O
patients	O
and	O
haplotype	O
analysis	O
by	O
restriction	O
fragment	O
length	O
polymorphisms	O
in	O
the	O
GALNS	O
gene	O
suggest	O
that	O
G301C	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

Investigation	O
of	O
the	O
genetic	O
background	O
by	O
means	O
of	O
mtDNA	O
lineages	O
indicate	O
that	O
all	O
our	O
patients	O
are	O
probably	O
of	O
native	O
American	O
descent	O

Low	O
frequency	O
of	O
BRCA1	O
germline	O
mutations	O
in	O
45	O
German	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

In	O
this	O
study	O
we	O
investigated	O
45	O
German	O
breast	B
/	I
ovarian	I
cancer	I
families	O
for	O
germline	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
.	O

We	O
identified	O
four	O
germline	O
mutations	O
in	O
three	O
breast	B
cancer	I
families	O
and	O
in	O
one	O
breast	B
-	I
ovarian	I
cancer	I
family	O
.	O

among	O
these	O
were	O
one	O
frameshift	O
mutation	O
,	O
one	O
nonsense	O
mutation	O
,	O
one	O
novel	O
splice	O
site	O
mutation	O
,	O
and	O
one	O
missense	O
mutation	O
.	O

The	O
missense	O
mutation	O
was	O
also	O
found	O
in	O
2	O
.	O
8	O
%	O
of	O
the	O
general	O
population	O
,	O
suggesting	O
that	O
it	O
is	O
not	O
disease	O
associated	O
.	O

The	O
average	O
age	O
of	O
disease	O
onset	O
in	O
those	O
families	O
harbouring	O
causative	O
mutations	O
was	O
between	O
32	O
.	O

3	O
and	O
37	O
.	O
4	O
years	O
,	O
whereas	O
the	O
family	O
harbouring	O
the	O
missense	O
mutation	O
had	O
an	O
average	O
age	O
of	O
onset	O
of	O
51	O
.	O

2	O
years	O
.	O

These	O
findings	O
show	O
that	O
BRCA1	O
is	O
implicated	O
in	O
a	O
small	O
fraction	O
of	O
breast	B
/	I
ovarian	I
cancer	I
families	O
suggesting	O
the	O
involvement	O
of	O
another	O
susceptibility	O
gene	O
(	O
s	O
)	O

Paternal	O
transmission	O
of	O
congenital	B
myotonic	I
dystrophy	I
.	O

We	O
report	O
a	O
rare	O
case	O
of	O
paternally	O
transmitted	O
congenital	B
myotonic	I
dystrophy	I
(	O
DM	B
)	O
.	O

The	O
proband	O
is	O
a	O
23	O
year	O
old	O
,	O
mentally	B
retarded	I
male	O
who	O
suffers	O
severe	O
muscular	B
weakness	I
.	O

He	O
presented	O
with	O
respiratory	O
and	O
feeding	O
difficulties	O
at	O
birth	O
.	O

His	O
two	O
sibs	O
suffer	O
from	O
childhood	O
onset	O
DM	B
.	O

Their	O
late	O
father	O
had	O
the	O
adult	O
type	O
of	O
DM	B
,	O
with	O
onset	O
around	O
30	O
years	O
.	O

Only	O
six	O
other	O
cases	O
of	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
have	O
been	O
reported	O
recently	O
.	O

We	O
review	O
the	O
sex	O
related	O
effects	O
on	O
transmission	O
of	O
congenital	B
DM	I
.	O

Decreased	O
fertility	O
of	O
males	O
with	O
adult	O
onset	O
DM	B
and	O
contraction	O
of	O
the	O
repeat	O
upon	O
male	O
transmission	O
contribute	O
to	O
the	O
almost	O
absent	O
occurrence	O
of	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
.	O

Also	O
the	O
fathers	O
of	O
the	O
reported	O
congenitally	O
affected	O
children	O
showed	O
,	O
on	O
average	O
,	O
shorter	O
CTG	O
repeat	O
lengths	O
and	O
hence	O
less	O
severe	O
clinical	O
symptoms	O
than	O
the	O
mothers	O
of	O
children	O
with	O
congenital	B
DM	I
.	O

We	O
conclude	O
that	O
paternal	O
transmission	O
of	O
congenital	B
DM	I
is	O
rare	O
and	O
preferentially	O
occurs	O
with	O
onset	O
of	O
DM	B
past	O
30	O
years	O
in	O
the	O
father	O
..	O

The	O
RB1	O
gene	O
mutation	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
.	O

The	O
RB1	O
gene	O
mutation	O
was	O
investigated	O
in	O
a	O
child	O
with	O
ectopic	B
intracranial	I
retinoblastoma	I
using	O
DNA	O
obtained	O
from	O
both	O
the	O
pineal	B
and	I
retinal	I
tumours	I
of	O
the	O
patient	O
.	O

A	O
nonsense	O
mutation	O
in	O
exon	O
17	O
(	O
codon	O
556	O
)	O
of	O
the	O
RB1	O
gene	O
was	O
found	O
to	O
be	O
present	O
homozygously	O
in	O
both	O
the	O
retinal	B
and	I
the	I
pineal	I
tumours	I
.	O

The	O
same	O
mutation	O
was	O
present	O
heterozygously	O
in	O
the	O
DNA	O
from	O
the	O
constitutional	O
cells	O
of	O
the	O
patient	O
,	O
proving	O
it	O
to	O
be	O
of	O
germline	O
origin	O
.	O

The	O
initial	O
mutation	O
was	O
shown	O
to	O
have	O
occurred	O
in	O
the	O
paternally	O
derived	O
RB1	O
allele	O
.	O

The	O
mutation	O
is	O
in	O
an	O
area	O
of	O
the	O
gene	O
that	O
encodes	O
the	O
protein	O
-	O
binding	O
region	O
known	O
as	O
the	O
pocket	O
region	O
and	O
has	O
been	O
detected	O
in	O
other	O
cases	O
of	O
retinoblastoma	B
..	O

Low	O
levels	O
of	O
beta	O
hexosaminidase	O
A	O
in	O
healthy	O
individuals	O
with	O
apparent	O
deficiency	O
of	O
this	O
enzyme	O
.	O

Appreciable	O
beta	O
hexosaminidase	O
A	O
(	O
hex	O
A	O
)	O
activity	O
has	O
been	O
detected	O
in	O
cultured	O
skin	O
fibroblasts	O
and	O
melanoma	B
tissue	O
from	O
healthy	O
individuals	O
previously	O
reported	O
as	O
having	O
deficiency	B
of	I
hex	I
A	I
activity	O
indistinguishable	O
from	O
that	O
of	O
patients	O
with	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
.	O

Identification	O
and	O
quantitation	O
of	O
hex	O
A	O
,	O
amounting	O
to	O
3	O
.	O
5	O
%	O
-6	O
.	O

9	O
%	O
of	O
total	O
beta	O
hexosaminidase	O
activity	O
,	O
has	O
been	O
obtained	O
by	O
cellulose	O
acetate	O
gel	O
electrophoresis	O
,	O
DEAE	O
-	O
cellulose	O
ion	O
-	O
exchange	O
chromatography	O
,	O
radial	O
immunodiffusion	O
,	O
and	O
radioimmunoassay	O
.	O

Previous	O
family	O
studies	O
suggested	O
that	O
these	O
individuals	O
may	O
be	O
compound	O
heterozygotes	O
for	O
the	O
common	O
mutant	O
TSD	B
gene	O
and	O
a	O
rare	O
(	O
allelic	O
)	O
mutant	O
gene	O
.	O

Thus	O
,	O
the	O
postulated	O
rate	O
mutant	O
gene	O
appears	O
to	O
code	O
for	O
the	O
expression	O
of	O
low	O
amounts	O
of	O
hex	O
A.	O
Heterozygotes	O
for	O
the	O
rare	O
mutant	O
may	O
be	O
indistinguishable	O
from	O
heterozygotes	O
for	O
the	O
common	O
TSD	B
mutant	O
.	O

However	O
,	O
direct	O
visualization	O
and	O
quantitation	O
of	O
hex	O
A	O
by	O
the	O
methods	O
described	O
may	O
prevent	O
false	O
-	O
positive	O
prenatal	O
diagnosis	O
of	O
TSD	B
in	O
fetuses	O
having	O
the	O
incomplete	O
hex	B
A	I
deficiency	I
of	O
the	O
type	O
described	O
in	O
the	O
four	O
healthy	O
individuals	O

The	O
tumor	B
suppressor	O
gene	O
Smad4	O
/	O
Dpc4	O
is	O
required	O
for	O
gastrulation	O
and	O
later	O
for	O
anterior	O
development	O
of	O
the	O
mouse	O
embryo	O
.	O

Mutations	O
in	O
the	O
SMAD4	O
/	O
DPC4	O
tumor	B
suppressor	O
gene	O
,	O
a	O
key	O
signal	O
transducer	O
in	O
most	O
TGFbeta	O
-	O
related	O
pathways	O
,	O
are	O
involved	O
in	O
50	O
%	O
of	O
pancreatic	B
cancers	I
.	O

Homozygous	O
Smad4	O
mutant	O
mice	O
die	O
before	O
day	O
7	O
.	O

5	O
of	O
embryogenesis	O
.	O

Mutant	O
embryos	O
have	O
reduced	O
size	O
,	O
fail	O
to	O
gastrulate	O
or	O
express	O
a	O
mesodermal	O
marker	O
,	O
and	O
show	O
abnormal	O
visceral	O
endoderm	O
development	O
.	O

Growth	B
retardation	I
of	O
the	O
Smad4-deficient	O
embryos	O
results	O
from	O
reduced	O
cell	O
proliferation	O
rather	O
than	O
increased	O
apoptosis	O
.	O

Aggregation	O
of	O
mutant	O
Smad4	O
ES	O
cells	O
with	O
wild	O
-	O
type	O
tetraploid	O
morulae	O
rescues	O
the	O
gastrulation	B
defect	I
.	O

These	O
results	O
indicate	O
that	O
Smad4	O
is	O
initially	O
required	O
for	O
the	O
differentiation	O
of	O
the	O
visceral	O
endoderm	O
and	O
that	O
the	O
gastrulation	B
defect	I
in	O
the	O
epiblast	O
is	O
secondary	O
and	O
non	O
-	O
cell	O
autonomous	O
.	O

Rescued	O
embryos	O
show	O
severe	O
anterior	O
truncations	O
,	O
indicating	O
a	O
second	O
important	O
role	O
for	O
Smad4	O
in	O
anterior	O
patterning	O
during	O
embryogenesis	O
.	O

Prevalence	O
of	O
p16	O
and	O
CDK4	O
germline	O
mutations	O
in	O
48	O
melanoma	B
-	O
prone	O
families	O
in	O
France	O
.	O

The	O
French	O
Familial	B
Melanoma	I
Study	O
Group	O
.	O

Germline	O
mutations	O
in	O
the	O
p16	O
and	O
CDK4	O
genes	O
have	O
been	O
reported	O
in	O
a	O
subset	O
of	O
melanoma	B
pedigrees	O
,	O
but	O
their	O
prevalence	O
is	O
not	O
well	O
known	O
.	O

We	O
searched	O
for	O
such	O
germline	O
mutations	O
in	O
48	O
French	O
melanoma	B
-	O
prone	O
families	O
selected	O
according	O
to	O
two	O
major	O
criteria	O
families	O
with	O
at	O
least	O
three	O
affected	O
members	O
(	O
n	O
=	O
20	O
)	O
or	O
families	O
with	O
two	O
affected	O
members	O
,	O
one	O
of	O
them	O
affected	O
before	O
the	O
age	O
of	O
50	O
(	O
n	O
=	O
28	O
)	O
,	O
and	O
one	O
additional	O
minor	O
criterion	O
.	O

Sixteen	O
different	O
p16	O
germline	O
mutations	O
were	O
found	O
in	O
21	O
families	O
,	O
while	O
one	O
germline	O
mutation	O
,	O
Arg24His	O
,	O
was	O
detected	O
in	O
the	O
CDK4	O
gene	O
.	O

The	O
frequency	O
of	O
p16	O
gene	O
mutation	O
in	O
our	O
sample	O
(	O
44	O
%	O
)	O
is	O
among	O
the	O
highest	O
rates	O
yet	O
reported	O
and	O
the	O
CDK4	O
mutation	O
is	O
the	O
second	O
mutation	O
detected	O
in	O
this	O
gene	O
worldwide	O
.	O

In	O
summary	O
,	O
our	O
results	O
show	O
frequent	O
involvement	O
of	O
the	O
p16	O
gene	O
in	O
familial	B
melanoma	I
and	O
confirm	O
the	O
role	O
of	O
the	O
CDK4	O
gene	O
as	O
a	O
melanoma	B
-	O
predisposing	O
gene	O
..	O

Progression	O
of	O
somatic	O
CTG	O
repeat	O
length	O
heterogeneity	O
in	O
the	O
blood	O
cells	O
of	O
myotonic	B
dystrophy	I
patients	O
.	O

The	O
genetic	O
basis	O
of	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
the	O
expansion	O
of	O
an	O
unstable	O
CTG	O
repeat	O
in	O
the	O
34	O
UTR	O
of	O
the	O
DM	B
protein	O
kinase	O
gene	O
on	O
chromosome	O
19	O
.	O

One	O
of	O
the	O
principal	O
features	O
of	O
the	O
DM	B
mutation	O
is	O
an	O
extraordinarily	O
high	O
level	O
of	O
somatic	O
mosaicism	O
,	O
due	O
to	O
an	O
extremely	O
high	O
degree	O
of	O
somatic	O
instability	O
both	O
within	O
and	O
between	O
different	O
tissues	O
.	O

This	O
instability	O
appears	O
to	O
be	O
biased	O
towards	O
further	O
expansion	O
and	O
continuous	O
throughout	O
the	O
life	O
of	O
an	O
individual	O
,	O
features	O
that	O
could	O
be	O
associated	O
with	O
the	O
progressive	O
nature	O
of	O
the	O
disease	O
.	O

Although	O
increasing	O
measured	O
allele	O
size	O
between	O
patients	O
clearly	O
correlates	O
with	O
an	O
increased	O
severity	O
of	O
symptoms	O
and	O
an	O
earlier	O
age	O
of	O
onset	O
,	O
this	O
correlation	O
is	O
not	O
precise	O
and	O
measured	O
allele	O
length	O
can	O
not	O
be	O
used	O
as	O
an	O
accurate	O
predictor	O
of	O
age	O
of	O
onset	O
.	O

In	O
order	O
to	O
further	O
characterize	O
the	O
dynamics	O
of	O
DM	B
CTG	O
repeat	O
somatic	O
instability	O
,	O
we	O
have	O
studied	O
repeat	O
length	O
changes	O
over	O
time	O
in	O
111	O
myotonic	B
dystrophy	I
patients	O
with	O
varying	O
clinical	O
severity	O
and	O
CTG	O
repeat	O
size	O
over	O
time	O
intervals	O
of	O
1	O
-	O
7	O
years	O
.	O

We	O
have	O
found	O
a	O
direct	O
progression	O
of	O
the	O
size	O
heterogeneity	O
over	O
time	O
related	O
to	O
initial	O
CTG	O
repeat	O
size	O
and	O
the	O
time	O
interval	O
and	O
always	O
biased	O
towards	O
further	O
expansion	O
.	O

Attempts	O
to	O
mathematically	O
model	O
the	O
dynamics	O
have	O
proved	O
only	O
partially	O
successful	O
suggesting	O
that	O
individual	O
specific	O
genetic	O
and/or	O
environmental	O
factors	O
also	O
play	O
a	O
role	O
in	O
somatic	O
mosaicism	O
..	O

Aspartylglucosaminuria	B
among	O
Palestinian	O
Arabs	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
rare	O
disorder	B
of	I
glycoprotein	I
metabolism	I
caused	O
by	O
the	O
deficiency	B
of	I
the	I
lysosomal	I
enzyme	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

AGU	B
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
and	O
occurs	O
with	O
a	O
high	O
frequency	O
in	O
Finland	O
because	O
of	O
a	O
founder	O
effect	O
.	O

While	O
very	O
few	O
patients	O
with	O
AGU	B
have	O
been	O
reported	O
from	O
non	O
-	O
Finnish	O
origin	O
,	O
we	O
diagnosed	O
the	O
disorder	O
in	O
8	O
patients	O
originating	O
from	O
3	O
unrelated	O
families	O
,	O
all	O
Palestinian	O
Arabs	O
from	O
the	O
region	O
of	O
Jerusalem	O
.	O

The	O
clinical	O
diagnosis	O
of	O
AGU	B
is	O
often	O
difficult	O
,	O
in	O
particular	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
,	O
and	O
most	O
of	O
the	O
patients	O
are	O
diagnosed	O
after	O
the	O
age	O
of	O
5	O
years	O
.	O

However	O
,	O
since	O
these	O
patients	O
excrete	O
early	O
large	O
amounts	O
of	O
aspartylglucosamine	O
in	O
urine	O
,	O
biochemical	O
screening	O
is	O
easy	O
by	O
urine	O
chromatography	O
..	O

Detection	O
of	O
heterozygous	O
carriers	O
of	O
the	O
ataxia	B
-	I
telangiectasia	I
(	O
ATM	O
)	O
gene	O
by	O
G2	O
phase	O
chromosomal	O
radiosensitivity	O
of	O
peripheral	O
blood	O
lymphocytes	O
.	O

In	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
patients	O
,	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
ATM	O
,	O
result	O
in	O
an	O
autosomal	B
recessive	I
syndrome	I
that	O
embraces	O
a	O
variety	O
of	O
clinical	O
features	O
and	O
manifests	O
extreme	O
radiosensitivity	O
and	O
a	O
strong	O
pre	O
-	O
disposition	O
to	O
malignancy	B
.	O

Heterozygotes	O
for	O
the	O
ATM	O
gene	O
have	O
no	O
clinical	O
expression	O
of	O
A	B
-	I
T	I
but	O
may	O
be	O
cancer	B
prone	O
with	O
a	O
moderate	O
increase	O
in	O
in	O
vitro	O
radiosensitivity	O
.	O

We	O
performed	O
a	O
blind	O
chromosomal	O
analysis	O
on	O
G2-phase	O
lymphocytes	O
from	O
7	O
unrelated	O
A	B
-	I
T	I
patients	O
,	O
13	O
obligate	O
A	B
-	I
T	I
heterozygotes	O
(	O
parents	O
of	O
the	O
patients	O
)	O
,	O
and	O
14	O
normal	O
controls	O
following	O
X	O
-	O
irradiation	O
with	O
1	O
Gy	O
in	O
order	O
to	O
evaluate	O
this	O
cytogenetic	O
method	O
as	O
a	O
tool	O
for	O
detection	O
of	O
ATM	O
carriers	O
.	O

Both	O
A	B
-	I
T	I
homozygotes	O
and	O
heterozygotes	O
showed	O
significantly	O
increased	O
levels	O
of	O
radiation	O
-	O
induced	O
chromatid	O
damage	O
relative	O
to	O
that	O
of	O
normal	O
controls	O
.	O

These	O
results	O
show	O
that	O
the	O
G2-phase	O
chromosomal	O
radiosensitivity	O
assay	O
can	O
be	O
used	O
for	O
the	O
detection	O
of	O
A	B
-	I
T	I
heterozygotes	O
.	O

In	O
combination	O
with	O
molecular	O
genetic	O
analyses	O
,	O
this	O
test	O
may	O
be	O
of	O
value	O
in	O
studies	O
of	O
familial	B
and	I
sporadic	I
cancers	I
aimed	O
at	O
determination	O
of	O
the	O
potential	O
involvement	O
of	O
ATM	O
mutations	O
in	O
tumor	B
risk	O
or	O
development	O
..	O

Ataxia	B
-	I
telangiectasia	I
:	O
identification	O
and	O
detection	O
of	O
founder	O
-	O
effect	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
ethnic	O
populations	O
.	O

To	O
facilitate	O
the	O
evaluation	O
of	O
ATM	O
heterozygotes	O
for	O
susceptibility	O
to	O
other	O
diseases	O
,	O
such	O
as	O
breast	B
cancer	I
,	O
we	O
have	O
attempted	O
to	O
define	O
the	O
most	O
common	O
mutations	O
and	O
their	O
frequencies	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
homozygotes	O
from	O
10	O
ethnic	O
populations	O
.	O

Both	O
genomic	O
mutations	O
and	O
their	O
effects	O
on	O
cDNA	O
were	O
characterized	O
.	O

Protein	O
-	O
truncation	O
testing	O
of	O
the	O
entire	O
ATM	O
cDNA	O
detected	O
92	O
(	O
66	O
%	O
)	O
truncating	O
mutations	O
in	O
140	O
mutant	O
alleles	O
screened	O
.	O

The	O
haplotyping	O
of	O
patients	O
with	O
identical	O
mutations	O
indicates	O
that	O
almost	O
all	O
of	O
these	O
represent	O
common	O
ancestry	O
and	O
that	O
very	O
few	O
spontaneously	O
recurring	O
ATM	O
mutations	O
exist	O
.	O

Assays	O
requiring	O
minimal	O
amounts	O
of	O
genomic	O
DNA	O
were	O
designed	O
to	O
allow	O
rapid	O
screening	O
for	O
common	O
ethnic	O
mutations	O
.	O

These	O
rapid	O
assays	O
detected	O
mutations	O
in	O
76	O
%	O
of	O
Costa	O
Rican	O
patients	O
(	O
3	O
)	O
,	O
50	O
%	O
of	O
Norwegian	O
patients	O
(	O
1	O
)	O
,	O
25	O
%	O
of	O
Polish	O
patients	O
(	O
4	O
)	O
,	O
and	O
14	O
%	O
of	O
Italian	O
patients	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
in	O
patients	O
of	O
Amish	O
/	O
Mennonite	O
and	O
Irish	O
English	O
backgrounds	O
.	O

Additional	O
mutations	O
were	O
observed	O
in	O
Japanese	O
,	O
Utah	O
Mormon	O
,	O
and	O
African	O
American	O
patients	O
.	O

These	O
assays	O
should	O
facilitate	O
screening	O
for	O
A	B
-	I
T	I
heterozygotes	O
in	O
the	O
populations	O
studied	O
..	O

The	O
von	B
Hippel	I
-	I
Lindau	I
tumor	I
suppressor	O
gene	O
is	O
required	O
for	O
cell	O
cycle	O
exit	O
upon	O
serum	O
withdrawal	O
.	O

The	O
inactivation	O
of	O
the	O
von	B
Hippel	I
-	I
Lindau	I
(	I
VHL	I
)	I
tumor	I
suppressor	O
gene	O
predisposes	O
affected	O
individuals	O
to	O
the	O
human	O
VHL	B
cancer	I
syndrome	I
and	O
is	O
associated	O
with	O
sporadic	B
renal	I
cell	I
carcinomas	I
(	O
RCC	B
)	O
and	O
brain	B
hemangioblastomas	I
.	O

VHL	O
-	O
negative	O
786	O
-	O
0	O
RCC	B
cells	O
are	O
tumorigenic	O
in	O
nude	O
mice	O
which	O
is	O
suppressed	O
by	O
the	O
reintroduction	O
of	O
VHL	B
.	O

Remarkably	O
,	O
this	O
occurs	O
without	O
affecting	O
the	O
growth	O
rate	O
and	O
cell	O
cycle	O
profile	O
of	O
these	O
cells	O
in	O
culture	O
.	O

The	O
786	O
-	O
0	O
cell	O
line	O
,	O
like	O
many	O
cancer	B
cells	O
,	O
fails	O
to	O
exit	O
the	O
cell	O
cycle	O
upon	O
serum	O
withdrawal	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
reintroduction	O
of	O
the	O
wild	O
-	O
type	O
VHL	B
gene	O
restores	O
the	O
ability	O
of	O
VHL	O
-	O
negative	O
RCC	B
cancer	I
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
and	O
enter	O
G0	O
/	O
quiescence	O
in	O
low	O
serum	O
.	O

Both	O
VHL	O
-	O
positive	O
and	O
VHL	O
-	O
negative	O
RCC	B
cells	O
exit	O
the	O
cell	O
cycle	O
by	O
contact	O
inhibition	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
,	O
p27	O
,	O
accumulates	O
upon	O
serum	O
withdrawal	O
,	O
only	O
in	O
the	O
presence	O
of	O
VHL	B
,	O
as	O
a	O
result	O
of	O
the	O
stabilization	O
of	O
the	O
protein	O
.	O

We	O
propose	O
that	O
the	O
loss	O
of	O
wild	O
-	O
type	O
VHL	B
gene	O
results	O
in	O
a	O
specific	O
cellular	O
defect	O
in	O
serum	O
-	O
dependent	O
growth	O
control	O
,	O
which	O
may	O
initiate	O
tumor	B
formation	O
.	O

This	O
is	O
corrected	O
by	O
the	O
reintroduction	O
of	O
wild	O
-	O
type	O
VHL	B
,	O
implicating	O
VHL	B
as	O
the	O
first	O
tumor	B
suppressor	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
exit	O
,	O
which	O
is	O
consistent	O
with	O
its	O
gatekeeper	O
function	O
in	O
the	O
kidney	O
..	O

Piebaldism	B
with	O
deafness	B
:	O
molecular	O
evidence	O
for	O
an	O
expanded	O
syndrome	O
.	O

In	O
a	O
South	O
African	O
girl	O
of	O
Xhosa	O
stock	O
with	O
severe	O
piebaldism	B
and	O
profound	O
congenital	O
sensorineural	B
deafness	I
we	O
identified	O
a	O
novel	O
missense	O
substitution	O
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
intracellular	O
kinase	O
domain	O
of	O
the	O
KIT	O
proto	O
-	O
oncogene	O
,	O
R796	O
G	O
.	O

Though	O
auditory	B
anomalies	I
have	O
been	O
observed	O
in	O
mice	O
with	O
dominant	O
white	O
spotting	O
(	O
W	O
)	O
due	O
to	O
KIT	O
mutations	O
,	O
deafness	B
is	O
not	O
typical	O
in	O
human	O
piebaldism	B
.	O

Thus	O
,	O
the	O
occurrence	O
of	O
sensorineural	B
deafness	I
in	O
this	O
patient	O
extends	O
considerably	O
the	O
phenotypic	O
range	O
of	O
piebaldism	B
due	O
to	O
KIT	O
gene	O
mutation	O
in	O
humans	O
and	O
tightens	O
the	O
clinical	O
similarity	O
between	O
piebaldism	B
and	O
the	O
various	O
forms	O
of	O
Waardenburg	B
syndrome	I
..	O

Cycloheximide	O
facilitates	O
the	O
identification	O
of	O
aberrant	O
transcripts	O
resulting	O
from	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
often	O
show	O
decreased	O
expression	O
of	O
type	O
XVII	O
collagen	O
,	O
a	O
transmembrane	O
hemidesmosomal	O
protein	O
encoded	O
by	O
COL17A1	O
.	O

This	O
report	O
documents	O
a	O
novel	O
splice	O
-	O
site	O
mutation	O
in	O
COL17A1	O
in	O
a	O
patient	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
and	O
applies	O
a	O
new	O
methodology	O
to	O
define	O
and	O
characterize	O
the	O
resulting	O
mRNA	O
splice	O
variants	O
.	O

Mutational	O
analysis	O
of	O
COL17A1	O
identified	O
a	O
maternally	O
inherited	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	O
the	O
-1	O
position	O
of	O
exon	O
32	O
.	O

This	O
acceptor	O
splice	O
-	O
site	O
mutation	O
led	O
to	O
the	O
formation	O
of	O
aberrant	O
transcripts	O
present	O
at	O
extremely	O
low	O
levels	O
.	O

Based	O
on	O
our	O
recent	O
finding	O
that	O
cycloheximide	O
stabilized	O
mutant	O
COL17A1	O
transcripts	O
in	O
keratinocytes	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
the	O
effects	O
of	O
the	O
splice	O
-	O
site	O
mutation	O
on	O
splicing	O
of	O
COL17A1	O
transcripts	O
were	O
determined	O
using	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
of	O
total	O
RNA	O
from	O
keratinocytes	O
incubated	O
for	O
2	O
.	O
5	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
10	O
microg	O
cycloheximide	O
per	O
ml	O
.	O

Using	O
this	O
approach	O
,	O
an	O
abnormally	O
spliced	O
transcript	O
was	O
identified	O
that	O
contains	O
an	O
extra	O
264	O
bases	O
upstream	O
from	O
exon	O
32	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
27	O
bp	O
downstream	O
from	O
the	O
cryptic	O
splice	O
site	O
.	O

Three	O
other	O
splice	O
variants	O
,	O
including	O
one	O
derived	O
from	O
the	O
skipping	O
of	O
exon	O
32	O
,	O
were	O
also	O
identified	O
.	O

These	O
results	O
indicate	O
the	O
usefulness	O
of	O
cycloheximide	O
treatment	O
in	O
evaluating	O
the	O
abnormal	O
processing	O
of	O
mRNA	O
due	O
to	O
splice	O
-	O
site	O
mutations	O
,	O
because	O
(	O
i	O
)	O
aberrant	O
splicing	O
often	O
generates	O
a	O
premature	O
termination	O
codon	O
,	O
(	O
ii	O
)	O
transcripts	O
with	O
premature	O
termination	O
codons	O
can	O
occur	O
at	O
low	O
or	O
undetectable	O
levels	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
and	O
(	O
iii	O
)	O
the	O
levels	O
of	O
these	O
transcripts	O
can	O
be	O
increased	O
by	O
cycloheximide	O
.	O

A	O
deletion	O
mutation	O
in	O
COL17A1	O
in	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
represents	O
propagation	O
of	O
an	O
ancestral	O
allele	O
.	O

Patients	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
,	O
a	O
usually	O
nonlethal	O
form	O
of	O
junctional	B
epidermolysis	I
bullosa	I
,	O
have	O
generalized	O
blistering	B
,	O
nail	B
dystrophy	I
,	O
patchy	B
alopecia	I
,	O
and	O
dental	B
abnormalities	I
.	O

Skin	B
fragility	I
in	O
most	O
cases	O
is	O
due	O
to	O
mutations	O
in	O
the	O
gene	O
encoding	O
type	O
XVII	O
collagen	O
(	O
COL17A1	O
)	O
.	O

Recently	O
,	O
we	O
reported	O
five	O
Austrian	O
families	O
with	O
generalized	O
atrophic	B
benign	I
epidermolysis	I
bullosa	I
who	O
share	O
the	O
same	O
COL17A1	O
mutation	O
.	O

Affected	O
individuals	O
in	O
three	O
families	O
are	O
homozygous	O
for	O
4003delTC	O
,	O
whereas	O
those	O
in	O
two	O
others	O
are	O
compound	O
heterozygotes	O
.	O

To	O
determine	O
if	O
the	O
occurrence	O
of	O
4003delTC	O
in	O
these	O
unrelated	O
families	O
signifies	O
propagation	O
of	O
an	O
ancestral	O
allele	O
or	O
a	O
mutational	O
hot	O
spot	O
,	O
haplotypes	O
were	O
determined	O
for	O
polymorphisms	O
both	O
within	O
and	O
flanking	O
COL17A1	O
.	O

Five	O
intragenic	O
polymorphisms	O
were	O
chosen	O
based	O
on	O
their	O
informativeness	O
.	O

One	O
of	O
these	O
,	O
not	O
previously	O
reported	O
,	O
was	O
2988	O
A	O
or	O
C	O
that	O
introduces	O
a	O
new	O
restriction	O
site	O
for	O
Eco0109	O
I.	O
All	O
the	O
4003delTC	O
alleles	O
showed	O
the	O
same	O
haplotype	O
for	O
these	O
five	O
polymorphic	O
markers	O
.	O

Fourteen	O
microsatellite	O
polymorphisms	O
were	O
selected	O
based	O
on	O
their	O
high	O
heterozygosity	O
and	O
their	O
location	O
within	O
10q23-q25	O
near	O
COL17A1	O
.	O

Three	O
families	O
shared	O
microsatellite	O
polymorphisms	O
covering	O
at	O
most	O
19	O
cM	O
,	O
whereas	O
the	O
others	O
shared	O
smaller	O
regions	O
consistent	O
with	O
cross	O
-	O
over	O
events	O
during	O
passage	O
of	O
this	O
mutation	O
through	O
several	O
generations	O
.	O

These	O
results	O
indicate	O
that	O
4003delTC	O
occurs	O
on	O
a	O
single	O
ancestral	O
allele	O
..	O

The	O
haptoglobin	O
-	O
gene	O
deletion	O
responsible	O
for	O
anhaptoglobinemia	B
.	O

We	O
have	O
found	O
an	O
allelic	O
deletion	O
of	O
the	O
haptoglobin	O
(	O
Hp	O
)	O
gene	O
from	O
an	O
individual	O
with	O
anhaptoglobinemia	B
.	O

The	O
Hp	O
gene	O
cluster	O
consists	O
of	O
coding	O
regions	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
gene	O
(	O
Hp	O
)	O
and	O
of	O
the	O
alpha	O
chain	O
and	O
beta	O
chain	O
of	O
the	O
haptoglobin	O
-	O
related	O
gene	O
(	O
Hpr	O
)	O
,	O
in	O
tandem	O
from	O
the	O
5	O
side	O
.	O

Southern	O
blot	O
and	O
PCR	O
analyses	O
have	O
indicated	O
that	O
the	O
individual	O
with	O
anhaptoglobinemia	B
was	O
homozygous	O
for	O
the	O
gene	O
deletion	O
and	O
that	O
the	O
gene	O
deletion	O
was	O
included	O
at	O
least	O
from	O
the	O
promoter	O
region	O
of	O
Hp	O
to	O
Hpr	O
alpha	O
but	O
not	O
to	O
Hpr	O
beta	O
(	O
Hpdel	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
seven	O
individuals	O
with	O
hypohaptoglobinemia	B
in	O
three	O
families	O
,	O
and	O
the	O
genotypes	O
of	O
six	O
of	O
the	O
seven	O
individuals	O
were	O
found	O
to	O
be	O
Hp2	O
/	O
Hpdel	O
.	O

The	O
phenotypes	O
and	O
genotypes	O
in	O
one	O
of	O
these	O
three	O
families	O
showed	O
the	O
father	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
the	O
mother	O
to	O
be	O
Hp2	O
-	O
1	O
and	O
Hp1	O
/	O
Hp2	O
,	O
one	O
of	O
the	O
two	O
children	O
to	O
be	O
hypohaptoglobinemic	B
(	O
Hp2	O
)	O
and	O
Hp2	O
/	O
Hpdel	O
,	O
and	O
the	O
other	O
child	O
to	O
be	O
Hp1	O
and	O
Hp1	O
/	O
Hpdel	O
,	O
showing	O
an	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
in	O
the	O
child	O
with	O
Hp1	O
.	O

The	O
Hp2	O
/	O
Hpdel	O
individuals	O
had	O
an	O
extremely	O
low	O
level	O
of	O
Hp	O
(	O
mean	O
+	O
/-SD	O
=	O
0	O
.	O
049	O
+	O
/-0	O
.	O

043	O
mg	O
/	O
ml	O
;	O
n	O
=	O
6	O
)	O
,	O
compared	O
with	O
the	O
level	O
(	O
1	O
.	O
64	O
+	O
/-1	O
.	O

07	O
mg	O
/	O
ml	O
)	O
obtained	O
from	O
52	O
healthy	O
volunteers	O
having	O
phenotype	O
Hp2	O
,	O
whereas	O
the	O
serum	O
Hp	O
level	O
of	O
an	O
individual	O
with	O
Hp1	O
/	O
Hpdel	O
was	O
0	O
.	O
50	O
mg	O
/	O
ml	O
,	O
which	O
was	O
approximately	O
half	O
the	O
level	O
of	O
Hp	O
in	O
control	O
sera	O
from	O
the	O
Hp1	O
phenotype	O
(	O
1	O
.	O
26	O
+	O
/-0	O
.	O

33	O
mg	O
/	O
ml	O
;	O
n	O
=	O
9	O
)	O
,	O
showing	O
a	O
gene	O
-	O
dosage	O
effect	O
.	O

The	O
other	O
allele	O
(	O
Hp2	O
)	O
of	O
individuals	O
with	O
Hp2	O
/	O
Hpdel	O
was	O
found	O
to	O
have	O
,	O
in	O
all	O
exons	O
,	O
no	O
mutation	O
,	O
by	O
DNA	O
sequencing	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
,	O
the	O
mechanism	O
of	O
anhaptoglobinemia	B
and	O
the	O
mechanism	O
of	O
anomalous	O
inheritance	O
of	O
Hp	O
phenotypes	O
were	O
well	O
explained	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
hypohaptoglobinemia	B
remains	O
unknown	O

ATM	O
mutations	O
and	O
phenotypes	O
in	O
ataxia	B
-	I
telangiectasia	I
families	O
in	O
the	O
British	O
Isles	O
:	O
expression	O
of	O
mutant	O
ATM	O
and	O
the	O
risk	O
of	O
leukemia	B
,	O
lymphoma	B
,	O
and	O
breast	B
cancer	I
.	O

We	O
report	O
the	O
spectrum	O
of	O
59	O
ATM	O
mutations	O
observed	O
in	O
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
patients	O
in	O
the	O
British	O
Isles	O
.	O

Of	O
51	O
ATM	O
mutations	O
identified	O
in	O
families	O
native	O
to	O
the	O
British	O
Isles	O
,	O
11	O
were	O
founder	O
mutations	O
,	O
and	O
2	O
of	O
these	O
11	O
conferred	O
a	O
milder	O
clinical	O
phenotype	O
with	O
respect	O
to	O
both	O
cerebellar	B
degeneration	I
and	O
cellular	O
features	O
.	O

We	O
report	O
,	O
in	O
two	O
A	B
-	I
T	I
families	O
,	O
an	O
ATM	O
mutation	O
(	O
7271T--	O
>	O
G	O
)	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	B
cancer	I
in	O
both	O
homozygotes	O
and	O
heterozygotes	O
(	O
relative	O
risk	O
12	O
.	O
7	O
;	O
P	O
=	O
.	O
0025	O
)	O
,	O
although	O
there	O
is	O
a	O
less	O
severe	O
A	B
-	I
T	I
phenotype	O
in	O
terms	O
of	O
the	O
degree	O
of	O
cerebellar	B
degeneration	I
.	O

This	O
mutation	O
(	O
7271T--	O
>	O
G	O
)	O
also	O
allows	O
expression	O
of	O
full	O
-	O
length	O
ATM	O
protein	O
at	O
a	O
level	O
comparable	O
with	O
that	O
in	O
unaffected	O
individuals	O
.	O

In	O
addition	O
,	O
we	O
have	O
studied	O
18	O
A	B
-	I
T	I
patients	O
,	O
in	O
15	O
families	O
,	O
who	O
developed	O
leukemia	B
,	O
lymphoma	B
,	O
preleukemic	O
T	O
-	O
cell	O
proliferation	O
,	O
or	O
Hodgkin	B
lymphoma	I
,	O
mostly	O
in	O
childhood	O
.	O

A	O
wide	O
variety	O
of	O
ATM	O
mutation	O
types	O
,	O
including	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
deletions	O
,	O
were	O
seen	O
in	O
these	O
patients	O
.	O

We	O
also	O
show	O
that	O
25	O
%	O
of	O
all	O
A	B
-	I
T	I
patients	O
carried	O
in	O
-	O
frame	O
deletions	O
or	O
missense	O
mutations	O
,	O
many	O
of	O
which	O
were	O
also	O
associated	O
with	O
expression	O
of	O
mutant	O
ATM	O
protein	O
.	O

The	O
DMPK	O
gene	O
of	O
severely	O
affected	O
myotonic	B
dystrophy	I
patients	O
is	O
hypermethylated	O
proximal	O
to	O
the	O
largely	O
expanded	O
CTG	O
repeat	O
.	O

Using	O
methylation	O
-	O
sensitive	O
restriction	O
enzymes	O
,	O
we	O
characterized	O
the	O
methylation	O
pattern	O
on	O
the	O
5	O
side	O
of	O
the	O
CTG	O
repeat	O
in	O
the	O
DMPK	O
gene	O
of	O
normal	O
individuals	O
and	O
of	O
patients	O
affected	O
with	O
myotonic	B
dystrophy	I
,	O
showing	O
expansions	O
of	O
the	O
repetitive	O
sequence	O
.	O

The	O
gene	O
segment	O
analyzed	O
corresponds	O
to	O
the	O
genomic	O
SacI	O
-	O
HindIII	O
fragment	O
carrying	O
exons	O
11	O
-	O
15	O
.	O

There	O
is	O
constitutive	O
methylation	O
in	O
intron	O
12	O
at	O
restriction	O
sites	O
of	O
SacII	O
and	O
HhaI	O
,	O
localized	O
1	O
,	O
159	O
-	O
1	O
,	O
232	O
bp	O
upstream	O
of	O
the	O
CTG	O
repeat	O
,	O
whereas	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
other	O
sites	O
of	O
SacII	O
,	O
HhaI	O
,	O
and	O
HpaII	O
in	O
this	O
region	O
are	O
unmethylated	O
,	O
in	O
normal	O
individuals	O
and	O
most	O
of	O
the	O
patients	O
.	O

In	O
a	O
number	O
of	O
young	O
and	O
severely	O
affected	O
patients	O
,	O
however	O
,	O
complete	O
methylation	O
of	O
these	O
restriction	O
sites	O
was	O
found	O
in	O
the	O
mutated	O
allele	O
.	O

In	O
most	O
of	O
these	O
patients	O
,	O
the	O
onset	O
of	O
the	O
disease	O
was	O
congenital	O
.	O

Preliminary	O
in	O
vivo	O
footprinting	O
data	O
gave	O
evidence	O
for	O
protein	O
-	O
DNA	O
contact	O
in	O
normal	O
genes	O
at	O
an	O
Sp1	O
consensus	O
binding	O
site	O
upstream	O
of	O
the	O
CTG	O
repeat	O
and	O
for	O
a	O
significant	O
reduction	O
of	O
this	O
interaction	O
in	O
cells	O
with	O
a	O
hypermethylated	O
DMPK	O
gene	O
..	O

The	O
hemochromatosis	B
gene	O
product	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
and	O
lowers	O
its	O
affinity	O
for	O
ligand	O
binding	O
.	O

We	O
recently	O
reported	O
the	O
positional	O
cloning	O
of	O
a	O
candidate	O
gene	O
for	O
hereditary	B
hemochromatosis	I
called	O
HFE	O
.	O

The	O
gene	O
product	O
,	O
a	O
member	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
-	O
like	O
family	O
,	O
was	O
found	O
to	O
have	O
a	O
mutation	O
,	O
Cys-282	O
--	O
>	O
Tyr	O
(	O
C282Y	O
)	O
,	O
in	O
85	O
%	O
of	O
patient	O
chromosomes	O
.	O

This	O
mutation	O
eliminates	O
the	O
ability	O
of	O
HFE	O
to	O
associate	O
with	O
beta2-microglobulin	O
(	O
beta2	O
m	O
)	O
and	O
prevents	O
cell	O
-	O
surface	O
expression	O
.	O

A	O
second	O
mutation	O
that	O
has	O
no	O
effect	O
on	O
beta2	O
m	O
association	O
,	O
H63D	O
,	O
was	O
found	O
in	O
eight	O
out	O
of	O
nine	O
patients	O
heterozygous	O
for	O
the	O
C282Y	O
mutant	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
in	O
cultured	O
293	O
cells	O
overexpressing	O
wild	O
-	O
type	O
or	O
mutant	O
HFE	O
proteins	O
that	O
both	O
the	O
wild	O
-	O
type	O
and	O
H63D	O
HFE	O
proteins	O
form	O
stable	O
complexes	O
with	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
.	O

The	O
C282Y	O
mutation	O
nearly	O
completely	O
prevents	O
the	O
association	O
of	O
the	O
mutant	O
HFE	O
protein	O
with	O
the	O
TfR.	O
Studies	O
on	O
cell	O
-	O
associated	O
transferrin	O
at	O
37	O
degrees	O
C	O
suggest	O
that	O
the	O
overexpressed	O
wild	O
-	O
type	O
HFE	O
protein	O
decreases	O
the	O
affinity	O
of	O
the	O
TfR	O
for	O
transferrin	O
.	O

The	O
overexpressed	O
H63D	O
protein	O
does	O
not	O
have	O
this	O
effect	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
functional	O
consequence	O
of	O
the	O
H63D	O
mutation	O
.	O

Addition	O
of	O
soluble	O
wild	O
-	O
type	O
HFE	O
/	O
beta2	O
m	O
heterodimers	O
to	O
cultured	O
cells	O
also	O
decreased	O
the	O
apparent	O
affinity	O
of	O
the	O
TfR	O
for	O
its	O
ligand	O
under	O
steady	O
-	O
state	O
conditions	O
,	O
both	O
in	O
293	O
cells	O
and	O
in	O
HeLa	O
cells	O
.	O

Furthermore	O
,	O
at	O
4	O
degrees	O
C	O
,	O
the	O
added	O
soluble	O
complex	O
of	O
HFE	O
/	O
beta2	O
m	O
inhibited	O
binding	O
of	O
transferrin	O
to	O
HeLa	O
cell	O
TfR	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Scatchard	O
plots	O
of	O
these	O
data	O
indicate	O
that	O
the	O
added	O
heterodimer	O
substantially	O
reduced	O
the	O
affinity	O
of	O
TfR	O
for	O
transferrin	O
.	O

These	O
results	O
establish	O
a	O
molecular	O
link	O
between	O
HFE	O
and	O
a	O
key	O
protein	O
involved	O
in	O
iron	O
transport	O
,	O
the	O
TfR	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
alterations	O
in	O
this	O
regulatory	O
mechanism	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hereditary	B
hemochromatosis	I
..	O

Genomic	O
organization	O
of	O
the	O
UBE3A	O
/	O
E6-AP	O
gene	O
and	O
related	O
pseudogenes	O
.	O

The	O
UBE3A	O
gene	O
encodes	O
the	O
E6-AP	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
has	O
recently	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
Angelman	B
syndrome	I
patients	O
who	O
lack	O
15q11-q13	O
deletions	O
or	O
chromosome	O
15	O
paternal	O
uniparental	B
disomy	I
.	O

Previous	O
UBE3A	O
cDNA	O
analysis	O
has	O
shown	O
a	O
coding	O
region	O
of	O
approximately	O
2	O
.	O
6	O
kb	O
and	O
a	O
3-untranslated	O
region	O
(	O
UTR	O
)	O
of	O
<	O
50	O
bp	O
,	O
whereas	O
Northern	O
analysis	O
has	O
indicated	O
mRNA	O
sizes	O
of	O
5	O
-	O
8	O
kb	O
.	O

We	O
have	O
analyzed	O
additional	O
cDNA	O
clones	O
and	O
provide	O
evidence	O
for	O
an	O
additional	O
0	O
.	O
5	O
kb	O
of	O
5-UTR	O
and	O
>	O
2	O
kb	O
of	O
3-UTR	O
.	O

We	O
have	O
established	O
the	O
genomic	O
organization	O
of	O
UBE3A	O
and	O
the	O
sequence	O
of	O
intron	O
-	O
exon	O
borders	O
.	O

We	O
have	O
also	O
mapped	O
two	O
highly	O
homologous	O
processed	O
pseudogenes	O
,	O
UBE3AP1	O
and	O
UBE3AP2	O
,	O
to	O
chromosomes	O
2	O
and	O
21	O
,	O
respectively	O
,	O
and	O
determined	O
their	O
genomic	O
organization	O
.	O

These	O
results	O
will	O
form	O
the	O
basis	O
for	O
studies	O
of	O
mutation	O
and	O
imprinting	O
of	O
UBE3A	O
.	O

Mutation	O
spectrum	O
and	O
genotype	O
-	O
phenotype	O
analyses	O
in	O
Cowden	B
disease	I
and	O
Bannayan	B
-	I
Zonana	I
syndrome	I
,	O
two	O
hamartoma	B
syndromes	I
with	O
germline	O
PTEN	O
mutation	O
.	O

The	O
tumour	B
suppressor	O
gene	O
PTEN	O
,	O
which	O
maps	O
to	O
10q23	O
.	O

3	O
and	O
encodes	O
a	O
403	O
amino	O
acid	O
dual	O
specificity	O
phosphatase	O
(	O
protein	O
tyrosine	O
phosphatase	O
;	O
PTPase	O
)	O
,	O
was	O
shown	O
recently	O
to	O
play	O
a	O
broad	O
role	O
in	O
human	O
malignancy	B
.	O

Somatic	O
PTEN	O
deletions	O
and	O
mutations	O
were	O
observed	O
in	O
sporadic	B
breast	I
,	I
brain	I
,	I
prostate	I
and	I
kidney	I
cancer	I
cell	O
lines	O
and	O
in	O
several	O
primary	O
tumours	B
such	O
as	O
endometrial	B
carcinomas	I
,	O
malignant	B
melanoma	I
and	O
thyroid	B
tumours	I
.	O

In	O
addition	O
,	O
PTEN	O
was	O
identified	O
as	O
the	O
susceptibility	O
gene	O
for	O
two	O
hamartoma	B
syndromes	I
Cowden	B
disease	I
(	O
CD	B
;	O
MIM	O
158350	O
)	O
and	O
Bannayan	B
-	I
Zonana	I
(	I
BZS	I
)	I
or	I
Ruvalcaba	I
-	I
Riley	I
-	I
Smith	I
syndrome	I
(	O
MIM	O
153480	O
)	O
.	O

Constitutive	O
DNA	O
from	O
37	O
CD	B
families	O
and	O
seven	O
BZS	B
families	O
was	O
screened	O
for	O
germline	O
PTEN	O
mutations	O
.	O

PTEN	O
mutations	O
were	O
identified	O
in	O
30	O
of	O
37	O
(	O
81	O
%	O
)	O
CD	B
families	O
,	O
including	O
missense	O
and	O
nonsense	O
point	O
mutations	O
,	O
deletions	O
,	O
insertions	O
,	O
a	O
deletion	O
/	O
insertion	O
and	O
splice	O
site	O
mutations	O
.	O

These	O
mutations	O
were	O
scattered	O
over	O
the	O
entire	O
length	O
of	O
PTEN	O
,	O
with	O
the	O
exception	O
of	O
the	O
first	O
,	O
fourth	O
and	O
last	O
exons	O
.	O

A	O
hot	O
spot	O
for	O
PTEN	O
mutation	O
in	O
CD	B
was	O
identified	O
in	O
exon	O
5	O
that	O
contains	O
the	O
PTPase	O
core	O
motif	O
,	O
with	O
13	O
of	O
30	O
(	O
43	O
%	O
)	O
CD	B
mutations	O
identified	O
in	O
this	O
exon	O
.	O

Seven	O
of	O
30	O
(	O
23	O
%	O
)	O
were	O
within	O
the	O
core	O
motif	O
,	O
the	O
majority	O
(	O
five	O
of	O
seven	O
)	O
of	O
which	O
were	O
missense	O
mutations	O
,	O
possibly	O
pointing	O
to	O
the	O
functional	O
significance	O
of	O
this	O
region	O
.	O

Germline	O
PTEN	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
seven	O
(	O
57	O
%	O
)	O
BZS	B
families	O
studied	O
.	O

Interestingly	O
,	O
none	O
of	O
these	O
mutations	O
was	O
observed	O
in	O
the	O
PTPase	O
core	O
motif	O
.	O

It	O
is	O
also	O
worthy	O
of	O
note	O
that	O
a	O
single	O
nonsense	O
point	O
mutation	O
,	O
R233X	O
,	O
was	O
observed	O
in	O
the	O
germline	O
DNA	O
from	O
two	O
unrelated	O
CD	B
families	O
and	O
one	O
BZS	B
family	O
.	O

Genotype	O
-	O
phenotype	O
studies	O
were	O
not	O
performed	O
on	O
this	O
small	O
group	O
of	O
BZS	B
families	O
.	O

However	O
,	O
genotype	O
-	O
phenotype	O
analysis	O
inthe	O
group	O
of	O
CD	B
families	O
revealed	O
two	O
possible	O
associations	O
worthy	O
of	O
follow	O
-	O
up	O
in	O
independent	O
analyses	O
.	O

The	O
first	O
was	O
an	O
association	O
noted	O
in	O
the	O
group	O
of	O
CD	B
families	O
with	O
breast	B
disease	I
.	O

A	O
correlation	O
was	O
observed	O
between	O
the	O
presence	O
/	O
absence	O
of	O
a	O
PTEN	O
mutation	O
and	O
the	O
type	O
of	O
breast	O
involvement	O
(	O
unaffected	O
versus	O
benign	O
versus	O
malignant	O
)	O
.	O

Specifically	O
and	O
more	O
directly	O
,	O
an	O
association	O
was	O
also	O
observed	O
between	O
the	O
presence	O
of	O
a	O
PTEN	O
mutation	O
and	O
malignant	B
breast	I
disease	I
.	O

Secondly	O
,	O
there	O
appeared	O
to	O
be	O
an	O
interdependent	O
association	O
between	O
mutations	O
upstream	O
and	O
within	O
the	O
PTPase	O
core	O
motif	O
,	O
the	O
core	O
motif	O
containing	O
the	O
majority	O
of	O
missense	O
mutations	O
,	O
and	O
the	O
involvement	O
of	O
all	O
major	O
organ	O
systems	O
(	O
central	O
nervous	O
system	O
,	O
thyroid	O
,	O
breast	O
,	O
skin	O
and	O
gastrointestinal	O
tract	O
)	O
.	O

However	O
,	O
these	O
observations	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
studying	O
a	O
larger	O
number	O
of	O
CD	B
families	O
.	O

Molecular	O
defects	O
leading	O
to	O
human	O
complement	B
component	I
C6	I
deficiency	I
in	O
an	O
African	O
-	O
American	O
family	O
.	O

Complement	B
component	I
C6	I
deficiency	I
(	O
C6D	B
)	O
was	O
diagnosed	O
in	O
a	O
16-year	O
-	O
old	O
African	O
-	O
American	O
male	O
with	O
meningococcal	B
meningitis	I
.	O

The	O
patients	O
father	O
and	O
two	O
brothers	O
also	O
had	O
C6D	B
,	O
but	O
gave	O
no	O
history	O
of	O
meningitis	B
or	O
other	O
neisserial	B
infection	I
.	O

By	O
using	O
exon	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
/	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
as	O
a	O
screening	O
step	O
and	O
nucleotide	O
sequencing	O
of	O
target	O
exons	O
,	O
we	O
determined	O
that	O
the	O
proband	O
was	O
a	O
compound	O
heterozygote	O
for	O
two	O
C6	O
gene	O
mutations	O
.	O

The	O
first	O
,	O
1195delC	O
located	O
in	O
exon	O
7	O
,	O
is	O
a	O
novel	O
mutation	O
,	O
while	O
the	O
second	O
,	O
1936delG	O
in	O
exon	O
12	O
,	O
has	O
been	O
described	O
before	O
to	O
cause	O
C6D	B
in	O
an	O
unrelated	O
African	O
-	O
American	O
individual	O
.	O

Both	O
mutations	O
result	O
in	O
premature	O
termination	O
codons	O
and	O
C6	O
null	O
alleles	O
.	O

Allele	O
-	O
specific	O
PCR	O
indicated	O
that	O
the	O
probands	O
two	O
brothers	O
also	O
inherited	O
the	O
1195delC	O
mutation	O
from	O
their	O
heterozygous	O
mother	O
and	O
the	O
1936delG	O
mutation	O
from	O
their	O
homozygous	O
father	O
..	O

PAX6	O
mutations	O
reviewed	O
.	O

Mutations	O
in	O
PAX6	O
are	O
responsible	O
for	O
human	O
aniridia	B
and	O
have	O
also	O
been	O
found	O
in	O
patients	O
with	O
Peters	B
anomaly	I
,	O
with	O
congenital	B
cataracts	I
,	O
with	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
with	O
isolated	B
foveal	I
hypoplasia	I
.	O

No	O
locus	O
other	O
than	O
chromosome	O
11p13	O
has	O
been	O
implicated	O
in	O
aniridia	B
,	O
and	O
PAX6	O
is	O
clearly	O
the	O
major	O
,	O
if	O
not	O
only	O
,	O
gene	O
responsible	O
.	O

Twenty	O
-	O
eight	O
percent	O
of	O
identified	O
PAX6	O
mutations	O
are	O
C	O
-	O
T	O
changes	O
at	O
CpG	O
dinucleotides	O
,	O
20	O
%	O
are	O
splicing	O
errors	O
,	O
and	O
more	O
than	O
30	O
%	O
are	O
deletion	O
or	O
insertion	O
events	O
.	O

There	O
is	O
a	O
noticeably	O
elevated	O
level	O
of	O
mutation	O
in	O
the	O
paired	O
domain	O
compared	O
with	O
the	O
rest	O
of	O
the	O
gene	O
.	O

Increased	O
mutation	O
in	O
the	O
homeodomain	O
is	O
accounted	O
for	O
by	O
the	O
hypermutable	O
CpG	O
dinucleotide	O
in	O
codon	O
240	O
.	O

Very	O
nearly	O
all	O
mutations	O
appear	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
mutant	O
allele	O
,	O
and	O
more	O
than	O
80	O
%	O
of	O
exonic	O
substitutions	O
result	O
in	O
nonsense	O
codons	O
.	O

In	O
a	O
gene	O
with	O
such	O
extraordinarily	O
high	O
sequence	O
conservation	O
throughout	O
evolution	O
,	O
there	O
are	O
presumed	O
undiscovered	O
missense	O
mutations	O
,	O
these	O
are	O
hypothesized	O
to	O
exist	O
in	O
as	O
-	O
yet	O
unidentified	O
phenotypes	O
..	O

Genetic	O
heterogeneity	O
and	O
penetrance	O
analysis	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
genes	O
in	O
breast	B
cancer	I
families	O
.	O

The	O
Breast	B
Cancer	I
Linkage	O
Consortium	O
.	O

The	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
to	O
inherited	B
breast	I
cancer	I
was	O
assessed	O
by	O
linkage	O
and	O
mutation	O
analysis	O
in	O
237	O
families	O
,	O
each	O
with	O
at	O
least	O
four	O
cases	O
of	O
breast	B
cancer	I
,	O
collected	O
by	O
the	O
Breast	B
Cancer	I
Linkage	O
Consortium	O
.	O

Families	O
were	O
included	O
without	O
regard	O
to	O
the	O
occurrence	O
of	O
ovarian	B
or	I
other	I
cancers	I
.	O

Overall	O
,	O
disease	O
was	O
linked	O
to	O
BRCA1	O
in	O
an	O
estimated	O
52	O
%	O
of	O
families	O
,	O
to	O
BRCA2	O
in	O
32	O
%	O
of	O
families	O
,	O
and	O
to	O
neither	O
gene	O
in	O
16	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
6	O
%	O
-28	O
%	O
)	O
,	O
suggesting	O
other	O
predisposition	O
genes	O
.	O

The	O
majority	O
(	O
81	O
%	O
)	O
of	O
the	O
breast	B
-	I
ovarian	I
cancer	I
families	O
were	O
due	O
to	O
BRCA1	O
,	O
with	O
most	O
others	O
(	O
14	O
%	O
)	O
due	O
to	O
BRCA2	O
.	O

Conversely	O
,	O
the	O
majority	O
of	O
families	O
with	O
male	B
and	I
female	I
breast	I
cancer	I
were	O
due	O
to	O
BRCA2	O
(	O
76	O
%	O
)	O
.	O

The	O
largest	O
proportion	O
(	O
67	O
%	O
)	O
of	O
families	O
due	O
to	O
other	O
genes	O
was	O
found	O
in	O
families	O
with	O
four	O
or	O
five	O
cases	O
of	O
female	O
breast	B
cancer	I
only	O
.	O

These	O
estimates	O
were	O
not	O
substantially	O
affected	O
either	O
by	O
changing	O
the	O
assumed	O
penetrance	O
model	O
for	O
BRCA1	O
or	O
by	O
including	O
or	O
excluding	O
BRCA1	O
mutation	O
data	O
.	O

Among	O
those	O
families	O
with	O
disease	O
due	O
to	O
BRCA1	O
that	O
were	O
tested	O
by	O
one	O
of	O
the	O
standard	O
screening	O
methods	O
,	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
sequence	O
or	O
splice	O
sites	O
in	O
an	O
estimated	O
63	O
%	O
(	O
95	O
%	O
CI	O
51	O
%	O
-77	O
%	O
)	O
.	O

The	O
estimated	O
sensitivity	O
was	O
identical	O
for	O
direct	O
sequencing	O
and	O
other	O
techniques	O
.	O

The	O
penetrance	O
of	O
BRCA2	O
was	O
estimated	O
by	O
maximizing	O
the	O
LOD	O
score	O
in	O
BRCA2-mutation	O
families	O
,	O
over	O
all	O
possible	O
penetrance	O
functions	O
.	O

The	O
estimated	O
cumulative	O
risk	O
of	O
breast	B
cancer	I
reached	O
28	O
%	O
(	O
95	O
%	O
CI	O
9	O
%	O
-44	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
84	O
%	O
(	O
95	O
%	O
CI	O
43	O
%	O
-95	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

The	O
corresponding	O
ovarian	B
cancer	I
risks	O
were	O
0	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-1	O
%	O
)	O
by	O
age	O
50	O
years	O
and	O
27	O
%	O
(	O
95	O
%	O
CI	O
0	O
%	O
-47	O
%	O
)	O
by	O
age	O
70	O
years	O
.	O

The	O
lifetime	O
risk	O
of	O
breast	B
cancer	I
appears	O
similar	O
to	O
the	O
risk	O
in	O
BRCA1	O
carriers	O
,	O
but	O
there	O
was	O
some	O
suggestion	O
of	O
a	O
lower	O
risk	O
in	O
BRCA2	O
carriers	O
<	O
50	O
years	O
of	O
age	O
.	O

Eye	B
movement	I
abnormalities	I
correlate	O
with	O
genotype	O
in	O
autosomal	O
dominant	O
cerebellar	B
ataxia	I
type	I
I.	I
We	O
compared	O
horizontal	O
eye	O
movements	O
(	O
visually	O
guided	O
saccades	O
,	O
antisaccades	O
,	O
and	O
smooth	O
pursuit	O
)	O
in	O
control	O
subjects	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
three	O
forms	O
of	O
autosomal	O
dominant	O
cerebellar	B
ataxias	I
type	I
I	I
spinocerebellar	B
ataxias	I
1	I
and	I
2	I
(	O
SCA1	B
,	O
n	O
=	O
11	O
;	O
SCA2	B
,	O
n	O
=	O
10	O
)	O
and	O
SCA3	B
/	O
Machado	B
-	I
Joseph	I
disease	I
(	O
MJD	B
)	O
(	O
n	O
=	O
16	O
)	O
.	O

In	O
SCA1	B
,	O
saccade	O
amplitude	O
was	O
significantly	O
increased	O
,	O
resulting	O
in	O
hypermetria	B
.	O

The	O
smooth	O
pursuit	O
gain	O
was	O
decreased	O
.	O

In	O
SCA2	B
,	O
saccade	O
velocity	O
was	O
markedly	O
decreased	O
.	O

The	O
percentage	O
of	O
errors	O
in	O
antisaccades	O
was	O
greatly	O
increased	O
and	O
was	O
significantly	O
correlated	O
with	O
age	O
at	O
disease	O
onset	O
.	O

In	O
addition	O
,	O
a	O
correlation	O
between	O
smooth	O
pursuit	O
gain	O
and	O
the	O
number	O
of	O
trinucleotide	O
repeats	O
was	O
found	O
.	O

In	O
SCA3	B
,	O
gaze	B
-	I
evoked	I
nystagmus	I
was	O
often	O
present	O
as	O
was	O
saccade	O
hypometria	O
and	O
smooth	O
pursuit	O
gain	O
was	O
markedly	O
decreased	O
.	O

Three	O
major	O
criteria	O
,	O
saccade	O
amplitude	O
,	O
saccade	O
velocity	O
,	O
and	O
presence	O
of	O
gaze	B
-	I
evoked	I
nystagmus	I
,	O
permitted	O
the	O
correct	O
assignment	O
of	O
90	O
%	O
of	O
the	O
SCA1	B
,	O
90	O
%	O
of	O
the	O
SCA2	B
,	O
and	O
93	O
%	O
of	O
the	O
patients	O
with	O
SCA3	B
to	O
their	O
genetically	O
confirmed	O
patient	O
group	O
and	O
,	O
therefore	O
,	O
may	O
help	O
orient	O
diagnoses	O
of	O
SCA1	B
,	O
SCA2	B
,	O
and	O
SCA3	B
at	O
early	O
clinical	O
stages	O
of	O
the	O
diseases	O
..	O

Genetic	O
basis	O
and	O
molecular	O
mechanism	O
for	O
idiopathic	B
ventricular	I
fibrillation	I
.	O

Ventricular	B
fibrillation	I
causes	O
more	O
than	O
300	O
,	O
000	O
sudden	O
deaths	O
each	O
year	O
in	O
the	O
USA	O
alone	O
.	O

In	O
approximately	O
5	O
-	O
12	O
%	O
of	O
these	O
cases	O
,	O
there	O
are	O
no	O
demonstrable	O
cardiac	O
or	O
non	O
-	O
cardiac	O
causes	O
to	O
account	O
for	O
the	O
episode	O
,	O
which	O
is	O
therefore	O
classified	O
as	O
idiopathic	B
ventricular	I
fibrillation	I
(	O
IVF	B
)	O
.	O

A	O
distinct	O
group	O
of	O
IVF	B
patients	O
has	O
been	O
found	O
to	O
present	O
with	O
a	O
characteristic	O
electrocardiographic	O
pattern	O
.	O

Because	O
of	O
the	O
small	O
size	O
of	O
most	O
pedigrees	O
and	O
the	O
high	O
incidence	O
of	O
sudden	B
death	I
,	O
however	O
,	O
molecular	O
genetic	O
studies	O
of	O
IVF	B
have	O
not	O
yet	O
been	O
done	O
.	O

Because	O
IVF	B
causes	O
cardiac	O
rhythm	O
disturbance	O
,	O
we	O
investigated	O
whether	O
malfunction	O
of	O
ion	O
channels	O
could	O
cause	O
the	O
disorder	O
by	O
studying	O
mutations	O
in	O
the	O
cardiac	O
sodium	O
channel	O
gene	O
SCN5A	O
.	O

We	O
have	O
now	O
identified	O
a	O
missense	O
mutation	O
,	O
a	O
splice	O
-	O
donor	O
mutation	O
,	O
and	O
a	O
frameshift	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
SCN5A	O
in	O
three	O
IVF	B
families	O
.	O

We	O
show	O
that	O
sodium	O
channels	O
with	O
the	O
missense	O
mutation	O
recover	O
from	O
inactivation	O
more	O
rapidly	O
than	O
normal	O
and	O
that	O
the	O
frameshift	O
mutation	O
causes	O
the	O
sodium	O
channel	O
to	O
be	O
non	O
-	O
functional	O
.	O

Our	O
results	O
indicate	O
that	O
mutations	O
in	O
cardiac	O
ion	O
-	O
channel	O
genes	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
IVF	B
..	O

Molecular	O
heterogeneity	O
in	O
mucopolysaccharidosis	B
IVA	I
in	O
Australia	O
and	O
Northern	O
Ireland	O
:	O
nine	O
novel	O
mutations	O
including	O
T312S	O
,	O
a	O
common	O
allele	O
that	O
confers	O
a	O
mild	O
phenotype	O
.	O

Mucopolysaccharidosis	B
IVA	I
(	O
MPS	B
IVA	I
)	O
is	O
an	O
autosomal	B
recessive	I
lysosomal	I
storage	I
disorder	I
caused	O
by	O
a	O
genetic	B
defect	I
in	O
N	O
-	O
acetylgalactosamine-6-sulfate	O
sulfatase	O
(	O
GALNS	O
)	O
.	O

Previous	O
studies	O
of	O
patients	O
from	O
a	O
British	O
-	O
Irish	O
population	O
showed	O
that	O
the	O
I113F	O
mutation	O
is	O
the	O
most	O
common	O
single	O
mutation	O
among	O
MPS	B
IVA	I
patients	O
and	O
produces	O
a	O
severe	O
clinical	O
phenotype	O
.	O

We	O
studied	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
23	O
additional	O
MPS	B
IVA	I
patients	O
(	O
15	O
from	O
Australia	O
,	O
8	O
from	O
Northern	O
Ireland	O
)	O
,	O
with	O
various	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
16	O
cases	O
;	O
intermediate	O
,	O
4	O
cases	O
;	O
mild	O
,	O
3	O
cases	O
)	O
.	O

We	O
found	O
two	O
common	O
mutations	O
that	O
together	O
accounted	O
for	O
32	O
%	O
of	O
the	O
44	O
unrelated	O
alleles	O
in	O
these	O
patients	O
.	O

One	O
is	O
the	O
T312S	O
mutation	O
,	O
a	O
novel	O
mutation	O
found	O
exclusively	O
in	O
milder	O
patients	O
.	O

The	O
other	O
is	O
the	O
previously	O
described	O
I113F	O
that	O
produces	O
a	O
severe	O
phenotype	O
.	O

The	O
I113F	O
and	O
T312S	O
mutations	O
accounted	O
for	O
8	O
(	O
18	O
%	O
)	O
and	O
6	O
(	O
14	O
%	O
)	O
of	O
44	O
unrelated	O
alleles	O
,	O
respectively	O
.	O

The	O
relatively	O
high	O
residual	O
GALNS	O
activity	O
seen	O
when	O
the	O
T312S	O
mutant	O
cDNA	O
is	O
overexpressed	O
in	O
mutant	O
cells	O
provides	O
an	O
explanation	O
for	O
the	O
mild	O
phenotype	O
in	O
patients	O
with	O
this	O
mutation	O
.	O

The	O
distribution	O
and	O
relative	O
frequencies	O
of	O
the	O
I113F	O
and	O
T312S	O
mutations	O
in	O
Australia	O
corresponded	O
to	O
those	O
observed	O
in	O
Northern	O
Ireland	O
and	O
are	O
unique	O
to	O
these	O
two	O
populations	O
,	O
suggesting	O
that	O
both	O
mutations	O
were	O
probably	O
introduced	O
to	O
Australia	O
by	O
Irish	O
migrants	O
during	O
the	O
19th	O
century	O
.	O

Haplotype	O
analysis	O
using	O
6	O
RFLPs	O
provides	O
additional	O
data	O
that	O
the	O
I113F	O
mutation	O
originated	O
from	O
a	O
common	O
ancestor	O
.	O

The	O
other	O
9	O
novel	O
mutations	O
identified	O
in	O
these	O
23	O
patients	O
were	O
each	O
limited	O
to	O
a	O
single	O
family	O
.	O

These	O
data	O
provide	O
further	O
evidence	O
for	O
extensive	O
allelic	O
heterogeneity	O
in	O
MPS	B
IVA	I
in	O
British	O
-	O
Irish	O
patients	O
and	O
provide	O
evidence	O
for	O
their	O
transmission	O
to	O
Australia	O
by	O
British	O
-	O
Irish	O
migrants	O
..	O

Identification	O
of	O
constitutional	O
WT1	O
mutations	O
,	O
in	O
patients	O
with	O
isolated	O
diffuse	B
mesangial	I
sclerosis	I
,	O
and	O
analysis	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
by	O
use	O
of	O
a	O
computerized	O
mutation	O
database	O
.	O

Constitutional	O
mutations	O
of	O
the	O
WT1	O
gene	O
,	O
encoding	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
involved	O
in	O
renal	O
and	O
gonadal	O
development	O
,	O
are	O
found	O
in	O
most	O
patients	O
with	O
Denys	B
-	I
Drash	I
syndrome	I
(	O
DDS	B
)	O
,	O
or	O
diffuse	B
mesangial	I
sclerosis	I
(	O
DMS	B
)	O
associated	O
with	O
pseudohermaphroditism	B
and/or	O
Wilms	B
tumor	I
(	O
WT	B
)	O
.	O

Most	O
mutations	O
in	O
DDS	B
patients	O
lie	O
in	O
exon	O
8	O
or	O
exon	O
9	O
,	O
encoding	O
zinc	O
finger	O
2	O
or	O
zinc	O
finger	O
3	O
,	O
respectively	O
,	O
with	O
a	O
hot	O
spot	O
(	O
R394W	O
)	O
in	O
exon	O
9	O
.	O

We	O
analyzed	O
a	O
series	O
of	O
24	O
patients	O
,	O
10	O
with	O
isolated	B
DMS	I
(	O
IDMS	B
)	O
,	O
10	O
with	O
DDS	B
,	O
and	O
4	O
with	O
urogenital	B
abnormalities	I
and/or	O
WT	B
.	O

We	O
report	O
WT1	O
heterozygous	O
mutations	O
in	O
16	O
patients	O
,	O
4	O
of	O
whom	O
presented	O
with	O
IDMS	B
.	O

One	O
male	O
and	O
two	O
female	O
IDMS	B
patients	O
with	O
WT1	O
mutations	O
underwent	O
normal	O
puberty	O
.	O

Two	O
mutations	O
associated	O
with	O
IDMS	B
are	O
different	O
from	O
those	O
described	O
in	O
DDS	B
patients	O
.	O

No	O
WT1	O
mutations	O
were	O
detected	O
in	O
the	O
six	O
other	O
IDMS	B
patients	O
,	O
suggesting	O
genetic	O
heterogeneity	O
of	O
this	O
disease	O
.	O

We	O
analyzed	O
genotype	O
/	O
phenotype	O
correlations	O
,	O
on	O
the	O
basis	O
of	O
the	O
constitution	O
of	O
a	O
WT1	O
mutation	O
database	O
of	O
84	O
germ	O
-	O
line	O
mutations	O
,	O
to	O
compare	O
the	O
distribution	O
and	O
type	O
of	O
mutations	O
,	O
according	O
to	O
the	O
different	O
symptoms	O
.	O

This	O
demonstrated	O
(	O
1	O
)	O
the	O
association	O
between	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
and	O
DMS	B
;	O
(	O
2	O
)	O
among	O
patients	O
with	O
DMS	B
,	O
a	O
higher	O
frequency	O
of	O
exon	O
8	O
mutations	O
among	O
46	O
,	O
XY	O
patients	O
with	O
female	O
phenotype	O
than	O
among	O
46	O
,	O
XY	O
patients	O
with	O
sexual	O
ambiguity	O
or	O
male	O
phenotype	O
;	O
and	O
(	O
3	O
)	O
statistically	O
significant	O
evidence	O
that	O
mutations	O
in	O
exons	O
8	O
and	O
9	O
preferentially	O
affect	O
amino	O
acids	O
with	O
different	O
functions	O
..	O

The	O
185delAG	O
BRCA1	O
mutation	O
originated	O
before	O
the	O
dispersion	O
of	O
Jews	O
in	O
the	O
diaspora	O
and	O
is	O
not	O
limited	O
to	O
Ashkenazim	O
.	O

The	O
185delAG	O
mutation	O
in	O
BRCA1	O
is	O
detected	O
in	O
Ashkenazi	O
Jews	O
both	O
in	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
and	O
in	O
the	O
general	O
population	O
.	O

All	O
tested	O
Ashkenazi	O
mutation	O
carriers	O
share	O
the	O
same	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
this	O
Ashkenazi	O
mutation	O
also	O
occurs	O
in	O
Iraqi	O
Jews	O
with	O
a	O
similar	O
allelic	O
pattern	O
.	O

We	O
extended	O
our	O
analysis	O
to	O
other	O
non	O
-	O
Ashkenazi	O
subsets	O
354	O
of	O
Moroccan	O
origin	O
,	O
200	O
Yemenites	O
and	O
150	O
Iranian	O
Jews	O
.	O

Heteroduplex	O
analysis	O
complemented	O
by	O
direct	O
DNA	O
sequencing	O
of	O
abnormally	O
migrating	O
bands	O
were	O
employed	O
.	O

Four	O
of	O
Moroccan	O
origin	O
(	O
1	O
.	O
1	O
%	O
)	O
and	O
none	O
of	O
the	O
Yemenites	O
or	O
Iranians	O
was	O
a	O
carrier	O
of	O
the	O
185delAG	O
mutation	O
.	O

BRCA1	O
allelic	O
patterns	O
were	O
determined	O
for	O
four	O
of	O
these	O
individuals	O
and	O
for	O
12	O
additional	O
non	O
-	O
Ashkenazi	O
185delAG	O
mutation	O
carriers	O
who	O
had	O
breast	B
/	I
ovarian	I
cancer	I
.	O

Six	O
non	O
-	O
Ashkenazi	O
individuals	O
shared	O
the	O
common	O
Ashkenazi	O
haplotype	O
,	O
four	O
had	O
a	O
closely	O
related	O
pattern	O
,	O
and	O
the	O
rest	O
(	O
n	O
=	O
6	O
)	O
displayed	O
a	O
distinct	O
BRCA1	O
allelic	O
pattern	O
.	O

We	O
conclude	O
that	O
the	O
185delAG	O
BRCA1	O
mutation	O
occurs	O
in	O
some	O
non	O
-	O
Ashkenazi	O
populations	O
at	O
rates	O
comparable	O
with	O
that	O
of	O
Ashkenazim	O
.	O

The	O
majority	O
of	O
Jewish	O
185delAG	O
mutation	O
carriers	O
have	O
a	O
common	O
allelic	O
pattern	O
,	O
supporting	O
the	O
founder	O
effect	O
notion	O
,	O
but	O
dating	O
the	O
mutations	O
origin	O
to	O
an	O
earlier	O
date	O
than	O
currently	O
estimated	O
.	O

However	O
,	O
the	O
different	O
allelic	O
pattern	O
at	O
the	O
BRCA1	O
locus	O
even	O
in	O
some	O
Jewish	O
mutation	O
carriers	O
,	O
might	O
suggest	O
that	O
the	O
mutation	O
arose	O
independently	O
..	O

Crystal	O
structure	O
of	O
the	O
hemochromatosis	B
protein	O
HFE	O
and	O
characterization	O
of	O
its	O
interaction	O
with	O
transferrin	O
receptor	O
.	O

HFE	O
is	O
an	O
MHC	O
-	O
related	O
protein	O
that	O
is	O
mutated	O
in	O
the	O
iron	B
-	I
overload	I
disease	I
hereditary	B
hemochromatosis	I
.	O

HFE	O
binds	O
to	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
and	O
reduces	O
its	O
affinity	O
for	O
iron	O
-	O
loaded	O
transferrin	O
,	O
implicating	O
HFE	O
in	O
iron	O
metabolism	O
.	O

The	O
2	O
.	O
6	O
A	O
crystal	O
structure	O
of	O
HFE	O
reveals	O
the	O
locations	O
of	O
hemochromatosis	B
mutations	O
and	O
a	O
patch	O
of	O
histidines	O
that	O
could	O
be	O
involved	O
in	O
pH	O
-	O
dependent	O
interactions	O
.	O

We	O
also	O
demonstrate	O
that	O
soluble	O
TfR	O
and	O
HFE	O
bind	O
tightly	O
at	O
the	O
basic	O
pH	O
of	O
the	O
cell	O
surface	O
,	O
but	O
not	O
at	O
the	O
acidic	O
pH	O
of	O
intracellular	O
vesicles	O
.	O

TfR	O
HFE	O
stoichiometry	O
(	O
2	O
1	O
)	O
differs	O
from	O
TfR	O
transferrin	O
stoichiometry	O
(	O
2	O
2	O
)	O
,	O
implying	O
a	O
different	O
mode	O
of	O
binding	O
for	O
HFE	O
and	O
transferrin	O
to	O
TfR	O
,	O
consistent	O
with	O
our	O
demonstration	O
that	O
HFE	O
,	O
transferrin	O
,	O
and	O
TfR	O
form	O
a	O
ternary	O
complex	O
.	O

Identification	O
of	O
three	O
novel	O
mutations	O
and	O
a	O
high	O
frequency	O
of	O
the	O
Arg778Leu	O
mutation	O
in	O
Korean	O
patients	O
with	O
Wilson	B
disease	I
.	O

Four	O
mutations	O
--	O
R778L	O
,	O
A874V	O
,	O
L1083F	O
,	O
and	O
2304delC	O
--	O
in	O
the	O
copper	O
-	O
transporting	O
enzyme	O
,	O
P	O
-	O
type	O
ATPase	O
(	O
ATP7B	O
)	O
,	O
were	O
identified	O
in	O
Korean	O
Patients	O
with	O
Wilson	B
disease	I
.	O

Arg778Leu	O
,	O
the	O
most	O
frequently	O
reported	O
mutation	O
of	O
this	O
enzyme	O
,	O
was	O
found	O
in	O
six	O
of	O
eight	O
unrelated	O
patients	O
studied	O
,	O
an	O
allele	O
frequency	O
of	O
37	O
.	O
5	O
%	O
,	O
which	O
is	O
considerably	O
higher	O
than	O
those	O
in	O
other	O
Asian	O
populations	O
.	O

The	O
novel	O
single	O
nucleotide	O
deletion	O
,	O
2304delC	O
,	O
was	O
found	O
in	O
one	O
patient	O
.	O

Since	O
a	O
mutation	O
at	O
cDNA	O
nucleotide	O
2302	O
(	O
2302insC	O
)	O
had	O
been	O
previously	O
described	O
,	O
this	O
region	O
of	O
the	O
ATP7B	O
gene	O
may	O
be	O
susceptible	O
to	O
gene	O
rearrangements	O
causing	O
Wilson	B
disease	I
.	O

Disruption	O
of	O
splicing	O
regulated	O
by	O
a	O
CUG	O
-	O
binding	O
protein	O
in	O
myotonic	B
dystrophy	I
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	B
gene	O
.	O

One	O
model	O
of	O
DM	B
pathogenesis	O
suggests	O
that	O
RNAs	O
from	O
the	O
expanded	O
allele	O
create	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
by	O
the	O
inappropriate	O
binding	O
of	O
proteins	O
to	O
the	O
CUG	O
repeats	O
.	O

Data	O
presented	O
here	O
indicate	O
that	O
the	O
conserved	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
,	O
CUG	O
-	O
binding	O
protein	O
(	O
CUG	O
-	O
BP	O
)	O
,	O
may	O
mediate	O
the	O
trans	O
-	O
dominant	O
effect	O
of	O
the	O
RNA	O
.	O

CUG	O
-	O
BP	O
was	O
found	O
to	O
bind	O
to	O
the	O
human	O
cardiac	O
troponin	O
T	O
(	O
cTNT	O
)	O
pre	O
-	O
messenger	O
RNA	O
and	O
regulate	O
its	O
alternative	O
splicing	O
.	O

Splicing	O
of	O
cTNT	O
was	O
disrupted	O
in	O
DM	B
striated	O
muscle	O
and	O
in	O
normal	O
cells	O
expressing	O
transcripts	O
that	O
contain	O
CUG	O
repeats	O
.	O

Altered	O
expression	O
of	O
genes	O
regulated	O
posttranscriptionally	O
by	O
CUG	O
-	O
BP	O
therefore	O
may	O
contribute	O
to	O
DM	B
pathogenesis	O
..	O

Identification	O
of	O
a	O
novel	O
nonsense	O
mutation	O
and	O
a	O
missense	O
substitution	O
in	O
the	O
vasopressin	O
-	O
neurophysin	O
II	O
gene	O
in	O
two	O
Spanish	O
kindreds	O
with	O
familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
.	O

Familial	B
neurohypophyseal	I
diabetes	I
insipidus	I
(	O
FNDI	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
caused	O
by	O
deficiency	O
in	O
the	O
antidiuretic	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
encoded	O
by	O
the	O
AVP	O
-	O
neurophysin	O
II	O
(	O
AVP	O
-	O
NPII	O
)	O
gene	O
on	O
chromosome	O
20p13	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
two	O
families	O
with	O
FNDI	B
using	O
direct	O
automated	O
fluorescent	O
,	O
solid	O
phase	O
,	O
single	O
-	O
stranded	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
AVP	O
-	O
NPII	O
DNA	O
.	O

In	O
one	O
of	O
the	O
families	O
,	O
affected	O
individuals	O
presented	O
a	O
novel	O
nonsense	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
gene	O
,	O
consisting	O
in	O
a	O
G	O
to	O
T	O
transition	O
at	O
nucleotide	O
2101	O
,	O
which	O
produces	O
a	O
stop	O
signal	O
in	O
codon	O
82	O
(	O
Glu	O
)	O
of	O
NPII	O
.	O

The	O
premature	O
termination	O
eliminates	O
part	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NPII	O
,	O
including	O
a	O
cysteine	O
residue	O
in	O
position	O
85	O
,	O
which	O
could	O
be	O
involved	O
in	O
the	O
correct	O
folding	O
of	O
the	O
prohormone	O
.	O

In	O
the	O
second	O
family	O
,	O
a	O
G279A	O
substitution	O
at	O
position	O
-1	O
of	O
the	O
signal	O
peptide	O
was	O
observed	O
in	O
all	O
affected	O
individuals	O
.	O

This	O
missense	O
mutation	O
,	O
which	O
replaces	O
Ala	O
with	O
Thr	O
,	O
is	O
frequent	O
among	O
FNDI	B
patients	O
and	O
is	O
thought	O
to	O
reduce	O
the	O
efficiency	O
of	O
cleavage	O
by	O
signal	O
peptidases	O
..	O

Genetic	O
heterogeneity	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
due	O
to	O
TWIST	O
and	O
FGFR	O
mutations	O
.	O

Thirty	O
-	O
two	O
unrelated	O
patients	O
with	O
features	O
of	O
Saethre	B
-	I
Chotzen	I
syndrome	I
,	O
a	O
common	O
autosomal	B
dominant	I
condition	I
of	O
craniosynostosis	B
and	O
limb	B
anomalies	I
,	O
were	O
screened	O
for	O
mutations	O
in	O
TWIST	O
,	O
FGFR2	O
,	O
and	O
FGFR3	O
.	O

Nine	O
novel	O
and	O
three	O
recurrent	O
TWIST	O
mutations	O
were	O
found	O
in	O
12	O
families	O
.	O

Seven	O
families	O
were	O
found	O
to	O
have	O
the	O
FGFR3	O
P250R	O
mutation	O
,	O
and	O
one	O
individual	O
was	O
found	O
to	O
have	O
an	O
FGFR2	O
VV269	O
-	O
270	O
deletion	O
.	O

To	O
date	O
,	O
our	O
detection	O
rate	O
for	O
TWIST	O
or	O
FGFR	O
mutations	O
is	O
68	O
%	O
in	O
our	O
Saethre	B
-	I
Chotzen	I
syndrome	I
patients	O
,	O
including	O
our	O
five	O
patients	O
elsewhere	O
reported	O
with	O
TWIST	O
mutations	O
.	O

More	O
than	O
35	O
different	O
TWIST	O
mutations	O
are	O
now	O
known	O
in	O
the	O
literature	O
.	O

The	O
most	O
common	O
phenotypic	O
features	O
,	O
present	O
in	O
more	O
than	O
a	O
third	O
of	O
our	O
patients	O
with	O
TWIST	O
mutations	O
,	O
are	O
coronal	B
synostosis	I
,	O
brachycephaly	B
,	O
low	B
frontal	I
hairline	I
,	O
facial	B
asymmetry	I
,	O
ptosis	B
,	O
hypertelorism	B
,	O
broad	B
great	I
toes	I
,	O
and	O
clinodactyly	B
.	O

Significant	O
intra-	O
and	O
interfamilial	O
phenotypic	O
variability	O
is	O
present	O
for	O
either	O
TWIST	O
mutations	O
or	O
FGFR	O
mutations	O
.	O

The	O
overlap	O
in	O
clinical	O
features	O
and	O
the	O
presence	O
,	O
in	O
the	O
same	O
genes	O
,	O
of	O
mutations	O
for	O
more	O
than	O
one	O
craniosynostotic	B
condition	I
-	O
such	O
as	O
Saethre	B
-	I
Chotzen	I
,	I
Crouzon	I
,	I
and	I
Pfeiffer	I
syndromes	I
-	O
support	O
the	O
hypothesis	O
that	O
TWIST	O
and	O
FGFRs	O
are	O
components	O
of	O
the	O
same	O
molecular	O
pathway	O
involved	O
in	O
the	O
modulation	O
of	O
craniofacial	O
and	O
limb	O
development	O
in	O
humans	O
..	O

Mutation	O
analysis	O
of	O
UBE3A	O
in	O
Angelman	B
syndrome	I
patients	O
.	O

Angelman	B
syndrome	I
(	O
AS	B
)	O
is	O
caused	O
by	O
chromosome	O
15q11-q13	O
deletions	O
of	O
maternal	O
origin	O
,	O
by	O
paternal	O
uniparental	B
disomy	I
(	O
UPD	B
)	O
15	O
,	O
by	O
imprinting	O
defects	O
,	O
and	O
by	O
mutations	O
in	O
the	O
UBE3A	O
gene	O
.	O

UBE3A	O
encodes	O
a	O
ubiquitin	O
-	O
protein	O
ligase	O
and	O
shows	O
brain	O
-	O
specific	O
imprinting	O
.	O

Here	O
we	O
describe	O
UBE3A	O
coding	O
-	O
region	O
mutations	O
detected	O
by	O
SSCP	O
analysis	O
in	O
13	O
AS	B
individuals	O
or	O
families	O
.	O

Two	O
identical	O
de	O
novo	O
5-bp	O
duplications	O
in	O
exon	O
16	O
were	O
found	O
.	O

Among	O
the	O
other	O
11	O
unique	O
mutations	O
,	O
8	O
were	O
small	O
deletions	O
or	O
insertions	O
predicted	O
to	O
cause	O
frameshifts	O
,	O
1	O
was	O
a	O
mutation	O
to	O
a	O
stop	O
codon	O
,	O
1	O
was	O
a	O
missense	O
mutation	O
,	O
and	O
1	O
was	O
predicted	O
to	O
cause	O
insertion	O
of	O
an	O
isoleucine	O
in	O
the	O
hect	O
domain	O
of	O
the	O
UBE3A	O
protein	O
,	O
which	O
functions	O
in	O
E2	O
binding	O
and	O
ubiquitin	O
transfer	O
.	O

Eight	O
of	O
the	O
cases	O
were	O
familial	O
,	O
and	O
five	O
were	O
sporadic	O
.	O

In	O
two	O
familial	O
cases	O
and	O
one	O
sporadic	O
case	O
,	O
mosaicism	O
for	O
UBE3A	O
mutations	O
was	O
detected	O
in	O
the	O
mother	O
of	O
three	O
AS	B
sons	O
,	O
in	O
the	O
maternal	O
grandfather	O
of	O
two	O
AS	B
first	O
cousins	O
,	O
and	O
in	O
the	O
mother	O
of	O
an	O
AS	B
daughter	O
.	O

The	O
frequencies	O
with	O
which	O
we	O
detected	O
mutations	O
were	O
5	O
(	O
14	O
%	O
)	O
of	O
35	O
in	O
sporadic	O
cases	O
and	O
8	O
(	O
80	O
%	O
)	O
of	O
10	O
in	O
familial	O
cases	O
..	O

The	O
hemochromatosis	B
845	O
G-->A	O
and	O
187	O
C-->G	O
mutations	O
:	O
prevalence	O
in	O
non	O
-	O
Caucasian	O
populations	O
.	O

Hemochromatosis	B
,	O
the	O
inherited	B
disorder	I
of	I
iron	I
metabolism	I
,	O
leads	O
,	O
if	O
untreated	O
,	O
to	O
progressive	O
iron	B
overload	I
and	O
premature	B
death	I
.	O

The	O
hemochromatosis	B
gene	O
,	O
HFE	O
,	O
recently	O
has	O
been	O
identified	O
,	O
and	O
characterization	O
of	O
this	O
gene	O
has	O
shown	O
that	O
it	O
contains	O
two	O
mutations	O
that	O
result	O
in	O
amino	O
acid	O
substitutions	O
-	O
cDNA	O
nucleotides	O
845	O
G--	O
>	O
A	O
(	O
C282Y	O
)	O
and	O
187	O
C--	O
>	O
G	O
(	O
H63D	O
)	O
.	O

Although	O
hemochromatosis	B
is	O
common	O
in	O
Caucasians	O
,	O
affecting	O
>	O
=	O
1	O
/	O
300	O
individuals	O
of	O
northern	O
European	O
origin	O
,	O
it	O
has	O
not	O
been	O
recognized	O
in	O
other	O
populations	O
.	O

The	O
present	O
study	O
used	O
PCR	O
and	O
restriction	O
-	O
enzyme	O
digestion	O
to	O
analyze	O
the	O
frequency	O
of	O
the	O
845	O
G--	O
>	O
A	O
and	O
187	O
C--	O
>	O
G	O
mutations	O
in	O
HLA	O
-	O
typed	O
samples	O
from	O
non	O
-	O
Caucasian	O
populations	O
,	O
comprising	O
Australian	O
Aboriginal	O
,	O
Chinese	O
,	O
and	O
Pacific	O
Islanders	O
.	O

Results	O
showed	O
that	O
the	O
845	O
G--	O
>	O
A	O
mutation	O
was	O
present	O
in	O
these	O
populations	O
(	O
allele	O
frequency	O
0	O
.	O
32	O
%	O
)	O
,	O
and	O
,	O
furthermore	O
,	O
it	O
was	O
always	O
seen	O
in	O
conjunction	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
845	O
G--	O
>	O
A	O
may	O
have	O
been	O
introduced	O
into	O
these	O
populations	O
by	O
Caucasian	O
admixture	O
.	O

187	O
C--	O
>	O
G	O
was	O
present	O
at	O
an	O
allele	O
frequency	O
of	O
2	O
.	O
68	O
%	O
in	O
the	O
two	O
populations	O
analyzed	O
(	O
Australian	O
Aboriginal	O
and	O
Chinese	O
)	O
.	O

In	O
the	O
Australian	O
Aboriginal	O
samples	O
,	O
187	O
C--	O
>	O
G	O
was	O
found	O
to	O
be	O
associated	O
with	O
HLA	O
haplotypes	O
common	O
in	O
Caucasians	O
,	O
suggesting	O
that	O
it	O
was	O
introduced	O
by	O
recent	O
admixture	O
.	O

In	O
the	O
Chinese	O
samples	O
analyzed	O
,	O
187	O
C--	O
>	O
G	O
was	O
present	O
in	O
association	O
with	O
a	O
wide	O
variety	O
of	O
HLA	O
haplotypes	O
,	O
showing	O
this	O
mutation	O
to	O
be	O
widespread	O
and	O
likely	O
to	O
predate	O
the	O
more	O
genetically	O
restricted	O
845	O
G--	O
>	O
A	O
mutation	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
.	O

Germ	O
-	O
line	O
mutations	O
of	O
the	O
tumor	B
suppressor	O
APC	O
are	O
implicated	O
in	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
(	O
AAPC	B
)	O
,	O
a	O
variant	O
of	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

AAPC	B
is	O
recognized	O
by	O
the	O
occurrence	O
of	O
<	O
100	O
colonic	B
adenomas	I
and	O
a	O
later	O
onset	O
of	O
colorectal	B
cancer	I
(	O
age	O
>	O
40	O
years	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
AAPC	B
families	O
.	O

By	O
protein	O
-	O
truncation	O
test	O
(	O
PTT	O
)	O
assay	O
,	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	B
gene	O
was	O
screened	O
in	O
affected	O
individuals	O
from	O
11	O
AAPC	B
kindreds	O
,	O
and	O
their	O
phenotypic	O
differences	O
were	O
examined	O
.	O

Five	O
novel	O
germ	O
-	O
line	O
APC	B
mutations	O
were	O
identified	O
in	O
seven	O
kindreds	O
.	O

Mutations	O
were	O
located	O
in	O
three	O
different	O
regions	O
of	O
the	O
APC	B
gene	O
(	O
1	O
)	O
at	O
the	O
5	O
end	O
spanning	O
exons	O
4	O
and	O
5	O
,	O
(	O
2	O
)	O
within	O
exon	O
9	O
,	O
and	O
(	O
3	O
)	O
at	O
the	O
3	O
distal	O
end	O
of	O
the	O
gene	O
.	O

Variability	O
in	O
the	O
number	O
of	O
colorectal	B
adenomas	I
was	O
most	O
apparent	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
and	O
upper	O
-	O
gastrointestinal	O
manifestations	O
were	O
more	O
severe	O
in	O
them	O
.	O

In	O
individuals	O
with	O
mutations	O
in	O
either	O
region	O
2	O
or	O
region	O
3	O
,	O
the	O
average	O
number	O
of	O
adenomas	B
tended	O
to	O
be	O
lower	O
than	O
those	O
in	O
individuals	O
with	O
mutations	O
in	O
region	O
1	O
,	O
although	O
age	O
at	O
diagnosis	O
was	O
similar	O
.	O

In	O
all	O
AAPC	B
kindreds	O
,	O
a	O
predominance	O
of	O
right	O
-	O
sided	O
colorectal	B
adenomas	I
and	O
rectal	B
polyp	I
sparing	O
was	O
observed	O
.	O

No	O
desmoid	B
tumors	I
were	O
found	O
in	O
these	O
kindreds	O
.	O

Our	O
data	O
suggest	O
that	O
,	O
in	O
AAPC	B
families	O
,	O
the	O
location	O
of	O
the	O
APC	B
mutation	O
may	O
partially	O
predict	O
specific	O
phenotypic	O
expression	O
.	O

This	O
should	O
help	O
in	O
the	O
design	O
of	O
tailored	O
clinical	O
-	O
management	O
protocols	O
in	O
this	O
subset	O
of	O
FAP	B
patients	O
..	O

Wilms	B
'	I
tumor	I
1	O
and	O
Dax-1	O
modulate	O
the	O
orphan	O
nuclear	O
receptor	O
SF-1	O
in	O
sex	O
-	O
specific	O
gene	O
expression	O
.	O

Products	O
of	O
steroidogenic	O
factor	O
1	O
(	O
SF-1	O
)	O
and	O
Wilms	B
tumor	I
1	O
(	O
WT1	O
)	O
genes	O
are	O
essential	O
for	O
mammalian	O
gonadogenesis	O
prior	O
to	O
sexual	O
differentiation	O
.	O

In	O
males	O
,	O
SF-1	O
participates	O
in	O
sexual	O
development	O
by	O
regulating	O
expression	O
of	O
the	O
polypeptide	O
hormone	O
Mullerian	O
inhibiting	O
substance	O
(	O
MIS	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
WT1	O
-KTS	O
isoforms	O
associate	O
and	O
synergize	O
with	O
SF-1	O
to	O
promote	O
MIS	O
expression	O
.	O

In	O
contrast	O
,	O
WT1	O
missense	O
mutations	O
,	O
associated	O
with	O
male	B
pseudohermaphroditism	I
in	O
Denys	B
-	I
Drash	I
syndrome	I
,	O
fail	O
to	O
synergize	O
with	O
SF-1	O
.	O

Additionally	O
,	O
the	O
X	O
-	O
linked	O
,	O
candidate	O
dosage	O
-	O
sensitive	O
sex	O
-	O
reversal	O
gene	O
,	O
Dax-1	O
,	O
antagonizes	O
synergy	O
between	O
SF-1	O
and	O
WT1	O
,	O
most	O
likely	O
through	O
a	O
direct	O
interaction	O
with	O
SF-1	O
.	O

We	O
propose	O
that	O
WT1	O
and	O
Dax-1	O
functionally	O
oppose	O
each	O
other	O
in	O
testis	O
development	O
by	O
modulating	O
SF-1-mediated	O
transactivation	O
..	O

A	O
mouse	O
model	O
for	O
Prader	B
-	I
Willi	I
syndrome	I
imprinting	O
-	O
centre	O
mutations	O
.	O

Imprinting	O
in	O
the	O
15q11-q13	O
region	O
involves	O
an	O
imprinting	O
centre	O
(	O
IC	O
)	O
,	O
mapping	O
in	O
part	O
to	O
the	O
promoter	O
and	O
first	O
exon	O
of	O
SNRPN	O
.	O

Deletion	O
of	O
this	O
IC	O
abolishes	O
local	O
paternally	O
derived	O
gene	O
expression	O
and	O
results	O
in	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
have	O
created	O
two	O
deletion	O
mutations	O
in	O
mice	O
to	O
understand	O
PWS	B
and	O
the	O
mechanism	O
of	O
this	O
IC	O
.	O

Mice	O
harbouring	O
an	O
intragenic	O
deletion	O
in	O
Snrpn	O
are	O
phenotypically	O
normal	O
,	O
suggesting	O
that	O
mutations	O
of	O
SNRPN	O
are	O
not	O
sufficient	O
to	O
induce	O
PWS	B
.	O

Mice	O
with	O
a	O
larger	O
deletion	O
involving	O
both	O
Snrpn	O
and	O
the	O
putative	O
PWS	O
-	O
IC	O
lack	O
expression	O
of	O
the	O
imprinted	O
genes	O
Zfp127	O
(	O
mouse	O
homologue	O
of	O
ZNF127	O
)	O
,	O
Ndn	O
and	O
Ipw	O
,	O
and	O
manifest	O
several	O
phenotypes	O
common	O
to	O
PWS	B
infants	O
.	O

These	O
data	O
demonstrate	O
that	O
both	O
the	O
position	O
of	O
the	O
IC	O
and	O
its	O
role	O
in	O
the	O
coordinate	O
expression	O
of	O
genes	O
is	O
conserved	O
between	O
mouse	O
and	O
human	O
,	O
and	O
indicate	O
that	O
the	O
mouse	O
is	O
a	O
suitable	O
model	O
system	O
in	O
which	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
imprinting	O
in	O
this	O
region	O
of	O
the	O
genome	O
..	O

Mutations	O
of	O
the	O
ATM	O
gene	O
detected	O
in	O
Japanese	O
ataxia	B
-	I
telangiectasia	I
patients	O
:	O
possible	O
preponderance	O
of	O
the	O
two	O
founder	O
mutations	O
4612del165	O
and	O
7883del5	O
.	O

The	O
ATM	O
(	O
A	O
-	O
T	O
,	O
mutated	O
)	O
gene	O
on	O
human	O
chromosome	O
11q22	O
.	O

3	O
has	O
recently	O
been	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
the	O
human	O
recessive	B
disease	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
.	O

In	O
order	O
to	O
define	O
the	O
types	O
of	O
disease	O
-	O
causing	O
ATM	O
mutations	O
in	O
Japanese	O
A	B
-	I
T	I
patients	O
as	O
well	O
as	O
to	O
look	O
for	O
possible	O
mutational	O
hotspots	O
,	O
reverse	O
-	O
transcribed	O
RNA	O
derived	O
from	O
ten	O
patients	O
belonging	O
to	O
eight	O
unrelated	O
Japanese	O
A	B
-	I
T	I
families	O
was	O
analyzed	O
for	O
mutations	O
by	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
method	O
.	O

As	O
has	O
been	O
reported	O
by	O
others	O
,	O
mutations	O
that	O
lead	O
to	O
exon	O
skipping	O
or	O
premature	O
protein	O
truncation	O
were	O
also	O
predominant	O
in	O
our	O
mutants	O
.	O

Six	O
different	O
mutations	O
were	O
identified	O
on	O
12	O
of	O
the	O
16	O
alleles	O
examined	O
.	O

Four	O
were	O
deletions	O
involving	O
a	O
loss	O
of	O
a	O
single	O
exon	O
exon	O
7	O
,	O
exon	O
16	O
,	O
exon	O
33	O
or	O
exon	O
35	O
.	O

The	O
others	O
were	O
minute	O
deletions	O
,	O
4649delA	O
in	O
exon	O
33	O
and	O
7883del5	O
in	O
exon	O
55	O
.	O

The	O
mutations	O
4612del165	O
and	O
7883del5	O
were	O
found	O
in	O
more	O
than	O
two	O
unrelated	O
families	O
;	O
44	O
%	O
(	O
7	O
of	O
16	O
)	O
of	O
the	O
mutant	O
alleles	O
had	O
one	O
of	O
the	O
two	O
mutations	O
.	O

The	O
4612del165	O
mutations	O
in	O
three	O
different	O
families	O
were	O
all	O
ascribed	O
to	O
the	O
same	O
T--	O
>	O
A	O
substitution	O
at	O
the	O
splice	O
donor	O
site	O
in	O
intron	O
33	O
.	O

Microsatellite	O
genotyping	O
around	O
the	O
ATM	O
locus	O
also	O
indicated	O
that	O
a	O
common	O
haplotype	O
was	O
shared	O
by	O
the	O
mutant	O
alleles	O
in	O
both	O
mutations	O
.	O

This	O
suggests	O
that	O
these	O
two	O
founder	O
mutations	O
may	O
be	O
predominant	O
among	O
Japanese	O
ATM	O
mutant	O
alleles	O
.	O

W474C	O
amino	O
acid	O
substitution	O
affects	O
early	O
processing	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
and	O
is	O
associated	O
with	O
subacute	O
G	B
(	I
M2	I
)	I
gangliosidosis	I
.	O

Mutations	O
in	O
the	O
HEXA	O
gene	O
,	O
encoding	O
the	O
alpha	O
-	O
subunit	O
of	O
beta	O
-	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
,	O
that	O
abolish	O
Hex	O
A	O
enzyme	O
activity	O
cause	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
,	O
the	O
fatal	O
infantile	B
form	I
of	I
G	I
(	I
M2	I
)	I
gangliosidosis	I
,	I
Type	I
1	I
.	O

Less	O
severe	O
,	O
subacute	O
(	O
juvenile	O
-	O
onset	O
)	O
and	O
chronic	O
(	O
adult	O
-	O
onset	O
)	O
variants	O
are	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
are	O
associated	O
with	O
residual	O
levels	O
of	O
Hex	O
A	O
enzyme	O
activity	O
.	O

We	O
identified	O
a	O
1422	O
G--	O
>	O
C	O
(	O
amino	O
acid	O
W474C	O
)	O
substitution	O
in	O
the	O
first	O
position	O
of	O
exon	O
13	O
of	O
HEXA	O
of	O
a	O
non	O
-	O
Jewish	O
proband	O
who	O
manifested	O
a	O
subacute	O
variant	O
of	O
G	B
(	I
M2	I
)	I
gangliosidosis	I
.	O

On	O
the	O
second	O
maternally	O
inherited	O
allele	O
,	O
we	O
identified	O
the	O
common	O
infantile	O
disease	O
-	O
causing	O
4-bp	O
insertion	O
,	O
+	O
TATC	O
1278	O
,	O
in	O
exon	O
11	O
.	O

Pulse	O
-	O
chase	O
analysis	O
using	O
proband	O
fibroblasts	O
revealed	O
that	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
precursor	O
was	O
normally	O
synthesized	O
,	O
but	O
not	O
phosphorylated	O
or	O
secreted	O
,	O
and	O
the	O
mature	O
lysosomal	O
alpha	O
-	O
subunit	O
was	O
not	O
detected	O
.	O

When	O
the	O
W474C	O
-	O
containing	O
alpha	O
-	O
subunit	O
was	O
transiently	O
co	O
-	O
expressed	O
with	O
the	O
beta	O
-	O
subunit	O
to	O
produce	O
Hex	O
A	O
(	O
alphabeta	O
)	O
in	O
COS-7	O
cells	O
,	O
the	O
mature	O
alpha	O
-	O
subunit	O
was	O
present	O
,	O
but	O
its	O
level	O
was	O
much	O
lower	O
than	O
that	O
from	O
normal	O
alpha	O
-	O
subunit	O
transfections	O
,	O
although	O
higher	O
than	O
in	O
those	O
cells	O
transfected	O
with	O
an	O
alpha	O
-	O
subunit	O
associated	O
with	O
infantile	O
TSD	B
.	O

Furthermore	O
,	O
the	O
precursor	O
level	O
of	O
the	O
W474C	O
alpha	O
-	O
subunit	O
was	O
found	O
to	O
accumulate	O
in	O
comparison	O
to	O
the	O
normal	O
alpha	O
-	O
subunit	O
precursor	O
levels	O
.	O

We	O
conclude	O
that	O
the	O
1422	O
G--	O
>	O
C	O
mutation	O
is	O
the	O
cause	O
of	O
Hex	B
A	I
enzyme	I
deficiency	I
in	O
the	O
proband	O
.	O

The	O
resulting	O
W474C	O
substitution	O
clearly	O
interferes	O
with	O
alpha	O
-	O
subunit	O
processing	O
,	O
but	O
because	O
the	O
base	O
substitution	O
falls	O
at	O
the	O
first	O
position	O
of	O
exon	O
13	O
,	O
aberrant	O
splicing	O
may	O
also	O
contribute	O
to	O
Hex	B
A	I
deficiency	I
in	O
this	O
proband	O
..	O

Two	O
frequent	O
missense	O
mutations	O
in	O
Pendred	B
syndrome	I
.	O

Pendred	B
syndrome	I
is	O
an	O
autosomal	B
recessive	I
disorder	I
characterized	O
by	O
early	O
childhood	O
deafness	B
and	O
goiter	B
.	O

A	O
century	O
after	O
its	O
recognition	O
as	O
a	O
syndrome	O
by	O
Vaughan	O
Pendred	O
,	O
the	O
disease	O
gene	O
(	O
PDS	O
)	O
was	O
mapped	O
to	O
chromosome	O
7q22-q31	O
.	O

1	O
and	O
,	O
recently	O
,	O
found	O
to	O
encode	O
a	O
putative	O
sulfate	O
transporter	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
PDS	B
gene	O
in	O
patients	O
from	O
14	O
Pendred	B
families	O
originating	O
from	O
seven	O
countries	O
and	O
identified	O
all	O
mutations	O
.	O

The	O
mutations	O
include	O
three	O
single	O
base	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O
10	O
missense	O
mutations	O
.	O

One	O
missense	O
mutation	O
(	O
L236P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
two	O
consanguineous	O
families	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
five	O
additional	O
non	O
-	O
consanguineous	O
families	O
.	O

Another	O
missense	O
mutation	O
(	O
T416P	O
)	O
was	O
found	O
in	O
a	O
homozygous	O
state	O
in	O
one	O
family	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
four	O
families	O
.	O

Pendred	B
patients	O
in	O
three	O
non	O
-	O
consanguineous	O
families	O
were	O
shown	O
to	O
be	O
compound	O
heterozygotes	O
for	O
L236P	O
and	O
T416P	O
.	O

In	O
total	O
,	O
one	O
or	O
both	O
of	O
these	O
mutations	O
were	O
found	O
in	O
nine	O
of	O
the	O
14	O
families	O
analyzed	O
.	O

The	O
identification	O
of	O
two	O
frequent	O
PDS	B
mutations	O
will	O
facilitate	O
the	O
molecular	O
diagnosis	O
of	O
Pendred	B
syndrome	I
.	O

Insertional	O
mutation	O
by	O
transposable	O
element	O
,	O
L1	O
,	O
in	O
the	O
DMD	B
gene	O
results	O
in	O
X	B
-	I
linked	I
dilated	I
cardiomyopathy	I
.	O

X	B
-	I
linked	I
dilated	I
cardiomyopathy	I
(	O
XLDCM	B
)	O
is	O
a	O
clinical	O
phenotype	O
of	O
dystrophinopathy	B
which	O
is	O
characterized	O
by	O
preferential	O
myocardial	B
involvement	I
without	O
any	O
overt	O
clinical	O
signs	O
of	O
skeletal	B
myopathy	I
.	O

To	O
date	O
,	O
several	O
mutations	O
in	O
the	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
,	O
DMD	O
,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
XLDCM	B
,	O
but	O
a	O
pathogenic	O
correlation	O
of	O
these	O
cardiospecific	O
mutations	O
in	O
DMD	O
with	O
the	O
XLDCM	B
phenotype	O
has	O
remained	O
to	O
be	O
elucidated	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
unique	O
de	O
novo	O
L1	O
insertion	O
in	O
the	O
muscle	O
exon	O
1	O
in	O
DMD	O
in	O
three	O
XLDCM	B
patients	O
from	O
two	O
unrelated	O
Japanese	O
families	O
.	O

The	O
insertion	O
was	O
a	O
5-truncated	O
form	O
of	O
human	O
L1	O
inversely	O
integrated	O
in	O
the	O
5-untranslated	O
region	O
in	O
the	O
muscle	O
exon	O
1	O
,	O
which	O
affected	O
the	O
transcription	O
or	O
the	O
stability	O
of	O
the	O
muscle	O
form	O
of	O
dystrophin	O
transcripts	O
but	O
not	O
that	O
of	O
the	O
brain	O
or	O
Purkinje	O
cell	O
form	O
,	O
probably	O
due	O
to	O
its	O
unique	O
site	O
of	O
integration	O
.	O

We	O
speculate	O
that	O
this	O
insertion	O
of	O
an	O
L1	O
sequence	O
in	O
DMD	O
is	O
responsible	O
for	O
some	O
of	O
the	O
population	O
of	O
Japanese	O
patients	O
with	O
XLDCM	B
..	O

Severe	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
caused	O
by	O
POMC	O
mutations	O
in	O
humans	O
.	O

Sequential	O
cleavage	O
of	O
the	O
precursor	O
protein	O
pre	O
-	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
generates	O
the	O
melanocortin	O
peptides	O
adrenocorticotrophin	O
(	O
ACTH	O
)	O
,	O
melanocyte	O
-	O
stimulating	O
hormones	O
(	O
MSH	O
)	O
alpha	O
,	O
beta	O
and	O
gamma	O
as	O
well	O
as	O
the	O
opioid	O
-	O
receptor	O
ligand	O
beta	O
-	O
endorphin	O
.	O

While	O
a	O
few	O
cases	O
of	O
isolated	O
ACTH	B
deficiency	I
have	O
been	O
reported	O
(	O
OMIM	O
201400	O
)	O
,	O
an	O
inherited	O
POMC	O
defect	O
has	O
not	O
been	O
described	O
so	O
far	O
.	O

Recent	O
studies	O
in	O
animal	O
models	O
elucidated	O
a	O
central	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
the	O
regulation	O
of	O
food	O
intake	O
by	O
activation	O
of	O
the	O
brain	O
melanocortin-4-receptor	O
(	O
MC4-R	O
;	O
refs	O
3	O
-	O
5	O
)	O
and	O
the	O
linkage	O
of	O
human	O
obesity	B
to	O
chromosome	O
2	O
in	O
close	O
proximity	O
to	O
the	O
POMC	O
locus	O
,	O
led	O
to	O
the	O
proposal	O
of	O
an	O
association	O
of	O
POMC	O
with	O
human	O
obesity	B
.	O

The	O
dual	O
role	O
of	O
alpha	O
-	O
MSH	O
in	O
regulating	O
food	O
intake	O
and	O
influencing	O
hair	O
pigmentation	O
predicts	O
that	O
the	O
phenotype	O
associated	O
with	O
a	O
defect	O
in	O
POMC	O
function	O
would	O
include	O
obesity	B
,	O
alteration	O
in	O
pigmentation	O
and	O
ACTH	B
deficiency	I
.	O

The	O
observation	O
of	O
these	O
symptoms	O
in	O
two	O
probands	O
prompted	O
us	O
to	O
search	O
for	O
mutations	O
within	O
their	O
POMC	O
genes	O
.	O

Patient	O
1	O
was	O
found	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
exon	O
3	O
(	O
G7013	O
T	O
,	O
C7133delta	O
)	O
which	O
interfere	O
with	O
appropriate	O
synthesis	O
of	O
ACTH	O
and	O
alpha	O
-	O
MSH	O
.	O

Patient	O
2	O
was	O
homozygous	O
for	O
a	O
mutation	O
in	O
exon	O
2	O
(	O
C3804A	O
)	O
which	O
abolishes	O
POMC	O
translation	O
.	O

These	O
findings	O
represent	O
the	O
first	O
examples	O
of	O
a	O
genetic	B
defect	I
within	O
the	O
POMC	O
gene	O
and	O
define	O
a	O
new	O
monogenic	B
endocrine	I
disorder	I
resulting	O
in	O
early	O
-	O
onset	O
obesity	B
,	O
adrenal	B
insufficiency	I
and	O
red	O
hair	O
pigmentation	O
..	O

A	O
European	O
multicenter	O
study	O
of	O
phenylalanine	B
hydroxylase	I
deficiency	I
:	O
classification	O
of	O
105	O
mutations	O
and	O
a	O
general	O
system	O
for	O
genotype	O
-	O
based	O
prediction	O
of	O
metabolic	O
phenotype	O
.	O

Phenylketonuria	B
(	O
PKU	B
)	O
and	O
mild	B
hyperphenylalaninemia	I
(	O
MHP	B
)	O
are	O
allelic	B
disorders	I
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
PAH	B
deficiency	I
correlate	O
with	O
PAH	O
genotypes	O
.	O

We	O
identified	O
both	O
causative	O
mutations	O
in	O
686	O
patients	O
from	O
seven	O
European	O
centers	O
.	O

On	O
the	O
basis	O
of	O
the	O
phenotypic	O
characteristics	O
of	O
297	O
functionally	O
hemizygous	O
patients	O
,	O
105	O
of	O
the	O
mutations	O
were	O
assigned	O
to	O
one	O
of	O
four	O
arbitrary	O
phenotype	O
categories	O
.	O

We	O
proposed	O
and	O
tested	O
a	O
simple	O
model	O
for	O
correlation	O
between	O
genotype	O
and	O
phenotypic	O
outcome	O
.	O

The	O
observed	O
phenotype	O
matched	O
the	O
predicted	O
phenotype	O
in	O
79	O
%	O
of	O
the	O
cases	O
,	O
and	O
in	O
only	O
5	O
of	O
184	O
patients	O
was	O
the	O
observed	O
phenotype	O
more	O
than	O
one	O
category	O
away	O
from	O
that	O
expected	O
.	O

Among	O
the	O
seven	O
contributing	O
centers	O
,	O
the	O
proportion	O
of	O
patients	O
for	O
whom	O
the	O
observed	O
phenotype	O
did	O
not	O
match	O
the	O
predicted	O
phenotype	O
was	O
4	O
%	O
-23	O
%	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
suggesting	O
that	O
differences	O
in	O
methods	O
used	O
for	O
mutation	O
detection	O
or	O
phenotype	O
classification	O
may	O
account	O
for	O
a	O
considerable	O
proportion	O
of	O
genotype	O
-	O
phenotype	O
inconsistencies	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
PAH	O
-	O
mutation	O
genotype	O
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
PAH	B
deficiency	I
.	O

In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
PAH	O
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia	B
in	O
newborns	O
.	O

Somatic	O
instability	O
of	O
the	O
CTG	O
repeat	O
in	O
mice	O
transgenic	O
for	O
the	O
myotonic	B
dystrophy	I
region	O
is	O
age	O
dependent	O
but	O
not	O
correlated	O
to	O
the	O
relative	O
intertissue	O
transcription	O
levels	O
and	O
proliferative	O
capacities	O
.	O

A	O
(	O
CTG	O
)	O
nexpansion	O
in	O
the	O
3-untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DM	O
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
is	O
responsible	O
for	O
causing	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
.	O

Major	O
instability	O
,	O
with	O
very	O
large	O
expansions	O
between	O
generations	O
and	O
high	O
levels	O
of	O
somatic	O
mosaicism	O
,	O
is	O
observed	O
in	O
patients	O
.	O

There	O
is	O
a	O
good	O
correlation	O
between	O
repeat	O
size	O
(	O
at	O
least	O
in	O
leucocytes	O
)	O
,	O
clinical	O
severity	O
and	O
age	O
of	O
onset	O
.	O

The	O
trinucleotide	O
repeat	O
instability	O
mechanisms	O
involved	O
in	O
DM	B
and	O
other	O
human	O
genetic	B
diseases	I
are	O
unknown	O
.	O

We	O
studied	O
somatic	O
instability	O
by	O
measuring	O
the	O
CTG	O
repeat	O
length	O
at	O
several	O
ages	O
in	O
various	O
tissues	O
of	O
transgenic	O
mice	O
carrying	O
a	O
(	O
CTG	O
)	O
55expansion	O
surrounded	O
by	O
45	O
kb	O
of	O
the	O
human	O
DM	B
region	O
,	O
using	O
small	O
-	O
pool	O
PCR	O
.	O

These	O
mice	O
have	O
been	O
shown	O
to	O
reproduce	O
the	O
intergenerational	O
and	O
somatic	O
instability	O
of	O
the	O
55	O
CTG	O
repeat	O
suggesting	O
that	O
surrounding	O
sequences	O
and	O
the	O
chromatin	O
environment	O
are	O
involved	O
in	O
instability	O
mechanisms	O
.	O

As	O
observed	O
in	O
some	O
of	O
the	O
tissues	O
of	O
DM	B
patients	O
,	O
there	O
is	O
a	O
tendency	O
for	O
repeat	O
length	O
and	O
somatic	O
mosaicism	O
to	O
increase	O
with	O
the	O
age	O
of	O
the	O
mouse	O
.	O

Furthermore	O
,	O
we	O
observed	O
no	O
correlation	O
between	O
the	O
somatic	O
mutation	O
rate	O
and	O
tissue	O
proliferation	O
capacity	O
.	O

The	O
somatic	O
mutation	O
rates	O
in	O
different	O
tissues	O
were	O
also	O
not	O
correlated	O
to	O
the	O
relative	O
inter	O
-	O
tissue	O
difference	O
in	O
transcriptional	O
levels	O
of	O
the	O
three	O
genes	O
(	O
DMAHP	O
,	O
DMPK	O
and	O
59	O
)	O
surrounding	O
the	O
repeat	O
..	O

A	O
novel	O
missense	O
mutation	O
in	O
patients	O
from	O
a	O
retinoblastoma	B
pedigree	O
showing	O
only	O
mild	O
expression	O
of	O
the	O
tumor	B
phenotype	O
.	O

We	O
have	O
used	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
study	O
the	O
27	O
exons	O
of	O
the	O
RB1	O
gene	O
in	O
individuals	O
from	O
a	O
family	O
showing	O
mild	O
expression	O
of	O
the	O
retinoblastoma	B
phenotype	O
.	O

In	O
this	O
family	O
affected	O
individuals	O
developed	O
unilateral	B
tumors	I
and	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
,	O
unaffected	O
mutation	O
carriers	O
were	O
also	O
identified	O
within	O
the	O
pedigree	O
.	O

A	O
single	O
band	O
shift	O
using	O
SSCP	O
was	O
identified	O
in	O
exon	O
21	O
which	O
resulted	O
in	O
a	O
missense	O
mutation	O
converting	O
a	O
cys--	O
>	O
arg	O
at	O
nucleotide	O
position	O
28	O
in	O
the	O
exon	O
.	O

The	O
mutation	O
destroyed	O
an	O
NdeI	O
restriction	O
enzyme	O
site	O
.	O

Analysis	O
of	O
all	O
family	O
members	O
demonstrated	O
that	O
the	O
missense	O
mutation	O
co	O
-	O
segregated	O
with	O
patients	O
with	O
tumors	B
or	O
who	O
,	O
as	O
a	O
result	O
of	O
linkage	O
analysis	O
had	O
been	O
predicted	O
to	O
carry	O
the	O
predisposing	O
mutation	O
.	O

These	O
observations	O
point	O
to	O
another	O
region	O
of	O
the	O
RB1	O
gene	O
where	O
mutations	O
only	O
modify	O
the	O
function	O
of	O
the	O
gene	O
and	O
raise	O
important	O
questions	O
for	O
genetic	O
counseling	O
in	O
families	O
with	O
these	O
distinctive	O
phenotypes	O
..	O

Maternal	B
disomy	I
and	O
Prader	B
-	I
Willi	I
syndrome	I
consistent	O
with	O
gamete	O
complementation	O
in	O
a	O
case	O
of	O
familial	O
translocation	O
(	O
3;15	O
)	O
(	O
p25;q11.2	O
)	O
.	O

Maternal	B
uniparental	I
disomy	I
(	I
UPD	I
)	I
for	I
chromosome	I
15	I
is	O
responsible	O
for	O
an	O
estimated	O
30	O
%	O
of	O
cases	O
of	O
Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
.	O

We	O
report	O
on	O
an	O
unusual	O
case	O
of	O
maternal	B
disomy	I
15	I
in	O
PWS	B
that	O
is	O
most	O
consistent	O
with	O
adjacent-1	O
segregation	O
of	O
a	O
paternal	O
t	O
(	O
3	O
;	O
15	O
)	O
(	O
p25	O
;	O
q11	O
.	O

2	O
)	O
with	O
simultaneous	O
maternal	O
meiotic	O
nondisjunction	O
for	O
chromosome	O
15	O
.	O

The	O
patient	O
(	O
J.	O
B.	O
)	O
,	O
a	O
17-year	O
-	O
old	O
white	O
male	O
with	O
PWS	B
,	O
was	O
found	O
to	O
have	O
47	O
chromosomes	O
with	O
a	O
supernumerary	O
,	O
paternal	O
der	O
(	O
15	O
)	O
consisting	O
of	O
the	O
short	O
arm	O
and	O
the	O
proximal	O
long	O
arm	O
of	O
chromosome	O
15	O
,	O
and	O
distal	O
chromosome	O
arm	O
3p	O
.	O

The	O
t	O
(	O
3	O
;	O
15	O
)	O
was	O
present	O
in	O
the	O
balanced	O
state	O
in	O
the	O
patients	O
father	O
and	O
a	O
sister	O
.	O

Fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
the	O
PWS	B
critical	O
region	O
resided	O
on	O
the	O
derivative	O
chromosome	O
3	O
and	O
that	O
there	O
was	O
no	O
deletion	O
of	O
the	O
PWS	B
region	O
on	O
the	O
normal	O
pair	O
of	O
15s	O
present	O
in	O
J.	O
B.	O
Methylation	O
analysis	O
at	O
exon	O
alpha	O
of	O
the	O
small	O
nuclear	O
ribonucleoprotein	O
-	O
associated	O
polypeptide	O
N	O
(	O
SNRPN	O
)	O
gene	O
showed	O
a	O
pattern	O
characteristic	O
of	O
only	O
the	O
maternal	O
chromosome	O
15	O
in	O
J.	O
B.	O
Maternal	B
disomy	I
was	O
confirmed	O
by	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
microsatellite	O
repeats	O
at	O
the	O
gamma	O
-	O
aminobutyric	O
acid	O
receptor	O
beta3	O
subunit	O
(	O
GABRB3	O
)	O
locus	O
.	O

A	O
niece	O
(	O
B.	O
B.	O
)	O
with	O
45	O
chromosomes	O
and	O
the	O
derivative	O
3	O
but	O
without	O
the	O
der	O
(	O
15	O
)	O
demonstrated	O
a	O
phenotype	O
consistent	O
with	O
that	O
reported	O
for	O
haploinsufficiency	O
of	O
distal	O
3	O
p.	O
Uniparental	B
disomy	I
associated	O
with	O
unbalanced	O
segregation	O
of	O
non	O
-	O
Robertsonian	O
translocations	O
has	O
been	O
reported	O
previously	O
but	O
has	O
not	O
,	O
to	O
our	O
knowledge	O
,	O
been	O
observed	O
in	O
a	O
case	O
of	O
PWS	B
.	O

Furthermore	O
,	O
our	O
findings	O
are	O
best	O
interpreted	O
as	O
true	O
gamete	O
complementation	O
resulting	O
in	O
maternal	B
UPD	I
15	I
and	O
PWS	B

Schwartz	B
-	I
Jampel	I
syndrome	I
type	I
2	I
and	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
:	O
a	O
case	O
for	O
""""	O
lumping	O
""""	O
.	O

Recent	O
studies	O
demonstrated	O
the	O
existence	O
of	O
a	O
genetically	O
distinct	O
,	O
usually	O
lethal	O
form	O
of	O
the	O
Schwartz	B
-	I
Jampel	I
syndrome	I
(	O
SJS	B
)	O
of	O
myotonia	B
and	O
skeletal	B
dysplasia	I
,	O
which	O
we	O
called	O
SJS	B
type	I
2	I
.	O

This	O
disorder	O
is	O
reminiscent	O
of	O
another	O
rare	O
condition	O
,	O
the	O
Stuve	B
-	I
Wiedemann	I
syndrome	I
(	O
SWS	B
)	O
,	O
which	O
comprises	O
campomelia	B
at	O
birth	O
with	O
skeletal	B
dysplasia	I
,	O
contractures	B
,	O
and	O
early	B
death	I
.	O

To	O
test	O
for	O
possible	O
nosologic	O
identity	O
between	O
these	O
disorders	O
,	O
we	O
reviewed	O
the	O
literature	O
and	O
obtained	O
a	O
follow	O
-	O
up	O
of	O
the	O
only	O
two	O
surviving	O
patients	O
,	O
one	O
with	O
SJS	B
type	I
2	I
at	O
age	O
10	O
years	O
and	O
another	O
with	O
SWS	B
at	O
age	O
7	O
years	O
.	O

Patients	O
reported	O
as	O
having	O
either	O
neonatal	O
SJS	B
or	O
SWS	B
presented	O
a	O
combination	O
of	O
a	O
severe	O
,	O
prenatal	O
-	O
onset	O
neuromuscular	B
disorder	I
(	O
with	O
congenital	B
joint	I
contractures	I
,	O
respiratory	O
and	O
feeding	O
difficulties	O
,	O
tendency	O
to	O
hyperthermia	B
,	O
and	O
frequent	O
death	O
in	O
infancy	O
)	O
with	O
a	O
distinct	O
campomelic	B
-	I
metaphyseal	I
skeletal	I
dysplasia	I
.	O

The	O
similarity	O
of	O
the	O
clinical	O
and	O
radiographic	O
findings	O
is	O
so	O
extensive	O
that	O
these	O
disorders	O
appear	O
to	O
be	O
a	O
single	O
entity	O
.	O

The	O
follow	O
-	O
up	O
observation	O
of	O
an	O
identical	O
and	O
unique	O
pattern	O
of	O
progressive	O
bone	B
dysplasia	I
in	O
the	O
two	O
patients	O
(	O
one	O
with	O
SJS	B
type	I
2	I
,	O
one	O
with	O
SWS	B
)	O
surviving	O
beyond	O
infancy	O
adds	O
to	O
the	O
evidence	O
in	O
favor	O
of	O
identity	O
.	O

The	O
hypothesis	O
that	O
SWS	B
and	O
SJS	B
type	I
2	I
are	O
the	O
same	O
disorder	O
should	O
be	O
testable	O
by	O
molecular	O
methods	O
..	O

A	O
mouse	O
model	O
of	O
severe	O
von	B
Willebrand	I
disease	I
:	O
defects	O
in	O
hemostasis	O
and	O
thrombosis	B
.	O

von	B
Willebrand	I
factor	I
(	I
vWf	I
)	I
deficiency	I
causes	O
severe	O
von	B
Willebrand	I
disease	I
in	O
humans	O
.	O

We	O
generated	O
a	O
mouse	O
model	O
for	O
this	O
disease	O
by	O
using	O
gene	O
targeting	O
.	O

vWf	B
-	I
deficient	I
mice	O
appeared	O
normal	O
at	O
birth	O
;	O
they	O
were	O
viable	O
and	O
fertile	O
.	O

Neither	O
vWf	O
nor	O
vWf	O
propolypeptide	O
(	O
von	B
Willebrand	I
antigen	O
II	O
)	O
were	O
detectable	O
in	O
plasma	O
,	O
platelets	O
,	O
or	O
endothelial	O
cells	O
of	O
the	O
homozygous	O
mutant	O
mice	O
.	O

The	O
mutant	O
mice	O
exhibited	O
defects	O
in	O
hemostasis	O
with	O
a	O
highly	O
prolonged	O
bleeding	O
time	O
and	O
spontaneous	O
bleeding	O
events	O
in	O
approximately	O
10	O
%	O
of	O
neonates	O
.	O

As	O
in	O
the	O
human	O
disease	O
,	O
the	O
factor	O
VIII	O
level	O
in	O
these	O
mice	O
was	O
reduced	O
strongly	O
as	O
a	O
result	O
of	O
the	O
lack	O
of	O
protection	O
provided	O
by	O
vWf	O
.	O

Defective	O
thrombosis	B
in	O
mutant	O
mice	O
was	O
also	O
evident	O
in	O
an	O
in	O
vivo	O
model	O
of	O
vascular	B
injury	I
.	O

In	O
this	O
model	O
,	O
the	O
exteriorized	O
mesentery	O
was	O
superfused	O
with	O
ferric	O
chloride	O
and	O
the	O
accumulation	O
of	O
fluorescently	O
labeled	O
platelets	O
was	O
observed	O
by	O
intravital	O
microscopy	O
.	O

We	O
conclude	O
that	O
these	O
mice	O
very	O
closely	O
mimic	O
severe	O
human	O
von	B
Willebrand	I
disease	I
and	O
will	O
be	O
very	O
useful	O
for	O
investigating	O
the	O
role	O
of	O
vWf	O
in	O
normal	O
physiology	O
and	O
in	O
disease	O
models	O
..	O

Oral	O
contraceptives	O
and	O
the	O
risk	O
of	O
hereditary	B
ovarian	I
cancer	I
.	O

Hereditary	B
Ovarian	I
Cancer	I
Clinical	O
Study	O
Group	O
.	O

BACKGROUND	O
Women	O
with	O
mutations	O
in	O
either	O
the	O
BRCA1	O
or	O
the	O
BRCA2	O
gene	O
have	O
a	O
high	O
lifetime	O
risk	O
of	O
ovarian	B
cancer	I
.	O

Oral	O
contraceptives	O
protect	O
against	O
ovarian	B
cancer	I
in	O
general	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
they	O
also	O
protect	O
against	O
hereditary	B
forms	I
of	I
ovarian	I
cancer	I
.	O

METHODS	O
We	O
enrolled	O
207	O
women	O
with	O
hereditary	B
ovarian	I
cancer	I
and	O
161	O
of	O
their	O
sisters	O
as	O
controls	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

All	O
the	O
patients	O
carried	O
a	O
pathogenic	O
mutation	O
in	O
either	O
BRCA1	O
(	O
179	O
women	O
)	O
or	O
BRCA2	O
(	O
28	O
women	O
)	O
.	O

The	O
control	O
women	O
were	O
enrolled	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
had	O
either	O
mutation	O
.	O

Lifetime	O
histories	O
of	O
oral	O
-	O
contraceptive	O
use	O
were	O
obtained	O
by	O
interview	O
or	O
by	O
written	O
questionnaire	O
and	O
were	O
compared	O
between	O
patients	O
and	O
control	O
women	O
,	O
after	O
adjustment	O
for	O
year	O
of	O
birth	O
and	O
parity	O
.	O

RESULTS	O
The	O
adjusted	O
odds	O
ratio	O
for	O
ovarian	B
cancer	I
associated	O
with	O
any	O
past	O
use	O
of	O
oral	O
contraceptives	O
was	O
0	O
.	O
5	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O

8)	O
.	O

The	O
risk	O
decreased	O
with	O
increasing	O
duration	O
of	O
use	O
(	O
P	O
for	O
trend	O
,	O
<	O
0	O
.	O
001	O
)	O
;	O
use	O
for	O
six	O
or	O
more	O
years	O
was	O
associated	O
with	O
a	O
60	O
percent	O
reduction	O
in	O
risk	O
.	O

Oral	O
-	O
contraceptive	O
use	O
protected	O
against	O
ovarian	B
cancer	I
both	O
for	O
carriers	O
of	O
the	O
BRCA1	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
5	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
3	O
to	O
0	O
.	O
9	O
)	O
and	O
for	O
carriers	O
of	O
the	O
BRCA2	O
mutation	O
(	O
odds	O
ratio	O
,	O
0	O
.	O
4	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0	O
.	O
2	O
to	O
1	O
.	O
1	O
)	O
.	O

CONCLUSIONS	O
Oral	O
-	O
contraceptive	O
use	O
may	O
reduce	O
the	O
risk	O
of	O
ovarian	B
cancer	I
in	O
women	O
with	O
pathogenic	O
mutations	O
in	O
the	O
BRCA1	O
or	O
BRCA2	O
gene	O

A	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
with	O
a	O
codon	O
291	O
deletion	O
:	O
a	O
clinical	O
,	O
biochemical	O
,	O
pathological	O
,	O
and	O
genetic	O
report	O
.	O

We	O
report	O
a	O
Japanese	O
family	O
with	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
with	O
a	O
three	O
base	O
pair	O
deletion	O
(	O
delGAG	O
291	O
)	O
in	O
the	O
ALD	B
gene	O
.	O

A	O
variety	O
of	O
phenotypes	O
were	O
observed	O
within	O
this	O
family	O
.	O

While	O
the	O
proband	O
(	O
patient	O
1	O
)	O
was	O
classified	O
as	O
having	O
a	O
rare	O
intermediate	O
type	O
of	O
adult	O
cerebral	O
and	O
cerebello	O
-	O
brain	O
stem	O
forms	O
,	O
his	O
younger	O
brother	O
(	O
patient	O
2	O
)	O
and	O
nephew	O
(	O
patient	O
3	O
)	O
had	O
a	O
childhood	O
ALD	B
type	O
.	O

Another	O
nephew	O
(	O
patient	O
4	O
)	O
of	O
patient	O
1	O
was	O
classified	O
as	O
having	O
an	O
adolescent	O
form	O
.	O

The	O
tau	O
level	O
in	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
in	O
patient	O
1	O
was	O
as	O
high	O
as	O
that	O
of	O
patients	O
with	O
Alzheimers	B
disease	I
(	O
AD	B
)	O
.	O

His	O
brain	O
magnetic	O
resonance	O
image	O
(	O
MRI	O
)	O
showed	O
abnormalities	B
in	I
the	I
bilateral	I
cerebellar	I
hemispheres	I
and	O
brain	O
stem	O
,	O
but	O
not	O
in	O
the	O
cerebral	O
white	O
matter	O
,	O
where	O
marked	O
reductions	O
of	O
the	O
cerebral	O
blood	O
flow	O
and	O
oxygen	O
metabolism	O
were	O
clearly	O
demonstrated	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

In	O
patients	O
2	O
and	O
3	O
,	O
the	O
autopsy	O
findings	O
showed	O
massive	O
demyelination	B
of	I
the	I
cerebral	I
white	I
matter	I
with	O
sparing	O
of	O
the	O
U	O
-	O
fibers	O
,	O
compatible	O
with	O
the	O
findings	O
of	O
childhood	O
ALD	B
.	O

Oleic	O
and	O
erucic	O
acids	O
(	O
Lorenzos	O
Oil	O
)	O
were	O
administered	O
to	O
patients	O
1	O
and	O
4	O
,	O
but	O
sufficient	O
effectiveness	O
was	O
not	O
obtained	O
.	O

The	O
findings	O
in	O
this	O
family	O
suggest	O
that	O
delGAG291	O
is	O
part	O
of	O
the	O
cause	O
of	O
Japanese	O
ALD	B
with	O
phenotypic	O
variations	O
.	O

Moreover	O
,	O
although	O
the	O
scale	O
of	O
the	O
study	O
is	O
limited	O
,	O
there	O
is	O
a	O
possibility	O
that	O
PET	O
can	O
detect	O
an	O
insidious	B
lesion	I
which	O
is	O
undetectable	O
by	O
computed	O
tomogram	O
(	O
CT	O
)	O
or	O
MRI	O
analysis	O
,	O
and	O
that	O
the	O
higher	O
level	O
of	O
tau	O
reflects	O
the	O
process	O
of	O
neuronal	B
degeneration	I
in	O
ALD	B
.	O

Lorenzos	O
Oil	O
should	O
be	O
given	O
in	O
the	O
early	O
stage	O
..	O

Nonsense	O
mutation	O
in	O
exon	O
4	O
of	O
human	O
complement	O
C9	O
gene	O
is	O
the	O
major	O
cause	O
of	O
Japanese	O
complement	B
C9	I
deficiency	I
.	O

Deficiency	B
of	I
the	I
ninth	I
component	I
of	I
human	I
complement	I
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B
deficiency	I
in	O
Japan	O
but	O
is	O
rare	O
in	O
other	O
countries	O
.	O

We	O
studied	O
the	O
molecular	O
basis	O
of	O
C9	B
deficiency	I
in	O
four	O
Japanese	O
C9-deficient	B
patients	O
who	O
had	O
suffered	O
from	O
meningococcal	B
meningitis	I
.	O

Direct	O
sequencing	O
of	O
amplified	O
C9	O
cDNA	O
and	O
DNA	O
revealed	O
a	O
nonsense	O
substitution	O
(	O
CGA--	O
>	O
TGA	O
)	O
at	O
codon	O
95	O
in	O
exon	O
4	O
in	O
the	O
four	O
C9-deficient	B
individuals	O
.	O

An	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
indicated	O
that	O
all	O
the	O
four	O
patients	O
were	O
homozygous	O
for	O
the	O
mutation	O
in	O
exon	O
4	O
and	O
that	O
the	O
parents	O
of	O
patient	O
2	O
were	O
heterozygous	O
.	O

The	O
common	O
mutation	O
at	O
codon	O
95	O
in	O
exon	O
4	O
might	O
be	O
responsible	O
for	O
most	O
Japanese	O
C9	B
deficiency	I
..	O

BRCA1	O
required	O
for	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
.	O

The	O
breast	B
and	I
ovarian	I
cancer	I
susceptibility	O
gene	O
BRCA1	O
encodes	O
a	O
zinc	O
finger	O
protein	O
of	O
unknown	O
function	O
.	O

Association	O
of	O
the	O
BRCA1	O
protein	O
with	O
the	O
DNA	O
repair	O
protein	O
Rad51	O
and	O
changes	O
in	O
the	O
phosphorylation	O
and	O
cellular	O
localization	O
of	O
the	O
protein	O
after	O
exposure	O
to	O
DNA	O
-	O
damaging	O
agents	O
are	O
consistent	O
with	O
a	O
role	O
for	O
BRCA1	O
in	O
DNA	O
repair	O
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
mouse	O
embryonic	O
stem	O
cells	O
deficient	B
in	I
BRCA1	I
are	O
defective	O
in	O
the	O
ability	O
to	O
carry	O
out	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
,	O
and	O
are	O
hypersensitive	O
to	O
ionizing	O
radiation	O
and	O
hydrogen	O
peroxide	O
.	O

These	O
results	O
suggest	O
that	O
BRCA1	O
participates	O
,	O
directly	O
or	O
indirectly	O
,	O
in	O
transcription	O
-	O
coupled	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
..	O

Truncation	O
mutations	O
in	O
the	O
transactivation	O
region	O
of	O
PAX6	O
result	O
in	O
dominant	O
-	O
negative	O
mutants	O
.	O

PAX6	O
is	O
a	O
transcription	O
factor	O
with	O
two	O
DNA	O
-	O
binding	O
domains	O
(	O
paired	O
box	O
and	O
homeobox	O
)	O
and	O
a	O
proline	O
-	O
serine	O
-	O
threonine	O
(	O
PST	O
)	O
-rich	O
transactivation	O
domain	O
.	O

PAX6	O
regulates	O
eye	O
development	O
in	O
animals	O
ranging	O
from	O
jellyfish	O
to	O
Drosophila	O
to	O
humans	O
.	O

Heterozygous	O
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
result	O
in	O
various	O
phenotypes	O
,	O
including	O
aniridia	B
,	O
Peters	B
anomaly	I
,	O
autosomal	B
dominant	I
keratitis	I
,	O
and	O
familial	B
foveal	I
dysplasia	I
.	O

It	O
is	O
believed	O
that	O
the	O
mutated	O
allele	O
of	O
PAX6	O
produces	O
an	O
inactive	O
protein	O
and	O
aniridia	B
is	O
caused	O
due	O
to	O
genetic	O
haploinsufficiency	O
.	O

However	O
,	O
several	O
truncation	O
mutations	O
have	O
been	O
found	O
to	O
occur	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
PAX6	O
in	O
patients	O
with	O
Aniridia	B
resulting	O
in	O
mutant	O
proteins	O
that	O
retain	O
the	O
DNA	O
-	O
binding	O
domains	O
but	O
have	O
lost	O
most	O
of	O
the	O
transactivation	O
domain	O
.	O

It	O
is	O
not	O
clear	O
whether	O
such	O
mutants	O
really	O
behave	O
as	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
as	O
predicted	O
by	O
haploinsufficiency	O
.	O

Contrary	O
to	O
this	O
theory	O
,	O
our	O
data	O
showed	O
that	O
these	O
mutants	O
are	O
dominant	O
-	O
negative	O
in	O
transient	O
transfection	O
assays	O
when	O
they	O
are	O
coexpressed	O
with	O
wild	O
-	O
type	O
PAX6	O
.	O

We	O
found	O
that	O
the	O
dominant	O
-	O
negative	O
effects	O
result	O
from	O
the	O
enhanced	O
DNA	O
binding	O
ability	O
of	O
these	O
mutants	O
.	O

Kinetic	O
studies	O
of	O
binding	O
and	O
dissociation	O
revealed	O
that	O
various	O
truncation	O
mutants	O
have	O
3	O
-	O
5-fold	O
higher	O
affinity	O
to	O
various	O
DNA	O
-	O
binding	O
sites	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
PAX6	O
.	O

These	O
results	O
provide	O
a	O
new	O
insight	O
into	O
the	O
role	O
of	O
mutant	O
PAX6	O
in	O
causing	O
aniridia	B
..	O

Reversal	O
of	O
severe	O
hypertrophic	B
cardiomyopathy	I
and	O
excellent	O
neuropsychologic	O
outcome	O
in	O
very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
deficiency	I
.	O

Very	B
-	I
long	I
-	I
chain	I
acyl	I
-	I
coenzyme	I
A	I
dehydrogenase	I
(	I
VLCAD	I
)	I
deficiency	I
is	O
a	O
disorder	O
of	O
fatty	O
acid	O
beta	O
oxidation	O
that	O
reportedly	O
has	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
.	O

We	O
describe	O
the	O
outcome	O
of	O
a	O
5-year	O
-	O
old	O
girl	O
with	O
VLCAD	B
deficiency	I
who	O
was	O
first	O
seen	O
at	O
5	O
months	O
of	O
age	O
with	O
severe	O
hypertrophic	B
cardiomyopathy	I
,	O
hepatomegaly	B
,	O
encephalopathy	B
,	O
and	O
hypotonia	B
.	O

Biochemical	O
studies	O
indicated	O
VLCAD	B
deficiency	I
caused	O
by	O
a	O
stable	O
yet	O
inactive	O
enzyme	O
.	O

Molecular	O
genetic	O
analysis	O
of	O
her	O
VLCAD	O
gene	O
revealed	O
a	O
T1372C	O
(	O
F458L	O
)	O
missense	O
mutation	O
and	O
a	O
1668	O
ACAG	O
1669	O
splice	O
site	O
mutation	O
.	O

After	O
initial	O
treatment	O
with	O
intravenous	O
glucose	O
and	O
carnitine	O
,	O
the	O
patient	O
has	O
thrived	O
on	O
a	O
low	O
-	O
fat	O
diet	O
supplemented	O
with	O
medium	O
-	O
chain	O
triglyceride	O
oil	O
and	O
carnitine	O
and	O
avoidance	O
of	O
fasting	O
.	O

Her	O
ventricular	O
hypertrophy	O
resolved	O
significantly	O
over	O
1	O
year	O
,	O
and	O
cognitively	O
,	O
she	O
is	O
in	O
the	O
superior	O
range	O
for	O
age	O
.	O

Clinical	O
recognition	O
of	O
VLCAD	B
deficiency	I
is	O
important	O
because	O
it	O
is	O
one	O
of	O
the	O
few	O
directly	O
treatable	O
causes	O
of	O
cardiomyopathy	B
in	O
children	O
..	O

Cloning	O
of	O
a	O
novel	O
member	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
family	O
.	O

A	O
gene	O
encoding	O
a	O
novel	O
transmembrane	O
protein	O
was	O
identified	O
by	O
DNA	O
sequence	O
analysis	O
within	O
the	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
(	O
IDDM	B
)	O
locus	O
IDDM4	O
on	O
chromosome	O
11q13	O
.	O

Based	O
on	O
its	O
chromosomal	O
position	O
,	O
this	O
gene	O
is	O
a	O
candidate	O
for	O
conferring	O
susceptibility	O
to	O
diabetes	B
.	O

The	O
gene	O
,	O
termed	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
related	O
protein	O
5	O
(	O
LRP5	O
)	O
,	O
encodes	O
a	O
protein	O
of	O
1615	O
amino	O
acids	O
that	O
contains	O
conserved	O
modules	O
which	O
are	O
characteristic	O
of	O
the	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
receptor	O
family	O
.	O

These	O
modules	O
include	O
a	O
putative	O
signal	O
peptide	O
for	O
protein	O
export	O
,	O
four	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
repeats	O
with	O
associated	O
spacer	O
domains	O
,	O
three	O
LDL	O
-	O
receptor	O
(	O
LDLR	O
)	O
repeats	O
,	O
a	O
single	O
transmembrane	O
spanning	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

The	O
encoded	O
protein	O
has	O
a	O
unique	O
organization	O
of	O
EGF	O
and	O
LDLR	O
repeats	O
;	O
therefore	O
,	O
LRP5	O
likely	O
represents	O
a	O
new	O
category	O
of	O
the	O
LDLR	O
family	O
.	O

Both	O
human	O
and	O
mouse	O
LRP5	O
cDNAs	O
have	O
been	O
isolated	O
and	O
the	O
encoded	O
mature	O
proteins	O
are	O
95	O
%	O
identical	O
,	O
indicating	O
a	O
high	O
degree	O
of	O
evolutionary	O
conservation	O
..	O

The	O
APC	B
variants	O
I1307	O
K	O
and	O
E1317Q	O
are	O
associated	O
with	O
colorectal	B
tumors	I
,	O
but	O
not	O
always	O
with	O
a	O
family	O
history	O
.	O

Classical	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
a	O
high	O
-	O
penetrance	O
autosomal	B
dominant	I
disease	I
that	O
predisposes	O
to	O
hundreds	O
or	O
thousands	O
of	O
colorectal	B
adenomas	I
and	I
carcinoma	I
and	O
that	O
results	O
from	O
truncating	O
mutations	O
in	O
the	O
APC	B
gene	O
.	O

A	O
variant	O
of	O
FAP	B
is	O
attenuated	B
adenomatous	I
polyposis	I
coli	I
,	O
which	O
results	O
from	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
5	O
and	O
3	O
regions	O
of	O
the	O
APC	B
gene	O
.	O

Attenuated	B
adenomatous	I
polyposis	I
coli	I
patients	O
have	O
""""	O
multiple	O
""""	O
colorectal	B
adenomas	I
(	O
typically	O
fewer	O
than	O
100	O
)	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B
.	O

Another	O
group	O
of	O
patients	O
with	O
multiple	O
adenomas	B
has	O
no	O
mutations	O
in	O
the	O
APC	B
gene	O
,	O
and	O
their	O
phenotype	O
probably	O
results	O
from	O
variation	O
at	O
a	O
locus	O
,	O
or	O
loci	O
,	O
elsewhere	O
in	O
the	O
genome	O
.	O

Recently	O
,	O
however	O
,	O
a	O
missense	O
variant	O
of	O
APC	B
(	O
I1307	O
K	O
)	O
was	O
described	O
that	O
confers	O
an	O
increased	O
risk	O
of	O
colorectal	B
tumors	I
,	O
including	O
multiple	O
adenomas	B
,	O
in	O
Ashkenazim	O
.	O

We	O
have	O
studied	O
a	O
set	O
of	O
164	O
patients	O
with	O
multiple	O
colorectal	B
adenomas	I
and/or	I
carcinoma	I
and	O
analyzed	O
codons	O
1263	O
-	O
1377	O
(	O
exon	O
15	O
G	O
)	O
of	O
the	O
APC	B
gene	O
for	O
germ	O
-	O
line	O
variants	O
.	O

Three	O
patients	O
with	O
the	O
I1307	O
K	O
allele	O
were	O
detected	O
,	O
each	O
of	O
Ashkenazi	O
descent	O
.	O

Four	O
patients	O
had	O
a	O
germ	O
-	O
line	O
E1317Q	O
missense	O
variant	O
of	O
APC	O
that	O
was	O
not	O
present	O
in	O
controls	O
;	O
one	O
of	O
these	O
individuals	O
had	O
an	O
unusually	O
large	O
number	O
of	O
metaplastic	B
polyps	I
of	I
the	I
colorectum	I
.	O

There	O
is	O
increasing	O
evidence	O
that	O
there	O
exist	O
germ	O
-	O
line	O
variants	O
of	O
the	O
APC	B
gene	O
that	O
predispose	O
to	O
the	O
development	O
of	O
multiple	O
colorectal	B
adenomas	I
and	I
carcinoma	I
,	O
but	O
without	O
the	O
florid	O
phenotype	O
of	O
classical	O
FAP	B
,	O
and	O
possibly	O
with	O
importance	O
for	O
colorectal	B
cancer	I
risk	O
in	O
the	O
general	O
population	O
..	O

Genomic	O
structure	O
of	O
the	O
human	O
congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
gene	O
.	O

Congenital	B
chloride	I
diarrhea	I
(	O
CLD	B
)	O
is	O
caused	O
by	O
mutations	O
in	O
a	O
gene	O
which	O
encodes	O
an	O
intestinal	O
anion	O
transporter	O
.	O

We	O
report	O
here	O
the	O
complete	O
genomic	O
organization	O
of	O
the	O
human	O
CLD	B
gene	O
which	O
spans	O
approximately	O
39	O
kb	O
,	O
and	O
comprises	O
21	O
exons	O
.	O

All	O
exon	O
/	O
intron	O
boundaries	O
conform	O
to	O
the	O
GT	O
/	O
AG	O
rule	O
.	O

An	O
analysis	O
of	O
the	O
putative	O
promoter	O
region	O
sequence	O
shows	O
a	O
putative	O
TATA	O
box	O
and	O
predicts	O
multiple	O
transcription	O
factor	O
binding	O
sites	O
.	O

The	O
genomic	O
structure	O
was	O
determined	O
using	O
DNA	O
from	O
several	O
sources	O
including	O
multiple	O
large	O
-	O
insert	O
libaries	O
and	O
genomic	O
DNA	O
from	O
Finnish	O
CLD	B
patients	O
and	O
controls	O
.	O

Exon	O
-	O
specific	O
primers	O
developed	O
in	O
this	O
study	O
will	O
facilitate	O
mutation	O
screening	O
studies	O
of	O
patients	O
with	O
the	O
disease	O
.	O

Genomic	O
sequencing	O
of	O
a	O
BAC	O
clone	O
H_RG364P16	O
revealed	O
the	O
presence	O
of	O
another	O
,	O
highly	O
homologous	O
gene	O
3	O
of	O
the	O
CLD	B
gene	O
,	O
with	O
a	O
similar	O
genomic	O
structure	O
,	O
recently	O
identified	O
as	O
the	O
Pendred	B
syndrome	I
gene	O
(	O
PDS	B
)	O
..	O

The	O
APCI1307	O
K	O
allele	O
and	O
cancer	B
risk	O
in	O
a	O
community	O
-	O
based	O
study	O
of	O
Ashkenazi	O
Jews	O
.	O

Mutations	O
in	O
APC	O
are	O
classically	O
associated	O
with	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
a	O
highly	O
penetrant	O
autosomal	B
dominant	I
disorder	I
characterized	O
by	O
multiple	O
intestinal	O
polyps	B
and	O
,	O
without	O
surgical	O
intervention	O
,	O
the	O
development	O
of	O
colorectal	B
cancer	I
(	O
CRC	B
)	O
.	O

APC	B
is	O
a	O
tumour	O
-	O
suppressor	O
gene	O
,	O
and	O
somatic	O
loss	O
occurs	O
in	O
tumours	B
.	O

The	O
germline	O
T	O
-	O
to	O
-	O
A	O
transversion	O
responsible	O
for	O
the	O
APC	O
I1307	O
K	O
allele	O
converts	O
the	O
wild	O
-	O
type	O
sequence	O
to	O
a	O
homopolymer	O
tract	O
(	O
A8	O
)	O
that	O
is	O
genetically	O
unstable	O
and	O
prone	O
to	O
somatic	O
mutation	O
.	O

The	O
I1307	O
K	O
allele	O
was	O
found	O
in	O
6	O
.	O
1	O
%	O
of	O
unselected	O
Ashkenazi	O
Jews	O
and	O
higher	O
proportions	O
of	O
Ashkenazim	O
with	O
family	O
or	O
personal	O
histories	O
of	O
CRC	B
(	O
ref	O
.	O

2	O
)	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
I1307	O
K	O
in	O
cancer	B
,	O
we	O
genotyped	O
5	O
,	O
081	O
Ashkenazi	O
volunteers	O
in	O
a	O
community	O
survey	O
.	O

Risk	O
of	O
developing	O
colorectal	B
,	I
breast	I
and	I
other	I
cancers	I
were	O
compared	O
between	O
genotyped	O
I1307	O
K	O
carriers	O
and	O
non	O
-	O
carriers	O
and	O
their	O
first	O
-	O
degree	O
relatives	O
.	O

Sperm	O
DNA	O
analysis	O
in	O
a	O
Friedreich	B
ataxia	I
premutation	O
carrier	O
suggests	O
both	O
meiotic	O
and	O
mitotic	O
expansion	O
in	O
the	O
FRDA	B
gene	O
.	O

Friedreich	B
ataxia	I
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
FRDA	B
gene	O
.	O

Occasionally	O
,	O
a	O
fully	O
expanded	O
allele	O
has	O
been	O
found	O
to	O
arise	O
from	O
a	O
premutation	O
of	O
100	O
or	O
less	O
triplet	O
repeats	O
.	O

We	O
have	O
examined	O
the	O
sperm	O
DNA	O
of	O
a	O
premutation	O
carrier	O
.	O

This	O
mans	O
leucocyte	O
DNA	O
showed	O
one	O
normal	O
allele	O
and	O
one	O
allele	O
of	O
approximately	O
100	O
repeats	O
.	O

His	O
sperm	O
showed	O
an	O
expanded	O
allele	O
in	O
a	O
tight	O
range	O
centering	O
on	O
a	O
size	O
of	O
approximately	O
320	O
trinucleotide	O
repeats	O
.	O

His	O
affected	O
son	O
has	O
repeat	O
sizes	O
of	O
1040	O
and	O
540	O
.	O

These	O
data	O
suggest	O
that	O
expansion	O
occurs	O
in	O
two	O
stages	O
,	O
the	O
first	O
during	O
meiosis	O
followed	O
by	O
a	O
second	O
mitotic	O
expansion	O
.	O

We	O
also	O
show	O
that	O
in	O
all	O
informative	O
carrier	O
father	O
to	O
affected	O
child	O
transmissions	O
,	O
with	O
the	O
notable	O
exception	O
of	O
the	O
premutation	O
carrier	O
,	O
the	O
expansion	O
size	O
decreases	O
..	O

The	O
R496H	O
mutation	O
of	O
arylsulfatase	O
A	O
does	O
not	O
cause	O
metachromatic	B
leukodystrophy	I
.	O

Deficiency	B
of	I
arylsulfatase	I
A	I
(	O
ARSA	O
)	O
enzyme	O
activity	O
causes	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
.	O

A	O
number	O
of	O
ARSA	O
gene	O
mutations	O
responsible	O
for	O
MLD	B
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
was	O
proposed	O
to	O
be	O
a	O
cause	O
of	O
MLD	B
(	O
Draghia	O
et	O
al.	O
,	O
1997	O
)	O
.	O

We	O
have	O
investigated	O
the	O
R496H	O
mutation	O
and	O
found	O
this	O
mutation	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
an	O
African	O
American	O
population	O
(	O
f	O
=	O
0	O
.	O
09	O
,	O
n	O
=	O
61	O
subjects	O
)	O
.	O

The	O
ARSA	O
enzyme	O
activity	O
in	O
subjects	O
with	O
and	O
without	O
the	O
R496H	O
mutation	O
was	O
determined	O
and	O
found	O
to	O
be	O
normal	O
.	O

It	O
is	O
therefore	O
concluded	O
that	O
the	O
R496H	O
mutation	O
of	O
ARSA	O
does	O
not	O
negatively	O
influence	O
the	O
activity	O
of	O
ARSA	O
and	O
is	O
not	O
a	O
cause	O
of	O
MLD	B

Down	O
-	O
regulation	O
of	O
transmembrane	O
carbonic	O
anhydrases	O
in	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
by	O
wild	O
-	O
type	O
von	B
Hippel	I
-	I
Lindau	I
transgenes	O
.	O

To	O
discover	O
genes	O
involved	O
in	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
-mediated	O
carcinogenesis	O
,	O
we	O
used	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
stably	O
transfected	O
with	O
wild	O
-	O
type	O
VHL	O
-	O
expressing	O
transgenes	O
.	O

Large	O
-	O
scale	O
RNA	O
differential	O
display	O
technology	O
applied	O
to	O
these	O
cell	O
lines	O
identified	O
several	O
differentially	O
expressed	O
genes	O
,	O
including	O
an	O
alpha	O
carbonic	O
anhydrase	O
gene	O
,	O
termed	O
CA12	O
.	O

The	O
deduced	O
protein	O
sequence	O
was	O
classified	O
as	O
a	O
one	O
-	O
pass	O
transmembrane	O
CA	O
possessing	O
an	O
apparently	O
intact	O
catalytic	O
domain	O
in	O
the	O
extracellular	O
CA	O
module	O
.	O

Reintroduced	O
wild	O
-	O
type	O
VHL	B
strongly	O
inhibited	O
the	O
overexpression	O
of	O
the	O
CA12	O
gene	O
in	O
the	O
parental	O
renal	B
cell	I
carcinoma	I
cell	O
lines	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
CA9	O
,	O
encoding	O
another	O
transmembrane	O
CA	O
with	O
an	O
intact	O
catalytic	O
domain	O
.	O

Although	O
both	O
domains	O
of	O
the	O
VHL	B
protein	O
contribute	O
to	O
regulation	O
of	O
CA12	O
expression	O
,	O
the	O
elongin	O
binding	O
domain	O
alone	O
could	O
effectively	O
regulate	O
CA9	O
expression	O
.	O

We	O
mapped	O
CA12	O
and	O
CA9	O
loci	O
to	O
chromosome	O
bands	O
15q22	O
and	O
17q21	O
.	O

2	O
respectively	O
,	O
regions	O
prone	O
to	O
amplification	O
in	O
some	O
human	O
cancers	B
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
define	O
the	O
role	O
of	O
CA	O
IX	O
and	O
CA	O
XII	O
enzymes	O
in	O
the	O
regulation	O
of	O
pH	O
in	O
the	O
extracellular	O
microenvironment	O
and	O
its	O
potential	O
impact	O
on	O
cancer	B
cell	O
growth	O
.	O

A	O
gene	O
encoding	O
a	O
transmembrane	O
protein	O
is	O
mutated	O
in	O
patients	O
with	O
diabetes	B
mellitus	I
and	O
optic	B
atrophy	I
(	O
Wolfram	B
syndrome	I
)	O
.	O

Wolfram	B
syndrome	I
(	O
WFS	B
;	O
OMIM	O
222300	O
)	O
is	O
an	O
autosomal	B
recessive	I
neurodegenerative	I
disorder	I
defined	O
by	O
young	O
-	O
onset	O
non	O
-	O
immune	O
insulin	B
-	I
dependent	I
diabetes	I
mellitus	I
and	O
progressive	O
optic	B
atrophy	I
.	O

Linkage	O
to	O
markers	O
on	O
chromosome	O
4p	O
was	O
confirmed	O
in	O
five	O
families	O
.	O

On	O
the	O
basis	O
of	O
meiotic	O
recombinants	O
and	O
disease	O
-	O
associated	O
haplotypes	O
,	O
the	O
WFS	B
gene	O
was	O
localized	O
to	O
a	O
BAC	O
/	O
P1	O
contig	O
of	O
less	O
than	O
250	O
kb	O
.	O

Mutations	O
in	O
a	O
novel	O
gene	O
(	O
WFS1	O
)	O
encoding	O
a	O
putative	O
transmembrane	O
protein	O
were	O
found	O
in	O
all	O
affected	O
individuals	O
in	O
six	O
WFS	B
families	O
,	O
and	O
these	O
mutations	O
were	O
associated	O
with	O
the	O
disease	O
phenotype	O
.	O

WFS1	O
appears	O
to	O
function	O
in	O
survival	O
of	O
islet	O
beta	O
-	O
cells	O
and	O
neurons	O
..	O

Stable	O
interaction	O
between	O
the	O
products	O
of	O
the	O
BRCA1	O
and	O
BRCA2	O
tumor	B
suppressor	O
genes	O
in	O
mitotic	O
and	O
meiotic	O
cells	O
.	O

BRCA1	O
and	O
BRCA2	O
account	O
for	O
most	O
cases	O
of	O
familial	O
,	O
early	O
onset	O
breast	B
and/or	I
ovarian	I
cancer	I
and	O
encode	O
products	O
that	O
each	O
interact	O
with	O
hRAD51	O
.	O

Results	O
presented	O
here	O
show	O
that	O
BRCA1	O
and	O
BRCA2	O
coexist	O
in	O
a	O
biochemical	O
complex	O
and	O
colocalize	O
in	O
subnuclear	O
foci	O
in	O
somatic	O
cells	O
and	O
on	O
the	O
axial	O
elements	O
of	O
developing	O
synaptonemal	O
complexes	O
.	O

Like	O
BRCA1	O
and	O
RAD51	O
,	O
BRCA2	O
relocates	O
to	O
PCNA	O
+	O
replication	O
sites	O
following	O
exposure	O
of	O
S	O
phase	O
cells	O
to	O
hydroxyurea	O
or	O
UV	O
irradiation	O
.	O

Thus	O
,	O
BRCA1	O
and	O
BRCA2	O
participate	O
,	O
together	O
,	O
in	O
a	O
pathway	O
(	O
s	O
)	O
associated	O
with	O
the	O
activation	O
of	O
double	O
-	O
strand	O
break	O
repair	O
and/or	O
homologous	O
recombination	O
.	O

Dysfunction	O
of	O
this	O
pathway	O
may	O
be	O
a	O
general	O
phenomenon	O
in	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	B
breast	I
and/or	I
ovarian	I
cancer	I
..	O

A	O
novel	O
Arg362Ser	O
mutation	O
in	O
the	O
sterol	O
27-hydroxylase	O
gene	O
(	O
CYP27	O
)	O
:	O
its	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
and	O
enzyme	O
activity	O
.	O

A	O
novel	O
C	O
to	O
A	O
mutation	O
in	O
the	O
sterol	O
27-hydroxylase	O
gene	O
(	O
CYP27	O
)	O
was	O
identified	O
by	O
sequencing	O
amplified	O
CYP27	O
gene	O
products	O
from	O
a	O
patient	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
.	O

The	O
mutation	O
changed	O
the	O
adrenodoxin	O
cofactor	O
binding	O
residue	O
362Arg	O
to	O
362Ser	O
(	O
CGT	O
362Arg	O
to	O
AGT	O
362Ser	O
)	O
,	O
and	O
was	O
responsible	O
for	O
deficiency	O
in	O
the	O
sterol	O
27-hydroxylase	O
activity	O
,	O
as	O
confirmed	O
by	O
expression	O
of	O
mutant	O
cDNA	O
into	O
COS-1	O
cells	O
.	O

Quantitative	O
analysis	O
showed	O
that	O
the	O
expression	O
of	O
CYP27	O
gene	O
mRNA	O
in	O
the	O
patient	O
represented	O
52	O
.	O
5	O
%	O
of	O
the	O
normal	O
level	O
.	O

As	O
the	O
mutation	O
occurred	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
(	O
-2	O
position	O
of	O
exon	O
6-intron	O
6	O
splice	O
site	O
)	O
of	O
the	O
gene	O
,	O
we	O
hypothesized	O
that	O
the	O
mutation	O
may	O
partially	O
affect	O
the	O
normal	O
splicing	O
efficiency	O
in	O
exon	O
6	O
and	O
cause	O
alternative	O
splicing	O
elsewhere	O
,	O
which	O
resulted	O
in	O
decreased	O
transcript	O
in	O
the	O
patient	O
.	O

Transfection	O
of	O
constructed	O
minigenes	O
,	O
with	O
or	O
without	O
the	O
mutation	O
,	O
into	O
COS-1	O
cells	O
confirmed	O
that	O
the	O
mutant	O
minigene	O
was	O
responsible	O
for	O
a	O
mRNA	O
species	O
alternatively	O
spliced	O
at	O
an	O
activated	O
cryptic	O
5	O
splice	O
site	O
88	O
bp	O
upstream	O
from	O
the	O
3	O
end	O
of	O
exon	O
6	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
C	O
to	O
A	O
mutation	O
at	O
the	O
penultimate	O
nucleotide	O
of	O
exon	O
6	O
of	O
the	O
CYP27	O
gene	O
not	O
only	O
causes	O
the	O
deficiency	B
in	I
the	I
sterol	I
27-hydroxylase	I
activity	I
,	O
but	O
also	O
partially	O
leads	O
to	O
alternative	O
pre	O
-	O
mRNA	O
splicing	O
of	O
the	O
gene	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
effects	O
on	O
pre	O
-	O
mRNA	O
splicing	O
of	O
a	O
mutation	O
at	O
the	O
-2	O
position	O
of	O
a	O
5	O
splice	O
site	O
.	O

ATM	O
germline	O
mutations	O
in	O
classical	O
ataxia	B
-	I
telangiectasia	I
patients	O
in	O
the	O
Dutch	O
population	O
.	O

Germline	O
mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
determined	O
the	O
ATM	O
mutation	O
spectrum	O
in	O
19	O
classical	O
A	B
-	I
T	I
patients	O
,	O
including	O
some	O
immigrant	O
populations	O
,	O
as	O
well	O
as	O
12	O
of	O
Dutch	O
ethnic	O
origin	O
.	O

Both	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
and	O
the	O
restriction	O
endonuclease	O
fingerprinting	O
(	O
REF	O
)	O
method	O
were	O
used	O
and	O
compared	O
for	O
their	O
detection	O
efficiency	O
,	O
identifying	O
76	O
%	O
and	O
60	O
%	O
of	O
the	O
mutations	O
,	O
respectively	O
.	O

Most	O
patients	O
were	O
found	O
to	O
be	O
compound	O
heterozygote	O
.	O

Seventeen	O
mutations	O
were	O
distinct	O
,	O
of	O
which	O
10	O
were	O
not	O
reported	O
previously	O
.	O

Mutations	O
are	O
small	O
deletions	O
or	O
point	O
mutations	O
frequently	O
affecting	O
splice	O
sites	O
.	O

Moreover	O
,	O
a	O
16	O
.	O

7-kb	O
genomic	O
deletion	O
of	O
the	O
3	O
end	O
of	O
the	O
gene	O
,	O
most	O
likely	O
a	O
result	O
of	O
recombination	O
between	O
two	O
LINE	O
elements	O
,	O
was	O
identified	O
.	O

The	O
most	O
frequently	O
found	O
mutation	O
,	O
identified	O
in	O
three	O
unrelated	O
Turkish	O
A	B
-	I
T	I
individuals	O
,	O
was	O
previously	O
described	O
to	O
be	O
a	O
Turkish	O
A	B
-	I
T	I
founder	O
mutation	O
.	O

The	O
presence	O
of	O
a	O
founder	O
mutation	O
among	O
relatively	O
small	O
ethnic	O
population	O
groups	O
in	O
Western	O
Europe	O
could	O
indicate	O
a	O
high	O
carrier	O
frequency	O
in	O
such	O
communities	O
.	O

In	O
patients	O
of	O
Dutch	O
ethnic	O
origin	O
,	O
however	O
,	O
no	O
significant	O
founder	O
effect	O
could	O
be	O
identified	O
.	O

The	O
observed	O
genetic	O
heterogeneity	O
including	O
the	O
relative	O
high	O
percentage	O
of	O
splice	O
-	O
site	O
mutations	O
had	O
no	O
reflection	O
on	O
the	O
phenotype	O
.	O

All	O
patients	O
manifested	O
classical	O
A	B
-	I
T	I
and	O
increased	O
cellular	O
radioresistant	O
DNA	O
synthesis	O
.	O

Determination	O
of	O
the	O
genomic	O
structure	O
of	O
the	O
COL4A4	O
gene	O
and	O
of	O
novel	O
mutations	O
causing	O
autosomal	B
recessive	I
Alport	I
syndrome	I
.	O

Autosomal	B
recessive	I
Alport	I
syndrome	I
is	O
a	O
progressive	O
hematuric	B
glomerulonephritis	I
characterized	O
by	O
glomerular	B
basement	I
membrane	I
abnormalities	I
and	O
associated	O
with	O
mutations	O
in	O
either	O
the	O
COL4A3	O
or	O
the	O
COL4A4	O
gene	O
,	O
which	O
encode	O
the	O
alpha3	O
and	O
alpha4	O
type	O
IV	O
collagen	O
chains	O
,	O
respectively	O
.	O

To	O
date	O
,	O
mutation	O
screening	O
in	O
the	O
two	O
genes	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
genomic	O
structure	O
information	O
.	O

We	O
report	O
here	O
the	O
complete	O
characterization	O
of	O
the	O
48	O
exons	O
of	O
the	O
COL4A4	O
gene	O
,	O
a	O
comprehensive	O
gene	O
screen	O
,	O
and	O
the	O
subsequent	O
detection	O
of	O
10	O
novel	O
mutations	O
in	O
eight	O
patients	O
diagnosed	O
with	O
autosomal	B
recessive	I
Alport	I
syndrome	I
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
glycine	O
to	O
alanine	O
substitution	O
in	O
the	O
collagenous	O
domain	O
that	O
is	O
apparently	O
silent	O
in	O
the	O
heterozygous	O
carriers	O
,	O
in	O
11	O
.	O
5	O
%	O
of	O
all	O
control	O
individuals	O
,	O
and	O
in	O
one	O
control	O
individual	O
homozygous	O
for	O
this	O
glycine	O
substitution	O
.	O

There	O
has	O
been	O
no	O
previous	O
finding	O
of	O
a	O
glycine	O
substitution	O
that	O
is	O
not	O
associated	O
with	O
any	O
obvious	O
phenotype	O
in	O
homozygous	O
individuals	O
.	O

Founder	O
BRCA1	O
and	O
BRCA2	O
mutations	O
in	O
French	O
Canadian	O
breast	B
and	I
ovarian	I
cancer	I
families	O
.	O

We	O
have	O
identified	O
four	O
mutations	O
in	O
each	O
of	O
the	O
breast	B
cancer	I
-	O
susceptibility	O
genes	O
,	O
BRCA1	O
and	O
BRCA2	O
,	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
breast	B
/	I
ovarian	I
cancer	I
families	O
from	O
Quebec	O
.	O

To	O
identify	O
founder	O
effects	O
,	O
we	O
examined	O
independently	O
ascertained	O
French	O
Canadian	O
cancer	B
families	O
for	O
the	O
distribution	O
of	O
these	O
eight	O
mutations	O
.	O

Mutations	O
were	O
found	O
in	O
41	O
of	O
97	O
families	O
.	O

Six	O
of	O
eight	O
mutations	O
were	O
observed	O
at	O
least	O
twice	O
.	O

The	O
BRCA1	O
C4446	O
T	O
mutation	O
was	O
the	O
most	O
common	O
mutation	O
found	O
,	O
followed	O
by	O
the	O
BRCA2	O
8765delAG	O
mutation	O
.	O

Together	O
,	O
these	O
mutations	O
were	O
found	O
in	O
28	O
of	O
41	O
families	O
identified	O
to	O
have	O
a	O
mutation	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA1	O
mutations	O
was	O
18	O
.	O

7x	O
greater	O
if	O
one	O
or	O
more	O
cases	O
of	O
ovarian	B
cancer	I
were	O
also	O
present	O
in	O
the	O
family	O
.	O

The	O
odds	O
of	O
detection	O
of	O
any	O
of	O
the	O
four	O
BRCA2	O
mutations	O
was	O
5	O
.	O

3x	O
greater	O
if	O
there	O
were	O
at	O
least	O
five	O
cases	O
of	O
breast	B
cancer	I
in	O
the	O
family	O
.	O

Interestingly	O
,	O
the	O
presence	O
of	O
a	O
breast	B
cancer	I
case	O
<	O
36	O
years	O
of	O
age	O
was	O
strongly	O
predictive	O
of	O
the	O
presence	O
of	O
any	O
of	O
the	O
eight	O
mutations	O
screened	O
.	O

Carriers	O
of	O
the	O
same	O
mutation	O
,	O
from	O
different	O
families	O
,	O
shared	O
similar	O
haplotypes	O
,	O
indicating	O
that	O
the	O
mutant	O
alleles	O
were	O
likely	O
to	O
be	O
identical	O
by	O
descent	O
for	O
a	O
mutation	O
in	O
the	O
founder	O
population	O
.	O

The	O
identification	O
of	O
common	O
BRCA1	O
and	O
BRCA2	O
mutations	O
will	O
facilitate	O
carrier	O
detection	O
in	O
French	O
Canadian	O
breast	B
cancer	I
and	O
breast	B
/	I
ovarian	I
cancer	I
families	O
.	O

Are	O
Dp71	O
and	O
Dp140	O
brain	O
dystrophin	O
isoforms	O
related	O
to	O
cognitive	B
impairment	I
in	O
Duchenne	B
muscular	I
dystrophy	I
?	O

Molecular	O
study	O
and	O
neuropsychological	O
analysis	O
were	O
performed	O
concurrently	O
on	O
49	O
patients	O
with	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
in	O
order	O
to	O
find	O
a	O
molecular	O
explanation	O
for	O
the	O
cognitive	B
impairment	I
observed	O
in	O
most	O
DMD	B
patients	O
.	O

Complete	O
analysis	O
of	O
the	O
dystrophin	O
gene	O
was	O
performed	O
to	O
define	O
the	O
localization	O
of	O
deletions	O
and	O
duplications	O
in	O
relation	O
to	O
the	O
different	O
DMD	B
promoters	O
.	O

Qualitative	O
analysis	O
of	O
the	O
Dp71	O
transcript	O
and	O
testing	O
for	O
the	O
specific	O
first	O
exon	O
of	O
Dp140	O
were	O
also	O
carried	O
out	O
.	O

Neuropsychological	O
analysis	O
assessed	O
verbal	O
and	O
visuospatial	O
intelligence	O
,	O
verbal	O
memory	O
,	O
and	O
reading	O
skills	O
.	O

Comparison	O
of	O
molecular	O
and	O
psychometric	O
findings	O
demonstrated	O
that	O
deletions	O
and	O
duplications	O
that	O
were	O
localized	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
seemed	O
to	O
be	O
preferentially	O
associated	O
with	O
cognitive	B
impairment	I
.	O

Two	O
altered	O
Dp71	O
transcripts	O
and	O
two	O
deleted	O
Dp140	O
DNA	O
sequences	O
were	O
found	O
in	O
four	O
patients	O
with	O
severe	O
cerebral	B
dysfunction	I
.	O

These	O
findings	O
suggest	O
that	O
some	O
sequences	O
located	O
in	O
the	O
distal	O
part	O
of	O
the	O
gene	O
and	O
,	O
in	O
particular	O
,	O
some	O
DMD	B
isoforms	O
expressed	O
in	O
the	O
brain	O
may	O
be	O
related	O
to	O
the	O
cognitive	B
impairment	I
associated	O
with	O
DMD	B
..	O

I1307	O
K	O
APC	O
and	O
hMLH1	O
mutations	O
in	O
a	O
non	O
-	O
Jewish	O
family	O
with	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
.	O

We	O
describe	O
a	O
French	O
Canadian	O
hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
kindred	O
which	O
carries	O
a	O
novel	O
truncating	O
mutation	O
in	O
hMLH1	O
.	O

Interestingly	O
,	O
the	O
I1307	O
K	O
APC	O
polymorphism	O
,	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
colorectal	B
cancer	I
,	O
is	O
also	O
present	O
in	O
this	O
family	O
.	O

The	O
I1307	O
K	O
polymorphism	O
has	O
previously	O
only	O
been	O
identified	O
in	O
individuals	O
of	O
self	O
-	O
reported	O
Ashkenazi	O
Jewish	O
origins	O
.	O

In	O
addition	O
,	O
in	O
this	O
family	O
,	O
there	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
I1307	O
K	O
polymorphism	O
and	O
the	O
presence	O
or	O
absence	O
of	O
cancer	B
..	O

Identification	O
of	O
a	O
novel	O
mutation	O
of	O
the	O
CPO	O
gene	O
in	O
a	O
Japanese	O
hereditary	B
coproporphyria	I
family	O
.	O

Hereditary	B
coproporphyria	I
(	O
HCP	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
characterized	O
by	O
a	O
deficiency	B
of	I
coproporphyrinogen	I
oxidase	I
(	O
CPO	O
)	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
CPO	O
gene	O
.	O

Only	O
11	O
mutations	O
of	O
the	O
gene	O
have	O
been	O
reported	O
in	O
HCP	B
patients	O
.	O

We	O
report	O
another	O
mutation	O
in	O
a	O
Japanese	O
family	O
.	O

Polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformational	O
polymorphism	O
and	O
direct	O
sequence	O
analyses	O
demonstrated	O
a	O
C	O
to	O
T	O
substitution	O
in	O
exon	O
1	O
of	O
the	O
CPO	O
gene	O
at	O
nucleotide	O
position	O
85	O
,	O
which	O
lies	O
in	O
the	O
putative	O
presequence	O
for	O
targeting	O
to	O
mitochondria	O
.	O

This	O
mutation	O
changes	O
the	O
codon	O
for	O
glutamine	O
to	O
a	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
29	O
.	O

MaeI	O
restriction	O
analysis	O
showed	O
two	O
other	O
carriers	O
in	O
the	O
family	O
.	O

The	O
C	O
-	O
T	O
mutation	O
is	O
located	O
within	O
a	O
recently	O
proposed	O
putative	O
alternative	O
translation	O
initiation	O
codon	O
(	O
TIC-1	O
)	O
,	O
supporting	O
that	O
TIC-1	O
is	O
the	O
real	O
TIC	O
rather	O
than	O
TIC-2	O
..	O

Human	B
complement	I
factor	I
H	I
deficiency	I
associated	O
with	O
hemolytic	B
uremic	I
syndrome	I
.	O

This	O
study	O
reports	O
on	O
six	O
cases	O
of	O
deficiency	B
in	I
the	I
human	I
complement	I
regulatory	I
protein	I
Factor	I
H	I
(	O
FH	O
)	O
in	O
the	O
context	O
of	O
an	O
acute	B
renal	I
disease	I
.	O

Five	O
of	O
the	O
cases	O
were	O
observed	O
in	O
children	O
presenting	O
with	O
idiopathic	O
hemolytic	B
uremic	I
syndrome	I
(	O
HUS	B
)	O
.	O

Two	O
of	O
the	O
children	O
exhibited	O
a	O
homozygous	O
deficiency	O
characterized	O
by	O
the	O
absence	O
of	O
the	O
150-kD	O
form	O
of	O
Factor	O
H	O
and	O
the	O
presence	O
,	O
upon	O
immunoblotting	O
,	O
of	O
the	O
42-kD	O
Factor	O
H	O
-	O
like	O
protein	O
1	O
(	O
FHL-1	O
)	O
and	O
other	O
FH	O
-	O
related	O
protein	O
(	O
FHR	O
)	O
bands	O
.	O

Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
DNA	O
of	O
one	O
patient	O
with	O
homozygous	O
deficiency	O
ruled	O
out	O
the	O
presence	O
of	O
a	O
large	O
deletion	O
of	O
the	O
FH	O
gene	O
as	O
the	O
underlying	O
defect	O
for	O
the	O
deficiency	O
.	O

The	O
other	O
four	O
children	O
presented	O
with	O
heterozygous	O
deficiency	O
and	O
exhibited	O
a	O
normal	O
immunoblotting	O
pattern	O
of	O
proteins	O
of	O
the	O
FH	O
family	O
.	O

Factor	B
H	I
deficiency	I
is	O
the	O
only	O
complement	B
deficiency	I
associated	O
with	O
HUS	B
.	O

These	O
observations	O
suggest	O
a	O
role	O
for	O
FH	O
and/or	O
FH	O
receptors	O
in	O
the	O
pathogenesis	O
of	O
idiopathic	O
HUS	B
..	O

Further	O
evidence	O
for	O
a	O
major	O
ancient	O
mutation	O
underlying	O
myotonic	B
dystrophy	I
from	O
linkage	O
disequilibrium	O
studies	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
mutation	O
is	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
present	O
at	O
a	O
copy	O
number	O
of	O
5	O
-	O
37	O
repeats	O
on	O
normal	O
chromosomes	O
but	O
amplified	O
to	O
50	O
-	O
3000	O
copies	O
on	O
DM	B
chromosomes	O
.	O

Previous	O
findings	O
in	O
Caucasian	O
populations	O
of	O
a	O
DM	B
founder	O
chromosome	O
raise	O
a	O
question	O
about	O
the	O
molecular	O
events	O
involved	O
in	O
the	O
expansion	O
mutation	O
.	O

To	O
investigate	O
whether	O
a	O
founder	O
chromosome	O
for	O
the	O
DM	B
mutation	O
exists	O
in	O
the	O
Japanese	O
population	O
,	O
we	O
genotyped	O
families	O
using	O
polymorphic	O
markers	O
near	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
region	O
and	O
constructed	O
haplotypes	O
.	O

Six	O
different	O
haplotypes	O
were	O
found	O
and	O
DM	B
alleles	O
were	O
always	O
haplotype	O
A.	O
To	O
find	O
an	O
origin	O
of	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
mutation	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
expansion	O
mutation	O
in	O
the	O
Japanese	O
population	O
we	O
have	O
studied	O
90	O
Japanese	O
DM	B
families	O
comprising	O
190	O
affected	O
and	O
130	O
unaffected	O
members	O
.	O

The	O
results	O
suggest	O
that	O
a	O
few	O
common	O
ancestral	O
mutations	O
in	O
both	O
Caucasian	O
and	O
Japanese	O
populations	O
have	O
originated	O
by	O
expansion	O
of	O
an	O
ancestral	O
n	O
=	O
5	O
repeat	O
to	O
n	O
=	O
19	O
-	O
37	O
copies	O
.	O

These	O
data	O
support	O
multistep	O
models	O
of	O
triplet	O
repeat	O
expansion	O
that	O
have	O
been	O
proposed	O
for	O
both	O
DM	B
and	O
Friedreichs	B
ataxia	I
..	O

The	O
molecular	O
basis	O
of	O
C6	B
deficiency	I
in	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

Deficiency	B
of	I
the	I
sixth	I
component	I
of	I
human	I
complement	I
(	O
C6	O
)	O
has	O
been	O
reported	O
in	O
a	O
number	O
of	O
families	O
from	O
the	O
western	O
Cape	O
,	O
South	O
Africa	O
.	O

Meningococcal	B
disease	I
is	O
endemic	O
in	O
the	O
Cape	O
and	O
almost	O
all	O
pedigrees	O
of	O
total	O
C6	B
deficiency	I
(	O
C6Q0	O
)	O
have	O
been	O
ascertained	O
because	O
of	O
recurrent	O
disease	O
.	O

We	O
have	O
sequenced	O
the	O
expressed	O
exons	O
of	O
the	O
C6	O
gene	O
from	O
selected	O
cases	O
and	O
have	O
found	O
three	O
molecular	O
defects	O
leading	O
to	O
total	O
deficiency	O
879delG	O
,	O
which	O
is	O
the	O
common	O
defect	O
in	O
the	O
Cape	O
and	O
hitherto	O
unreported	O
,	O
and	O
1195delC	O
and	O
1936delG	O
,	O
which	O
have	O
been	O
previously	O
reported	O
in	O
African	O
-	O
Americans	O
.	O

We	O
also	O
show	O
that	O
the	O
879delG	O
and	O
1195delC	O
defects	O
are	O
associated	O
with	O
characteristic	O
C6	O
/	O
C7	O
region	O
DNA	O
marker	O
haplotypes	O
,	O
although	O
small	O
variations	O
were	O
observed	O
.	O

The	O
1936delG	O
defect	O
was	O
observed	O
only	O
once	O
in	O
the	O
Cape	O
,	O
but	O
its	O
associated	O
haplotype	O
could	O
be	O
deduced	O
.	O

The	O
data	O
from	O
the	O
haplotypes	O
indicate	O
that	O
these	O
three	O
molecular	O
defects	O
account	O
for	O
the	O
defects	O
in	O
all	O
the	O
38	O
unrelated	O
C6Q0	O
individuals	O
we	O
have	O
studied	O
from	O
the	O
Cape	O
.	O

We	O
have	O
also	O
observed	O
the	O
879delG	O
defect	O
in	O
two	O
Dutch	O
C6-deficient	B
kindreds	O
,	O
but	O
the	O
879delG	O
defect	O
in	O
the	O
Cape	O
probably	O
did	O
not	O
come	O
from	O
The	O
Netherlands	O
..	O

Complement	B
C7	I
deficiency	I
:	O
seven	O
further	O
molecular	O
defects	O
and	O
their	O
associated	O
marker	O
haplotypes	O
.	O

Seven	O
further	O
molecular	O
bases	O
of	O
C7	B
deficiency	I
are	O
described	O
.	O

All	O
these	O
new	O
molecular	O
defects	O
involve	O
single	O
-	O
nucleotide	O
events	O
,	O
deletions	O
and	O
substitutions	O
,	O
some	O
of	O
which	O
alter	O
splice	O
sites	O
,	O
and	O
others	O
codons	O
.	O

They	O
are	O
distributed	O
along	O
the	O
C7	O
gene	O
,	O
but	O
predominantly	O
towards	O
the	O
3	O
end	O
.	O

All	O
were	O
found	O
in	O
compound	O
heterozygous	O
individuals	O
.	O

The	O
C6	O
/	O
C7	O
marker	O
haplotypes	O
associated	O
with	O
most	O
C7	B
defects	I
are	O
tabulated	O
..	O

A	O
genome	O
-	O
wide	O
search	O
for	O
chromosomal	O
loci	O
linked	O
to	O
mental	O
health	O
wellness	O
in	O
relatives	O
at	O
high	O
risk	O
for	O
bipolar	B
affective	I
disorder	I
among	O
the	O
Old	O
Order	O
Amish	O
.	O

Bipolar	B
affective	I
disorder	I
(	O
BPAD	B
;	O
manic	B
-	I
depressive	I
illness	I
)	O
is	O
characterized	O
by	O
episodes	O
of	O
mania	B
and/or	O
hypomania	B
interspersed	O
with	O
periods	O
of	O
depression	B
.	O

Compelling	O
evidence	O
supports	O
a	O
significant	O
genetic	O
component	O
in	O
the	O
susceptibility	O
to	O
develop	O
BPAD	B
.	O

To	O
date	O
,	O
however	O
,	O
linkage	O
studies	O
have	O
attempted	O
only	O
to	O
identify	O
chromosomal	O
loci	O
that	O
cause	O
or	O
increase	O
the	O
risk	O
of	O
developing	O
BPAD	B
.	O

To	O
determine	O
whether	O
there	O
could	O
be	O
protective	O
alleles	O
that	O
prevent	O
or	O
reduce	O
the	O
risk	O
of	O
developing	O
BPAD	B
,	O
similar	O
to	O
what	O
is	O
observed	O
in	O
other	O
genetic	B
disorders	I
,	O
we	O
used	O
mental	O
health	O
wellness	O
(	O
absence	O
of	O
any	O
psychiatric	B
disorder	I
)	O
as	O
the	O
phenotype	O
in	O
our	O
genome	O
-	O
wide	O
linkage	O
scan	O
of	O
several	O
large	O
multigeneration	O
Old	O
Order	O
Amish	O
pedigrees	O
exhibiting	O
an	O
extremely	O
high	O
incidence	O
of	O
BPAD	B
.	O

We	O
have	O
found	O
strong	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4p	O
at	O
D4S2949	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
4	O
.	O
05	O
,	O
P	O
=	O
5	O
.	O
22	O
x	O
10	O
(	O
-4	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
3	O
x	O
10	O
(	O
-5	O
)	O
)	O
and	O
suggestive	O
evidence	O
for	O
a	O
locus	O
on	O
chromosome	O
4q	O
at	O
D4S397	O
(	O
maximum	O
GENEHUNTER	O
-	O
PLUS	O
nonparametric	O
linkage	O
score	O
=	O
3	O
.	O
29	O
,	O
P	O
=	O
2	O
.	O
57	O
x	O
10	O
(	O
-3	O
)	O
;	O
SIBPAL	O
Pempirical	O
value	O
<	O
1	O
x	O
10	O
(	O
-3	O
)	O
)	O
that	O
are	O
linked	O
to	O
mental	O
health	O
wellness	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
certain	O
alleles	O
could	O
prevent	O
or	O
modify	O
the	O
clinical	O
manifestations	O
of	O
BPAD	B
and	O
perhaps	O
other	O
related	O
affective	B
disorders	I
.	O

Segregation	O
distortion	O
in	O
myotonic	B
dystrophy	I
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
an	O
autosomal	B
dominant	I
disease	I
which	O
,	O
in	O
the	O
typical	O
pedigree	O
,	O
shows	O
a	O
three	O
generation	O
anticipation	O
cascade	O
.	O

This	O
results	O
in	O
infertility	B
and	O
congenital	B
myotonic	I
dystrophy	I
(	O
CDM	B
)	O
with	O
the	O
disappearance	O
of	O
DM	B
in	O
that	O
pedigree	O
.	O

The	O
concept	O
of	O
segregation	O
distortion	O
,	O
where	O
there	O
is	O
preferential	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	B
locus	O
,	O
has	O
been	O
put	O
forward	O
to	O
explain	O
partially	O
the	O
maintenance	O
of	O
DM	B
in	O
the	O
population	O
.	O

In	O
a	O
survey	O
of	O
DM	B
in	O
Northern	O
Ireland	O
,	O
59	O
pedigrees	O
were	O
ascertained	O
.	O

Sibships	O
where	O
the	O
status	O
of	O
all	O
the	O
members	O
had	O
been	O
identified	O
were	O
examined	O
to	O
determine	O
the	O
transmission	O
of	O
the	O
DM	B
expansion	O
from	O
affected	O
parents	O
to	O
their	O
offspring	O
.	O

Where	O
the	O
transmitting	O
parent	O
was	O
male	O
,	O
58	O
.	O
3	O
%	O
of	O
the	O
offspring	O
were	O
affected	O
,	O
and	O
in	O
the	O
case	O
of	O
a	O
female	O
transmitting	O
parent	O
,	O
68	O
.	O
7	O
%	O
were	O
affected	O
.	O

Studies	O
on	O
meiotic	O
drive	O
in	O
DM	B
have	O
shown	O
increased	O
transmission	O
of	O
the	O
larger	O
allele	O
at	O
the	O
DM	B
locus	O
in	O
non	O
-	O
DM	O
heterozygotes	O
for	O
CTGn	O
.	O

This	O
study	O
provides	O
further	O
evidence	O
that	O
the	O
DM	B
expansion	O
tends	O
to	O
be	O
transmitted	O
preferentially	O
.	O

Diagnosis	O
of	O
hemochromatosis	B
.	O

If	O
untreated	O
,	O
hemochromatosis	B
can	O
cause	O
serious	O
illness	O
and	O
early	B
death	I
,	O
but	O
the	O
disease	O
is	O
still	O
substantially	O
under	O
-	O
diagnosed	O
.	O

The	O
cornerstone	O
of	O
screening	O
and	O
case	O
detection	O
is	O
the	O
measurement	O
of	O
serum	O
transferrin	O
saturation	O
and	O
the	O
serum	O
ferritin	O
level	O
.	O

Once	O
the	O
diagnosis	O
is	O
suspected	O
,	O
physicians	O
must	O
use	O
serum	O
ferritin	O
levels	O
and	O
hepatic	O
iron	O
stores	O
on	O
liver	O
biopsy	O
specimens	O
to	O
assess	O
patients	O
for	O
the	O
presence	O
of	O
iron	B
overload	I
.	O

Liver	O
biopsy	O
is	O
also	O
used	O
to	O
establish	O
the	O
presence	O
or	O
absence	O
of	O
cirrhosis	B
,	O
which	O
can	O
affect	O
prognosis	O
and	O
management	O
.	O

A	O
DNA	O
-	O
based	O
test	O
for	O
the	O
HFE	O
gene	O
is	O
commercially	O
available	O
,	O
but	O
its	O
place	O
in	O
the	O
diagnosis	O
of	O
hemochromatosis	B
is	O
still	O
being	O
evaluated	O
.	O

Currently	O
,	O
the	O
most	O
useful	O
role	O
for	O
this	O
test	O
is	O
in	O
the	O
detection	O
of	O
hemochromatosis	B
in	O
the	O
family	O
members	O
of	O
patients	O
with	O
a	O
proven	O
case	O
of	O
the	O
disease	O
.	O

It	O
is	O
crucial	O
to	O
diagnose	O
hemochromatosis	B
before	O
hepatic	B
cirrhosis	I
develops	O
because	O
phlebotomy	O
therapy	O
can	O
avert	O
serious	O
chronic	O
disease	O
and	O
can	O
even	O
lead	O
to	O
normal	O
life	O
expectancy	O
..	O

Prevalence	O
of	O
the	O
I1307	O
K	O
APC	B
gene	O
variant	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

BACKGROUND	O
&	O
AIMS	O
Israeli	O
Jews	O
of	O
European	O
birth	O
,	O
i.	O
e.	O
,	O
Ashkenazim	O
,	O
have	O
the	O
highest	O
colorectal	B
cancer	I
incidence	O
of	O
any	O
Israeli	O
ethnic	O
group	O
.	O

The	O
I1307	O
K	O
APC	B
gene	O
variant	O
was	O
found	O
in	O
6	O
.	O
1	O
%	O
of	O
American	O
Jews	O
,	O
28	O
%	O
of	O
their	O
familial	O
colorectal	B
cancer	I
cases	O
,	O
but	O
not	O
in	O
non	O
-	O
Jews	O
.	O

We	O
assessed	O
the	O
I1307	O
K	O
prevalence	O
in	O
Israeli	O
Jews	O
of	O
differing	O
ethnic	O
origin	O
and	O
risk	O
for	O
colorectal	B
cancer	I
.	O

METHODS	O
DNA	O
samples	O
from	O
500	O
unrelated	O
Jews	O
of	O
European	O
or	O
non	O
-	O
European	O
origin	O
,	O
with	O
or	O
without	O
a	O
personal	O
and/or	O
family	O
history	O
of	O
neoplasia	B
,	O
were	O
examined	O
for	O
the	O
I1307	O
K	O
variant	O
by	O
the	O
allele	O
-	O
specific	O
oligonucleotide	O
(	O
ASO	O
)	O
method	O
.	O

RESULTS	O
In	O
persons	O
at	O
average	O
risk	O
for	O
colorectal	B
cancer	I
,	O
I1307	O
K	O
was	O
found	O
in	O
5	O
.	O
0	O
%	O
of	O
120	O
European	O
and	O
1	O
.	O
6	O
%	O
of	O
188	O
non	O
-	O
European	O
Jews	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

It	O
occurred	O
in	O
15	O
.	O
4	O
%	O
of	O
52	O
Ashkenazi	O
Israelis	O
with	O
familial	O
cancer	B
(	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
was	O
not	O
detected	O
in	O
51	O
non	O
-	O
European	O
Jews	O
at	O
increased	O
cancer	B
risk	O
.	O

Colorectal	B
neoplasia	I
occurred	O
personally	O
or	O
in	O
the	O
families	O
of	O
13	O
of	O
20	O
Ashkenazi	O
I1307	O
K	O
carriers	O
,	O
8	O
of	O
whom	O
also	O
had	O
a	O
personal	O
or	O
family	O
history	O
of	O
noncolonic	O
neoplasia	B
.	O

CONCLUSIONS	O
The	O
I1307	O
K	O
APC	O
variant	O
may	O
represent	O
a	O
susceptibility	O
gene	O
for	O
colorectal	B
,	I
or	I
other	I
,	I
cancers	I
in	O
Ashkenazi	O
Jews	O
,	O
and	O
partially	O
explains	O
the	O
higher	O
incidence	O
of	O
colorectal	B
cancer	I
in	O
European	O
Israelis	O
.	O

Systematic	O
analysis	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
defects	O
in	O
hereditary	B
coproporphyria	I
and	O
mutation	O
update	O
.	O

Hereditary	B
coproporphyria	I
(	O
HC	B
)	O
is	O
an	O
acute	O
hepatic	B
porphyria	I
with	O
autosomal	O
dominant	O
inheritance	O
caused	O
by	O
deficient	B
activity	I
of	I
coproporphyrinogen	I
III	I
oxidase	I
(	O
CPO	O
)	O
.	O

Clinical	O
manifestations	O
of	O
the	O
disease	O
are	O
characterized	O
by	O
acute	O
attacks	O
of	O
neurological	B
dysfunction	I
often	O
precipitated	O
by	O
drugs	O
,	O
fasting	O
,	O
cyclical	O
hormonal	O
changes	O
,	O
or	O
infectious	B
diseases	I
.	O

Skin	O
photosensitivity	O
may	O
also	O
be	O
present	O
.	O

The	O
seven	O
exons	O
,	O
the	O
exon	O
/	O
intron	O
boundaries	O
and	O
part	O
of	O
3	O
noncoding	O
sequence	O
of	O
the	O
CPO	O
gene	O
were	O
systematically	O
analyzed	O
by	O
an	O
exon	O
-	O
by	O
-	O
exon	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
strategy	O
followed	O
by	O
direct	O
sequencing	O
in	O
seven	O
unrelated	O
heterozygous	O
HC	B
patients	O
from	O
France	O
,	O
Holland	O
,	O
and	O
Czech	O
Republic	O
.	O

Seven	O
novel	O
mutations	O
and	O
two	O
new	O
polymorphisms	O
were	O
detected	O
.	O

Among	O
these	O
mutations	O
two	O
are	O
missense	O
(	O
G197W	O
,	O
W427R	O
)	O
,	O
two	O
are	O
nonsense	O
(	O
Q306X	O
,	O
Q385X	O
)	O
,	O
two	O
are	O
small	O
deletions	O
(	O
662de14bp	O
;	O
1168del3bp	O
removing	O
a	O
glycine	O
at	O
position	O
390	O
)	O
,	O
and	O
one	O
is	O
a	O
splicing	O
mutation	O
(	O
IVS1	O
-	O
15c--	O
>	O
g	O
)	O
which	O
creates	O
a	O
new	O
acceptor	O
splice	O
site	O
.	O

The	O
pathological	O
significance	O
of	O
the	O
point	O
mutations	O
G197W	O
,	O
W427R	O
,	O
and	O
the	O
in	O
-	O
frame	O
deletion	O
390delGly	O
were	O
assessed	O
by	O
their	O
respective	O
expression	O
in	O
a	O
prokaryotic	O
system	O
using	O
site	O
-	O
directed	O
mutagenesis	O
.	O

These	O
mutations	O
resulted	O
in	O
the	O
absence	O
or	O
a	O
dramatic	O
decrease	O
of	O
CPO	O
activity	O
.	O

The	O
two	O
polymorphisms	O
were	O
localized	O
in	O
noncoding	O
part	O
of	O
the	O
gene	O
1	O
)	O
a	O
C	O
/	O
G	O
polymorphism	O
in	O
the	O
promotor	O
region	O
,	O
142	O
bp	O
upstream	O
from	O
the	O
transcriptional	O
initiation	O
site	O
(	O
-142C	O
/	O
G	O
)	O
,	O
and	O
2	O
)	O
a	O
6	O
bp	O
deletion	O
polymorphism	O
in	O
the	O
3	O
noncoding	O
part	O
of	O
the	O
CPO	O
gene	O
,	O
574	O
bp	O
downstream	O
of	O
the	O
last	O
base	O
of	O
the	O
normal	O
termination	O
codon	O
(	O
+	O
574	O
delATTCTT	O
)	O
.	O

Five	O
intragenic	O
dimorphisms	O
are	O
now	O
well	O
characterized	O
and	O
the	O
high	O
degree	O
of	O
allelic	O
heterogeneity	O
in	O
HC	B
is	O
demonstrated	O
with	O
seven	O
new	O
different	O
mutations	O
making	O
a	O
total	O
of	O
nineteen	O
CPO	O
gene	B
defects	I
reported	O
so	O
far	O
..	O

Coincidence	O
of	O
two	O
novel	O
arylsulfatase	O
A	O
alleles	O
and	O
mutation	O
459	O
+	O
1G	O
>	O
A	O
within	O
a	O
family	O
with	O
metachromatic	B
leukodystrophy	I
:	O
molecular	O
basis	O
of	O
phenotypic	O
heterogeneity	O
.	O

In	O
a	O
family	O
with	O
three	O
siblings	O
,	O
one	O
developed	O
classical	O
late	O
infantile	O
metachromatic	B
leukodystrophy	I
(	O
MLD	B
)	O
,	O
fatal	O
at	O
age	O
5	O
years	O
,	O
with	O
deficient	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
and	O
increased	O
galactosylsulfatide	O
(	O
GS	O
)	O
excretion	O
.	O

The	O
two	O
other	O
siblings	O
,	O
apparently	O
healthy	O
at	O
12	O
(	O
1	O
/	O
2	O
)	O
and	O
15	O
years	O
,	O
respectively	O
,	O
and	O
their	O
father	O
,	O
apparently	O
healthy	O
as	O
well	O
,	O
presented	O
ARSA	O
and	O
GS	O
values	O
within	O
the	O
range	O
of	O
MLD	B
patients	O
.	O

Mutation	O
screening	O
and	O
sequence	O
analysis	O
disclosed	O
the	O
involvement	O
of	O
three	O
different	O
ARSA	O
mutations	O
being	O
the	O
molecular	O
basis	O
of	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

The	O
late	O
infantile	O
patient	O
inherited	O
from	O
his	O
mother	O
the	O
frequent	O
0-type	O
mutation	O
459	O
+	O
1	O
G	O
>	O
A	O
,	O
and	O
from	O
his	O
father	O
a	O
novel	O
,	O
single	O
basepair	O
microdeletion	O
of	O
guanine	O
at	O
nucleotide	O
7	O
in	O
exon	O
1	O
(	O
7delG	O
)	O
.	O

The	O
two	O
clinically	O
unaffected	O
siblings	O
carried	O
the	O
maternal	O
mutation	O
459	O
+	O
1	O
G	O
>	O
A	O
and	O
,	O
on	O
their	O
paternal	O
allele	O
,	O
a	O
novel	O
cytosine	O
to	O
thymidine	O
transition	O
at	O
nucleotide	O
2435	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
substitution	O
of	O
alanine	O
464	O
by	O
valine	O
(	O
A464V	O
)	O
.	O

The	O
fathers	O
genotype	O
thus	O
was	O
7delG	O
/	O
A464V	O
.	O

Mutation	O
A464V	O
was	O
not	O
found	O
in	O
18	O
unrelated	O
MLD	B
patients	O
and	O
50	O
controls	O
.	O

A464V	O
,	O
although	O
clearly	O
modifying	O
ARSA	O
and	O
GS	O
levels	O
,	O
apparently	O
bears	O
little	O
significance	O
for	O
clinical	O
manifestation	O
of	O
MLD	B
,	O
mimicking	O
the	O
frequent	O
ARSA	O
pseudodeficiency	O
allele	O
.	O

Our	O
results	O
demonstrate	O
that	O
in	O
certain	O
genetic	O
conditions	O
MLD	B
-	O
like	O
ARSA	O
and	O
GS	O
values	O
need	O
not	O
be	O
paralleled	O
by	O
clinical	O
disease	O
,	O
a	O
finding	O
with	O
serious	O
diagnostic	O
and	O
prognostic	O
implications	O
.	O

Moreover	O
,	O
further	O
ARSA	O
alleles	O
functionally	O
similar	O
to	O
A464V	O
might	O
exist	O
which	O
,	O
together	O
with	O
0-type	O
mutations	O
,	O
may	O
cause	O
pathological	O
ARSA	O
and	O
GS	O
levels	O
,	O
but	O
not	O
clinical	O
outbreak	O
of	O
the	O
disease	O
..	O

Human	O
MLH1	O
deficiency	O
predisposes	O
to	O
hematological	B
malignancy	I
and	O
neurofibromatosis	B
type	I
1	I
.	O

Heterozygous	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
DNA	O
mismatch	O
repair	O
genes	O
lead	O
to	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
.	O

The	O
disease	O
susceptibility	O
of	O
individuals	O
who	O
constitutionally	O
lack	O
both	O
wild	O
-	O
type	O
alleles	O
is	O
unknown	O
.	O

We	O
have	O
identified	O
three	O
offspring	O
in	O
a	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
family	O
who	O
developed	O
hematological	B
malignancy	I
at	O
a	O
very	O
early	O
age	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
displayed	O
signs	O
of	O
neurofibromatosis	B
type	I
1	I
(	O
NF1	B
)	O
.	O

DNA	O
sequence	O
analysis	O
and	O
allele	O
-	O
specific	O
amplification	O
in	O
two	O
siblings	O
revealed	O
a	O
homozygous	O
MLH1	O
mutation	O
(	O
C676T--	O
>	O
Arg226Stop	O
)	O
.	O

Thus	O
,	O
a	O
homozygous	O
germ	O
-	O
line	O
MLH1	O
mutation	O
and	O
consequent	O
mismatch	O
repair	O
deficiency	O
results	O
in	O
a	O
mutator	O
phenotype	O
characterized	O
by	O
leukemia	B
and/or	O
lymphoma	B
associated	O
with	O
neurofibromatosis	B
type	I
1	I
..	O

Missense	O
mutations	O
in	O
the	O
most	O
ancient	O
residues	O
of	O
the	O
PAX6	O
paired	O
domain	O
underlie	O
a	O
spectrum	O
of	O
human	O
congenital	B
eye	I
malformations	I
.	O

Mutations	O
of	O
the	O
human	O
PAX6	O
gene	O
underlie	O
aniridia	B
(	O
congenital	B
absence	I
of	I
the	I
iris	I
)	O
,	O
a	O
rare	O
dominant	O
malformation	B
of	I
the	I
eye	I
.	O

The	O
spectrum	O
of	O
PAX6	O
mutations	O
in	O
aniridia	B
patients	O
is	O
highly	O
biased	O
,	O
with	O
92	O
%	O
of	O
all	O
reported	O
mutations	O
leading	O
to	O
premature	O
truncation	O
of	O
the	O
protein	O
(	O
nonsense	O
,	O
splicing	O
,	O
insertions	O
and	O
deletions	O
)	O
and	O
just	O
2	O
%	O
leading	O
to	O
substitution	O
of	O
one	O
amino	O
acid	O
by	O
another	O
(	O
missense	O
)	O
.	O

The	O
extraordinary	O
conservation	O
of	O
the	O
PAX6	O
protein	O
at	O
the	O
amino	O
acid	O
level	O
amongst	O
vertebrates	O
predicts	O
that	O
pathological	O
missense	O
mutations	O
should	O
in	O
fact	O
be	O
common	O
even	O
though	O
they	O
are	O
hardly	O
ever	O
seen	O
in	O
aniridia	B
patients	O
.	O

This	O
indicates	O
that	O
there	O
is	O
a	O
heavy	O
ascertainment	O
bias	O
in	O
the	O
selection	O
of	O
patients	O
for	O
PAX6	O
mutation	O
analysis	O
and	O
that	O
the	O
missing	O
PAX6	O
missense	O
mutations	O
frequently	O
may	O
underlie	O
phenotypes	O
distinct	O
from	O
textbook	O
aniridia	B
.	O

Here	O
we	O
present	O
four	O
novel	O
PAX6	O
missense	O
mutations	O
,	O
two	O
in	O
association	O
with	O
atypical	O
phenotypes	O
ectopia	B
pupillae	I
(	O
displaced	B
pupils	I
)	O
and	O
congenital	B
nystagmus	I
(	O
searching	B
gaze	I
)	O
,	O
and	O
two	O
in	O
association	O
with	O
more	O
recognizable	O
aniridia	B
phenotypes	O
.	O

Strikingly	O
,	O
all	O
four	O
mutations	O
are	O
located	O
within	O
the	O
PAX6	O
paired	O
domain	O
and	O
affect	O
amino	O
acids	O
which	O
are	O
highly	O
conserved	O
in	O
all	O
known	O
paired	O
domain	O
proteins	O
.	O

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
under	O
-	O
representation	O
of	O
missense	O
mutations	O
is	O
caused	O
by	O
ascertainment	O
bias	O
and	O
suggest	O
that	O
a	O
substantial	O
burden	O
of	O
PAX6	B
-related	I
disease	I
remains	O
to	O
be	O
uncovered	O
..	O

The	O
chromosomal	O
order	O
of	O
genes	O
controlling	O
the	O
major	O
histocompatibility	O
complex	O
,	O
properdin	O
factor	O
B	O
,	O
and	O
deficiency	B
of	I
the	I
second	I
component	I
of	I
complement	I
.	O

The	O
relationship	O
of	O
the	O
genes	O
coding	O
for	O
HLA	O
to	O
those	O
coding	O
for	O
properdin	O
Factor	O
B	O
allotypes	O
and	O
for	O
deficiency	B
of	I
the	I
second	I
component	I
of	I
complement	I
(	O
C2	O
)	O
was	O
studied	O
in	O
families	O
of	O
patients	O
with	O
connective	O
tissue	O
disorders	O
.	O

Patients	O
were	O
selected	O
because	O
they	O
were	O
heterozygous	O
or	O
homozygous	O
for	O
C2	B
deficiency	I
.	O

12	O
families	O
with	O
15	O
matings	O
informative	O
for	O
C2	B
deficiency	I
were	O
found	O
.	O

Of	O
57	O
informative	O
meioses	O
,	O
two	O
crossovers	O
were	O
noted	O
between	O
the	O
C2	B
deficiency	I
gene	O
and	O
the	O
HLA	O
-	O
B	O
gene	O
,	O
with	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O
035	O
.	O

A	O
lod	O
score	O
of	O
13	O
was	O
calculated	O
for	O
linkage	O
between	O
C2	B
deficiency	I
and	O
HLA	O
-	O
B	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O
04	O
.	O
18	O
families	O
with	O
21	O
informative	O
matings	O
for	O
both	O
properdin	O
Factor	O
B	O
allotype	O
and	O
HLA	O
-	O
B	O
were	O
found	O
.	O

Of	O
72	O
informative	O
meioses	O
,	O
three	O
recombinants	O
were	O
found	O
,	O
giving	O
a	O
recombinant	O
fraction	O
of	O
0	O
.	O
042	O
.	O

A	O
lod	O
score	O
of	O
16	O
between	O
HLA	O
-	O
B	O
and	O
Factor	O
B	O
allotypes	O
was	O
calculated	O
at	O
a	O
maximum	O
likelihood	O
value	O
of	O
the	O
recombinant	O
fraction	O
of	O
0	O
.	O
04	O
.	O

A	O
crossover	O
was	O
shown	O
to	O
have	O
occurred	O
between	O
genes	O
for	O
Factor	O
B	O
and	O
HLA	O
-	O
D	O
,	O
in	O
which	O
HLA	O
-	O
D	O
segregared	O
with	O
HLA	O
-	O
A	O
and	O
B.	O
These	O
studies	O
suggest	O
that	O
the	O
genes	O
for	O
Factor	O
B	O
and	O
C2	B
deficiency	I
are	O
located	O
outside	O
those	O
for	O
HLA	O
,	O
that	O
the	O
order	O
of	O
genese	O
is	O
HLA	O
-	O
A	O
,	O
-B	O
,	O
-D	O
,	O
Factor	O
B	O
allotype	O
,	O
C2	B
deficiency	I
,	O
that	O
the	O
genes	O
coding	O
for	O
C2	B
deficiency	I
and	O
Factor	O
B	O
allotypes	O
are	O
approximately	O
3	O
-	O
-5	O
centimorgans	O
from	O
the	O
HLA	O
-	O
A	O
and	O
HLA	O
-	O
B	O
loci	O
,	O
and	O
that	O
the	O
apparent	O
lack	O
of	O
recombinants	O
between	O
the	O
Factor	O
B	O
gene	O
and	O
C2	B
deficiency	I
gene	O
suggests	O
that	O
these	O
two	O
genes	O
lie	O
in	O
close	O
proximity	O
to	O
one	O
another	O
.	O

Distribution	O
of	O
emerin	O
and	O
lamins	O
in	O
the	O
heart	O
and	O
implications	O
for	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
.	O

Emerin	O
is	O
a	O
nuclear	O
membrane	O
protein	O
which	O
is	O
missing	O
or	O
defective	O
in	O
Emery	B
-	I
Dreifuss	I
muscular	I
dystrophy	I
(	O
EDMD	B
)	O
.	O

It	O
is	O
one	O
member	O
of	O
a	O
family	O
of	O
lamina	O
-	O
associated	O
proteins	O
which	O
includes	O
LAP1	O
,	O
LAP2	O
and	O
lamin	O
B	O
receptor	O
(	O
LBR	O
)	O
.	O

A	O
panel	O
of	O
16	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
has	O
been	O
mapped	O
to	O
six	O
specific	O
sites	O
throughout	O
the	O
emerin	O
molecule	O
using	O
phage	O
-	O
displayed	O
peptide	O
libraries	O
and	O
has	O
been	O
used	O
to	O
localize	O
emerin	O
in	O
human	O
and	O
rabbit	O
heart	O
.	O

Several	O
mAbs	O
against	O
different	O
emerin	O
epitopes	O
did	O
not	O
recognize	O
intercalated	O
discs	O
in	O
the	O
heart	O
,	O
though	O
they	O
recognized	O
cardiomyocyte	O
nuclei	O
strongly	O
,	O
both	O
at	O
the	O
rim	O
and	O
in	O
intranuclear	O
spots	O
or	O
channels	O
.	O

A	O
polyclonal	O
rabbit	O
antiserum	O
against	O
emerin	O
did	O
recognize	O
both	O
nuclear	O
membrane	O
and	O
intercalated	O
discs	O
but	O
,	O
after	O
affinity	O
purification	O
against	O
a	O
pure	O
-	O
emerin	O
band	O
on	O
a	O
western	O
blot	O
,	O
it	O
stained	O
only	O
the	O
nuclear	O
membrane	O
.	O

These	O
results	O
would	O
not	O
be	O
expected	O
if	O
immunostaining	O
at	O
intercalated	O
discs	O
were	O
due	O
to	O
a	O
product	O
of	O
the	O
emerin	O
gene	O
and	O
,	O
therefore	O
,	O
cast	O
some	O
doubt	O
upon	O
the	O
hypothesis	O
that	O
cardiac	B
defects	I
in	O
EDMD	B
are	O
caused	O
by	O
absence	O
of	O
emerin	O
from	O
intercalated	O
discs	O
.	O

Although	O
emerin	O
was	O
abundant	O
in	O
the	O
membranes	O
of	O
cardiomyocyte	O
nuclei	O
,	O
it	O
was	O
absent	O
from	O
many	O
non	O
-	O
myocyte	O
cells	O
in	O
the	O
heart	O
.	O

This	O
distribution	O
of	O
emerin	O
was	O
similar	O
to	O
that	O
of	O
lamin	O
A	O
,	O
a	O
candidate	O
gene	O
for	O
an	O
autosomal	O
form	O
of	O
EDMD	B
.	O

In	O
contrast	O
,	O
lamin	O
B1	O
was	O
absent	O
from	O
cardiomyocyte	O
nuclei	O
,	O
showing	O
that	O
lamin	O
B1	O
is	O
not	O
essential	O
for	O
localization	O
of	O
emerin	O
to	O
the	O
nuclear	O
lamina	O
.	O

Lamin	O
B1	O
is	O
also	O
almost	O
completely	O
absent	O
from	O
skeletal	O
muscle	O
nuclei	O
.	O

In	O
EDMD	B
,	O
the	O
additional	O
absence	O
of	O
lamin	O
B1	O
from	O
heart	O
and	O
skeletal	O
muscle	O
nuclei	O
which	O
already	O
lack	O
emerin	O
may	O
offer	O
an	O
alternative	O
explanation	O
of	O
why	O
these	O
tissues	O
are	O
particularly	O
affected	O
..	O

Genetic	O
mapping	O
of	O
the	O
copper	B
toxicosis	I
locus	O
in	O
Bedlington	O
terriers	O
to	O
dog	O
chromosome	O
10	O
,	O
in	O
a	O
region	O
syntenic	O
to	O
human	O
chromosome	O
region	O
2p13-p16	O
.	O

Abnormal	O
hepatic	B
copper	I
accumulation	I
is	O
recognized	O
as	O
an	O
inherited	B
disorder	I
in	O
man	O
,	O
mouse	O
,	O
rat	O
and	O
dog	O
.	O

The	O
major	O
cause	O
of	O
hepatic	B
copper	I
accumulation	I
in	O
man	O
is	O
a	O
dysfunctional	O
ATP7B	O
gene	O
,	O
causing	O
Wilson	B
disease	I
(	O
WD	B
)	O
.	O

Mutations	O
in	O
the	O
ATP7B	O
genes	O
have	O
also	O
been	O
demonstrated	O
in	O
mouse	O
and	O
rat	O
.	O

The	O
ATP7B	O
gene	O
has	O
been	O
excluded	O
in	O
the	O
much	O
rarer	O
human	O
copper	B
overload	I
disease	O
non	B
-	I
Indian	I
childhood	I
cirrhosis	I
,	O
indicating	O
genetic	O
heterogeneity	O
.	O

By	O
investigating	O
the	O
common	O
autosomal	O
recessive	O
copper	B
toxicosis	I
(	O
CT	B
)	O
in	O
Bedlington	O
terriers	O
,	O
we	O
have	O
identified	O
a	O
new	O
locus	O
involved	O
in	O
progressive	O
liver	B
disease	I
.	O

We	O
examined	O
whether	O
the	O
WD	B
gene	O
ATP7B	O
was	O
also	O
causative	O
for	O
CT	B
by	O
investigating	O
the	O
chromosomal	O
co	O
-	O
localization	O
of	O
ATP7B	O
and	O
C04107	O
,	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

C04107	O
is	O
an	O
anonymous	O
microsatellite	O
marker	O
closely	O
linked	O
to	O
CT	B
.	O

However	O
,	O
BAC	O
clones	O
containing	O
ATP7B	O
and	O
C04107	O
mapped	O
to	O
the	O
canine	O
chromosome	O
regions	O
CFA22q11	O
and	O
CFA10q26	O
,	O
respectively	O
,	O
demonstrating	O
that	O
WD	B
can	O
not	O
be	O
homologous	O
to	O
CT	B
.	O

The	O
copper	O
transport	O
genes	O
CTR1	O
and	O
CTR2	O
were	O
also	O
excluded	O
as	O
candidate	O
genes	O
for	O
CT	B
since	O
they	O
both	O
mapped	O
to	O
canine	O
chromosome	O
region	O
CFA11q22	O
.	O

2	O
-	O
22	O
.	O
5	O
.	O

A	O
transcribed	O
sequence	O
identified	O
from	O
the	O
C04107-containing	O
BAC	O
was	O
found	O
to	O
be	O
homologous	O
to	O
a	O
gene	O
expressed	O
from	O
human	O
chromosome	O
2p13-p16	O
,	O
a	O
region	O
devoid	O
of	O
any	O
positional	O
candidate	O
genes	O
.	O

Molecular	O
analysis	O
of	O
the	O
APC	B
gene	O
in	O
205	O
families	O
:	O
extended	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
FAP	B
and	O
evidence	O
for	O
the	O
role	O
of	O
APC	B
amino	O
acid	O
changes	O
in	O
colorectal	B
cancer	I
predisposition	O
.	O

BACKGROUND	O
/	O
AIMS	O
The	O
development	O
of	O
colorectal	B
cancer	I
and	O
a	O
variable	O
range	O
of	O
extracolonic	O
manifestations	O
in	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
is	O
the	O
result	O
of	O
the	O
dominant	O
inheritance	O
of	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
mutations	O
.	O

In	O
this	O
study	O
,	O
direct	O
mutation	O
analysis	O
of	O
the	O
APC	B
gene	O
was	O
performed	O
to	O
determine	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
nine	O
extracolonic	O
manifestations	O
and	O
to	O
investigate	O
the	O
incidence	O
of	O
APC	B
mutations	O
in	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
.	O

METHODS	O
The	O
APC	B
gene	O
was	O
analysed	O
in	O
190	O
unrelated	O
FAP	B
and	O
15	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
the	O
protein	O
truncation	O
test	O
,	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
Chain	O
terminating	O
signals	O
were	O
only	O
identified	O
in	O
patients	O
belonging	O
to	O
the	O
FAP	B
group	O
(	O
105	O
patients	O
)	O
.	O

Amino	O
acid	O
changes	O
were	O
identified	O
in	O
four	O
patients	O
,	O
three	O
of	O
whom	O
belonged	O
to	O
the	O
non	O
-	O
FAP	O
group	O
of	O
colorectal	B
cancer	I
patients	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
identified	O
significant	O
differences	O
in	O
the	O
nature	O
of	O
certain	O
extracolonic	O
manifestations	O
in	O
FAP	B
patients	O
belonging	O
to	O
three	O
mutation	O
subgroups	O
.	O

CONCLUSIONS	O
Extended	O
genotype	O
-	O
phenotype	O
correlations	O
made	O
in	O
this	O
study	O
may	O
have	O
the	O
potential	O
to	O
determine	O
the	O
most	O
appropriate	O
surveillance	O
and	O
prophylactic	O
treatment	O
regimens	O
for	O
those	O
patients	O
with	O
mutations	O
associated	O
with	O
life	O
threatening	O
conditions	O
.	O

This	O
study	O
also	O
provided	O
evidence	O
for	O
the	O
pathological	O
nature	O
of	O
amino	O
acid	O
changes	O
in	O
APC	O
associated	O
with	O
both	O
FAP	B
and	O
non	O
-	O
FAP	O
colorectal	B
cancer	I
patients	O
..	O

Inherited	B
colorectal	I
polyposis	I
and	O
cancer	B
risk	O
of	O
the	O
APC	O
I1307	O
K	O
polymorphism	O
.	O

Germ	O
-	O
line	O
and	O
somatic	O
truncating	O
mutations	O
of	O
the	O
APC	B
gene	O
are	O
thought	O
to	O
initiate	O
colorectal	B
tumor	I
formation	O
in	O
familial	B
adenomatous	I
polyposis	I
syndrome	I
and	O
sporadic	O
colorectal	O
carcinogenesis	O
,	O
respectively	O
.	O

Recently	O
,	O
an	O
isoleucine--	O
>	O
lysine	O
polymorphism	O
at	O
codon	O
1307	O
(	O
I1307	O
K	O
)	O
of	O
the	O
APC	B
gene	O
has	O
been	O
identified	O
in	O
6	O
%	O
-7	O
%	O
of	O
the	O
Ashkenazi	O
Jewish	O
population	O
.	O

To	O
assess	O
the	O
risk	O
of	O
this	O
common	O
APC	B
allelic	O
variant	O
in	O
colorectal	O
carcinogenesis	O
,	O
we	O
have	O
analyzed	O
a	O
large	O
cohort	O
of	O
unselected	O
Ashkenazi	O
Jewish	O
subjects	O
with	O
adenomatous	B
polyps	I
and	O
.	O
or	O
colorectal	B
cancer	I
,	I
for	O
the	O
APC	O
I1307	O
K	O
polymorphism	O
.	O

The	O
APC	O
I1307	O
K	O
allele	O
was	O
identified	O
in	O
48	O
(	O
10	O
.	O
1	O
%	O
)	O
of	O
476	O
patients	O
.	O

Compared	O
with	O
the	O
frequency	O
in	O
two	O
separate	O
population	O
control	O
groups	O
,	O
the	O
APC	O
I1307	O
K	O
allele	O
is	O
associated	O
with	O
an	O
estimated	O
relative	O
risk	O
of	O
1	O
.	O

5	O
-	O
1	O
.	O
7	O
for	O
colorectal	B
neoplasia	I
(	O
both	O
P	O
=	O
.	O

01	O
)	O
.	O

Furthermore	O
,	O
compared	O
with	O
noncarriers	O
,	O
APC	O
I1307	O
K	O
carriers	O
had	O
increased	O
numbers	O
of	O
adenomas	B
and	O
colorectal	B
cancers	I
per	O
patient	O
(	O
P	O
=	O
.	O
03	O
)	O
,	O
as	O
well	O
as	O
a	O
younger	O
age	O
at	O
diagnosis	O
.	O

We	O
conclude	O
that	O
the	O
APC	O
I1307	O
K	O
variant	O
leads	O
to	O
increased	O
adenoma	B
formation	O
and	O
directly	O
contributes	O
to	O
3	O
%	O
-4	O
%	O
of	O
all	O
Ashkenazi	O
Jewish	O
colorectal	B
cancer	I
.	O

The	O
estimated	O
relative	O
risk	O
for	O
carriers	O
may	O
justify	O
specific	O
clinical	O
screening	O
for	O
the	O
360	O
,	O
000	O
Americans	O
expected	O
to	O
harbor	O
this	O
allele	O
,	O
and	O
genetic	O
testing	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
-	O
outcome	O
studies	O
may	O
impact	O
significantly	O
on	O
colorectal	B
cancer	I
prevention	O
in	O
this	O
population	O
.	O

Localization	O
of	O
human	O
BRCA1	O
and	O
its	O
loss	O
in	O
high	O
-	O
grade	O
,	O
non	B
-	I
inherited	I
breast	I
carcinomas	I
.	O

Although	O
the	O
link	O
between	O
the	O
BRCA1	O
tumour	B
-	O
suppressor	O
gene	O
and	O
hereditary	B
breast	I
and	I
ovarian	I
cancer	I
is	O
established	O
,	O
the	O
role	O
,	O
if	O
any	O
,	O
of	O
BRCA1	O
in	O
non	B
-	I
familial	I
cancers	I
is	O
unclear	O
.	O

BRCA1	O
mutations	O
are	O
rare	O
in	O
sporadic	B
cancers	I
,	O
but	O
loss	O
of	O
BRCA1	O
resulting	O
from	O
reduced	O
expression	O
or	O
incorrect	O
subcellular	O
localization	O
is	O
postulated	O
to	O
be	O
important	O
in	O
non	B
-	I
familial	I
breast	I
and	I
ovarian	I
cancers	I
.	O

Epigenetic	O
loss	O
,	O
however	O
,	O
has	O
not	O
received	O
general	O
acceptance	O
due	O
to	O
controversy	O
regarding	O
the	O
subcellular	O
localization	O
of	O
BRCA1	O
proteins	O
,	O
reports	O
of	O
which	O
have	O
ranged	O
from	O
exclusively	O
nuclear	O
,	O
to	O
conditionally	O
nuclear	O
,	O
to	O
the	O
ER	O
/	O
golgi	O
,	O
to	O
cytoplasmic	O
invaginations	O
into	O
the	O
nucleus	O
.	O

In	O
an	O
attempt	O
to	O
resolve	O
this	O
issue	O
,	O
we	O
have	O
comprehensively	O
characterized	O
19	O
anti	O
-	O
BRCA1	O
antibodies	O
.	O

These	O
reagents	O
detect	O
a	O
220-kD	O
protein	O
localized	O
in	O
discrete	O
nuclear	O
foci	O
in	O
all	O
epithelial	O
cell	O
lines	O
,	O
including	O
those	O
derived	O
from	O
breast	B
malignancies	I
.	O

Immunohistochemical	O
staining	O
of	O
human	O
breast	O
specimens	O
also	O
revealed	O
BRCA1	O
nuclear	O
foci	O
in	O
benign	O
breast	O
,	O
invasive	B
lobular	I
cancers	I
and	O
low	B
-	I
grade	I
ductal	I
carcinomas	I
.	O

Conversely	O
,	O
BRCA1	O
expression	O
was	O
reduced	O
or	O
undetectable	O
in	O
the	O
majority	O
of	O
high	O
-	O
grade	O
,	O
ductal	B
carcinomas	I
,	O
suggesting	O
that	O
absence	O
of	O
BRCA1	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
a	O
significant	O
percentage	O
of	O
sporadic	B
breast	I
cancers	I
..	O

